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Abstract 
 
The present thesis focuses on amino acids (a.a.) and their metabolism by Chinese 
hamster ovary cells, the workhorse of the multibillion dollar biopharmaceutical industry. The 
aim of the research was to explore a.a. transport and metabolism and define optimal operating 
conditions during fed-batch culture, which is the most common process mode used 
industrially. A fast and reliable way to calculate a.a. concentration ranges in media and feeds 
is of vital importance, as a.a. are the monomers of proteins, which account for 70% of dry 
cell weight. The desired recombinant product of bioprocesses is typically also a protein.  
The transport of a.a. into the cells was studied at the mRNA level of a.a. transporters 
for the first time in a bioprocessing context. The presented results demonstrate that a.a. 
transport is not the limiting step for recombinant protein formation. Also, the study allowed 
for a staged feeding strategy to be designed, where a.a. were not fed altogether. 
Following linear projection of an integral of viable cell concentration target and using 
the specific a.a. consumption rates during batch culture, six feeds were formulated containing 
a.a. and glucose. Three designs were based on the results of the a.a. transport study; however, 
they underperformed in comparison to the other feeds. In the latter, all nutrients were fed at 
the same time, resulting in cell culture performance comparable to that obtained with a 
commercial feed that was tested in parallel. This renders the presented method the first to 
define a traceable quantitative way to calculate amount of nutrients in the feeds.  
Flux balance analysis, a powerful technique that allows for investigation of 
intracellular dynamics, was used to analyse the metabolic data. An enhanced intracellular 
network was created by coupling two pre-existing in the literature that also for the first time 
included the glycosylation of the host proteins in the biomass equation.  
Finally, a novel methodology was developed and coded in R to calculate specific rates 
of consumption/production of various metabolites in cell culture. The methodology couples 
mass balances for fed-batch culture operation with constructed vectors of the sampling and 
feeding schemes. This can be further developed to a bioprocess relevant software platform for 
analysing cell culture data.       
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Notation 
 
Latin Letters 
a Artificial vector of feeding  
a.a.  Amino acid 
ADP   Adenosine diphosphate 
Ala   Alanine 
Amm  Ammonia 
Arg  Arginine 
Asn   Asparagine 
Asp  Aspartate 
AT  Active transport 
ATC  Anatomical therapeutic chemical classification 
ATP  Adenosine triphosphate 
b Artificial vector of sampling  
Batch_300mL Batch culture with a starting volume of 300mL in CD CHO medium 
(Invitrogen, UK)  
Batch_50mL Batch culture with a starting volume of 50mL in CD CHO medium 
(Invitrogen, UK)  
BCAA  Branched chain amino acids (Ile, Leu and Val) 
BCH   2- aminobicyclo-(2,2,1)-heptane-2-carboxylic acid  
C  Concentration of a metabolite 
c Artificial vector of sampling after feed  
CCD  Central composite design 
CCL  Continuous cell line 
Ccomp  Artificial/computed vector of the concentration of a metabolite 
CD  Chemically defined 
CHO   Chinese hamster ovary cells 
Cin  Concentration of a metabolite in a feed 
Notation   vi   
Cit  Citrate  
CoA  Coenzyme A 
CS_total  Total required culture concentration of substrate S in feed  
csv  Comma-separated values  
Cys  Cysteine 
DAE  Differential algebraic equations 
DCW  Dry cell weight 
DNA   Deoxyribonucleic acid 
DOE  Design of experiments 
E.C.  Enzyme commission 
EAA  Essential amino acids 
EMA   European medicine’s agency 
ER  Endoplasmic reticulum 
F_all  Feed all. Fed-batch culture with 50mL starting volume, prepared from scaling 
up the observed in “Batch_300mL” a.a. and Glc rates and diluting one to one 
in the medium (CD CHO, Invitrogen, UK)  
F_all_pl40  Feed all plus 40% more. Feed containing 40% more than the ingredients in 
“F_all” and diluted one to one in CD CHO medium (Invitrogen, UK)  
F_all_pl40_NO_CD_CHO Feed all plus 40% more, no CD CHO medium. Exact same feed 
as “F_all_pl40”, however, not diluted one to one in CD CHO 
(Invitrogen, UK);  
F_BC_TM_1hr First Branched Chain a.a. Then Most at 1hr interval. Reverse staged 
feeding strategy as the one for feed “F_M_TBC_1hr”  
F_C_Inv  Feed C Invitrogen. Commercially available feed for GS-CHO cells lines (CD 
EfficientFeedTM C AGTTM, Invitrogen, UK) 
F_M_TBC_1hr  First Most Then Branched Chain a.a. at 1hr interval. Fed-batch culture 
with 50mL starting volume and feed prepared based on “F_all”. 
Branched amino acids (BC) follow the addition of most amino acids 
(M) at 1hr intervals  
F_M_TBC_pl40_12hr First Most Then Branched Chain a.a. plus 40% more, 12hr 
interval. Feed similar with “F_M_TBC_1hr”, however, now 
staged feeding occurs at 12 hour intervals and the feed is 
prepared based on “F_all_pl40” 
F6P Fructose-6-phosphate 
Notation   vii   
FBA  Flux balance analysis 
FDA   Food and Drug administration 
Fin  Volumetric rate of feeding  
Fout   Volumetric rate of sampling 
FoutafF  Volumetric rate of sampling after feed 
Fuc   Fucose  
Gal   Galactose  
GalNAc  N-acetylgalactosamine  
GC-MS Gas chromatography- mass spectrometry 
gDCW  Grams of dry cell weight   
Glc  Glucose 
Glclss  Glycolysis   
GlcNAc  N-acetylglucosamine  
Gln  Glutamine 
Glu  Glutamate 
Gly  Glycine  
Glyc   Glycerol  
Glyc3PC  Glycero-3-phosphocholine  
GOI  Gene of interest 
GS  Glutamine synthetase 
GS35  Low-producing cell line (rprotein is an IgG4 mAb) 
GS46   High-producing cell line (rprotein is an IgG4 mAb) 
GSn8  Null cell line (not producing any rprotein)  
HEK  Human embryonic kidney 
His  Histidine 
hr  Hour 
IgG4   Immunoglobulin of γ isotype and 4 subclass 
Ile  Isoleucine 
Isobut   Isobutyrate  
Isoval   Isovalerate 
IVC  Integral of viable cells 
IVCC  Integral viable cell concentration 
IVCCestimate_tharvest IVCC estimate at the day of harvest  
k  Degradation rate of a metabolite 
Notation   viii   
kd  Specific death rate 
KEGG  Kyoto encyclopaedia of genes and genome 
Km  Michaelis-Menten constant 
KS  Monod model substrate constant 
Lac   Lactate 
Leu  Leucine 
LP  Linear programming 
Lys   Lysine 
mAb  Monoclonal antibodies 
Mann   Mannose  
MeAIB  2-methylaminoisobutyric acid 
Met  Methionine 
MFA  Metabolic flux analysis 
mRNA  Messenger RNA 
MSX   Methionine sulfoximine  
mtblts  Metabolites 
MTHF  5-Methyltetrahydrofolate 
mTORC1 Mammalian target of rapamycin complex 1  
NA  Not applicable 
NADH  Nicotinamide adenine dinucleotide 
NADPH  Nicotinamide adenine dinucleotide phosphate 
Ncltds  Nucleotides 
NEAA  Non-essential amino acids 
Neu5Gc  N-Glycolylneuraminic acid 
P  Product derived from a bioprocess 
PB  Plackett-Burman statistical design 
PBM  Population balance model 
PCA   Principal component analysis 
Pcholine Phosphocholine 
PCR  Polymerase chain reaction 
Phe  Phenylalanine 
PLS  Partial least squares regression 
PPP  Pentose phosphate pathway 
Pro  Proline 
Notation   ix   
PTRSC Putrescine 
Pyr  Pyruvate 
q  Specific production/consumption rate of a specific metabolite 
QbD  Quality by design 
qRT-PCR Quantitative reverse transcription polymerase chain reaction 
qS_tlim Specific consumption rate of substrate S, when the first substrate becomes 
limiting in batch culture. 
QTPP  Quality target product performance  
rDNA  Recombinant DNA 
RNA  Ribonucleic acid 
rprotein Recombinant protein  
RSM   Response surface methodology 
rxns  Reactions 
S  Substrate 
SBML  Systems Biology Markup Language  
SCM  Single cell model 
Ser  Serine 
SLC   Solute carriers 
Succ  Succinate 
t  Time 
TCA  Tricarboxylic acid  
TCDB  Transporters’ classification database 
tcomp   Artificial/computed time vector  
tF   Duration of feeding 
tfeed.int  Time occurrence of feeding interval  
tharvest   Day of harvest  
Thr  Threonine 
tlim  Time-point at which the first substrate becomes limiting in batch culture  
Trp  Tryptophan 
tS  Duration of sampling  
tSafF  Duration of sampling after feed 
Tyr  Tyrosine 
v  Substrate production/consumption rate 
V  Volume of culture 
Notation   x   
Val  Valine 
Vcomp  Artificial/computed volume vector 
vmax  Maximum reaction rate parameter for Michaelis-Menten kinetics  
XD  Non-viable cells concentration 
XV  Viable cells concentration 
 
Greek Letters 
μ  Growth rate 
μapp  Apparent growth rate (equals μ-kd) 
μmax  Maximum growth rate Monod constant 
μtlim Specific growth rate until the time-point that the first substrate becomes 
limiting in batch culture 
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Chapter 1                                             
Introduction 
 
Chinese hamster ovary (CHO) cells are the most widely used hosts for the production 
of recombinant DNA (rDNA) technology drugs (Kyriakopoulos and Kontoravdi 2012). This 
drug category represents a large part of total number of therapeutics (20%, i.e. 126 rDNA 
drugs out of 640 approved drugs in total, based on June 2012 data) approved by the European 
Medicines Agency (EMA) and the majority of the biopharmaceutical products (60%). 
Biopharmaceuticals are defined as drugs produced from biological sources using 
biotechnology methods (Walsh 2010). These drugs are not native to the biological sources 
used for their production and they may include proteins, glycoproteins and nucleic acids. The 
majority of these kinds of drugs are produced using microbial (referred to as fermentation) or 
animal cell culture, while some involve propagation of viruses (vaccines).    
Biopharmaceutical drugs are estimated to account for about 50% of the world sales 
income from the top 100 prescription products by year 2018 (EvaluatePharma 2013), while in 
2011 the biopharmaceutical sector achieved $53.8 billion worth of sales in the U.S.A. alone 
(Aggarwal 2012). By 2018 six of the top ten selling drugs are predicted to be produced using 
mammalian cell culture (EvaluatePharma 2013), five of which are produced using CHO cells 
(Kyriakopoulos and Kontoravdi 2012). Specifically, mammalian hosts, with the most 
dominant being CHO cells (Figure 1-1A), are used industrially for the production of active 
drug substances with complicated structure, termed as glycoproteins, i.e. involving proteins 
with attached sugars on them. These kind of proteins are the most prominent type of proteins 
in mammals and hence more relevant therapeutically for humans.  
The idea behind the use of proteins (and glycoproteins; both usually termed as 
proteins) as therapeutics is that proteins are directly responsible for catalysing important 
biological reactions. Unhealthy people generally present malfunctioning biological reactions, 
e.g. in the case of chronic renal failure, patients do not produce enough erythropoietin, a 
glycoprotein that stimulates the production of red blood cells. Hence, certain diseases can be 
treated by administering relevant proteins, i.e. in the chronic renal failure case: 
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erythropoietin. These proteins can either catalyse the problematic reactions or in the case of 
monoclonal antibodies (mAbs), the main class of glycoprotein drugs (Figure 1-1B),  may act 
as “magic bullets” identifying targets (potentially other proteins) that cause a problem and 
subsequently generate an immune response against the specific molecule (Jimenez del Val et 
al. 2010; Strebhardt and Ullrich 2008). MAbs may also be used as highly specific delivery 
vehicles of other biological active molecules. In the latter case mAbs are engineered, firstly to 
be able to carry the desired molecule, secondly to target a specific tissue and finally to release 
the carried molecule effectively.   
 
Figure 1-1: Glycoprotein drugs approved by EMA. 
Classification is presented based on: A) the hosts that were industrially used to produce 
them (CHO: Chinese hamster ovary cells, Murine myeloma: hybridoma mouse cell 
lines, BHK: Baby hamster kidney cells, HT-1080: human fibrosarcoma cell line, 
Quadroma: cell line resulted from a mouse/rat hybrid hybridoma, Human plasma: 
isolated from blood plasma of healthy donors); B) their molecule types, and C) the 
Anatomical Therapeutic Chemical classification system (ATC), which is a coding system 
for sorting pharmaceuticals, with codes given in sequence for the three aforementioned 
possible classifications. Created from data in: Kyriakopoulos and Kontoravdi (2012).  
 
Biopharmaceuticals and especially glycoproteins are much more complicated drugs 
than the chemically synthesized ones. In Figure 1-2 a structure of a monoclonal antibody is 
compared against three chemically synthesized drugs, where the aforementioned statement 
regarding the complexity of the molecules is evident. Glycoproteins are prescribed to treat 
serious illnesses such as cancer (antineoplastics and antianemics, as presented by the ATC 
classification in Figure 1-1C), autoimmune disorders (immunosuppresants in Figure 1-1C) 
and inherited diseases (antihemorrhagics in Figure 1-1C, associated with the treatment of 
haemophilia and also the therapeutic enzymes category in Figure 1-1C). Despite the 
importance of the associated diseases, treatment costs are extremely high. A single patient 
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treatment with a frequently cancer-prescribed drug, produced from CHO cells (Avastin®), 
costs about $50,000-$90,000 per year (Herper 2010; Siddiqui and Rajkumar 2012). While 
there are many reasons contributing to the high costs of biopharmaceuticals, reviewed in 
Siddiqui and Rajkumar (2012), manufacturing costs are also on the list. 
 
Figure 1-2: Chemical structure of a monoclonal antibody (presented in A) against three 
chemically synthesized drugs prescribed for cancer and autoimmune disorders.  
The following chemically synthesized drugs are illustrated: Fluorouracil (B), 
Methotrexate (C) and Tofacitinib (D). From: Jimenez del Val (2013). 
 
The therapeutic recombinant protein (rprotein) production process involves a complex 
sequence of steps (Kelley 2009). In brief, these include inserting, with rDNA technology 
techniques, a product of interest to a host cell line, the subsequent selection of high producers 
and generation of a cell bank, their cultivation in large vessels to produce the rprotein of 
interest in relevant amounts, followed by the purification of the product and the final 
formulation for administration to patients. The cultivation of cells takes place in large stirred 
tank bioreactors (maximum size is 20,000 litres) and the preferred process mode is fed-batch 
(De Jesus and Wurm 2011; Lu et al. 2013; Pollock et al. 2013; Yang and Liu 2013). The 
latter involves the frequent addition of feeds consisting of multiple components that are 
designed to enhance product yield.  
One of the many difficulties of industrial cell culture process is the long time scale 
involved, e.g. a typical fed-batch run for an antibody lasts 10-20 days and it may produce 
between 5-100kg of product (De Jesus and Wurm 2011; Kelley 2009; Shaughnessy 2012). In 
addition, current demand can reach up to 10,000 kg/year for a single branded mAb (Yang and 
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Liu 2013). This would equate to about 100 runs for the best case. In other words, a company 
with a single production bioreactor would need more than 2 years to produce the 
aforementioned amount.                
Given that the concentration of recombinant proteins attainable from mammalian cell 
culture is 2-5 fold higher than the current industrial yield, there is scope for significant 
improvement (De Jesus & Wurm, 2011). Research in various aspects of mammalian cell 
bioprocessing, including cell engineering and process design, can increase productivity thus 
paving the way to reduced costs and wider usage of high-value biopharmaceutical products. 
The way to go forward is by harnessing the recently published genome of the cells, but also 
rationalising the operation of existing processes (Kildegaard et al. 2013; Wuest et al. 2012; 
Yang and Liu 2013). 
 
1.1 Aim of the thesis 
 
The first US Food and Drug administration (FDA) approval of a drug produced in 
CHO cells was in 1987 (Genentech 1987); 26 years on bioprocesses have been hugely 
improved (De Jesus & Wurm, 2011). Specifically, a 20-fold increase of yield has been 
achieved, mainly due to improved media and feeds that allow for healthier cells that grow for 
much longer. However, still many aspects of CHO cell metabolism and physiology are barely 
understood (Altamirano et al. 2013; Datta et al. 2013; Kildegaard et al. 2013; Wuest et al. 
2012; Yang and Liu 2013; Young 2013). The aim of the present project is the development of 
a formal methodology for the design of optimal feeding strategies based on the understanding 
of amino acid metabolism and transport into CHO cells, with the ultimate goal being to get a 
step closer to the rationalization of the process.   
Amino acids are vital media and feed components. 70% of cells’ dry mass (w/w) 
consists of proteins (Selvarasu et al. 2012), the monomers of which are amino acids. 
Furthermore, the desired product from a bioprocess, the rprotein, also consists of amino 
acids. Consequently, amino acids need to be constantly provided to ensure growth and 
rprotein formation during a bioprocess run. Simultaneously in order for the amino acids to be 
transported into the cells, membrane proteins will have to be employed by the cells to ensure 
the uptake of the required nutrients. The current project therefore faces two scientific 
challenges: rationalising the extremely complicated metabolism of amino acids in 
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mammalian cells and linking this to the even more complicated process of amino acid uptake 
by transporter proteins that have not been studied in a bioprocessing context before.  
   6 
Chapter 2                                                 
Literature review  
 
 This chapter summarises the important literature related to the aim of this thesis. The 
chapter is divided into three parts. The first part focuses on the biological background. The 
second presents the bioprocess engineering discipline. The third part focuses on in silico 
methods to model bioprocess engineering principles.  
 
2.1 Biological background 
 
2.1.1 Classification of cell types 
  
The most basic classification of biological cells relates to the structure of their 
nucleus. In relation to this they are classified either as prokaryotes or eukaryotes (Alberts et 
al. 2002). The main difference is that prokaryotes do not have a distinct nucleus, which is an 
intracellular organelle where the deoxyribonucleic acid (DNA), the molecule responsible for 
the storage of hereditary information, is enclosed, while eukaryotes present a distinct nuclear 
structure. Moreover, the structure of prokaryotic cells is much simpler than eukaryotic cells, 
containing fewer and much simpler membrane-bound organelles.   
Despite major differences between cell types, they all have a very important 
similarity, which pertains to the way they express the genetic information (Alberts et al. 
2002). The flow of genetic information is always from DNA to ribonucleic acid (RNA), to 
which DNA is transcribed and then from RNA to protein, with a process called translation 
(see also Figure 2-1). Also, reversible flow from RNA to DNA has been reported for a few 
biological systems, which is beyond the purposes of the current analysis. Proteins are the 
molecules associated with function in a living cell. The expression of the genetic information 
is a fundamental principle of molecular biology and for this reason is termed as the central 
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dogma of molecular biology. The current project focuses on mammalian cells, which are 
eukaryotic and hence other types of cells will not be further discussed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1: Flow of genetic information in biological cells: DNA transcribed to mRNA, 
which subsequently is translated to proteins. 
Modified from: Shimizu (2012). 
 
2.1.2 Mammalian cell structure 
 
Most eukaryotic cells have a similar set of membrane-bound organelles (Alberts et al. 
2002). Organelles are defined as compartments that are isolated by at least one selective 
permeable membrane from the rest of the cell. Although, most of the organelles exist in most 
eukaryotic cell types their volume, abundance and size can be significantly different between 
various differentiated cells. In Figure 2-2 a general structure of a eukaryotic mammalian cell 
is presented. 
The nucleus is the organelle that contains the DNA, which is packed by proteins and 
stored into separate chromosomes (Alberts et al. 2002). In the nucleus DNA replication and 
RNA synthesis take place. The aforementioned compounds are also termed as nucleic acids, 
since they are acids occurring in the nucleus. The cytoplasm is the part of the cell 
surrounding the nucleus that contains the cytosol and the other organelles.  
The endoplasmic reticulum (ER) is directly connected with the nuclear envelope and 
is a labyrinthic structure, where protein synthesis takes place with the aid of the ribosomes 
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(Alberts et al. 2002). Ribosomes are small protein structures responsible for the synthesis of 
proteins. The ER occurs in two forms the smooth and the rough. Ribosomes are bound to the 
rough ER. The latter is involved for the production of lipids and is also used to store calcium 
ions. Moreover, the ER is responsible for transferring most of the proteins and lipids to the 
Golgi apparatus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2: The structure of a mammalian cell.  
Modified from: Alberts et al. (2002). 
 
The Golgi apparatus is the site of the cell where the glycosylation of proteins and 
lipids takes place (Alberts et al. 2002). Glycosylation refers to the process of adding glycans 
to organic molecules. Mitochondria are the organelles responsible for the production of the 
energy required for cellular functions, mainly in the form of adenosine triphosphate (ATP) 
molecules (Alberts et al. 2002). Lysosomes contain digestive enzymes that degrade unwanted 
molecules. Endosomes are organelles mainly used for the screening of molecules before 
reaching lysosomes. Finally, peroxisomes are organelles that contain vital enzymes for the 
degradation of various molecules, mainly fatty acids (Gabaldon 2010). 
The organelles have a characteristic position in the cell. This position is regulated via 
the cytoskeleton (Alberts et al. 2002). The cytoskeleton is a protein-based filamentous 
structure responsible for giving shape to cells by supporting the cell membrane. The 
cytoskeleton also has an important function during cell division; it is responsible for dividing 
firstly the replicated DNA and secondly the two resulting cells. 
Literature review  9   
 
2.1.3 Cellular metabolism 
 
The understanding of mammalian metabolism from a biological textbook perspective 
is vital for the study of metabolic functions in a particular type of cell. The textbook 
knowledge can be used as a basis in order to compare the metabolic phenotype of different 
cell lines. This part presents a basic description of mammalian cell metabolism, while the last 
part focuses on the metabolic characteristics of mammalian cells used during bioprocessing. 
Cellular organelles assist cells in performing their two main activities: survival and 
division or replication. Equally important is the function of metabolism. This controls how 
cells acquire substances from their environment and transform them into useful molecules 
necessary for their survival and replication (Alberts et al. 2002). The two major streams of 
chemical reactions that take place during metabolism, which are also coupled, but completely 
separated (i.e. not reverse pathways) are catabolism and anabolism.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3: Major metabolic network in mammalian cells. 
PPP: pentose phosphate pathway, TCA: tricarboxylic acid cycle. From: Zamorano et al. 
(2010). 
 
The catabolism of molecules in the cellular environment involves their breakdown 
into smaller and simpler molecules, such as monosaccharides (monomers of complex sugars- 
carbohydrates), amino acids (monomers of proteins), fatty acids (main monomers of lipids) 
and nucleotides (monomers of nucleic acids). This process simultaneously produces energy, 
mainly in the form of ATP molecules.   
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On the other hand, anabolism or biosynthesis refers to those pathways that use both 
the energy and simple molecules produced from the catabolism to produce more tailor made 
macromolecules for the needs of the cells (Alberts et al. 2002). A simplified map that 
associates anabolism and catabolism and the important pathways that will be analysed in this 
section is presented in Figure 2-3. Anabolism will not be further discussed, as it is a 
procedure highly dependent on the “quality” of the catabolism and mainly from the energy 
generated by the latter (Young 2013).  
Catabolism comprises three stages (Alberts et al. 2002). The first stage involves the 
digestion of macromolecules (proteins, carbohydrates, lipids) and their conversion into their 
monomers. This stage occurs either extracellularly (in whole organisms) with the aid of 
enzymes excreted by cells, or intracellularly in the lysosomes. The second stage involves the 
breakdown of the simpler molecules derived from the first stage to acetyl coenzyme A (acetyl 
CoA). Then the third step involves the conversion of acetyl CoA to water and carbon dioxide 
(CO2). There are two processes involved during this conversion, termed as: tricarboxylic acid 
(TCA) cycle and oxidative phosphorylation. At this 3rd stage large amounts of energy are 
generated in the form of nicotinamide adenine dinucleotide (NADH), another molecule used 
as energy currency, and ATP molecules, occurring entirely in the mitochondria.   
 
2nd stage of catabolism: Catabolism of sugars, amino acids and lipids 
More specifically, the second stage of catabolism involves the conversion of the 
monomers of the macromolecules: proteins, polysaccharides and fats, namely: amino acids, 
simple sugars and fatty acids (and glycerol), respectively, into acetyl CoA. Glycolysis that 
occurs entirely in the cytosol corresponds to the process where a sugar molecule is converted 
to pyruvate. Glucose, which is the main sugar monomer, carbon donor and energy supplier 
for most cells, is converted into two pyruvate molecules (Alberts et al. 2002). While, also two 
ATP molecules are produced. Other sugars are similarly converted into pyruvate, but first 
they have to be converted to one of the intermediate molecules of the glycolysis pathway. 
Pyruvate then under aerobic conditions (presence of oxygen) is transferred to the 
mitochondria, where the third stage of the metabolism takes place. Pyruvate is also associated 
with the production of lactate under anaerobic conditions, which is a well-documented by-
product of metabolism. All metabolic reactions between different compounds are catalysed 
by highly specific enzymes that are expressed by cells based on their needs (as depicted in 
Figure 2-4). 
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Glycolysis is coupled with the pentose phosphate pathway (PPP) or hexose-phosphate 
shunt, which also occurs in the cytosol (Alberts et al. 2002). In that pathway, ribose-5-
phosphate, a precursor for nucleic acids synthesis, erythrose-4-phosphate, a precursor of 
aromatic amino acids synthesis and another energy molecule with reducing power (i.e. 
nicotinamide adenine dinucleotide phosphate, NADPH) are formed.       
As amino acids (a.a.) are the building blocks of proteins they are an essential part of all 
living cells’ nutrients. A chemical classification of the so-called canonical or proteinogenic 
amino acids (20 in total) according to their charge and chemistry of their side chain is 
presented in Table I-1 in Appendix I. Many other amino acids occur in mammalian cells, 
with the broad chemical term, however, in literature the term “amino acids” usually refers to 
the 20 proteinogenic ones (Alberts et al. 2002). This nomenclature will be adopted for the rest 
of the present thesis. 
 
Figure 2-4: A representative map of cellular metabolism from KEGG (Kanehisa et al. 
2012). 
The reaction network related to amino acid metabolism is represented with orange 
colour. Nodes represent metabolites, whereas lines represent reactions. Each reaction is 
catalysed by a highly specific enzyme.   
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Amino acids are also important metabolic components often used as carriers or donors 
of nitrogen in major metabolic processes. More importantly, in mammalian cells amino acids 
and specifically glutamine serve as primary carbon sources, along with glucose (Burgess 
2011). Cultured mammalian cells can only produce some of the required amino acids for 
protein synthesis (Eagle 1959; Xie and Wang 1994b), termed as non-essential amino acids 
(NEAA). Consequently, they require certain amino acids to be provided externally. These are 
termed as essential amino acids (EAA). The NEAA are: alanine (Ala), asparagine (Asn), 
aspartate (Asp), glutamate (Glu), glycine (Gly), proline (Pro) and serine (Ser). On the other 
hand, the EAA are: arginine (Arg), cysteine (Cys), glutamine (Gln), histidine (His), 
isoleucine (Ile), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), threonine 
(Thr), tryptophan (Trp), tyrosine (Tyr) and Valine (Val). 
Amino acid metabolism is a very complicated network of reactions. The Kyoto 
encyclopaedia of genes and genome (KEGG), which is an effort to create an atlas of 
metabolism by collecting all published genes and their associated function (Kanehisa et al. 
2012), includes more than 10 maps under the amino acid metabolism category (summarised 
in Figure 2-4). These maps involve many interconversions between the different amino acids 
until they are either converted to TCA intermediates or to other essential molecules, such as 
nucleotides. In general, some amino acids are directly converted to pyruvate (Cys, Ser) and 
others to TCA cycle intermediates (Asp, Glu, Ile, Leu, Lys, Trp, Tyr, Val). Some have to be 
converted to other amino acids before they are more effectively utilized metabolically (Ala, 
Arg, Asn, Gln, Gly, His, Met, Phe, Pro, Thr), while the ones that are in excess are degraded 
or excreted, since they cannot be stored (Grohmann and Bronte 2010).  
The remaining type of macromolecules, the lipids, are broken down to fatty acids and 
glycerol, which are metabolised in the cell to produce acetyl CoA (Alberts et al. 2002). The 
catabolism, however, of lipids is much slower than that of glucose and are mainly used for 
energy storage during anabolism. 
 
3rd stage of catabolism: TCA cycle and oxidative phosphorylation 
Tricarboxylic acid (TCA) cycle, Krebs cycle and citric acid cycle all refer to the same 
process that takes place in the mitochondria and generates, along with oxidative 
phosphorylation, significant amounts of energy for the cells (Alberts et al. 2002). These two 
processes correspond to the 3rd stage of catabolism. The acetyl group of acetyl CoA is 
transferred to oxaloacetate, a four-carbon molecule, which is the molecule initiating the citric 
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acid cycle, where energy in the form of the electron carrier molecule NADH is produced and 
CO2.  
The high energy electrons of NADH then produce a concentration gradient between 
the inner membrane space of the mitochondria (space between the two membranes 
surrounding them) and their matrix, which gradient is responsible for the phosphorylation of 
ADP to form ATP (Alberts et al. 2002). This last step is driven by the electron transport 
through the inner membrane of mitochondria and is known as oxidative phosphorylation. 
During oxidative phosphorylation oxygen is consumed, which reacts with hydrogen to 
produce water.  
 
Metabolic characteristics of cultured mammalian cells 
 Cultured mammalian cells, also termed as continuous cell lines (CCLs), are 
characterized by two distinct metabolic phenotypes occurring at the following two phases of 
cell culture (see also Figure 2-5): the exponential growth phase, starting from the seeding of 
the culture and the stationary phase, preceding the seizure of exponential growth (Ahn and 
Antoniewicz 2013; Carinhas et al. 2013; Dean and Reddy 2013; Young 2013). During the 
exponential phase, CCLs exhibit a high rate of glycolysis resulting to high levels of lactate 
from the utilization of glucose, which is the main carbon source. The latter usually occurs 
during conditions of oxygen deprivation. CCLs are cultured under aerobic conditions and so 
the observed phenotype can be characterized as unexpected theoretically, however it is 
universally observed.  
Furthermore, exponential growth is characterised by high consumption of glutamine 
resulting also to high accumulation of ammonia, which along with lactate, is a by-product, 
high levels of which negatively affect cell growth (Young 2013). This exponential growth 
phenotype is wasteful (high ammonia and lactate production) and highly inefficient in terms 
of carbon source utilization. Glycolysis only generates two ATP molecules per one glucose 
molecule instead of up to 36 in the case that cells had channelled pyruvate into mitochondria 
for TCA cycle and oxidative phosphorylation.    
On the other hand, during stationary phase cells are characterised by a much higher 
rate of oxidative metabolism (Young 2013). At this phase cells exhibit lower uptake rates of 
glucose, which is channelled to the TCA cycle and hence metabolic by-products are reduced.    
Amino acid metabolism during cell culture is highly dependent on the cultured cell 
line. EAA and NEAA may vary based on cell line. For example, all CHO cell lines are 
deficient in proline synthesis (Wurm and Hacker 2011), although proline has been 
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documented as a NEAA (Eagle 1959). Moreover, in cell culture NEAA are mainly produced 
from Gln resulting in a high production of ammonia. In order to limit the accumulation of 
ammonia, it has been firmly suggested to provide all amino acids in the medium of CCLs 
(Xie and Wang 1994b; Xie and Wang 1996). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5: Main metabolic characteristics of cultured mammalian cells. 
(a) Overview of glucose metabolism in continuous cell lines (CCLs) during exponential 
growth phase. CCLs are characterised by a wasteful metabolism and an unexpectedly 
high glycolytic rate, even though at aerobic conditions. (b) The metabolic phenotype of 
CCLs at stationary phase. Cells present a higher rate of oxidative metabolism, i.e. full 
oxidation of glucose via the TCA cycle, which generates much more energy than 
glycolysis. A higher proportion of glucose is channelled towards the PPP pathway than 
in the exponential phase, probably in order to gain additional energy in the form of 
NADPH. Obtained from Young (2013) with licence.    
 
The most noteworthy example of altered amino acid metabolism between cell lines 
during cultivation is the use of the glutamine synthetase (GS) selection vector for CHO cells. 
As will be further described in part 2.2, after being transfected with a gene of interest, cells 
need to be screened for high producers. One widely used technique, which is also really 
successful, involves growing the cells on medium without glutamine (Bebbington et al. 1992; 
Cockett et al. 1990; Fan et al. 2012; Noh et al. 2013). As discussed earlier glutamine is an 
important carbon source for mammalian cells and hence cells not able to produce glutamine 
from other nutrients will not survive. Exactly because the gene of interest is on the same 
vector with the gene encoding for glutamine synthetase, an enzyme catalysing the production 
of glutamine from glutamate, cells with the gene of interest will remain viable and hence will 
be selected. In order to increase the selection pressure, especially for CHO cells that may 
present endogenous GS activity, methionine sulfoximine (MSX) is also added to the medium 
at optimized concentrations. MSX is an inhibitor of GS and is added in order to suppress the 
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expression of endogenous GS and, more importantly, to select cells with high recombinant 
GS activity.  
Clearly, cell lines transfected with the GS amplification vector display different a.a. 
metabolic characteristics than those described earlier for CCLs. The GS-cells are grown in 
medium that does not contain glutamine and for this reason they mainly rely on glutamate 
that, in this case, takes all the characteristics of glutamine described earlier. For the purpose 
of this thesis GS-CHO cells were used and hence this mention is of particular importance.           
   
2.1.4 Transport of molecules in & out of cells  
 
The cell membrane is a semi-permeable membrane surrounding the cytoplasm of the 
cell. It has the role of maintaining the shape of the cell, as well as protecting its integrity by 
selectively allowing substances to go into or out of the cells. The main ingredients of cell 
membrane are lipid molecules, while proteins and sugars are also embedded in it. Proteins 
work as carriers/ transporters of molecules, while the sugars attached to lipids (glycolipids) or 
on membrane proteins act as receptors of signals from the extracellular environment (Alberts 
et al. 2002). Transport is also important through organelles within the cells, but this is not 
investigated in this thesis. Consequently, this part mainly concentrates on transport through 
the cell membrane. 
Two major types of transport are observed in cells: passive transport and active 
transport (Alberts et al. 2002), as also presented in Figure 2-6. Passive transport corresponds 
to a process that follows the concentration gradient of the transported molecule and includes 
simple diffusion, where the molecule simply passes across the cell membrane without the aid 
of any other molecule. Facilitated diffusion is another form of passive transport, where the 
transported molecule is facilitated by a protein-carrier. On the other hand, active transport 
refers to the process where the cell has to consume energy in order to transport a molecule. 
Active transport occurs against the concentration gradient. There are two types of active 
transport: primary active transport and secondary active transport, which will be further 
analysed in this section.  
 Transporters are protein molecules attached to the cellular membrane that mediate the 
uptake of molecules. Cell transporters are very selective, since uptake and release of 
molecules in and out of a cell is strongly correlated with cell survival. Transport through the 
cell membrane consists of three steps: binding of transported molecule at one side, 
translocation through the membrane and discharging the molecule at the other side. In such a 
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mediated transport, as the concentration of the transported molecule is increased the transport 
does not increase infinitely but reaches a saturation point. This point is illustrated by a 
rectangular hyperbola in the velocity of uptake versus concentration of solute diagram 
(Guidotti and Gazzola 1992). Every mediated transport through cell membranes is 
characterised kinetically by the aforementioned saturation, which can be mathematically 
described by Michaelis-Menten kinetics.  
 
Figure 2-6: Overview of plasma membrane transporter proteins. 
Two main types are apparent: channel and carrier proteins. Carrier proteins, as amino 
acid transporters, are further divided based on energy utilization, while carrying 
substrates to: facilitated diffusion (mainly termed as uniports, where facilitative 
diffusion is used without energy coupling and hence the molecule follows the 
concentration gradient), primary active (this kind of transporters consume directly 
energy in the form of ATP to translocate molecules against their concentration 
gradient) and secondary active transporters (usually coupled with a primary active 
transporter and hence indirectly associated with energy utilization, are further divided 
to symports and antiports based on the mode of transport they use). Based on the two 
available classifications of membrane proteins, SLC (Hediger et al. 2004) and TCDB 
(Saier et al. 2009) amino acid transporters are depicted under the relevant transporter 
groups. Modified from: Alberts et al. (2002) and Lodish et al. (2000).    
 
The selectivity of transporters is based on specific binding sites that they have. The 
transported molecule from either side of the membrane binds on those sites initiating the 
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transport of the molecule. According to their reactivity to substrates, termed as recognition 
ability, transporters are classified into groups relevant to their recognition properties. 
Transporters with the same recognition properties form a so-called transport system (Guidotti 
and Gazzola 1992). 
 A distinct transport system is characterised by several other properties apart from 
substrate recognition, such as functional-operational characteristics, energy utilisation, kinetic 
properties, response to cellular control mechanisms and boundary conditions susceptibility 
(Guidotti and Gazzola 1992). Cells from the same organism may have a significantly 
different transporter expression profile (Nishimura and Naito 2005; Nishimura and Naito 
2008) and this may also occur for cells of the same tissue, which experience different 
environmental conditions. The following paragraphs will only concentrate on amino acid 
transporters, which are relevant for the current project. 
From the aforementioned information, it is evident that amino acid requirements in a 
cell are fulfilled by a combination of intracellular metabolism and amino acid transport into 
the cell from its surroundings. Hence, transport of amino acids across the cell membrane is of 
major importance for all cells and appropriate regulation of membrane transport is vital. 
Currently, numerous transport systems have been identified as amino acid transporters. In the 
following few paragraphs their distinct properties will be described. 
 
Selectivity of amino acid transport systems 
Selectivity of amino acid transport systems is based on size, shape (steric 
conformation) and net charge of the transported amino acid. It is also affected by the position 
of the amino group in the molecule and alkyl substitutions (if any) in the amino group, as 
well as the structure, polarity and size of their side chain (Guidotti and Gazzola 1992). Also, 
the selectivity of coupled systems, those that when transporting a molecule have to co-
transport or counter- transport another molecule (depicted as symports or antiports, 
respectively, in Figure 2-6), is affected by the structural change of the transporter, when any 
of the transferred molecules is bound on it. 
 The reactive sites of the mammalian amino acids transporters are “incomplete”. This 
means that transport systems are not specific for each amino acid and can bind with different 
ones (Oxender and Christensen 1963a). Furthermore, even different transport systems may 
transfer same amino acids. However, different systems may exhibit significantly different 
reactivity when transporting a specific amino acid. Therefore, to study the transport of a 
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specific amino acid one has to take into account all the possible systems that may carry it in 
and out of the cell. 
 
Kinetic characteristics of amino acid transporters 
Kinetics of amino acid transporters, as also discussed earlier for most transporters, can 
be described by Michaelis-Menten kinetics (Michaelis and Menten 1913), similarly to 
kinetics for enzyme catalysis (Guidotti and Gazzola 1992). Hence, the rate of transport 
through a specific transporter is characterised by the values vmax and the affinity constant 
(Km), which correspond to the maximum rate of transport at a hypothetical infinite substrate 
concentration and to the substrate concentration at which rate of transport is half of the 
maximum, respectively (see Figure 2-7).  
Several other parameters affect amino acid transport kinetics. Equations similar to 
Michaelis-Menten kinetics have been developed to describe transport processes, where other 
molecules such as ions are being co-transported with amino acids (Sanders et al. 1984). 
Moreover, often there is inhibitory action from other molecules against amino acid transport, 
giving rise to an inhibition parameter, KI, which corresponds to the concentration of the 
inhibitor capable of reducing the rate of the transport to half of the maximum (Guidotti and 
Gazzola 1992). Furthermore, transport inhibition may also occur between the amino acids 
themselves, i.e. transport of a specific amino acid might be affected by another amino acid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-7: Amino acid transporters follow Michaelis-Menten kinetics. 
In the illustrated equation the following parameters are depicted: v is the rate of 
transport, vmax is the maximum rate and occurs when substrate concentration [S] tends 
to infinite, Km is the substrate concentration at which transport rate is half of the 
maximum.   
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Facilitative or mediated transport is a reversible process (Guidotti and Gazzola 1992). 
Different kinetic properties of the transporters at the two sides of the membrane 
(conformational change of the transporter) and specific environmental conditions (also called 
exchange phenomena) are some mechanisms that a cell uses to drive the transport reaction to 
the desired direction according to its needs. 
Cis-inhibition and trans-effects are the so-called exchange phenomena (Guidotti and 
Gazzola 1992). Trans-effects are phenomena such as trans- stimulation and trans- inhibition. 
Trans-inhibition refers to the phenomenon, where the elevated concentration of a substrate at 
the one side of the membrane causes a lack of the relevant transporters on the other side, 
inhibiting the transport of an identical molecule (homoexchange) or a similar one 
(heteroexchange) at the side where the transporter is at low concentration. Trans-stimulation 
refers to the process, where substrates at the one side of the membrane facilitate the transport 
of even more same or similar molecules at this side. On the other hand, cis-inhibition refers to 
the inhibition of a substrate’s transport by a competing molecule at the same side of the 
membrane. 
 
Energy coupling of amino acid transporters 
Transport of substrates by carrier proteins can be either passive (termed as facilitated 
diffusion) or active (primary or secondary), see also Figure 2-6 (Alberts et al. 2002; Guidotti 
and Gazzola 1992). Facilitated diffusion (the relevant transporters are termed uniports, see 
Figure 2-6) occurs due to a concentration gradient or electrochemical potential and hence 
energy is not consumed in this type of transport. For active transport to be employed a 
molecule will have to be transferred against its concentration or electrochemical potential. 
 Active transport of molecules can be mainly classified as primary or secondary 
(Guidotti and Gazzola 1992). Primary active transport refers to direct coupling of the energy 
reaction (usually ATP consumption to ADP, i.e. dephosphorylation) to a substrate’s transport. 
However, primary active transport is not utilized by amino acid transporters. On the other 
hand, secondary active transport of amino acids is always coupled with another molecule (co- 
or counter-transport), usually an ion that is transported following its electrochemical gradient. 
Secondary active transport is also always coupled with a primary active transporter 
responsible for keeping the electrochemical gradient constant according to the cells’ needs, 
which usually transports ions in and out of the cells. There is also tertiary active transport that 
involves cooperation with a secondary active transporter and hence indirect utilization of 
energy (described in more detail under a.a. transporters of system L, see also Figure 2-9). 
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Amino acid transport systems characterisation 
 Christensen and his group (Oxender and Christensen 1963a; Oxender and Christensen 
1963b; Oxender et al. 1977) have made major contributions to the characterisation of amino 
acid transport systems. In order for a distinct system to be identified elaborate experiments 
have to take place. Such experiments involve time-course evaluation of the uptake of amino 
acids by various transporters and concentration-dependent rate experiments. Additionally, it 
is also vital to examine how transport systems are affected by boundary conditions  such as 
concentration of various ions in the environment and pH, as well as how they react to 
changes of cell physiology due to alteration of the surrounding physical conditions, nutrient 
deprivation, etc. (Christensen 1966; Guidotti and Gazzola 1992). Furthermore, transporters 
have to be also checked for exchange phenomena (cis-inhibition or trans-stimulation, as 
discussed earlier).  
An important part of transport systems characterisation is the identification of amino 
acid analogues that are preferentially used as substrates by the transporters of a specific 
system (Guidotti and Gazzola 1992). Also, it is important to identify specific inhibitors for 
the transporters of a distinct system. Then the kinetic parameters of the system can be 
calculated since transporters from other systems would have been inhibited. Moreover, 
inhibition experiments are aided by the use of the preferential as substrate non-metabolizable 
analogue. Those analogues, although transported in the cell, do not participate in metabolic 
reactions and so can be easily quantified in intra- and extra-cellular space. In the cases where 
analogues cannot be used, thermodynamic approaches are employed to aid discrimination of 
the systems (Guidotti and Gazzola 1992). For example, an ion coupled co-transporter can be 
inhibited by eliminating the transmembrane ion gradient. In a similar manner, concentration 
gradient, electrochemical and electric potentials can be used to inhibit or enhance the activity 
of a distinct transport system. 
Finally, genetic approaches and molecular biology are also employed (Guidotti and 
Gazzola 1992). The genetic approach employs genetic expression of the transport proteins in 
a relevant biological system, i.e. usually another type of cell. The latter approach directly 
studies the phenotype of the resulting genetically modified cells. Molecular biology provides 
the knowledge of how transporters can be isolated from cells in order to be characterised in 
vitro. 
As also mentioned previously, as far as mammalian cells are concerned there is not a 
specific expression profile of amino acid transporter systems for a particular cell type. This 
profile is significantly different between cell types and only a few transport systems appear to 
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be ubiquitous, i.e. expressed in most cell types of an organism (Guidotti and Gazzola 1992). 
Even for closely related cells such as fibroblasts and endothelial cells, lymphocytes and 
macrophages the membrane transporter profiles are significantly different (Guidotti and 
Gazzola 1992; McGivan and Pastor-Anglada 1994).  
In Appendix II all the amino acid systems known to date are presented in several 
tables along with their corresponding genes. The list was compiled based on the information 
on the dedicated website that updates information on solute-carriers (SLC) research (Hediger 
et al. 2004) and several other amino acid transporter reviews (Broer 2008; Guidotti and 
Gazzola 1992; Kilberg et al. 1993; Mann et al. 2003; McGivan and Pastor-Anglada 1994; 
Shotwell et al. 1983). The SLC database tables are expanded regularly, including transporters 
that have not been characterised as parts of a broader transport system (putative) or when new 
transporters are discovered, but an effort has been made to present the most up-to-date picture 
(further analysis of the SLC database is provided later on in this section). Here, it also has to 
be mentioned that most of the research on characterising transporters has been conducted on 
human cell types and hence the data involve mainly these types of cell lines. The literature on 
amino acid transporters in CHO cells is minimal and will be further analysed at the end of 
this section.   
The following part will focus on the characteristics of the transporters that have been 
documented as ubiquitously expressed in all human cell types in an attempt to present the up-
to-date basic understanding of a.a. transport. The characteristics of the rest of the transporters 
are presented in a table format in Appendix II. 
 
Ubiquitous amino acid transport systems in mammalian cells 
There are three main transport systems for neutral amino acids, namely systems: A, 
ASC and L (Broer 2008; Guidotti and Gazzola 1992); two systems are mainly responsible for 
the transport of anionic (acidic) amino acids, systems X-AG and x-C, and one system, y+, is the 
main transport system for cationic (basic) amino acids. These systems are ubiquitous in most 
mammalian cell types and will be briefly analysed below to better illustrate the operation of 
amino acid transport systems.  
 
Neutral amino acid transporters of system A 
 System A transporters accept amino acids with unbranched side chains (L-alanine, L-
glutamine, glycine, L-methionine), but also the imino acid L-proline (Guidotti and Gazzola 
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1992). The system also tolerates methylamines (such as betaine and sarcosine). The system’s 
specific non-metabolizable analogue is 2-methylaminoisobutyric acid (MeAIB), which is 
widely used as model substrate.  
Other attributes of system A transporters are that they are sodium ion-dependent co-
transporters, sensitive to electric potential changes across the membrane and affected by 
trans-inhibition (Guidotti and Gazzola 1992). The transport mechanism of the transporters 
within system A is a secondary active one that consists of a sodium-dependent symport, with 
1:1 sodium to amino acid ratio. The transport is powered by a sodium gradient, which is 
generated by a primary active transport system that imports 2 potassium ions and exports 3 
sodium ions (see Figure 2-8).      
 
Figure 2-8: System A amino acid transport mechanism. 
System A transporter is depicted in the right-hand side. The transporter is coupled with 
a sodium pump (Na+-K+ ATPase, depicted in the left hand-side) and hence operates as a 
secondary active transporter. The exported sodium, against its electrochemical potential 
(ΔμNa), from the ATP driven sodium pump is used as a co-substrate for the uptake of a 
system’s A specific a.a. substrate. Modified from: Guidotti and Gazzola (1992). 
 
Neutral amino acid transporters of system ASC 
 System ASC carries amino acids with a linear side chain and of any length, such as L-
alanine and L-glutamine, but also has preference for some polar amino acids, such as L-
cysteine, L-serine and L-threonine (Guidotti and Gazzola 1992). System ASC is more 
stereoselective than system A and does not bind to molecules with alkyl-substitutions in their 
α-amino group (such as methylamines). Exactly like system A, ASC is sodium-dependent 
and sensitive to electrochemical potential changes. Furthermore, system ASC is stimulated by 
substrates in trans-compartment (i.e. affected by trans-stimulation). The kinetic mechanism of 
system ASC is similar to that of system A, but operates as an antiporter. 
    
Literature review  23   
 
Neutral amino acid transporters of system L 
 System L amino acid transporters exhibit broad specificity (Guidotti and Gazzola 
1992). They accept linear and branched chain amino acids of various lengths, but also 
aromatic structures. A non-metabolizable analogue that adequately serves as a substrate is 2- 
aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH). Substrates with alkyl substitution in 
the α-amino group are not accepted by L-system transporters. System L operates 
independently of ions and is stimulated by substrates on one side of the membrane (trans- 
stimulation).  
The transporters of system L operate as antiports and energy is provided by the 
concentration gradient of their own substrates (see Figure 2-9). Amino acids that are 
substrates of system L accumulate intracellularly through being transported from other 
relevant systems (e.g. system A). Aided by this concentration gradient, system L moves 
accumulated substrates out (as glutamine, illustrated in Figure 2-9) and imports another 
amino acid against its concentration gradient (as for example leucine, as illustrated in Figure 
2-9). For this reason this kind of antiport transport can also be termed as tertiary (Hundal and 
Taylor 2009).  
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-9: Transport mechanism of system L and its cooperation with system A. 
Primary, secondary and tertiary active transport mechanisms are also represented. 
Modified from Hundal and Taylor (2009). 
 
System X-AG 
 This is a system carrying acidic amino acids (i.e. aspartate and glutamate). The system 
has an anomalous stereoselectivity accepting L- and D- isomers of both acidic amino acids, 
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but not D- glutamate (Guidotti and Gazzola 1992). Hence, D- aspartate can be used as a non- 
metabolizable analogue. Transporters of the system are sodium dependent and sensitive to 
electrochemical gradient and operate as symporters.    
 
System x-C 
This system carries the acidic amino acid L-glutamate and L-cystine (a dipeptide of 
two L-cysteine amino acids). Its operation is very similar to that of system L (see Figure 2-9). 
System x-C is a tertiary active transport system operating via an antiport mechanism (Guidotti 
and Gazzola 1992). The glutamine-cystine cycle (Bannai and Ishii 1981), where glutamine is 
utilised for the uptake of cystine that is converted intracellularly to L-cysteine justifies this 
system’s transport mechanism as a tertiary system, cooperating with systems ASC, A and X-
AG. 
 
System y+ 
System y+ carries the basic amino acids: L-arginine, L-histidine and L-lysine, with 
strict stereoselectivity. It operates independently of sodium, but is affected by trans- 
membrane electric potential and by trans-stimulation. Furthermore, it operates as a uniport, 
driven by the trans-membrane electric potential difference (Guidotti and Gazzola 1992). 
 
Control/ regulation of amino acid systems  
As with all components of biological cells, various control mechanisms exist in cell, 
tissue and organism levels to regulate a.a. transporters (Guidotti and Gazzola 1992). 
Examples of control mechanisms are: adaptive regulation to changes of amino acid 
concentration in the environment (Hundal and Taylor 2009), regulation based on cell density 
and growth rate in cell cultures and regulation by the release of hormones and other 
signalling molecules, such as neurotransmitters (for the case of neuronal cells). Transport 
activity is also regulated according to which stage of the cell cycle cells are in (Shotwell et al. 
1983).   
 
Overview of amino acid transport proteins 
Solute carriers (SLC) are eukaryotic membrane bound proteins that are responsible 
for the transport of many solutes in and out of cells (Schlessinger et al. 2010). Solute types 
involve nutrients (carbohydrates, amino acids, lipids), ions and other molecules (drugs, 
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organic ions). This broad category includes a very wide group of transporters: exchangers, 
ion coupled transporters, passive transporters (uniports), mitochondrial and vesicular 
transporters (Hediger et al. 2004), see also Figure 2-10. 
The dedicated website: http://www.bioparadigms.org/slc/menu.asp; (Hediger et al. 
2004) monitoring the progress of research into solute carrier genes currently includes 55 
families of SLCs and about 400 genes (He et al. 2009). This classification is different than the 
Transporter Classification (TC) database (Saier et al. 2009), available online from: 
http://www.tcdb.org, that classifies transporters according to their mechanism (mainly 
channels, primary active transporters, electrochemical potential driven transporters).  
SLC proteins apart from their similar function, also share a similar structure 
consisting of many transmembrane domains (mainly 10-14 α-helices that cross the cell 
membrane (Hediger et al. 2004; Schlessinger et al. 2010)). Furthermore, in order for proteins 
to be classified as SLCs they have to demonstrate a 20-25% sequence similarity with the 
other members of the family (Hediger et al. 2004; Schlessinger et al. 2010). 
 
 
Figure 2-10: SLC transporters (highlighted in the black box) versus other transport 
proteins and their TCDB (Saier et al. 2009) coding.  
Modified from: Hediger et al. (2004). 
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All amino acid transporters are encoded by SLC genes (Hediger et al. 2004; Saier et 
al. 2009). The following SLC families have roles in amino acid transport (He et al. 2009; 
Hediger et al. 2004; Saier et al. 2009): SLC1, SLC3, SLC6, SLC7, SLC15, SLC16, SLC17 
(vesicular a.a. transporters), SLC25 (mitochondrial a.a. transport), SLC32 (vesicular a.a. 
transport), SLC36, SLC38, SLC43; all of which are also illustrated in Figure 2-6. To date 46 
proteins have been reported as a.a. cell membrane transporters that are included in 18 distinct 
transport systems and 12 SLC families. Furthermore, there are five a.a. vesicular transporters 
that carry amino acids in and out vesicles (small membrane enclosed structures able to store 
or transport substances that occur intracellularly, such as lysosomes) and six a.a. 
mitochondrial transporters (all further analysed in Appendix II).   
 
Amino acid transporters in CHO cells and bioprocess context relevant studies  
From all the transporters presented in Appendix II, a few have been identified in CHO 
cells at transcriptomic level, fewer at protein level, but only six have been discussed in the 
actual manuscripts of the papers. The amino acid transporters identified in CHO cells and the 
reason they were investigated are presented in Table 2-1. The full list of transporters, along 
with which of them were identified in either transcriptomic or proteomic level is presented in 
Appendix III. The data for the latter list have been extracted from the supplementary 
materials of the cited papers, which are mainly large scale microarray and protein sequencing 
papers. These studies have mainly used cells in the exponential phase and hence no 
conclusions can be drawn regarding the regulation of the transporters during the time-course 
of a bioprocess.   
Shotwell and his group have conducted experiments in CHO cells regarding different 
transport systems (Shotwell et al. 1981; Shotwell et al. 1983). Their work included radio-
labelling of amino acid substrates and system-specific inhibition of transporters. However, 
their work included no transcriptomics analysis and, more importantly, cells were perturbed 
far away from their state in bioprocess relevant conditions. Firstly, the aforementioned 
experiments were conducted on adherent cell lines, while currently in bioprocesses mainly 
cells in suspension are used (also discussed in section 2.2). Secondly experiments involved 
multiple washes with solutions containing a.a. and relevant system inhibitors that arguably is 
not the way they are cultured industrially. Consequently, the aforementioned studies, 
although extremely important for developing a basic understanding of the main neutral 
transporters in mammalian cells (A, ASC and L), cannot describe the regulation of the 
transporters in a bioprocessing context.  
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Table 2-1: A.a. transporter genes that have been studied in CHO cells. 
GENE STUDIED 
(Gene/ Protein names) Reason Reference 
slc38A2/ SNAT2, SAT2, 
ATA2 
The response of system A transporters was investigated at a.a. 
deprivation and hyperosmolarity. The purpose of the study was to 
understand system A a.a. transport in mammalian cell lines. Another 
system A gene (slc38a1) was also checked but unsuccessfully. The 
mRNA levels of slc38a2 gene were found to be elevated after a.a. 
deprivation, but not after hyperosmotic shock. 
Lopez-
Fontanals et 
al. (2003)  
The transporter was found to be upregulated in response to high 
osmolarity and high ionic strength by microarray in a bioprocess 
context relevant CHO cell microarray study. 
Shen et al. 
(2010)  
slc1a4/ ASCT1, SATT 
The transporter was investigated for its ability to carry retroviruses. 
The removal of an N- linked oligosaccharide by mutagenesis 
converted it to an active viral receptor. 
Marin et al. 
(2003)  
slc1a5/ ASCT2, AAAT 
The transporter was found to be downregulated in response to high 
osmolarity and high ionic strength in a bioprocess context relevant 
CHO cell microarray study. 
Shen et al. 
(2010)  
slc6A6/ TauT 
The transporter actually carries taurine, an osmolyte in biological 
context and hence not a proteinogenic a.a. The overexpression of the 
transporter was found to enhance CHO cell viability, product yield 
and to promote glutamine consumption. 
Tabuchi et 
al. (2010)  
slc1A3/ EAAT1, 
GLAST 
Researchers identified the transporter in the quest of whether CHO 
cells are able to uptake glutamate and with that way explain 
endogenous GS activity of CHO cells. 
Ji et al. 
(2007)  
slc7A1/ CAT-1 The glycosylation of the transporter against transport of retrovirus was investigated. 
Wang et al. 
(1996)  
 
Of particular mention regarding transporters in CHO cells, although not a.a. ones, in 
the context of bioprocessing is the work of Wlaschin and Hu (2007). In an attempt to reduce 
the increased glycolytic rate during exponential phase (discussed in part 2.1.3), the authors 
overexpressed a fructose transporter in CHO cells. This genetic engineering approach enabled 
cells to rely on fructose as a carbon source in the absence of glucose. Precisely because the 
fructose transporter has a much lower affinity for its substrate in relation to the affinity the 
glucose transporter has for glucose, cells were consuming fructose at a lower rate. 
Subsequently, much less lactate was produced and, consequently, a higher cell density was 
achieved.  
Another notable study, again however not focussing on proteinogenic a.a., involved 
the overexpression of the taurine transporter in CHO cells (Tabuchi et al. 2010). The 
researchers found the aforementioned transporter, also a member of the SLC database, slc6a6 
upregulated during the decline phase of fed-batch CHO cell culture. This behaviour led them 
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to overexpress this transporter, which enhanced both cell growth (high viability was 
prolonged) and product yield (47%).  
The two aforementioned studies proved that membrane transporters can be promising 
genetic engineering targets. Nicklin et al. (2009) demonstrated that understanding of a.a. 
transport can aid in devising nutritional strategies. Particularly, they showed that staged 
feeding in human cell lines can enhance uptake of EAA, such as Leu (a branched chain a.a., 
BCAA), Arg, Phe and Trp. EAA and BCAA are a carbon source for the TCA cycle (as 
discussed in section 2.1.3) and are therefore used for energy generation by the cells. It has 
also been reported that these a.a. activate the mammalian target of rapamycin complex 1 
(mTORC1), which is a protein complex known to regulate the production of cellular protein 
(Nicklin et al. 2009). Briefly, the researchers showed that simultaneous feeding with Gln and 
an EAA mix was less effective in the production of cellular protein than staged feeding of 
Gln first and subsequently, after 60 minutes, the EAA mix (Nicklin et al. 2009). This 
behaviour is attributed to the cooperation of the neutral a.a. transporters of systems ASC 
(slc1a5) and L (heteromeric transporter with a heavy chain from the gene slc7a5 and a light 
from slc3a2), which were discussed earlier. Slc1a5 transporter is responsible for the uptake of 
Gln, whereas slc3a2/ slc7a5 complex for the simultaneous efflux of Gln and the uptake of 
EAA.                  
 As presented in this part, a.a. transport is a very complicated process in mammalian 
cells. The sheer number of a.a. transporters (46) known to exist so far demonstrates the 
aforementioned complexity. Furthermore, the overlapping substrates and the complex 
inhibition/ stimulation mechanisms (termed as exchange phenomena) further complicate the 
process. Studies have shown a) the importance of targeting transporters in bioprocessing and 
b) that feeding strategies can be devised based on a basic understanding of molecule 
transport. The former has been shown for bioprocess relevant cells but not specifically for 
a.a. transporters, while the latter has been shown for a.a. but not for bioprocess relevant cell 
lines. Consequently, the need to study a.a. transport in industrially relevant mammalian cells 
arises naturally and promisingly.    
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2.2 Bioprocess engineering: Mammalian cells as factories of desired 
products 
 
Bioprocess engineering is the discipline involved with the design of manufacturing 
processes for biologically-derived commercial products. This part will focus on the 
biopharmaceutical production process, i.e. the desired commercial products in this case are 
pharmaceuticals and specifically biopharmaceuticals produced from cell culture. Such a 
process consists of many steps illustrated in Figure 2-11 and Figure 2-12.  
The process starts upstream with the development of the cell line (Li et al. 2010). 
After the protein of interest has been identified, a suitable host cell line has to be selected. In 
the case that the protein has a complicated structure, e.g. glycoprotein, mammalian cells will 
be the only choice under current capabilities (see also Figure 1-1). Cells that will be used in a 
drug production process should be able to grow in suspension in appropriate environments 
that support their growth. Mammalian cell culture used to be adherent in the initial isolation 
studies (Alberts et al. 2002). However, from an industrial perspective these kinds of cultures 
do not support high cell densities and hence are avoided if possible.  
 
 
 
 
 
 
 
 
 
Figure 2-11: Common steps during the production of biopharmaceuticals from large 
scale cell culture (Li et al. 2010; Noh et al. 2013). 
 
The gene encoding for the desired protein, termed as gene of interest (GOI) has to be 
inserted to the host organism, using molecular biology techniques, with a process called 
transfection (or transformation for bacterial cells). The most important part of the cell line 
development process is the selection of high producers from the pool of all the possible 
variants resulting from the transfection process. There are several techniques involved here, 
reviewed in Noh et al. (2013). 
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Following the successful creation of a cell line, large scale cultivation takes place in 
order to produce the protein of interest in large amounts. As discussed earlier (Chapter 1) the 
preferred mode of operation is fed-batch, where after the inoculation of the main bioreactor 
with cells concentrated feeds are added at specific time intervals to maintain cell growth and 
protein production (De Jesus and Wurm 2011; Lu et al. 2013; Pollock et al. 2013; Yang and 
Liu 2013). Amongst others, important considerations during large scale fed-batch production 
are the media used to grow the cells in, the composition of feeds and the schedule of feeding, 
as well as the control of pH, temperature and gases (mainly CO2 and oxygen). The most 
relevant of these for the present thesis are the media and feeds used that will be further 
described in the following subsections.       
  
Figure 2-12: A flow sheet of an industrial mAb producing bioprocess. 
The process starts with inoculating the bioreactors. Media and feeds have to be 
carefully designed to enhance the cultivation of the cells and subsequently the rprotein 
production. A centrifugation step follows along with several filtration steps in order to 
isolate supernatant from cells and cell debris. Further downstream four 
chromatographic steps are included along with viral filtration and several 
concentration/diafiltration steps. The latter involve changing the buffer of the resulting 
rprotein solution to further enhance the following step. Obtained from Birch and 
Racher (2006) with license.  
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Finally, the large scale bioreactor production step is followed by downstream 
purification and polishing of the product. This comprises a very laborious process, further 
depicted in Figure 2-12. Lastly, the product is appropriately formulated in order to be 
administered to patients. 
 
2.2.1 Media and feeds composition in mammalian cell culture 
 
Whilst in a culture, cells need specific nutrients in order to grow efficiently and 
simultaneously produce the desired protein of interest. Nutritional requirements of 
mammalian cells need to be optimised for maximum growth and product formation. 
However, because media are currently based on empirical complicated compositions that 
remain undisclosed, since they have resulted from decades of research within industrial 
companies, optimisation of the concentration of critical substances still remains a difficult 
process (De Jesus and Wurm 2011). The inherent biological variability even within the same 
cell line (Lu et al. 2013) and the fact that medium can contain up to 50-100 components 
(Jordan et al. 2013) also largely contribute to the complexity of the optimisation process. 
It also has to be mentioned that feeding and media should be designed taking into 
consideration the quality of the product and not only the quantity (Crowell et al. 2007; 
Gawlitzek et al. 2009; Jordan et al. 2013). The quality of the product in mammalian cell 
culture, although beyond the purposes of the present thesis, mainly involves the correct 
glycosylation of the molecule, based on desired attributes of the attached sugars, reviewed in 
Jimenez del Val et al. (2010). Another quality attribute that has recently been found to be 
affected by the media and feeds is the a.a. sequence of the antibody. Feeney et al. (2013) have 
identified rprotein sequence variants in some of their runs, where the mis-incorporated a.a. 
(tyrosine) was limiting. Currently, it is unknown how these sequence variants may affect 
patients, however it is an aspect that has to be taken into serious consideration. The quality of 
the product is another aspect that makes the described procedure of optimization even more 
complicated, as it requires additional analytical techniques for data acquisition.   
There are two major categories of nutrients that are required by all kinds of cells: 
macronutrients and micronutrients (Shuler and Kargı 2002). Macronutrients are needed in 
concentrations larger than 0.1mM. Such nutrients include:  
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• carbon sources. The main carbon sources for mammalian cells are glucose and 
glutamine (Burgess 2011; Young 2013). Carbon is used to form all the complicated organic 
molecules needed for life and carbon sources are therefore very important in cell cultures. 
• nitrogen. Nitrogen is a major ingredient of proteins and nucleic acids. It is introduced 
in the forms of ammonium salts in bacterial cultures, but because ammonium concentrations 
are toxic for mammalian cells, amino acids are employed as nitrogen sources in animal cell 
culture.  
• oxygen. Oxygen is introduced as a gas in the culture and is essential for all aerobic 
organisms. 
• hydrogen. It is mainly produced from the catabolism of most organic compounds. It is 
required for numerous reactions within cells. 
• phosphorus. It is the main ingredient of nucleic acids; introduced as phosphate salts. 
• Mg2+, K+ and other ions essential for the growth of cells.  
On the other hand, micronutrients are needed by the cells in quantities less than 
0.1mM (Shuler and Kargı 2002). Micronutrients include:  
• trace elements (Cu2+, Mn2+, Fe, Ca2+),  
• compounds such as vitamins, hormones (proteins), growth factors that stimulate 
growth.  
Another very important consideration in mammalian cell culture is the use of defined 
or complex media (Shuler and Kargı 2002). Defined media include known concentrations of 
all the ingredients and are the most favourable in the industry. Conversely, complex media 
contain substances with varying concentrations, such as serum, which is a blood component 
that is commonly used in cell cultures (van der Valk et al. 2010). Complex media are 
generally avoided during industrial bioprocesses since the quality and quantity of the protein 
produced are very difficult to control. Furthermore, defined media are much easier to be 
optimised, so that the whole bioprocess is more effective.  
Usually basal media contain a large number of components. A patented basal medium 
able to sustain growth for a variety of cell lines is presented in Table IV-13 in Appendix IV, 
in an attempt to present the main ingredients and their concentration in industrially relevant 
media. Such media contain carbon sources (glucose and pyruvate), bulk ions and trace 
elements (e.g. NaCl, CaCl2, CuSO4). Other components include amino acids (both EAA and 
NEAA) and amino acid derivatives (glutathione, putrescine). Also, media contain water 
soluble vitamins and co-enzymes (e.g. biotin, folic acid). Nucleic acid derivatives, such as 
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adenine and hypoxanthine are also essential components of basal media. Finally, lipids and 
lipid derivatives are included, as well as components of buffer mixtures (e.g. NaOH, 
NaHCO3) in order to maintain the pH of the solution at the desired levels. Many other 
supplements are important for mammalian cell cultures and usually added in basal media. 
These supplements are those that make the whole media optimisation procedure even more 
complicated. The most important supplements to be used in serum-free media are listed 
below (van der Valk et al. 2010): 
• hormones and growth factors. Both are important ingredients of blood and hence also 
present in serum in various amounts. These proteins are produced from bioprocesses as 
described within this chapter, but from microbial organisms (such as bacteria and yeasts) 
purified and then added to mammalian cell culture. Examples include: glucocorticoids, 
triiodothyronine (T3), water soluble steroids and in some cases mitogens (forskolin, 
antidiuretic hormone, parathyroid hormone, prostaglandin E2, glucagon) that stimulate cell 
division. Also, transferrin, responsible for iron regulation in biological systems, and insulin, 
involved in lipid and glucose metabolism, may be used (Keenan et al. 2006).  
• other proteins. Several proteins that are included in serum are important for 
mammalian cell growth, such as albumin that is used as a lipid carrier. As with hormones and 
growth factor, these proteins are produced with rDNA technology in microbial organisms and 
then added to mammalian cell culture. 
• shear force protectors. They are important for cells that are cultured in bioreactors, 
where shear stress is high. Surfactants, such as pluronic F68, are commonly used as shear 
force protectors and have to be carefully selected (Hossler et al. 2013). 
 The concentration of the various nutrients in the media is of major importance. The 
concentration of glucose for example has to be optimised, since it might lead to the formation 
of lactate, a documented toxic metabolic by-product in mammalian cell cultures as described 
in 2.1.3. The same occurs for other nutrients, as for example high concentrations of glutamine 
may result in high ammonia concentrations in the culture.     
 Feeds in fed-batch culture mainly consist of concentrated media components and 
hence do not contain any different components than those discussed above (Li et al. 2010). 
Both media and feeds have to be optimized for specific cell lines. The most commonly used 
processes for optimization are described in the following paragraph.  
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2.2.2 Optimization strategies for feeds and media components 
 
The process of feeds and media optimization starts from a basal medium, exactly like 
the one presented in Appendix IV. Then, companies using mainly design of experiments 
(DOE), spent medium analysis, media blending and ultimately their experience, design 
“platform” processes able to adequately achieve desired growth and rprotein yields for a 
variety of cell lines from the same host. This “platform” approach, although not optimal is 
essential for the industry in order to follow the strict timelines dictated (Li et al. 2010). If 
required, companies can then use cell line specific requirements to further enhance the 
platform process, within the reported current limitation, i.e. leaving a margin, in most cases, 
for 2-5 fold improvement (De Jesus and Wurm 2011). 
The aforementioned technique is also termed a top-down approach. The alternative 
would involve a bottom-up approach for media/feeds design, where the medium is designed 
without the use of a pre-existing formulation. As, for example, the work of Xie and Wang 
(1994b) discussed in a following part (2.3.3) in more detail.    
 
Statistical analyses 
Statistical design of experiments (DOE) in combination with high-throughput scale-
down experimental models (like the 24-well plate format discussed in Barrett et al. (2010)) 
are the main techniques used during medium or feed optimisation studies (Li et al. 2010). 
Statistical DOE is an effort to maximize information resulting from experimental runs 
(NIST/SEMATECH 2012). DOE starts with the definition of the objectives of the study and 
the selection of the variables to be studied. In the case of bioprocessing, for example, input 
variables would be medium components, while output variables (dependent) could be one of 
the following: cell growth or viability or rprotein yield. The objectives may involve 
identifying a highly affecting component from a list of candidates (comparative analysis), to 
screen a group of important variables from a larger group of components (screening analysis), 
or to evaluate how the selected factors are interacting with each other and to calculate optimal 
concentrations (response surface objective). 
The most relevant objective bioprocess-wise is the response surface one. The 
appropriate design would involve using full or fractional factorial design (NIST/SEMATECH 
2012). The first design approach involves designing a series of experiments based on k 
factors and x levels of the factors. This would result in xk experiments for the full factorial 
case. For a 20 amino acids and glucose study at two levels for each factor 221=2,097,152 
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experiments would have to be performed. The two levels would usually involve high and low 
concentrations based on reported values for the investigated components. Consequently, the 
full factorial case cannot be an option for such a process. Instead, a fractional factorial design 
is used, in order to only select a fraction of the aforementioned number of experiments based 
on established statistical techniques. 
A simple case study for a two level, three-factor design is depicted in Figure 2-13. 
The full factorial design is depicted in Figure 2-13A and involves eight experiments, while 
the graphical interpretation is depicted in Figure 2-13B. This is the minimum amount of 
experiments, since it is recommended to consider repeating at least once more each 
experiment (Mandenius and Brundin 2008). Also, it is advisable to run an experiment with all 
factors at their central point, i.e. at the average of the selected low and high values.  
The output of each experiment, e.g. antibody concentration in a bioprocessing 
context, is depicted in Figure 2-13C. Based on the latter matrix the effect of each of the 
factors, as well as their combinatorial effect is calculated as depicted in Figure 2-13D. The 
latter shows a linear relationship between the factors and the selected output, however non-
linear relationships can also be considered (Mandenius and Brundin 2008). In fact, non-linear 
models are essential in the case where optimum concentrations need to be defined (response 
surface methodology, RSM). In order to reduce the amount of experiments, fractional 
factorial designs can be designed that are able to examine all possible effects of the 
investigated factors, as discussed earlier. One such case is depicted in Figure 2-13E, where 
the initial eight experimental runs have been reduced to four, by using the DOE principles. 
In order to construct the fractional factorial case further screening would be used in 
order to identify the highly affecting components, resulting to fewer factors during the 
experimental design. The Plackett-Burman (PB) statistical analysis is widely used to perform 
such a screening process (Plackett and Burman 1946). The method involves multiples of 4 
experimental runs and allows for k+1 experiments, while having k factors. Hence, the number 
of experimental runs is significantly reduced as compared to the full factorial designs. 
 
Literature review  36   
 
Figure 2-13: Design of experiments (DOE) methodology. 
(A) The full factorial design of a three factors (X1, X2, X3) two levels design is presented 
in a table format. This results to a minimum (see text) of eight experiments, where “+1” 
corresponds to a high level of a factor, e.g. a substrate in a bioprocessing context, and “-
1” for a low level. (B) A graphical representation of the design space is depicted, defined 
in A. (C) The response (Y) of each experiment is presented. In a bioprocess design, Y 
often refers to rprotein concentration. (D) The calculation of the effect of each factor to 
the selected response is presented, along with the final linear equation that often results 
from the application of the DOE methodology. The latter represents a relationship of 
the desired response with the selected factors and their interactions (multiplication of 
factors terms). (E) A fractional factorial attempt is presented, where the initial full 
factorial design is cut down to four experiments that can result to the same conclusions 
as the full factorial design. The fractional factorial design has to be orthogonal (sum of 
levels in columns has to be zero), i.e. all factors occur at low and high concentrations the 
same time. Redesigned from: NIST/SEMATECH (2012) and Nair (2000).     
  
DOE medium and feed optimization studies for biopharmaceutical production mainly 
concentrate on identifying two or three DOE methodologies that can be used sequentially. 
The latter studies aim, primarily, to reduce the total number of experimental runs towards the 
ultimate goal of identifying optimum concentrations of the components and subsequently to 
narrow down the available DOE methods to model the data. Sen and Roychoudhury (2013) 
performed a PB study to reduce the initial set of 29 medium components for a hybridoma cell 
line down to the seven most significant. Their components included glucose, the 20 a.a. and 
among others the concentrations of some salts. The 32 runs of the PB design were 
accomplished in six-well plates and the authors identified the following seven factors that 
significantly affected rprotein production (dependent variable in their studies): glucose, Thr, 
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Asn, Ser, serum, NaCl and NaH2PO4. The PB design was followed by a RSM methodology, 
which instructed for a further of 100 experiments with 7 factors and 5 levels (including the 
central concentrations of the ranges). Finally, the authors identified the optimal 
concentrations of the seven components. More importantly the predicted concentration of 
rprotein was close to the one predicted by their quadratic model, resulting from the RSM 
methodology. Also the rprotein concentration of the optimised medium increased two-fold 
from that obtained from the basal medium.      
In a similar study, but for very different components, Zhang et al. (2013) identified 
using PB statistical analysis, from a subset of 17 components, three that significantly affected 
rprotein production for a CHO cell line. Namely, the effects of a lipids mixture (containing 
cholesterol, liver oil fatty acids, poluoxyethylenesorbitan monooleate and α-tocopherol), 
putrescine and ammonium ferric citrate were identified as the most important after 20 
experimental runs in 125 mL Erlenmeyer flasks that were harvested at stationary phase. The 
aforementioned three components were further investigated at five levels by another RSM 
methodology termed as central composite design (CCD). The latter involved another round of 
20 experimental runs, still, however, significantly reduced from the full factorial case that 
would involve 53=125 runs. Subsequently, the optimal concentrations were quantified using a 
quadratic model and the optimised medium was found to be 18% better in rprotein yield than 
a commercial medium. Finally, by linking media components with glucose consumption in 
batch, as advised by Wlaschin and Hu (2006) (a spent medium analysis study described later 
on), the authors designed a concentrated feed based on their optimised medium. The feed 
included 41 components, the operating schedule involved feeding twice a day based on 
offline glucose measurements and the fed-batch culture achieved three-fold improvement of 
the yield observed in batch.      
Other statistical related techniques applied in bioprocessing involve more 
sophisticated methods, such as multivariate statistical analyses. Principal component analysis 
(PCA) and partial least squares regression (PLS) are often used to analyse acquired 
bioprocessing data. PCA involves the formal reduction of the dimensionality of a matrix with 
m observations (represented as rows) and n measurements (represented as columns). In the 
case of bioprocessing m can be the concentration of nutrients during a bioprocess run, while n 
can be the time points of sampling. Matrix algebra is then employed in order to build 
artificial vectors that can explain the maximum variance of the measurements (Smith 2002). 
Data will first have to be scaled, either mean-centred, i.e. by subtracting the mean value from 
each row, or mean and variance scaled. The latter is accomplished by dividing with the 
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variance for each row, after mean-scaling has been applied. Mean and variance scaled data 
will have unit variance.  
A very simple case of PCA analysis is presented in Figure 2-14. PCA has been 
performed for the initial data set (presented in Figure 2-14A), raw (the relevant PCA plot is 
depicted in Figure 2-14C) and subject to scaling (mean-centred and variance-scaled, Figure 
2-14D). The relevant table resulting from the scaled initial dataset is depicted in Figure 
2-14C. This case is presented in order to show the impact of scaling when performing data 
analysis. In this particular case the different behaviour of a very low concentration sample 
(being produced at time point t2) would not have been taken into consideration, if the initial 
data set had not been scaled.  
Also, as presented in Figure 2-14, principal component’s one (PC1) PCA score is 
given by the equation at the bottom of Figure 2-14. The equation shows that PCA is able to 
actually present a linear model between the artificial PCs and the concentrations of the 
substrates at the different time intervals. Looking only at the PCA plot, one can realise the 
reduced dimensionality that has been achieved, since now all the initial data set is depicted in 
one two dimensional graph, which explains the behaviour of all three substrates during the 
course of the culture and allows for conclusions to be drawn. For the three substrates case 
PCA probably does not aid much, but when both substrates and time points are substantially 
increased, as is the case in bioprocessing, PCA can become a very useful tool.   
PLS is a combination of PCA and multiple linear regressions (Abdi 2003; Geladi and 
Kowalski 1986). The latter involves similar equations resulting from DOE, i.e. linear models 
of a dependent variable against a plethora of input variables (independent). In comparison 
with PCA, in PLS one has to also define the dependent variables matrix. Then similarly with 
PCA, PLS calculates the scores and the loadings of the variables involved based on the 
principal component methodology, but this time the derived equations can be used to predict 
the outcome of the dependent variables.  
De Alwis et al. (2007) by using both PCA and PLS identified that two non-essential 
amino acids are positively correlated with growth (asparagine and aspartic acid) for a 
hybridoma cell line. They also identified a positive correlation of several amino acids (Gln, 
Ile, Leu, Lys, Thr and Val) with the rprotein. However, the aforementioned multivariate 
techniques were only used as screening tools for identifying important components rather 
than quantitative analysis. 
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Figure 2-14: A principal component analysis (PCA) case study. 
In (A) the initial data set is presented. It has m rows, corresponding to concentration of 
substrates (three substrates are depicted: s1, s2 and s3, in mM), while the n columns 
correspond to different time points (t1, t2, t3 and t4). The data have been also plotted in 
a concentration vs time bar plot exactly below the initial data set. Light blue colour 
corresponds to t1, red to t2, green to t3 and purple to t4.  In (B) the scaled data set is 
presented in a table and bar plot formats. The scaling aids in bringing all substrates to 
comparable levels. Otherwise the low concentration metabolites would have been 
skewed. (C) The PCA scores for the first two principal components (PC1 and PC2) are 
depicted for the raw initial data set (top table). The scores, in a mathematics 
terminology would correspond to the eigenvalues of the variance-covariance matrix of 
the initial data set and are calculated from the equation at the bottom of the Figure, 
where the “error” term corresponds to a very small value. On the other hand, the 
loadings correspond to the eigenvectors of the aforementioned variance-covariance 
matrix and are calculated using complicated matrix algebra (for more details see Smith 
(2002)). PC1 and PC2 loadings are depicted in the bottom table of this part of the 
Figure. The resulting PCA plot has two dimensions since only two PCs have been 
plotted and has resulted by the exact pairs of data presented in the tables next to the 
PCA plot (where the x values are the PC1 values and y values are the PC2 values). For 
the specific plot, the loadings are the different time points represented by the arrows, 
whereas the scores are the days of the culture. However, scores and loadings can be 
easily exchanged. (D) The scores, the loadings and the PCA score plot of the SCALED, 
this time, initial dataset is presented.   
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Using the same technique, Selvarasu et al. (2010a) identified that an increased 
isoleucine concentration in the medium, as well as maintaining low levels of aspartate, 
glutamate and asparagine in the medium would enhance productivity for a murine hybridoma 
cell line. In a more recent study for CHO cells (Selvarasu et al. 2012), the same group 
identified the expected correlation of glucose and lactate, glutamine and ammonia with PCA 
and PLS (as discussed in 2.1.3), but also a correlation of asparagine and ammonia (the higher 
the Asn consumption the higher the Amm accumulation). Also, PCA was used by Mohmad-
Saberi et al. (2013) to organize data from a metabolomics study in CHO cells grown in 
different types of media. The study identified that the accumulation of lysine and ornithine is 
associated with cell death, while asparagine was found to be associated with high rprotein 
yield and viability. As discussed, none of the aforementioned studies have used multivariate 
analyses for quantitative purposes. 
 
Spent medium analysis (metabolomics profiling) 
Since, statistical analysis, described earlier, involves a lot of tedious experiments and 
effort, spent medium analysis comes as a less time-consuming alternative in industry. It 
involves extracellular analysis of samples during the course of cell culture. The 
aforementioned analysis can then inform for specific nutrient addition. However, it is 
understandable that such an analysis results in a pre-existing basal medium and so it can be 
concluded that it can mainly be used to further enhance an established platform process (top-
down approach).  
 While performing such a study comparing both a low and a high concentration feeds 
Yu et al. (2011) identified that the depletion of tyrosine (EAA) for the low concentration feed 
case was the reason that productivity had ceased in the relevant culture. The researchers 
concluded that when a.a. become limiting, translation, but not transcription, of the rprotein 
also becomes limiting, since the study was also followed by intracellular rprotein levels 
analysis both at the protein and at the mRNA levels. For the high concentration case they 
concluded that the assembly and folding rate of the rprotein become limiting towards the end 
of the culture, when the cells start to enter the death phase. In another study from the same 
company (Feeney et al. 2013), researchers demonstrate the importance of spent medium 
analysis. They first identified tyrosine sequence variants in one of their processes, i.e. the 
desired rprotein did not have the expected a.a. sequence with respect to the positions where 
tyrosine was expected. They analysed extracellular samples and identified that tyrosine was 
limiting in the particular process. Subsequently, by adding an increased amount of tyrosine 
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the observed mis-incorporation was eliminated. The amount of tyrosine to be added was 
calculated based on offline samples prior to tyrosine addition. 
 Read et al. (2013) used the term “fermentanomics”, i.e. the comprehensive analysis of 
metabolites and nutrients during the course of cell culture, in order to describe spent medium 
analysis, as discussed herein. By monitoring the levels of a series of metabolites during a 
hybridoma cell culture the researchers identified several amino acids being depleted (Asp, 
Cys, Met, Trp and Tyr). They then identified that doubling their concentrations in the basal 
medium, with a special focus on Met, Trp and Tyr, is sufficient to enhance the observed 
rprotein yield. 
 Sun et al. (2013) presented an improved top-down approach to enhance fed-batch 
CHO cell cultures. Their method involved the design of two total media from an already 
existing basal one. The two media were designed by doubling and tripling the concentration 
of nutrients in the basal medium. Then all three media were tested as feeds, by adding them 
once (single shot) in cell cultures that reached a density of two million cells/mL (mid-
exponential growth phase). The researchers observed an average 1.7-fold increase in integral 
viable cell concentration (IVCC) from batch, while the high-concentration feed presented the 
lowest IVCC. Also, an average 2.6-fold increase in rprotein yield was observed from batch, 
but this time the highest concentration feed showed the highest yield. Then the nutrients 
incorporated in the feeds were divided into four groups: three different groups of amino acids 
(EAA, NEAA and supplemented to their very initial medium, from which they prepared the 
basal: Gln, Asn, Thr, Pro, His, Thr) and one vitamin group. The first round of optimization 
involved a further twelve experiments. The amounts of the four aforementioned groups were 
varied in the three aforementioned media, in a DOE manner. Subsequently, the medium 
showing both the highest maximum viable cell density and IVCC was selected for further 
optimisation. The second round involved another DOE approach with three factors (the 
different groups of a.a.) at two levels, resulting to six further experiments, while the vitamin 
group was set to the highest level, as it has be shown that it does not affect growth. This 
round after also a couple of daily-feeding experiments under hypothermia (a commonly used 
industrial method) identified that the feed having EAA and NEAA at high levels, while the 
supplemented a.a. at low levels was the best. Finally, a fed-batch experiment was performed 
to validate the resulted composition. The optimised medium achieved 3.9-fold higher yield 
than feeding with the simple medium and about 7-fold from the batch case. Here the authors 
present a DOE and spent medium analysis approach, which however requires multiple runs 
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(more than 20) and hence is time-consuming and labour intensive. Nevertheless, this type of 
approach results in an improved understanding of the system.          
 Sellick et al. (2011) studied the expression of a wide range of metabolites at 
extracellular and intracellular levels of a batch CHO cell culture using gas chromatography 
coupled with mass spectrometry (GC-MS). The authors identified that three amino acids were 
limiting during the culture (namely: Asp, Asn and Glu), along with pyruvate and glucose. 
Subsequently, the authors supplemented all aforementioned limiting components to a final 
concentration of 0.2 g/L on day four (close to mid-exponential phase of growth). This 
supplementation, although not justified in the manuscript, was able to double the observed 
batch yield.   
Two studies from Pfizer Inc. have used spent medium analysis to devise media and 
feeds for CHO and hybridoma cell lines (Hermes and Castro 2010; Ma et al. 2009). In both 
studies amino acid concentrations were calculated based on observed specific consumption 
rates during preliminary experiments, without however mentioning the exact way of scaling 
up their concentration for subsequent fed-batch experiments. The spent medium analysis 
approach was described as a way to identify overfed a.a. and reduce their concentrations in 
feeds, as their increased levels can significantly inhibit growth.   
In one of the few studies that present a straightforward way to calculate amounts in 
feeds, Wlaschin and Hu (2006) suggest a feed with observed stoichiometry, preferably from 
fed-batch experiments, based on basic/ reference nutrients, i.e. glucose or glutamine. The 
stoichiometry is calculated by plotting cumulative consumption of the reference nutrient on 
the x-axis and the cumulative consumption of another nutrient on the y-axis, and calculating 
the slope. The authors suggest that as long as this line remains linear throughout, then the 
stoichiometric ratio remains stable throughout culture, otherwise if the ratio changes more 
than two concentrated feeds have to be devised. According to the authors, this way can 
provide well-designed feeds in less than three experimental runs. What is not mentioned, 
however, is how to scale up the observed ratios and consumptions in order to successfully 
calculate the concentrations in feeds rather than just the ratios of the components. In another 
note, the authors also suggest a strategy of how to calculate unconsumed components in the 
feed (e.g. inorganic salts, magnesium/phosphate/potassium ions, transferrin, vitamins and/or 
lipids). The method involves a calculation, in order for them not to get overly diluted by the 
extra volume to be added, dictated by the feeding strategy.          
Concluding for this type of method as a tool for feeds and medium optimisation, there 
are a plethora of studies using this technique specifically for mammalian cells. However, 
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none of the presented studies provide a quantitative method to calculate the required amount 
of nutrients in feeds and media. The main strategies involved require calculation of the 
amount to be added based on offline measurements. The latter, although possibly the best 
approach, can arguably be characterised as a costly and time-consuming method of feeding. 
The rest studies that do not use the offline sampling approach involve multiple experimental 
runs that further contribute to the high cost.     
  
Media blending 
 This type of approach addresses the problem of poor solubility of some of the 
components during fed-batch culture. Poor solubility arises from the fact that feeds need to be 
highly concentrated in order not to overly dilute the culture. The media blending approach 
relies on pre-existing formulations that are mixed (using robots) with a defined way resulting 
in, usually, hundreds of possible feed formulations (Jordan et al. 2013). The feeds are then 
tested and evaluated in high throughput scale down cell culture systems using DOE 
methodology. The technique although presents a fast and convenient way to generate 
feeds/media, it suffers on identifying specific nutrients that significantly enhance 
productivity.  
Jordan et al. (2013), a study coming from the industry (Merck Serono), present a 
novel way to address the aforementioned disadvantage of the method. Particularly, they 
included the components’ concentrations in a formal way while designing the blending 
strategy. This way they were able to trace the concentration of specific nutrients into the 
resulting blend and subsequently to associate high performing blends with specific nutrients. 
It is important to mention here that the current robotic platforms technology allows blending 
192 mixtures from 10 basal media in two 96-well plates in about 2 hours. Cell culture 
performance was also tested in 96-well plates for a period of about two weeks, starting with a 
cell density of 106 cell/mL. In a follow up study the same company demonstrated a way to 
test 43 of 47 components of a basal medium from 16 initial formulations (Rouiller et al. 
2013). The DOE resulted into 376 different blends that were tested both for cell expansion, 
but also as additives in a fed-batch process. Interestingly, the latter was only performed in 
one round of experiments in 96-well plates.  
The described highly improved media blending technique is extremely promising in 
mammalian cell culture. However, the cost associated with the required equipment is a great 
consideration. Moreover, the method does not include any rational understanding of the 
system.   
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Gene expression profiling methods  
A recent study has demonstrated the importance of transciptomics profiling in 
developing media and feeds. By performing RNA analysis during a fed-batch process of a 
high and a low titer case for the same cell line using microarray technology, the researchers 
identified a subset of genes associated with lipid metabolism upregulated during the high titer 
case (Schaub et al. 2010). Subsequently, they increased the concentration of lipids in the 
basal medium three-fold. This addition allowed for a 20% further increase in yield 
demonstrating that transcriptomics profiling can aid in media and feed design. This is 
definitely a good approach to media optimization, however transcriptomic profiling can be an 
expensive process, plus, as for all the aforementioned methods in this part, is only a 
qualitative method.     
 
Model based optimization 
Although statistics allow for a reduced timeline during experimental runs, they do not 
include a mechanistic way to understand the system. For this reason more rational models of 
cell culture have arisen, mainly from academia. Part 2.3 presents the relevant literature on 
mathematical models for bioprocessing purposes, however, it has to be stated here that 
industrial processes mainly rely on statistical methods (Kontoravdi et al. 2013; Troup and 
Georgakis 2013). 
      
2.2.3 Feeding strategies during fed-batch culture 
 
As has been discussed (in Chapter 1) the fed-batch culture mode is the dominant 
platform in the industry. The other choice is perfusion or continuous cultures. The latter 
involve continuous cultivation of cells, where fresh medium is continuously supplied to cells, 
while part of the culture is also removed. However, fed-batch systems are preferred since 
they are less complicated in operation, more flexible, scalable and able to reach high yields 
(Pollock et al. 2013; Wlaschin and Hu 2006). The purpose of this part of the thesis is to 
discuss industrially relevant fed-batch strategies. The focus here is on published papers from 
industrial companies in an attempt to gather and understand the state of the art in existing 
feeding schedules.  
The feeding strategies employed so far may involve bolus feeding or dynamic nutrient 
feeding. Although it has been shown that dynamic feeding can significantly enhance 
Literature review  45   
 
productivity (Casablancas et al. 2013; Lu et al. 2013; Wlaschin and Hu 2007) as it takes into 
account the actual demand of the cells, it is not preferred industrially. The latter occurs since 
it further complicates the process, introduces additional sources of error and involves a high 
cost with respect to validating the method industrially (Li et al. 2010). 
During bolus feeding 10-15 times concentrated feed medium is supplied intermittently 
to the culture (Wlaschin and Hu 2006). For this reason fed-batch cultures start with a much 
lower volume than the indicated maximum (about 40-50% less). Generally companies have 
their own proprietary way of adding nutrients to the production bioreactor. Amgen, for 
example, as implied in one of their papers (Templeton et al. 2013), uses a feeding schedule 
that includes feeding 5%, 5% and 9% of concentrated feed v/v (based on initial volume) on 
three specific days of cell culture (namely, days 3, 6 and 8). Also, on the specific days, the 
company adjusts the levels of glucose at a specified concentration (namely 55.6 mM). The 
latter example shows that addition of nutrients may not rely on only one concentrated feed 
solution. In Amgen’s case two concentrated feeds are needed, a glucose and a full nutrient 
solution feed.  
In a study that was discussed earlier (2.2.2), Pfizer Inc. use a daily feed after the third 
day of cell culture (Ma et al. 2009). Furthermore, similarly to the aforementioned studies 
from Amgen, they have a separate glucose feed that allows for controlling glucose levels at 
approximately 2 g/L.   
Another company, Life TechnologiesTM, which develops and sells cell culture media 
and feeds, has used a schedule where a bolus-feed is supplied at 1.6% v/v daily after the third 
day of cell culture (close to mid-exponential phase). The latter was extracted by a feed and 
medium optimization study (Jiang et al. 2012), where the company’s researchers also 
concluded that the medium highly affects the performance of the feed and for this reason both 
feeds have to be optimized simultaneously.   
Genentech Inc., now part of Roche, the first company to get FDA approval for a CHO 
cell-produced drug, uses a combination of low and high concentration feeds in one of their 
studies (Yu et al. 2011). Their feeding strategy involves daily feeding from one of the two 
feeds based on offline determination of viable cells density. The disadvantage of this method, 
however, is that some amino acids with low solubility in water (e.g. tyrosine) might deplete 
even when supplying the high concentration feed and hence they also prepare a.a. separate 
stock solutions.  
Although, due to the proprietary nature of the industry it is hard to collect industrial 
methods of fed-batch cultivation of cells, the literature on fed-batch culture suggests that the 
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preferred method is by constant volume feeds, termed as bolus-feeding strategy. The strategy 
of having, however, a concentrated glucose feed, along with a full nutrient one appears to be 
also widely used. 
     
2.3 In silico modelling of bioprocesses and cell metabolism  
 
There are many important reasons to model biological systems. Mathematical models 
can guide experimental work and reduce cost and time of tedious laboratory experiments 
(Bailey 1998). Moreover, models make scientists logically take into account and calculate 
interactions and components that have an important role in a complex system. Also, models 
may help scientists to discover new methods or theories concerning certain biological 
systems. More importantly, due to the fact that many commercial products (drugs, food 
additives, etc.) are currently produced using cells as “factories”, models may help to improve 
productivity and reduce cost of such bioprocesses (Gombert and Nielsen 2000). The 
following paragraphs will focus on the methodology to construct relevant models, as well as 
on reviewing the existing models on mammalian cell metabolism.  
  
2.3.1 Classification of models for mammalian cells in the literature 
 
Mammalian cell models can be classified according to the long established 
classification system for microbial cells of Tsuchiya et al. (1966); depicted in Figure 2-15. 
Structured or unstructured models refer to models in which intracellular detail is accounted 
for or not, respectively.  
Models can also be unsegregated or segregated. This depends on whether the 
population of cells is considered to be homogeneous or not, respectively. If for example cells 
in a culture are considered to be in different stages of their cell cycle, then the model is 
considered to be segregated, as opposed to the case where the model would consider an 
“average” cell behaviour. Furthermore, models are classified as stochastic or deterministic, 
when they incorporate randomness that seems to be an important component of biological 
systems; or not, respectively. 
The aforementioned ways of modelling can be further organised in three ways (Sidoli 
et al. 2004): modelling at the single cell level, known as single cell models (SCM); modelling 
a population of cells, known as population balance models (PBM); and a third type which 
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involves the coupling of SCM and PBM models, often called hybrid models. This third type 
of modelling, although is computationally more demanding than the other types, is the most 
accurate description of the system (Kiparissides et al. 2010).  
 
 
 
 
 
 
 
 
 
Figure 2-15: Models describing mammalian cell systems. 
Classification according to: Tsuchiya et al. (1966). Modified from: Kiparissides et al. 
(2010). 
 
The main equations used in unstructured models involve Monod kinetics. Monod 
kinetics describe substrate limited growth, which is valid during the exponential growth 
phase of cell cultures (Monod 1949; Shuler and Kargı 2002). According to Monod kinetics 
cell growth, in a bioprocessing relevant case in batch culture, can be defined by the following 
equation: 
 
Equation 1: ?(?∙??)?? = ? ∙ ?? ∙ ? − ?? ∙ ?? ∙ ?        
 
XV corresponds to the viable cells concentration within the culture (cells per volume of 
culture), t corresponds to time, V is the volume of the culture and kd is the rate of biomass 
loss due to death, μ is the growth rate and often is set equal to:  
 
Equation 2: ? = ????∙?????            
 
S is the growth limiting substrate, Ks is the saturation constant equal to the concentration of 
the limiting substrate when the specific growth is half of the maximum growth rate (μmax). 
The latter could be achieved if the substrate concentration was provided at very high 
concentrations (S>>Ks).  
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 For unstructured models in order to define the consumption/ production of other 
components of cell culture (substrate used, formation of product, consumption of oxygen) 
often yield coefficients are used to correlate them with cells and other culture components’ 
concentrations (Shuler and Kargı 2002). Hence, for substrate formation the following 
coefficient is often introduced: 
 
Equation 3: ???/? = − ?????           
  
Equally for product (P) formation: 
 
Equation 4: ??/? = − ????           
 
The mass balance for the substrate in batch culture would be: 
 
Equation 5: ?(?∙?)?? = −?? ∙ ? ∙ ??         
 
Where q is the specific consumption rate of substrate that is usually defined as: 
 
Equation 6: ?? = ????/? + ??          
 
where the left part of the sum corresponds to specific consumption due to growth. While, mS 
corresponds to the substrate consumed for the maintenance energy of the cells. Similarly the 
product equation in batch will be: 
 
Equation 7: ?(?∙?)?? = ?? ∙ ? ∙ ??          
  
Yield coefficients have been also successfully used to describe the production/ 
consumption of intermediate compounds within cell culture medium (Kontoravdi et al. 2007), 
e.g. yield of production of a toxic product from the consumption of a specific amino acid. 
However, such yields have to be used with caution by modellers, since if the culture 
conditions are altered, yield coefficients change significantly and cannot be treated as 
constants. Furthermore, this kind of coefficients may significantly change within culture.  
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 One more important aspect of unstructured Monod-based models is the modification 
of the specific growth rate expression because of inhibition. Since cell cultures involve 
numerous components there are inevitably many components that can inhibit growth. Models 
have been developed including several types of inhibition such as substrate inhibition, 
product inhibition and inhibition of toxic metabolic products by modifying the expression of 
μ.    
Structured models are mainly used to describe SCM (see Figure 2-16). Such models 
include equations involving transport of nutrients into the cells, intracellular utilization due to 
metabolism (production/consumption) and dilution of the nutrients due to cellular growth 
(Sidoli et al. 2004). Within that type of modelling intracellular utilization or metabolic 
networks can be modelled with two different approaches (Gombert and Nielsen 2000), 
stoichiometric models and kinetic models.  
Stoichiometric models involve writing down all the relevant reactions that occur in 
the studied system and describing them mathematically (Orth et al. 2010; Sidoli et al. 2004). 
Those complex reactions are identified and their fluxes experimentally determined by using 
tools such as metabolic flux analysis (MFA) or flux balance analysis (FBA). Both techniques 
are further described in 2.3.3. Stoichiometric models give a static picture of the system and 
are valid only for specific culture conditions. Their advantage is that they can account for 
competing reactions in the metabolic networks of a cell.  
On the other hand, kinetic models correlate the different intracellular metabolites with 
kinetic laws (such as Michaelis-Menten kinetics, described in 2.1.4) and hence are 
represented by differential algebraic equations (DAE), which can be integrated over time and 
solved (Sidoli et al. 2004). Consequently, kinetic equations can describe a dynamic behaviour 
of the system and that is the reason that they are very valuable. However, kinetic models have 
the drawback that due to the complex kinetic laws that describe metabolic networks, complex 
non-linear equations may arise that can make the solution procedure very difficult. Moreover, 
there is a general lack of accurate values for kinetic parameters for each cell type. Even 
though studies have been carried out on metabolic enzymes in vitro, it is generally difficult to 
recreate the dynamic intracellular environment and the resulting interactions among the 
various components (Thiele and Palsson 2010). The values of kinetic parameters determined 
using ex vivo experiments are therefore often not directly applicable to simulations of the in 
vivo environment.   
 In both the aforementioned ways of structured modelling, data for the networks of 
metabolites are taken from online databases. One such database is the Kyoto Encyclopaedia 
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of Genes and Genomes (KEGG), where data for metabolic networks of various different 
organisms can be extracted. There are numerous such databases available on the internet, 
some of which are reviewed in Chen et al. (2012b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-16: Main modelling techniques for mammalian cell systems. 
Coupled: Sidoli et al. (2004) and Tsuchiya et al. (1966) classification. Modified from: 
Sidoli et al. (2004). 
 
A structured, segregated and stochastic model would be the most appropriate to 
describe the complicated phenomena occurring in biological systems (Sidoli et al. 2004). 
However, other considerations have to be taken into account before constructing a model, 
such as: the main aim of the model, the existing detail of knowledge for the system being 
studied, the time available to formulate the model and to solve it, the available computational 
power and the background of the person formulating the model.   
 An attempt to couple all the aforementioned ways of modelling is visualized in Figure 
2-16. In the latter it is depicted that PBM models can be also divided into multi or single 
variable models according to how many variables are used to describe cells’ properties. 
Additionally, they can be multi- or single-staged, for the former if they include cells in 
different part of their cell cycle. Finally, PBM models can be classified as mass or age 
structured according to which of two properties is used to distinguish between cells. The 
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following paragraph will focus on more relevant to the current thesis models of the literature 
that involve modelling amino acid metabolism in mammalian cells. 
  
2.3.2 Bioprocess relevant models related with amino acids optimization 
 
This section is an attempt to present recent models that involve amino acids. There are 
very few models in the literature targeting the improved yield during bioprocesses, which 
should come as a natural objective. Most models aim to develop our understanding of the 
system rather than to optimise it. Also, the trend is towards integrating intracellular structure 
with observed extracellular consumption (Carinhas et al. 2012). These efforts are represented 
by hybrid models that use constraint intracellular network modelling. These types of models 
are presented in detail in 2.3.3. 
 
Table 2-2: Bioprocess relevant models in the literature that do not include constraint 
network modelling and include amino acids. 
Type of model Description Main Achievements/ Weaknesses Reference 
Unstructured- 
Unsegregated 
Authors present a simple unstructured 
Monod model for Xv, glucose (Glc), 
Gln, ammonia (Amm) and lactate 
(Lac).  
 Comparison with logistic equation 
modelling, as well as a linear statistical 
model. Able to successfully describe 
scale-up studies, however experimental 
parameters had to be refined. Monod 
model was also superior to the other two 
modelling approaches.  
Craven et 
al. (2013)  
Unstructured- 
Unsegregated 
Monod based model for myeloma cell 
culture, followed by fed- batch and 
batch experiments determining 
extracellular concentrations of 
essential amino acids 
 Lysine as a growth limiting substrate, 
along with glucose and glutamine; 
describes well experimental data for 
extracellular amino acids and cell 
density; product formation not taken 
into consideration; a metabolic regulator 
for the Monod's constant μ is imposed to 
better describe the lag phase of the 
culture  
Liu et al. 
(2008)  
Unstructured- 
Unsegregated 
Monod based model describing cell 
growth and the metabolism of 19 
amino acids and glucose; validation 
with batch cell cultures for 2 different 
cell lines & experimental data for the 
extracellular concentrations of all the 
a.a. 
Model able to describe different kinds 
of cultures (both HEK and CHO cell 
lines); proposition for a library 
including all the relevant parameters of 
similar models for different cell lines; 
product formation is not included   
Kontoravdi 
et al. 
(2007)  
 
Ho et al. (2012) have developed a model that predicts the optimal induction time of 
hyperosmolarity during a myeloma cell culture. This is possibly one of the few models 
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targeted to increased rprotein production. A structured model of intracellular rprotein 
synthesis has been coupled to an unstructured growth model based on glucose and glutamine 
concentration in the medium in order to understand the effect of hyperosmotic conditions. 
The researchers predict and validate the optimal point for hyperosmotic induction in the 
culture that has been shown to present a maximum with time. Osmolarity was regulated by 
adding a sodium chloride solution, which, although, not a widely used technique shows that 
hyperosmolarity by nutrient addition is able to increase productivity alone. 
Table 2-2 presents the most recent bioprocess relevant models that have included 
amino acids and that are not coupled with intracellular constraint networks. The limited 
amount of models presented possibly shows that these types of models fail to successfully 
model the studied system. Nevertheless, such models can be used coupled to intracellular 
stoichiometric models in order to employ the latter with dynamic properties. Furthermore, the 
majority of them (Monod-based ones) include biological meaningful parameters, rather than 
artificial relationships with no mechanistic understanding, as for example is the case with 
statistical models.      
 
2.3.3 Quantitative analysis of biochemical networks (FBA/MFA) 
 
Flux analysis in biological systems, also termed as fluxomics, has recently received a 
lot of interest in studying biological systems (Nielsen 2003; Orth et al. 2010; Winter and 
Kromer 2013). The reason for this is that when studying a biological system other “-omics” 
technologies, e.g. genomics, transcriptomics, metabolomics are often not quantitative, 
although really well developed nowadays. More importantly, the experimentally obtained “-
omics” data are not able to identify all participating components of the system. For example, 
when studying a particular pathway proteomics can possibly, in the ideal case, identify 
participating enzymes and relative concentrations, metabolomics identify, in turn, 
participating substrates and their concentrations, however, still no in vivo kinetic parameters 
can be obtained for the system’s enzymes (Km and vmax values). Precisely, because fluxes, 
defined as rate (mass or concentration of a metabolite over time) per amount of cells (mass or 
actual number), are the end result of the complex regulation occurring in a biological system, 
they can give very important information about the studied system. As has been shown for 
bacteria and yeasts, for example, flux sensing is what regulates intracellular states and hence 
responses to changing environments and resulting phenotypes of cells (Huberts et al. 2012; 
Kotte et al. 2010). 
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The obtained fluxes acquired by fluxomics can be analysed in several ways 
quantitatively. The most recent efforts involve constraint intracellular network modelling that 
can ultimately guide genetic engineering strategies and process optimization in the context of 
bioprocessing. Three approaches are the most widely used for constraint modelling of 
intracellular dynamics (Antoniewicz 2013; Sims et al. 2013). The two most relevant for the 
present thesis are termed flux balance analysis (FBA) and metabolic flux analysis (MFA), 
also presented in Figure 2-17. The third technique involves isotopomer analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-17: Two widely used approaches for constraint modelling of biological 
intracellular networks. 
Metabolic flux analysis (left panel) is based on a simplified intracellular reaction 
network and is constrained by experimentally observed extracellular fluxes that fully 
define the chosen network. Flux balance analysis (right panel) is based on the full, 
known biochemical network for the particular cell types studied and due to this fact is 
generally constrained by an objective function, e.g. growth maximization or product 
formation in the case of bioprocessing. S: stoichiometric matrix, R: extracellular 
reactions in the model, rexperimental: experimentally observed fluxes, v: flux of a particular 
reaction, vgrowth: biomass reaction, LB: lower bound, UB: upper bound. Obtained from 
Antoniewicz (2013) with licence. 
  
A widely used technique for isotopomer analysis involves measuring intracellular 
fluxes by 13C carbon labelling of important substrates coupled with experimental quenching 
and extraction of intracellular metabolites from cells and analysis using mass spectrometry 
(MS) or nuclear magnetic resonance (NMR). The technique is used to investigate 
intracellular fluxes by exploiting asymmetries when atoms are transferred from particular 
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substrates to specific positions of products in biochemical (i.e. involving enzymes) reactions. 
The technique, however, has several disadvantages, such as high equipment and reagent 
costs, low resolution of some necessary to calculate metabolites with the existing analytical 
techniques and the associated complexity when designing experiments (Winter and Kromer 
2013). The latter mainly involves the correct selection of substrates, but also non-linear 
dynamics arising from reversible reactions and unknown or/and unexpected reactions.     
 MFA and FBA techniques constrain the intracellular reaction network by several 
means. Typical constraints are observed environmental conditions, i.e. observed experimental 
fluxes that usually define the lower (LB) and upper (UB) bounds of extracellular reactions 
(Lee et al. 2006; Orth et al. 2010). Other constraints involve physicochemical constraints, i.e. 
mass and energy conservation, and spatial restriction due to intracellular 
compartmentalization.  Both techniques rely on the assumption of pseudo-steady state (PSS), 
which means that the accumulation of species intracellularly is negligible in relation with the 
observed flux.  
In FBA, all the known reactions of the cells studied are extracted from literature 
sources and databases based on genomic data (Chen et al. 2012b). Then the stoichiometric 
matrix (S) is obtained by representing acquired reactions in the form of a table where the 
rows include all the metabolites of the network, whereas the columns represent the reactions. 
If a metabolite participates as a substrate in a reaction, a negative number representing the 
stoichiometric coefficient of the metabolite is added in the relevant row and column of the 
table, in the case the metabolite is a product then a positive number is added. The network 
reactions also include transport reactions into and out of the cell and other transport reactions 
through intracellular compartments (mainly mitochondria). The reactions also include the 
biomass reaction. The biomass reaction includes all the components (amino acids, nucleic 
acids, lipids, sugars, etc.) that are required for the production of biomass. These components 
are mainly defined experimentally by biochemical analysis of the actual cell population used. 
Along with essential components, also energy requirements, usually in the form of ATP are 
included in the biomass reaction.  
In the context of bioprocessing, an additional product reaction is included in the FBA 
reaction list, including all the components of the desired recombinant protein. Then the 
resulting network is solved assuming PSS, as a linear optimization problem defined by the 
multiplication of the stoichiometric matrix and the reaction rates vector (see Figure 2-17, 
right panel and Figure 2-18). Due to the number of reactions included the cellular state can 
have multiple steady states and for this reason the model needs an objective function that will 
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guide the solution space. In the context of bioprocessing the objective function would involve 
optimizing growth during exponential phase and possibly the recombinant product formation 
during stationary phase. A few other optimization strategies have been also used in the 
literature for CHO cells (see Table V-14) and several others for microbial cells (Edwards and 
Palsson 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-18: Flux balance analysis (FBA) methodology. 
a) Available genomic data define a set of metabolic reactions that can be used to model 
cellular metabolism, b) The set of reactions are represented mathematically as a matrix 
(named as stoichiometric matrix, S), where the rows represent the metabolites of the 
model and the columns the reactions. The latter include the biomass reaction (yellow 
column) and uptake or excretion reactions of important metabolites (green columns). c) 
The multiplication of the stoichiometric matrix with the rates of the reactions (v) defines 
the mass balance for each of the species of the initial model. The assumption of pseudo-
steady state is then employed to set all mass balances to zero and form a system of linear 
equations. d) The solution process is further simplified by setting an objective function 
(z) that will further guide intracellular fluxes to a desired outcome (e.g. optimization of 
growth). In the displayed equation all ci take the value of zero, except from the desired 
reaction to be optimized. e) Finally, linear programming is employed to identify the 
values of the fluxes of the model that maximize z. Obtained from Orth et al. (2010) with 
licence. 
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Irrespectively of the objective function, the solution strategy involves linear 
programming (LP). LP is a standard mathematical problem, where an optimal solution of a 
linear function has to be defined subject to specific linear constraints that may involve 
equalities or inequalities (Thie and Keough 2008). LP is a widely used mathematical 
technique developed since 1940, involves multiple solution approaches the analysis of which 
is beyond the purposes of the current thesis. It is important, however, to mention that the 
solution procedure is highly affected by the assigned initial conditions (e.g. in an FBA case, 
the upper and lower bounds of some reactions) and algorithm/available solver that will be 
used for solving the problem (e.g. CPLEX from IBM®; glpk, which is freeware; or Gurobi 
from Gurobi Optimization). 
On the other hand, MFA results from a much simpler network that, however, is fully 
defined by the measured extracellular reactions (Antoniewicz 2013). Hence, an optimization 
reaction is not required. In this case, also applicable in FBA (Selvarasu et al. 2012), a 
minimization function is used to minimize the difference of the obtained experimental fluxes 
against the in silico calculated values (Carinhas et al. 2013).  
The dynamic versions of FBA and MFA are much more realistic for biological 
systems, as cells demonstrate a constantly changing metabolism during mammalian cell 
cultivation and hence the assumption of PSS often does not hold (Antoniewicz 2013; Hoffner 
et al. 2013). However, an assumption here is that PSS is reached fast after a perturbation 
during cell culture and consequently that the process dynamics take much longer than 
intracellular PSS. This is a very valid assumption for industrial mammalian cell culture, as it 
involves a time scale of days, which is much slower than the cells need to reach intracellular 
PSS, after feeding, for example, takes place during a fed-batch process. The most widely used 
technique for mammalian cells is rewriting the FBA or MFA model in a kinetic way, i.e. 
Monod or Michaelis-Menten kinetics for the more basic reactions of the model (i.e. for the 
main carbon source: glucose and other important metabolites). Hence, the initial network is 
significantly reduced to include so-called “macroreactions” of essential metabolites 
(Meshram et al. 2013; Naderi et al. 2011; Nolan and Lee 2011; Zamorano et al. 2013). Other 
methods involve predicting intracellular or extracellular concentrations by separating the 
culture at several steady states and simultaneously calculating the specific rates of the 
metabolites involved. Subsequently, the concentrations of extra- and intra-cellular species is 
calculated by solving the inverse of the initial FBA problem, i.e. from fluxes calculating 
concentrations (Mahadevan et al. 2002).  
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 Several constraint network modelling approaches have been used in the literature in a 
bioprocessing context. Table V-14 in Appendix V presents an attempt to gather the most 
notable models for CHO cells used in the literature post 2010 in order to show the most 
recent trends and their application into bioprocessing. Regarding FBA in CHO cells, there are 
currently two models in the literature, resulting from pre-existing mouse models (Quek et al. 
2010; Selvarasu et al. 2012), as the CHO genome became available recently (Xu et al. 2011) 
and hence has not been yet “harnessed” model-wise (Kildegaard et al. 2013). The Selvarasu 
et al. (2012) model consists of 1540 reactions and 1302 metabolites and is the largest 
available and the most relevant to CHO cells, as has been expanded using in-house 
microarray data for this cell line. The latter researchers have also conducted comprehensive 
biomass analysis of CHO cells. 
There are many more MFA than FBA models in the literature for CHO cells (Table 
V-14 in Appendix V). Amongst others a very recent work presents an MFA approach for GS-
CHO cell lines (Carinhas et al. 2013). The researchers developed a NMR method able to 
quantify a large number of metabolites (39 in total) during CHO culture in their previous 
work (Duarte et al. 2013). The authors identified a large network that is well constraint from 
their observed fluxes that also for the first time includes glycosylation of the recombinant 
product. Interestingly, the authors identified many by-products resulting from the batch 
culture of CHO cells, resulting by the inefficient metabolism of the cells. The authors 
conclude that a dynamic model of their network could be more beneficial in identifying 
necessary concentrations of feeds and media for relevant process optimization, which 
generally shows the trend towards improved dynamic models than the already existing for 
CHO cells.  
Of particular mention here, although for other mammalian cells (hybridoma), is the 
pioneering work of Xie and Wang on applying stoichiometric analysis based on intracellular 
networks and biomass demands in media and feed design (Xie and Wang 1994a; Xie and 
Wang 1994b; Xie and Wang 1996). The authors reduced the initial set of biochemical 
reactions by lumping reactions based on the desired components to be added to the medium 
(glucose, 20 amino acids and 10 vitamins) and their association with biomass components 
(DNA, RNA, proteins). The devised method, although generating spectacular results (both 
for growth and rprotein yield), requires several experimental iterations (two minimum) 
mainly due to the unknown amount of glutamine flux towards non-essential amino acids, the 
flux of glucose towards lactate which is impossible to predict, the difficult to predict cellular 
energy sources (only glucose is assumed for these studies) and the variability of the biomass 
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content even between hybridoma cell lines. The aforementioned problems are typical when 
designing feeding strategies, since different cell lines derived from the same parent show an 
inherent variability in regulating nutrient uptake. This also suggests that feeding strategies 
should take a more “personalized” approach, i.e. based on observed behaviours for specific 
cell lines.      
As demonstrated in Table V-14 in Appendix V, only a few studies have directly used 
constraint modelling for designing of feeds during fed-batch CHO cell culture, since most 
models are used for the understanding of intracellular network dynamics. One of the 
presented studies that directly applies this technique (Xing et al. 2011) for feed development, 
relies mainly on the measured extracellular fluxes rather than the understanding of the 
system, which can be demonstrated by the very small network used (only 23 reactions). The 
researchers identified limiting a.a. in one of their runs that were subsequently provided in the 
next. Moreover, the optimized concentrations of amino acids have not been justified nor 
calculated based on flux analysis results.  
One more study that used a similar approach, however, for hybridoma cells focussed 
on a simplified energy metabolic pathway (Omasa et al. 2010). The researchers identified 
pyruvate and TCA cycle intermediates, citrate and malate, as potential nutrients that would 
enhance productivity in continuous cultures. Their results after adding the selected nutrients 
suggested up to 40% enhancement (for pyruvate) in specific productivity. However, as with 
the study mentioned earlier using constraint intracellular modelling, the concentrations of the 
added nutrients were not justified by the flux analysis. Also, two rounds of optimization were 
employed. 
Possibly the most successful study in using FBA in medium design involves the 
calculation of amino acids required to sustain hepatocyte culture (Yang et al. 2009). The 
authors using an appropriate objective function for the particular cell types calculated an 
optimized amount of amino acids to be added to the medium. However, the experimental 
results did not reproduce the predicted value of the objective function. The latter showing that 
alternate pathways may be apparent that were not included in their initial model of reactions. 
In a follow-up study, the same researchers using a combined model and experimental 
approach showed that transport of amino acids into the cells significantly affect cell 
metabolism (Yang et al. 2010). They used the same FBA model as in their previous study, 
however, they included more constraints, resulting from the transport regulation via system A 
(discussed in 2.1.4). Researchers concluded that there is a threshold of a maximum 
concentration of glutamine in the medium beyond which hepatocytes do not show liver- 
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specific functions. Moreover, increased glutamine concentrations inhibited the uptake of 
other amino acids (alanine and serine), demonstrating the complex nature of transport of 
nutrients within mammalian cells.     
Another conclusion from the work conducted so far on constraint network modelling 
is that the intracellular networks have variable size, as demonstrated in the column where the 
number of reactions and metabolites of each model are presented in Table V-14. The latter 
suggesting that possibly the intracellular network models (excluding isotopomer analysis and 
hence experimentally measured intracellular fluxes) are designed to fit observed data rather 
than holding true thanks to a good knowledge and understanding of the underlying system.         
 
2.3.4 Computation of specific rates of metabolites during cell culture 
 
During FBA or MFA there are several software packages in the literature to 
reformulate the identified reaction network into LP taking into account all user-defined 
constraints, reviewed in Lakshmanan et al. (2012). However, currently there are not many 
formal ways and/or computational software to calculate the specific rates of consumption/ 
production rates (q) that are used as inputs in the aforementioned constraint network 
modelling approaches. The calculation of q, as discussed earlier, involves rate (mass or 
concentration of a metabolite over time) per amount of cells (mass or actual number). Fast 
and accurate methods to calculate q are needed for bioprocessing. Instantaneous q can be 
used for controllers of bioreactors in order to online calculate the amount of feeds to be 
added. Qs are also needed as initial estimates for relevant Monod models of the system. 
  Murphy and Young (2013) and Goudar (2012) present excellent approaches to 
calculate q, however sophisticated calculations are needed requiring parameter estimation or 
linear regression that include additional complications while analysing data. Moreover, both 
operate as MATLAB toolboxes requiring a software licence to run. Finally, neither of the 
latter approaches includes feed concentrations in their calculations. In Murphy and Young 
(2013) the latter have to be included as experimental points, whereas in Goudar (2012) this is 
not an option.     
Formal ways of calculating qs can enable true transferrable comparisons of 
experimentally observed ones. The latter can serve in enhancing the current understanding of 
bioprocessing longer-term. 
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Chapter 3                                                 
Objectives & structure of the thesis  
 
Following the aim of the present thesis in part 1.1, which is the development of a 
formal methodology for the design of optimal feeding strategies based on the understanding 
of amino acid (a.a.) metabolism and transport into CHO cells, and the effort to discuss the 
associated literature (Chapter 2), the project objectives are presented in this section. Towards 
the investigation of a.a. transport, the current project will be the first to harness the published 
CHO genome in terms of a.a. membrane transporters in CHO cells. The following objectives 
naturally arise in a nutrient transport study within a bioprocessing context: 
1) Identify whether amino acid transport becomes limiting for recombinant protein 
formation. The following tasks will be undertaken in order to try to tackle this:  
a) The majority of a.a. transporters expressed in an industrially relevant CHO cell line 
will be identified at the mRNA level.  
b) The profiles of the transporters will be monitored in batch cell culture. This will occur 
for three different cell lines, a non-producer, a low and a high producer and will be 
complemented with intra- and extra-cellular a.a. analysis.   
2) Devise feeding strategies driven by the basic understanding of the system acquired in 
the first objective. Feeding strategies will be devised to probe a.a. transport and metabolic 
regulation further. Design approaches will be based on information regarding transporters 
found to be differentially expressed in the first objective and previous feeding strategies for 
other cell lines reviewed in 2.1.4. 
3) Explore cellular metabolism through experimentation and computational methods. It 
is envisaged that the perturbations introduced in fed-batch culture will also facilitate the 
understanding of metabolism in bioprocess-relevant conditions. Specifically, the answers to 
three questions will be sought: 
a) Is there a linear relationship between a.a. consumption and the integral viable cell 
concentration within culture? To answer this, it is planned to devise a feeding strategy 
from observed rates in batch and an IVCC estimate, by linearly scaling the former. 
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The idea will be to identify a fast and accurate formal way, as none has been reported 
(as described in 2.2.2), to scale up a.a. utilisation rates from batch culture data. In a 
second experiment, the concentrations of a.a. in feeds will also be varied while 
keeping their relative ratios constant. The results will be analysed by FBA to help 
understand a.a. metabolism and analyse observed phenotypes. In all cases, culture 
performance will be compared with that of a commercially available feed.  
b) Can constraint flux analysis tools be applied to guide the design of feeds? Based on 
the literature demonstrated in in silico analysis of bioprocesses part, there is not a 
defined way to use FBA or MFA in the design of feeds (described in 2.3.3). 
Consequently the application of such a constraint technique for designing feeds is a 
field that can be further investigated, which naturally comes as an objective of this 
thesis.  
c) Is there a method for calculating consumption rates without the need for linear 
regression or parameter estimation? Motivated by the insufficient and not automated 
ways to calculate specific rates in cell culture (presented in 2.3.4) and by the fact that 
these rates are vital in determining the intracellular state (as discussed in 2.3.3), the 
development of an improved way for calculating consumption rates will be attempted. 
 
In summary this project will focus on two main challenges in current CHO cells 
bioprocessing that are both topical and useful to the industry. The first involves unravelling 
the functionality of a small part of the recently published CHO genome. The second relates to 
identifying fast formal experimental techniques to guide media design. Both will aid in a 
further understanding of industrially relevant cell lines that is definitely not sufficient based 
on the literature presented in Chapter 2.  
 The following chapter (Chapter 4) presents the materials and methods that were used 
to tackle the objectives described herein. The subsequent three chapters present and discuss 
the results of the three distinct parts of this thesis.  
Chapter 5 focuses on the study of the regulation of a.a. transporters in CHO cell 
culture. In brief, the results of the expression of the majority of amino acid transporters along 
the course of a batch culture of three different cell lines (a null and two producing cell lines 
with different levels of productivity), using quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) are presented.  
 In Chapter 6 the design of six different feeds is described based on a simple linear 
projection of batch observed consumption rates and an estimate of the integral viable cell 
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concentration (IVCC). Some of these strategies include an insight from the basic 
understanding of transport in the previous chapter (Chapter 5). 
 Chapter 7 presents a novel methodology to quantify specific growth, death and 
metabolite rates in batch and fed-batch cultures of mammalian cells. Such a methodology can 
be proven useful for analysing typical bioprocessing data, i.e. time course concentration data. 
 Finally, Chapter 8 summarises the conclusions of this thesis. In the same chapter the 
relevant future work is presented.    
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Chapter 4                                                      
Materials and methods 
 
4.1 Cell lines and batch cell culture 
 
Three cell lines were kindly donated by Lonza Biologics.  GSn8 was transfected with 
a glutamine synthetase vector not including a recombinant protein.  GS35 and GS46 both 
express glutamine synthetase and the cB72.3 chimeric IgG4 (immunoglobulin of γ isotype 
and 4 subclass) antibody. GS46 has double the specific protein productivity of the GS35 cell 
line. Batch cultures were performed in triplicate in 1L single use Erlenmeyer flasks (Corning, 
UK) with a working volume of 300mL in CD CHO medium (Invitrogen, UK) supplemented 
with 25 μM MSX (Sigma, UK). Cells were sub-cultured every 3–4 days at a seeding density 
of 2x105 cells mL-1 and were maintained at 36.5°C, shaking at 140 rpm in 8% CO2 
humidified air. Viable cell concentration was determined daily using the trypan blue dye 
exclusion method and light microscopy. 
 
4.2 Feeding experiments 
 
All feeding experiments were performed using the highest producer (GS46) from the 
cell lines described in 4.1. 250 mL triplicate single use Erlenmeyer flasks (Corning, UK) 
were used in all cases, with a working volume of 50 mL in CD CHO medium (Invitrogen, 
UK).  Feeds were prepared as a ten times concentrated stock that was added on alternating 
days (i.e. every two days of culture) using tenfold diluted volume from the estimated culture 
volume at the time of addition. 2 mL samples were taken daily, while a 600 μL sample was 
taken immediately after the addition of the feeds.    
 The concentration of the components in the feeds was calculated based on the 
observed specific rates of the GS46 cell line in batch until the first component became 
limiting. The calculated consumption rates were then scaled up based on a projection of the 
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observed viable cell concentration (Xv) in batch until the integral of viable cell concentration 
(IVCC) was tripled from that obtained at day 9, when viability in batch culture dropped to 
zero. For the projection it was assumed that the cell density will remain the same as the 
average stationary one. The formula for scaling up the calculated consumption rates is 
presented below: 
 
Equation 8: ??????? = ?????? ∙ ????????????????????           
 
where ???????  corresponds to the total required culture concentration of substrate S to sustain 
the ???????????????????? , which is the IVCC estimate at the day of harvest (tharvest, i.e. day 18 
for the purposes of this thesis). While, ??????  is the specific consumption rate of substrate S, 
when the first substrate becomes limiting in batch culture (tlim). The actual concentration of a 
substrate in the feed (??????) will be calculated by the formula: 
 
Equation 9: ?????? = ???????? ∙ ???????????????????????????????.?????? ?          
 
where the dilution term refers to the desired times the feed will be diluted in order to be 
added in the medium (i.e. in this case is 10). ????????is the concentration of S supplied in the 
medium and ?????.??? is the desired feeding interval (i.e. in this case is 2 days). The “-1” term 
in the denominator is only applied if the harvest day is a multiple of the feeding interval, as 
feeding does not take place the day of harvest. ????????  for each of the component was 
determined based on a day zero sample after the seeding volume was added in the main 
experimental flasks. 
 The a.a. analysis method used (described in 4.9) does not detect cysteine. Cysteine’s 
consumption rate (????) was calculated based on the biomass content reported for CHO cells 
(Selvarasu et al. 2012), i.e. ??????????? = 0.0793 and the IgG4 sequence of the product ( ????????????? = 34) and the observed specific growth rate (?????) and specific production rate 
(????????? , in g/cell/day) until tlim. The following equation was used: 
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Equation 10: ???? = ??????????? ???????.???? ∙  ?????  + ?????????????∙?.?.???? ∙ ?????????    
            
where ?. ?.???? is the molecular weight of the secreted product described in 4.1. 
Two basic feeds were prepared and tested against a commercially available feed (CD 
EfficientFeedTM C AGTTM, Invitrogen, UK). The feed termed “F_all” contains the exact 
amount of amino acids calculated with the method above, except for those found to be 
accumulating in cell culture (i.e. Ala, Gln, Gly) that are not included in the feed. Glucose 
concentration was kept close to the one in the industrial feed (CD EfficientFeedTM C AGTTM, 
Invitrogen, UK) in order only to determine the effect of the a.a., when comparing the feeds. 
The concentration of glucose in the commercial feed was estimated by samples before and 
after feeding intervals.   
 
Table 4-1: Glucose and a.a. concentrations in the prepared feeds. 
F_all_pl40 contains 40% more amount for all the components, except tyrosine. The 
required concentration of tyrosine was much higher than the reported and hence was 
not increased. Nevertheless, in both feeds heating up the components as presented in 4.3 
resulted in a clear solution. Also, both feeds were diluted one to one with CD CHO 
medium (Invitrogen, UK). The solubility of amino acids in water at 25oC is presented in 
the right column based on Anaspec (1993). 
Components 
Feed 1 (10x, 
mM), encoded 
as: F_all 
Feed 2 (10x, 
mM), encoded 
as: F_all_pl40 
Solubility at 
25oC (mM) 
Glucose 144.44 202.21 5051.07 
Arg 8.07 11.29 861.07 
Asn 73.64 103.10 267.19 
Asp 13.72 19.21 58.45 
Cys 2.30 3.22 >8253.67 
Glu 21.35 29.89 58.72 
His 2.72 3.80 270.05 
Ile 8.66 12.12 313.86 
Leu 18.90 26.46 184.95 
Lys 10.46 14.65 >6840.53 
Met 3.67 5.14 226.59 
Phe 5.48 7.67 179.49 
Pro 10.12 14.17 8685.80 
Ser 29.43 41.20 477.96 
Thr 6.51 9.11 >8394.96 
Trp 2.16 3.03 55.62 
Tyr 4.15 4.15 2.50 
Val 14.52 20.33 755.47 
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The second feed was prepared by adding 40% more of all the components calculated 
for F_all and is denoted as ‘F_all_pl40’. The F_all_pl40 feed did not contain 40% more of 
Tyr, as tyrosine was already in F_all beyond the reported solubility. Both of the 
aforementioned feeds were prepared in one to one water to medium (CD CHO, Invitrogen, 
UK) ratio, in order to provide, even at a very low dose, some other essential components 
other than a.a. or glucose (discussed in 2.2.1). The concentrations of the amino acids and 
glucose in both F_all and F_all_pl40 feeds are presented in Table 4-1. A negative control 
feed was also tested based on the concentrations of nutrients in F_all_pl40, termed as 
F_all_pl40_NO_CD_CHO. This feed was solely prepared in water.  
The feeds for the staged feeding experiments were calculated based either on F_all or 
F_all_pl40. In both cases a branched chain a.a. (Ile, Leu, Val) solution was prepared in water 
with double the concentration of that reported in F_all or F_all_pl40. The remaining a.a. 
(except for Ala, Gly and Gln that were found to be accumulating) were dissolved in pure CD 
CHO medium (Invitrogen, UK), with double the amount of that reported for F_all and 
F_all_pl40 (displayed in Table 4-1). The total added volume was exactly the same as the 
single feed above, only this time was split into two parts, i.e. BCAA and the rest amino acids 
(except those found to be accumulating: Ala, Gly, Gln).      
 The staged feeding experiments were performed as follows. Based on F_all, BCAA 
feed followed the addition of a solution of all except BCAA and those found to be 
accumulating, at 1 hour interval encoded as: FMTBC (First Most a.a., Then Branched Chain 
a.a.). Then, FBCTM (First Branched Chain a.a. Then Most a.a.) feeding was also tested. In 
both the aforementioned cases, the first addition (BCAA or the rest a.a.) followed the 
schedule of the F_all feed and the second feed was added 1 hour later as discussed before. 
Based on F_all_pl_40 feed the exact same feeding strategy was employed at 12 hour interval. 
This time, however, only the FMTBC strategy was tested.   
 
4.3  Preparation of feeds 
 
Feeds were prepared by dissolving the appropriate amount of amino acids and glucose 
in water or one to one in CD CHO medium (Invitrogen, UK), accordingly. All components 
were purchased from Sigma-Aldrich (UK), except Asn and Lys (both purchased from Acros 
Organics, UK). In order to fully solubilize all the components the aqueous part only of the 
feeds was heated up in a 60oC water bath for one hour at most (until all components were 
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added). Following the formation of a clear solution, the feeds were left at room temperature 
until they reached 37oC, when CD CHO medium (Invitrogen, UK) was added, where 
appropriate. The calculated amount of Tyr, the least soluble amino acid, was beyond the 
reported solubility at 25oC (Anaspec 1993), however, the method described herein 
successfully solubilized it.  
Subsequently, pH was adjusted to 7 by adding a 5N NaOH solution (less than 2 mL 
per 300mL of feed were required) at 37oC using an electronic pH meter (Mettler Toledo S20-
K, US). Finally, all feeds were filtered using a 0.2 um filter device (Thermo Scientific 
Nalgene, UK), were kept at room temperature and used within one month. 
 
4.4 Determination of dry cell weight 
 
The dry cell weight of pellets was determined using duplicate 50mL cultures in 
250mL Erlenmeyer flasks in batch and fed-batch (with F_all_pl40 feed only) conditions and 
at exponential (day 4, only for batch) and stationary phase (day 8) of cell culture. 
Specifically, 40mL of culture was spun down at 1000g for 1 minute in a pre-weighed 50mL 
falcon tube, after cell count was performed as described in 4.1. Subsequently, the supernatant 
was removed and the pellet was washed once with 40mL 0.9% w/v NaCl solution (purchased 
from Sigma-Aldrich, UK) and spun again at 1000g for 1min. The supernatant was discarded 
and the pellet was left to dry in a non-humidified incubator at 37oC (NuAire, Triple Red, UK) 
until a stable weight was obtained (ACCULAB, Sartorius group, UK balance, 1mg 
readability).    
 
4.5 RNA extraction and cDNA construction (batch cultures) 
 
Total RNA was isolated on days 4, 6, 7 for all cell lines in batch culture, day 3 for 
producers and day 9 for the null cell line using the peqGold RNA S-line extraction kit 
(Peqlab, UK) on 107 cells with DNaseI (Fermentas, UK) treatment on the RNA binding 
column (100 enzyme units, 37oC, 15 minutes). RNA was quantified with NanoDrop 1000 
(Thermo Scientific, UK).  250 ng RNA was reverse transcribed using the QuantiTect reverse 
transcription kit (Qiagen, UK). 
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4.6 Quantitative reverse transcription polymerase chain reaction (qRT-
PCR)  
 
qRT-PCR was performed with SYBR® Green JumpStart™ Taq ReadyMix™ (Sigma, 
UK) in a Mastercycler® ep realplex4 S device (Eppendorf, UK) in 10μL reactions containing 
0.25 μL of cDNA and 0.5 μL of a 500 nM primer stock in triplicate wells of 96-well plates 
(Eppendorf, UK) sealed with thermal film (Bioline, UK). 2 step PCR was used: initial 
denaturation for 2min at 92oC and then 40 cycles of 15s at 92oC followed by 1 minute at 
62.7oC. Amplified products were validated by melting curve analysis (62.7oC to 92oC with 
0.025oC per second increment) and agarose gel electrophoresis. Ct values were determined by 
the Mastercycler ep realplex software (Eppendorf, UK) with a threshold of 100 (arbitrary 
fluorescence units). Copy numbers per cell for the target genes were calculated based on 
relative quantification to actb using efficiency correction and then scaled by the average actb 
mRNA copy numbers per cell (3000 copies/cell in Wong et al. (2010)). 
 
4.7 Primer design 
 
Primers were designed using the CHO genome (www.chogenome.org) and 
synthesized by Invitrogen (UK). Gradient PCR reactions and agarose gel electrophoresis 
were used to select primer pairs that gave a single PCR product at 62.7oC (Table VI-15 in 
Appendix VI). For primer efficiency calculations, cDNA was serially diluted four-fold up to 
1000 times and qRT-PCR reactions were performed in duplicate using at least 4 different 
cDNA concentrations. Efficiencies were determined based on Pfaffl (2001) and results are 
provided in Table VII-16 in Appendix VII. 
 
4.8 Housekeeping genes 
 
Two more housekeeping genes (hirip3 and vezt) along with actb, from a panel of a 
total of six (actb, b2m, eif3i, hirip3, pabn1, vezt, selected based on Bahr et al. (2009)), were 
simultaneously tested in all samples to ensure the accuracy of the results. From the panel of 
six, the three best housekeeping genes were selected using the BestKeeper software (Pfaffl et 
al. 2004) allowing for efficiency correction. Pearson correlation coefficients for all three 
selected housekeeping genes with the hypothetical BestKeeper were over 0.87 for all three 
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cell lines. The maximum threshold cycle (Ct) standard deviation of all samples for a specific 
housekeeping gene was 0.71. 
 
4.9 Amino acid analysis  
 
Quenching and extraction of intracellular metabolites was performed based on 
Dietmair et al. (2010). Briefly, an appropriate volume of culture containing 1.5x107 cells was 
immediately quenched in 4x volume of ice cold 0.9% (w/v) sodium chloride solution and 
centrifuged at 1000g for 1 min. The cells were washed with the same volume of the same 
solution and centrifuged at 1000g for 1min. The supernatant was removed and pellets were 
extracted using 3 mL ice cold 50% aqueous acetonitrile. Samples were incubated for 15 
minutes on ice and centrifuged at 21,000g at 0oC (Hermle Z233, Germany). Samples were 
thoroughly dried using a SpeedVac (Savant SC210A, US). Metabolites were recovered in 250 
μL of water, filtered with a 10kDa centrifugal filter (Millipore, UK) for 40min, 14,000g at 
0oC; and then through a 0.2 μm filter (VWR, UK). 40μL of the final solution were derivatized 
based on the PicoTag (Waters, UK) free amino acid protocol.  For extracellular amino acid 
analysis, supernatant was collected and filtered as described above. 5 μL was derivatized 
according to the PicoTag (Waters, UK) free amino acid protocol. Amino acid specific rates 
were calculated by plotting the integral viable cell concentration (IVCC) vs. cumulative 
concentration. 
 
4.10 Derivatization of amino acids  
 
 The PicoTag method (Waters, UK) employs phenyl-isothiocyanate (PITC) for pre-
column derivatization of amino acids. Methionine sulfone (Sigma, UK) was added as an 
internal standard to assess the derivatization efficiency. HPLC (Alliance, Waters, UK) with 
UV detection at 254nm was used for quantification. 
 
4.11 Analysis of other metabolites  
 
Lactate, ammonia, glucose, osmolarity, sodium, potassium and pH were monitored 
using the Bioprofile 400 analyzer (NOVA Biomedical, US). The later performs automated 
enzymatic assays on the samples for glucose and lactate. Ammonia, sodium and potassium 
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ions and pH are directly measured by electrochemical means. Osmolarity is calculated by a 
formula relating the majority of the aforementioned metabolites (along with glutamine and 
glutamate that are also measured by enzymatic assays). Pyruvate was quantified using a 
commercially available kit (Abcam, UK). The specific rates of these metabolites were 
calculated by plotting the integral viable cell concentration (IVCC) vs. the cumulative 
concentration.  
 
4.12 Statistical analysis  
 
 Regarding differences in gene expression, a two tailed t-test assuming unequal 
variances against an equally sized sample (n=3) with values of 2 was used to assess a level of 
upregulation significantly higher than two-fold from the lowest expressed sample at a 
particular condition. Principal component analysis (PCA) was performed using the R 
workspace (R Development Core Team 2010). The observed mRNA copies per cell were 
mean centered and variance scaled before performing the PCA. Regarding the metabolites 
PCA plots, consumption/production rates were used as absolute values and were not scaled. 
 For assessing differences between the different amino acid uptake rates between cell 
lines, as well as differences in IVCC, yield and specific productivity between different feeds, 
Levene’s test for means was used initially to test the homogeneity of variances. For a p-value 
greater than 0.05 in Levene’s test, ANOVA followed by Tukey’s test were used. In the 
opposite case Welch’s ANOVA followed by Games-Howell post-hoc test were performed. 
The statistical analysis was performed in R workspace (R Development Core Team 2010). 
For the differences between lactate producing and lactate consuming phases for a given cell 
line a two-tailed t-test assuming unequal variances was used.  
 
4.13 Antibody quantification 
 
 Recombinant protein was quantified using an IgG4 antibody ELISA kit (Bethyl 
Laboratories, US). Specific rates of monoclonal antibody production were calculated by 
plotting the integral viable cell concentration (IVCC) vs the cumulative concentration. IgG4 
concentration was also verified with a biolayer interferometry device (BLItz® system, 
ForteBio, Pall, US).   
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4.14 Calculation of specific rates  
 
The following way presents a formal way of calculating specific rates. The problem 
with fed-batch cultures is the fact that due to intermittent feeding it is hard to continuously 
integrate for the continuous variables that occur in such a process, e.g. Xv, S and P. The latter 
are all dependent on the volume of the culture and more importantly the addition of the feeds. 
The presented method tackles this problem by introducing artificial vectors of sampling and 
feeding schemes and by splitting the feeding or sampling interval into two time steps, as will 
be described below.     
An important variable during fed-batch cultivation is the volume of the culture, which 
changes multiple times during culture due to the plethora of sampling and feeding events. 
The instantaneous volume V can be defined with the following expression, for the case that 
also a sample is taken after feed: 
 
Equation 11: ???? = a???? − ?????? − ?????????      ⇔ ?? = a?????? − ???????? − ??????????? 
 
Integrating for any experimental time point with t2>t1: 
⇔ ? ?? = ? a?????? −????
??
?? ? ????????
??
?? − ? ???????????
??
??  
⇔ ??? − ??? = ? a?????? −???? ? a?????? −
??
?? ? ????????
??
?? + ? ????????
??
?? − ? ???????????
??
??
+ ? ???????????????  
 
where: at is a time associated variable that takes values zero at all time points except two at 
the middle of the feeding interval and bt and ct equally as for at, however the latter take the 
value of 2 at the middle of the sampling and the sampling after feed intervals, respectively. 
The value of two is given because of the way the variables are defined: the sampling or 
feeding interval takes a form of a triangle rather than a rectangle, with the triangle having half 
of the rectangle’s area, thus it is separated to two distinct parts (Figure 4-1). These variables 
have been introduced with that way in order to make the feeding/sampling intervals 
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continuous and hence integratable along with the rest variables. The integrals in the equation 
above can be approximated by the trapezoid rule as such, e.g. for the feeding term: 
 ? a?????????? = ?????????????? (?? − ??) and 
? a?????????? = a????? + a?????2 (?? − ??) + ? a??????
??
??  
   
The definition of the time vector (in the case where: feeding interval occurs exactly 
after sampling interval) is as such: zero to harvest time with the step of sampling interval, 
then at this vector the time of sampling out at the relevant time points is added, followed by 
the time of feeding for each relevant interval and the time for sampling out (see also Figure 
4-1B for a graphical representation). Then an additional time step is added at the centre of 
each sampling and feeding interval.  
It is important to mention here that the methods discussed herein only apply for t1 and 
t2 of the initial/experimental time vector (i.e. the one resulting by the number of sampling 
points) and not the “artificial” vectors created afterwards. The latter can be calculated, but the 
results can be erroneous. 
Fin, Fout, FoutafF are the volumetric rates of feeding, sampling and sampling after feed, 
respectively. These rates are calculated for fed-batch cultures as percentage of volume to be 
fed on the initial volume, sampled or sampled after feed over the duration of feeding, 
sampling or sampling after feed (tF, tS, tSafF, respectively). The associated error with the 
aforementioned calculations can be calculated by error propagation with “the traditional 
calculus-based approach” as discussed in Gardenier et al. (2011).  
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Figure 4-1: Illustration of the artificial vectors of feeding (a), sampling (b) and sample 
after feed (c) applied to the volume of the culture of the feeding experiments discussed 
in 4.2.  
A) Feeding, sampling and sampling after feed rates (F in L/day) are presented in the left 
y-axis, during 14 days of culture (x-axis). Intermittent sampling (every day, light red 
dashed line), feeding (alternate days, light blue dashed line) and sampling after feed 
(light green dashed line) rates are presented as a function of time. The right y-axis 
(thick black line) corresponds to the cumulative (Cum.) volume during culture time (x-
axis). The dark blue line corresponds to the cumulative feeding volume added to the 
culture. The dark red line corresponds to the cumulative volume taken out due to 
sampling and the green to the cumulative volume taken out due to the sampling after 
feed sample. The purple line corresponds to the total volume of the culture. B) 
Sampling, feeding and sampling after feeding rates (left y-axis and their respective 
cumulative volumes (right y-axis) are depicted zoomed on the second day of culture. 
The artificial vectors take the value of two in the middle of the duration of the different 
events that take or add volume in the system. 
 
The viable cells concentration (Xv) mass balance will equally be as below, from 
where the instantaneous apparent specific growth rate (μapp=μ-kd) for all time points t can be 
approximated, assuming exponential growth at all points:  
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Equation 12: ?(???)?? = ???? − ????? − ???????? − ???????????    ⇔  ?(???) = (? − ??)??? ?? − ?????????? − ????????????? 
 
Integrating for any experimental time point with t2>t1: 
 
⇔ ? ?(???) = ? (? − ??)??? ?? −????
??
?? ? ??????????
??
?? − ? ?????????????
??
??  
⇔ (? − ??) = ?????? − ?????? + ? ?????????????? + ? ?????????????????? ??? ??????  ⇔ (? − ??) = ???? =
= ?????? − ?????? + ? ?????????????? − ? ?????????????? + ? ????????????? − ? ?????????????????????? ??? ?????? − ? ??? ??????  ⇔ ????
= ?????? − ?????? + ? ?????????????? − ? ?????????????? + ? ????????????? − ? ?????????????????????????? − ?????  
 
where IVC is the integral of viable cells, i.e. the area under the XvV vs t graph rather than Xv 
vs t, the latter being the IVCC, integral of viable cell concentration. IVC can be approximated 
by the trapezoid rule: 
 
????? = ???????????????? ?? and 
????? = ??????? + ???????2 (?? − ??) + ????? 
 
 Equally the rest integrals at the right hand side can be approximated: ? ?????????????  
and ? ????????????????  that correspond to the total number of cells taken out due to sampling 
and sampling after feed, respectively. For example, the integral of the former can be 
approximated as: 
 
? ?????????????? = ???????????????????????? (?? − ??) and 
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? ?????????????? =
??????????? + ???????????2 (?? − ??) + ? ??????????????  
 
 At sampling intervals, for the artificially defined time points, by solving for Xt2 in the 
above mass balance and assuming that μ is equal to zero at this short time interval it holds 
that (also from the dilution law, just because growth or death is not considered to be 
significant at this short time interval): 
 
Equation 13: ??? = ???????(???????)???(???????)???      
.  
In turn the specific consumption/ production of a metabolite/product/by-product can 
be estimated by the following mass balance, assuming first order chemical degradation if any: 
 
Equation 14: ?(??)?? = a??????? − ??????? − ?????????? + ???? + ???   ⇔ ?(??) = a????????? − ????????? − ???????????? + ?????? + ????? 
 
Between any t1, t2, with t2>t1: 
 
⇔ ? ?(??)???? = ? a?????????
??
?? − ? ?????????
??
?? − ? ????????????
??
?? + ? ??????
??
??
+ ? ?????????  ⇔ ?????? − ?????? =
= ? a????????????? − ? a?????????
??
?? − ? ?????????
??
?? + ? ?????????
??
??
− ? ???????????????? + ? ????????????
??
?? + ?[? ?????
??
?? − ? ?????
??
?? ]
+ ?[? ???????? − ? ????
??
?? ] ⇔ ? =
= ?????? − ?????? + ?? a????????????? − ? a????????????? ? + ?? ????????????? − ? ????????????? ? + ?? ???????????????? − ? ???????????????? ? + ?(???? − ????)????? − ?????  
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At the artificial points added due to sampling and feeding, based on the dilution law, 
similarly with Xv it holds that: 
 
Equation 15: ??? = ????????????????????????????????????????????????????(?????)???    
            
where C is the concentration of a metabolite, k is the chemical/non-enzymatic degradation of 
the metabolite and Cin is the concentration of the metabolite in the feed. Regarding the 
degradation constant, it is reported, for example, that glutamine spontaneously degrades to 
ammonia and pyrrolidonecarboxylic acid (Ozturk and Palsson 1990) with a rate of 0.0031 h-1 
(Murphy and Young 2013). In the case that k is negative the equation stands as is; in a 
different case C in the above equation has to be replaced by the concentration of the 
metabolite that degrades to C (e.g. if C is Amm then for the degradation only term in the 
equation  above C should correspond to Gln).   
The above calculations were coded in R workspace (R Development Core Team 
2010) in order to automate the process of calculating fluxes from time-concentration data that 
regularly arise from bioprocessing studies. The algorithm reads experimental data from 
comma-separated values files (.csv) that are fully compatible with MS Excel. The 
experimental data include concentrations of cells and metabolites at sampling points only, i.e. 
the user does not have to include the concentration of metabolites after the addition of feeds. 
Other data include the feeding interval, the sampling interval, the duration of feeding, the 
duration of sampling, the duration of sampling after feeding, the volume taken out due to 
sampling or due to sampling after feeding and the volume introduced to the culture due to 
feeding, the initial volume of the culture, the significant digits needed to be taken into 
consideration, the number of samples analysed and the required confidence interval. The 
sampling after feed interval does not have to be specified as for the purposes of this thesis is 
assumed to occur exactly after feed has been added. Figure 4-2 illustrates the data needed as 
inputs for the calculation of specific rates. 
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Figure 4-2: Input data for the calculation of specific rates with the developed code. 
The first two columns (A and B) request basic characteristics of the culture, i.e. in order 
of appearance: the number of significant digits needed for the calculations, initial 
volume of the culture, standard deviation (error) in the calculation of volume, harvest 
day of culture, standard deviation (error) in the calculation of time, number of 
experimental replicates, required confidence interval, feeding interval (i.e. every two 
days, if set to zero then the culture will be treated as batch), standard deviation of the 
feeding interval, volume added due to feeding, duration of feeding, standard deviation 
of the duration of the feeding, sampling interval (i.e. every one day), standard deviation 
of the sampling interval, volume taken out due to sampling, standard deviation of the 
volume taken out, duration of sampling, standard deviation of the duration of sampling, 
volume taken out due to sample after feeding, standard deviation of the volume taken 
out due to sampling after feeding, duration of sampling after feeding and standard 
deviation of the duration of sampling after feeding.  
Column C is not read, but actually represents the experimental time points. Also, 
this column reminds to the user that exactly below the experimental data points the 
following parameters must be entered: concentration of the metabolites in the feed (Cin) 
if applicable, followed by its standard deviation and the degradation rate (k), followed 
by the relevant standard deviation. 
In the next six columns (D to I) the concentrations followed by their standard 
deviation of viable cells (Xv), dead cells (Xd) and recombinant protein (rprotein) have to be 
supplied. The rest columns can include any user-defined metabolite followed by the 
relevant standard deviations (e.g. column J and I include the concentration of Ammonia 
and the standard deviation respectively, while L and M the concentration and standard 
deviation of Glucose). In column J and row 19 the degradation rate of glutamine to 
Ammonia is defined followed in the next row by its standard deviation in units of days-1 
and is given a positive value to denote that Ammonia concentration is increased by this. 
Also, in column L row 17 the concentration of glucose in the feed has to be defined and 
in the next row the relevant standard deviation. Similarly, the rest of the metabolites 
can be read from the columns right from column M. 
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The algorithm for the calculation includes the following steps:  
1) Creation of the artificial/computed time vector (tcomp), i.e. the ones resulting from all 
the events occurring during cell culture. The provided experimental time points are increased 
by including the two additional time points resulting from sampling; one at the centre of the 
sampling interval and one at the end, since sampling interval has been divided into two parts. 
The same occurs for the rest events (feeding and sampling after feeding). For example for a 
14 days culture period the artificially computed time vector will include 65 in total time 
points in order to accommodate all the aforementioned events. 
2) Creation of the artificial feeding (a), sampling (b) and sampling after feeding (c) 
vectors. As discussed earlier, these vectors take the value of two at the centre of the time-
length of the relevant event, while at all other points take the value of zero. 
3) Following the definition of the artificial time and event vectors the calculation of the 
volume along tcomp (Vcomp) takes place exactly as presented in Equation 11. 
4) Then the calculation of Xv (and Xd) along tcomp (Xvcomp) follows and the calculation of 
IVCC. Special consideration is needed while Xvcomp is calculated as at the added time points 
Xvcomp is calculated based on Equation 13. Following the analytical solution of Equation 12 
presented earlier μapp between any two time points, t1, t2, can be calculated. 
5) Finally, C is calculated along tcomp (Ccomp) with care at the artificial time points where 
Ccomp is calculated by Equation 15. Subsequently, the calculation of q between any two time 
points t1, t2, from the analytical solution of Equation 14, as presented above, takes place.        
The calculation of error takes place in parallel with the aforementioned steps for V, 
Xv or C, as discussed earlier. The basic raw code is provided in the form of a function in 
Appendix XIII. 
     
4.15 Flux balance analysis (FBA)  
 
Flux balance analysis was performed using the R workspace (R Development Core 
Team 2010) and the Sybil package (Gelius-Dietrich et al. 2013). The latter forms a given 
network of reactions into a LP problem (see also part 2.3.3). The glpk solver (Makhorin 
2012) was used in order to solve the LP problem.  
The network of Carinhas et al. (2013) was used as the basis for the FBA study and the 
biomass from Selvarasu et al. (2012), without including cysteine. The latter a.a. is also not 
included in the Carinhas et al. (2013) model. In order to couple the two aforementioned 
models, the twenty in total reactions highlighted with green in Table X-20 in Appendix X had 
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to be added on top of those reported in Carinhas et al. (2013). The final model contains 97 
intracellular reactions (occurring in the cytosol, including the biomass and rprotein 
production), 54 transport reactions and 120 metabolites. In the exponential phase, the 
optimization function of the FBA involved maximization of both growth and IgG4 (rprotein) 
formation, whereas at stationary phase maximization only of IgG4. 
The experimentally observed extracellular reactions included all the a.a., measured by 
HPLC as discussed in 4.9 and 4.10; Amm, Glc, Lac and Pyr, measured as discussed in 4.11. 
The upper and lower bounds were set within one standard deviation of triplicate experiments. 
The remaining extracellular fluxes (degrees of freedom) for the FBA model were set close 
(±20%) to the observed for the high producer in Carinhas et al. (2013), who used a similar 
CHO IgG4 producing cell line. Namely, those extracellular reactions included the following 
species that were found to accumulate in cell culture (twelve in total): acetate, choline, citrate 
(Cit), formate, fumarate (Fum), glycerol (Glyc), glycero-3-phosphocholine (Glyc3PC), 
isobutyrate (Isobut), isovalerate (Isoval), malate (Mal), phosphocholine (Pcholine) and 
succinate (Succ). Also, to the latter list Choline has to be added, acting this time as a substrate 
for the synthesis of lipids. While, folate (Fol) and spermine (SPRM) uptake reactions had to 
be added in order to match the Selvarasu et al. (2012) biomass reaction’s demands. These two 
nutrients were also provided in the aforementioned study. It is important to mention here that 
the significance of the remaining uptake reactions in Table X-20 in Appendix X, i.e. ATP, 
NAD, NADH, etc., is to calculate how much of these molecules would be needed in order to 
satisfy the selected optimization function of the FBA problem.    
Finally, in the biomass equation in order to assess the flux of glucose towards 
nucleotides and nucleotide sugars in a more representative way, glycosylation of the host 
proteins was also included. The following species were added in order to include this: N-
acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), mannose (Mann), fucose 
(Fuc), galactose (Gal) and N-Glycolylneuraminic acid (Neu5Gc). While their amount in 
biomass were estimated from CHO cells MS glycan data (Stanley 2010) and the occurrence 
of N- and O- linked glycans based on a.a. sequence observed in Apweiler et al. (1999). The 
latter study identified that N-linked glycans occur: 0.004001 times/ mol a.a., while O-linked 
0.003705 times/mol a.a. by performing a comprehensive analysis on the majority of the 
glycoproteins found in the SWISS-PROT database (Bairoch and Apweiler 2000). The 
calculated stoichiometric coefficients (mmol per gram of dry cell weight, mmol/gDCW) can 
be found in the biomass reaction in Table X-20 in Appendix X.     
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 FBA results were visualized by writing the resulting network in Systems Biology 
Markup Language, SBML (Hucka et al. 2003) and loading it in Cytoscape (Saito et al. 2012). 
The Cytoscape plugins CySBML (Konig et al. 2012) and CyFluxViz (Konig and Holzhutter 
2010) were used to read the SBML model and to illustrate the calculated fluxes linearly by 
arrow thickness, respectively. 
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Chapter 5                                                         
Amino acid transport 
 
As discussed in part 2.1.4 there is not a comprehensive study of amino acid transport 
for CHO cells with a bioprocessing context in the literature. Towards that direction the 
expression profiles of 40 a.a. transporters at different phases of batch CHO cell cultures using 
quantitative reverse-transcription polymerase chain reaction (qRT-PCR) were analysed. The 
understanding of the complicated phenomenon of nutrient transport can aid in devising more 
rational feeding strategies during bioprocesses. The rest of this chapter will present the 
associated results and discussion that have been recently published in Kyriakopoulos et al. 
(2013).  
 
5.1 Experimental system and rationale of the analysis 
 
RNA samples for the qRT-PCR analysis were collected at the exponential, stationary 
and decline cell growth phases of three different glutamine synthetase (GS)-CHO cell lines: a 
non-producer and two cell lines expressing a recombinant antibody product (also discussed in 
4.1). The extra- and intra-cellular concentrations of amino acids were also analysed to 
complement the transcriptomic data. The exact time points, when the RNA samples were 
collected are depicted in Figure 5-1.  
In Figure 5-1A the growth curves of the three different cell lines are depicted. Figure 
5-1B presents the relative levels of IVCC, yield and specific productivity for all cell lines. 
There it is evident that the highest producing cell line demonstrates two times higher specific 
productivity than the other rprotein producer cell line (GS35) that was used for the purposes 
of this analysis. 
From the total of 46 known for mammalian cells (also presented in Appendix II) 
amino acid cellular membrane transporters, 40 were examined for the purposes of this part. 
22 transporters were found to be actively transcribed, 14 were transcribed at fractional copy 
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numbers per cell and 4 genes were below the detection limit (also depicted in Figure 5-2). 
Firstly, in order to identify genes that are positively correlated with recombinant protein 
(rprotein) production, it was examined whether the three selected cell lines present any 
differences in their expression levels at a given time point of cell culture (“regulation between 
cell lines”). Secondly, it was examined whether regulation within culture for a given cell line 
was apparent, i.e. whether the expression levels differed at a given phase of cell culture.  
 
Figure 5-1: Growth curve and productivity related data for the three cell lines used in 
the a.a. transport study. 
A) Viable cells concentration (Xv, in cells/mL) is depicted in the left y-axis, for all three 
cell lines (see also part 4.1): “GSn8” (blue colour, null producer), “GS35” (red colour) 
and GS46 (green colour, highest producer). In the right y-axis (depicted with a thick 
black line) the viability (in percentage of total cells) is presented. The x-axis represents 
the culture time in days. Orange arrows demonstrate the time, when RNA samples were 
taken for the qRTPCR analysis for all three cell lines. Dark grey arrow depicts RNA 
samples only for producer cell lines, while light grey only for the null one. 
B) The relative levels of integral of viable cells concentration (IVCC, in 106cells/mL*hr), 
yield (in g/L) and specific productivity (in pg/cell/day) for all cell lines are depicted. 
Obtained from Kyriakopoulos et al. (2013) with licence. 
 
An increase in mRNA transcript levels significantly higher than two-fold above the 
lowest expressed sample is used to define genes as “regulated”. This is a value commonly 
used in the literature for mRNA studies that do not include proteomic analysis (Clarke et al. 
2011; Doolan et al. 2008; Wong et al. 2010). The normalization of all samples was performed 
on a widely used housekeeping gene in the literature, actb at a particular time point and cell 
line, as discussed in 4.6. Then results were also normalised to the lowest expressed sample.  
In order to ensure that the choice of housekeeping genes did not affect the analysis of 
the results, two more housekeeping genes were tested along with actb (see also section 4.8). 
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These include hirip3, which encodes for a protein that acts in the nucleus, and vezt, which 
encodes for a transmembrane protein. 
 
Figure 5-2: Overall results regarding the regulation of the amino acid transporters 
investigated within cell culture and between the different cell lines tested. 
Red colour refers to a transporter presenting regulation within culture. Green colour is 
used for a transporter presenting regulation between the three different cell lines tested. 
Purple colour refers to transporters presenting both of the aforementioned regulations. 
With white background colour, genes that do not present any regulation are depicted. 
With yellow colour transporters that present low signal during the qRTPCR are 
depicted. A.a. transporters highlighted with black background refer to transporters 
below the detection levels. With grey background transporters that were not checked 
are presented. The two tables in the right hand side display the so far known a.a. 
transporters in mammalian cells (also analysed in more detail in Appendix II). The bar-
chart on the bottom left summarises the experimental results. 
*Regulation refers to statistically significant two fold up- or down-regulation against the 
mRNA levels of a control sample, e.g. against another day of cell culture (“regulation 
within culture”) or another cell line on the same day of culture (“regulation between cell 
lines”). Obtained from Kyriakopoulos et al. (2013) with licence. 
 
A summary of the observations discussed in the following sections is depicted in 
Figure 5-2. Regulation within culture of at least one cell line was observed for four genes. 
Regulation between cell lines was observed for six genes. Eight genes presented both types of 
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the aforementioned regulations. Four more genes were found to be present, but without any 
regulation between cell lines or within cell culture. 
 
5.2 Regulation between cell lines  
 
A principal component analysis (PCA) score plot of the variance-scaled and mean-
centred mRNA copies per cell for the different cell lines is presented in Figure 5-3. 
Interestingly, as it is depicted the majority of transporters are upregulated for the rprotein-
producing cell lines compared to the non-producer. This is evident since most scores in the 
PCA fall on the left side of the plot, pointed by the rprotein cell lines loading arrows.  
The genes that are regulated at all the tested time points for the protein producers may 
be associated with rprotein productivity and represent good genetic engineering targets. 
These were found to be, as depicted in Figure 5-3B, gene slc43a2 (from system L, which is 
associated with leucine and branched-chain amino acids transport) and slc1a2 (from system 
X-AG, associated with glutamate and aspartate transport). Other genes from the same systems, 
i.e. system L (slc7a5, slc43a3) or system X-AG (slc1a3), or genes for transporters that carry 
similar amino acids (e.g. system y+L) were not found to be upregulated.  
Recombinant protein associated genes, discussed earlier, might be promising genetic 
engineering targets. Genes, however, associated with high productivity can be even more 
promising. The latter can be identified from Figure 5-3A by the genes indicated from the 
loading arrow of the GS46 cell line. The levels of these genes should present statistically two-
fold or higher upregulation from the other two cell lines (or at least from the lower producer), 
which is the purpose of the table depicted in Figure 5-3B. Only one gene presents the 
aforementioned regulation. This is gene slc6a6, associated with the transport of taurine and β-
alanine and so not with the transport of proteinogenic a.a. The transporter has been found to 
be upregulated on days 3 (not shown in the aforementioned figure, since on day 3 data have 
only been analysed for the producer cell lines, but can be extracted from Appendix VIII) and 
4 against both the other cell lines.  Therefore, this transporter (slc6a6) could be a potential 
selection marker for high producers. 
The over-expression of slc6a6 led to significantly enhanced productivity and cell 
growth in another study (Tabuchi et al. 2010), also discussed in section 2.1.4. This transporter 
was found to be highly upregulated in late culture phases in the aforementioned study, where 
cells are usually exposed to hypertonic media. This was the reason that it was over-expressed 
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along with the fact that the transporter has an osmoprotective role. This role of the 
transporter, due to the import of other osmolytes along with taurine (Tabuchi et al. 2010), can 
explain, the observed herein, upregulation of the transporter at early stages of cell culture 
(day 4), where osmolarity was found to be high (Figure 5-5D).  
 
Figure 5-3: Analysis of the regulated between cell lines transporters. 
A) PCA score plot of the first two principal components (PC1 & PC2) of the scaled 
mRNA copies per cell for the a.a. transporter genes that present regulation between cell 
lines. The loadings depict the different cell lines (GSn8, GS35 and GS46). The colours 
for the cell lines are exactly the same as in Figure 5-2. The scores have been coloured as 
such: blue is for day four, gold for day six and brown for day seven. 
B) A table presenting the statistical analysis regarding the regulation between cell lines. 
The levels are reported scaled to the lowest sample (the full dataset is provided in 
Appendix VIII). Genes that present statistically higher than two-fold regulation have 
been highlighted with the respective colour of each of the cell lines. Statistical analysis 
has been performed as described in section 4.12. *:p<0.05, **:p<0.01. Obtained from 
Kyriakopoulos et al. (2013) with licence. 
 
 Another transporter, slc7a7, can also be a possible selection biomarker. This gene was 
found to be upregulated for the null producer cell line, showing an inverse relationship with 
the specific protein productivity of the producing cell lines on day 4. 
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5.3 Regulation within culture  
 
PCA was also used to analyse genes found to be regulated within culture for a 
particular cell line. The loadings of Figure 5-4A represent the weights of each variable in the 
projection to each principal component, whereas the scores represent how strongly each 
observation (mean centred and variance scaled mRNA copies per cell) is explained by each 
principal component. The variables, i.e. loadings of the PCA plot, represent this time the days 
of culture in contrast with Figure 5-3A, where the loadings represent the different cell lines. 
Figure 5-4B presents the list of the aforementioned genes and the changes in their expression 
levels along with the statistical analysis. Interestingly, all tested genes, apart from slc6a6 
discussed earlier, were found to be upregulated at stationary phase for all cell lines.  
The results demonstrate a significant upregulation of the transporters carrying amino 
acids associated with glutathione synthesis. The relevant metabolic reactions of this pathway 
are depicted in Appendix IX. Glutathione has been reported as a marker of oxidative stress in 
CHO cells (Selvarasu et al. 2012). Also, high levels of this metabolite have been associated 
with high productivity (Chong et al. 2012). The amino acids: cysteine, its oxidized form 
cystine, glutamate, alanine and glycine are associated with glutathione biosynthesis. The 
following genes are associated with the transport of the aforementioned a.a. and were found 
to be significantly upregulated at stationary phase for all cell lines tested: slc1a4 (alanine and 
cysteine), slc6a9 (glycine), slc1a2 (glutamate and aspartate), slc7a11 (cystine and glutamate), 
and heteromeric transporter slc3a2 which partners with slc7a11. 
As transport of nutrient is a process that involves very complex biology (also 
discussed in 2.1.4), the regulation of a transporter during cell culture has to be carefully 
interpreted. For example, the depletion of the intracellular pools of amino acids might be the 
reason of the observed upregulation of a specific transporter. This upregulation would 
indicate the addition of the relevant nutrients in the culture at a specific time point. Hence, the 
profiling of the transporter may result in a better insight in feeding strategies. However, the 
observed upregulation may also be because of the high concentration of one of its substrates 
in the medium, in the case, for example, where trans-simulation (see also section 2.1.4) 
occurs, i.e. in systems ASC, L and y+. Another reason for the upregulation of a specific 
transporter can be that the concentration of one of the inhibitors of a desired nutrient is in 
very high levels in the medium. This would be the case for a transporter subject to 
competitive inhibition, i.e. in system x-c (also discussed in 2.1.4). Feeding strategy-wise, the 
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latter would suggest that the concentration of the relevant inhibitor in the medium should be 
reduced.    
 
Figure 5-4: Analysis of the regulated within cell culture of a particular cell line 
transporters.  
A) PCA score plot of the scaled mRNA copies per cell for the first two principal 
components. The variables (loadings) of the PCA plot are the days of the culture. The 
same colour format is used as in Figure 5-3. 
B) Table depicting the statistical analysis of the levels of the transporters, scaled to the 
lowest expressed sample (the full dataset is provided in Appendix VIII). Genes that 
present statistically higher than two-fold regulation have been highlighted with the 
respective colour of each of the cell lines. Statistical analysis has been performed as 
described in section 4.12. *:p<0.05, **:p<0.01, ***:p<0.001. Obtained from 
Kyriakopoulos et al. (2013) with licence. 
 
5.4 Is there transport limitation of a.a. for rprotein formation? 
 
In order to answer the question of whether transport limitation is an issue in rprotein 
formation extracellular amino acid analysis was carried out. Unexpectedly, the results (Table 
5-1) demonstrate that the majority of the metabolites are consumed with higher rate for the 
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non-producing cell line (GSn8) during the lactate-producing phase that coincides with the 
exponential growth interval. This occurs between days zero (inoculation) and day four for all 
cell lines. The following amino acids: methionine, isoleucine, leucine, phenylalanine, 
tryptophan and lysine were found to be consumed at a significantly higher rate by the null 
producer than the other two cell lines. Interestingly, the specific growth rate for the same time 
interval is the lowest for the null producer. The latter, suggests that the observed high 
consumption is not due to higher growth than the other two cell lines, pointing to a lower 
metabolic efficiency of the null cell line. This conclusion is also strengthened by the 
observation that lactate and glycine were produced at a significantly higher rate by the null 
cell line than any of the rprotein producers.  
The null cell line presents significantly lower consumption for the acidic amino acids 
aspartate and glutamate during the lactate-production interval than the other two cell lines. 
The high producer presents the lowest asparagine consumption rate. However, the high 
producer demonstrates a higher consumption of phenylalanine and the branched chain amino 
acids valine and isoleucine than the low producer. Generally, since the highest producer 
results in a higher production of rprotein (see also in Table 5-1 the values for qmAb) it would 
be expected to present the highest consumption rates for the majority of the amino acids, 
since it also demonstrates similar growth rate with the low producer. As results suggest, 
however, this does not occur.  
As far as the lactate consumption phase (from day 4 until the final day of each batch 
culture) is concerned, there are fewer differences with respect to the production/consumption 
specific rates among the cell lines. Serine, aspartate and glutamate consumption appears to be 
much higher for the null producer than the other two cell lines, contrary to the lactate 
production phase. Comparing the two producer cell lines, it appears that there is significantly 
lower consumption of lactate, isoleucine and leucine, but higher consumption of asparagine 
by the high producer. Moreover, an overall production of alanine for the high producer is 
observed, whereas the same amino acid is consumed by the other two cell lines. 
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Table 5-1: Specific rates of the main metabolites for the three cell lines tested. 
The batch culture has been divided into two distinct phases (see also section 2.1.3): 
lactate production (between days 0 to 4) and lactate consumption phase (between day 4 
and until viability in all cultures drops to zero). Statistical analysis has been performed 
as discussed in 4.12. *:p<0.05, **:p<0.01, ***:p<0.001. Modified from: Kyriakopoulos et 
al. (2013). 
Metabolites 
Lactate Production Phase  
(day 0 to day 4) 
Lactate Consumption Phase (day 4 
and after) 
GSn8 GS35 GS46 GSn8 GS35 GS46 
Lactate  3578** 2044 2592 -506 -456 -374 
μ (1/day) 0.69* 0.89 0.81 -0.11 -0.10 -0.05* 
qmAb 
(pg/cell/day) 0 12 27*** 0 4 8** 
Asp -24** -109 -110 -34*** -7 -7 
Glu -18** -180 -163 -47*** -8 -9 
Ser -329 -294 -313 -90* -59 -56 
Asn -925 -729 -412* -56 
-46 (* 
from 
GS46) 
-75 (* 
from 
GS35) 
Gly 164* 96 114 74 73 53 
Gln 18* 51 32 -3 -4 -3 
His -37 -35 -38 -4 -3 -2 
Thr -86 -72 -83 -8 -6 -7 
Ala 153 150 77** -23 -25 15** 
Arg -104 -52 -112 
-9 (** 
from 
GS35) 
10 (** 
from 
GSn8) 
1 
Pro -193 (* from GS35) 
-6 (* from 
GSn8) -112 -3 -5 4 
Tyr -86  (* from GS46) -14 
-38 (* 
from 
GSn8) 
-3 -11 -4 
Val -224 (** from GS35) 
-59 (** 
from 
GSn8) 
-143* -24 -30 -17 
Met -81** -19 -34 -2.3 -2.1 -0.1 
Ile -138* -22* -81* -15 
-21 (* 
from 
GS46) 
-12 (* 
from 
GS35) 
Leu -301* -57 -173 -38 
-51 (* 
from 
GS46) 
-30 (* 
from 
GS35) 
Phe -94* -10* -49* -4 -4 -1 
Trp -41* 19* -11* -4 -3 0 
Lys -211* -13 -83 -6 -5 -1 
 
 
Overall the consumption/production rates results demonstrate that uptake rates among 
the cell lines present a random manner. Apart from certain exception the high producer does 
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not exhibit higher uptake rates. This was also observed in Dietmair et al. (2012) where amino 
acid uptake rates for parental and rprotein-producing HEK293 (human embryonic kidney) 
cell lines were found to be similar. This finding leads to the conclusion that amino acid 
transport is not the limiting step for rprotein synthesis. Further analysis using the FBA 
approach discussed in 6.2.4 (as depicted in Figure 6-10 for the exponential phase interval), 
reveals the demands for a.a. for rprotein is much lower than the demand for biomass. This 
analysis backs-up the conclusion about a.a. transport not being the limiting step for rprotein 
formation. A more accurate picture regarding differences in rprotein regulation between cell 
lines could be obtained by performing a similar transcriptomic and metabolomic study for a 
wider array of cell lines. 
Specific rates of most nutrients appear to be significantly higher in the lactate 
production phase to those during lactate consumption for a given cell line. This correlates 
well with the transcriptomic results showing that the majority of the transporters are 
upregulated at stationary phase of cell culture (also depicted in Figure 5-4A). This 
upregulation can be attributed as a response to reduced extracellular metabolite concentration. 
The transporters that are significantly upregulated can be characterised as responsive to 
starvation.  
 
5.5 Mapping of amino acid transport for the high producer cell line 
 
A possible mapping of amino acid transport for the high producer cell line is 
presented in Figure 5-5. The transporters that presented significant differential expression 
within culture of the aforementioned cell line have been coupled with the concentration 
profiles of their substrates. The figure omits non-proteinogenic amino acid transporters, i.e. 
slc6a6 (taurine and β-alanine) and the heteromeric transporter slc3a2. The latter partners with 
a variety of other transporters, since it is a heavy chain of several heteromeric transporters 
(see also Appendix II). Both aforementioned transporters were found to be differentially 
expressed within cell culture of the high producer (Figure 5-4B).  
The slc38a4 transporter from system A (for Alanine) appears to be upregulated on day 
6 of culture (Figure 5-5C). Transporters of this system operate as symporters of sodium and 
amino acids with linear side chain in a one to one ratio (Guidotti and Gazzola 1992; 
Mackenzie and Erickson 2004a). They are also subject to trans-inhibition (Guidotti and 
Gazzola 1992). The latter means that the rate of internalization of a substrate would be 
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lowered by higher concentrations of substrates in the extracellular space than in the 
intracellular compartment. Slc38a2 transporter from the same system was found to be 
upregulated under hyperosmotic conditions in a study in CHO cells (Shen et al. 2010). 
Despite an osmolarity increase on day 6 of culture (Figure 5-5D), the aforementioned 
upregulation is not evident in the results presented herein (as presented in Appendix VIII).  
System ASC (for Alanine, Serine and Cysteine) transporters can cooperate with 
system A transporters. As ASC system transporters are tertiary active transporters (see also 
section 2.1.4), they export amino acids imported by other systems (e.g. system A) in order to 
facilitate the transport of other amino acids required by the cell (Kanai and Hediger 2004). 
Amino acids with a linear side chain of any length (alanine, glutamine) are substrates of ASC 
system transporters. The latter, have a preference for certain polar amino acids (cysteine, 
serine, threonine) and are sodium dependent. System ASC appears to be trans-stimulated 
(Guidotti and Gazzola 1992). This means that a substrate would be carried toward the side of 
the membrane, where the highest concentration of this substrate occurs. Slc1a4 transporter of 
this system was found to be upregulated on day 6 (Figure 5-5C). The decrease in extracellular 
serine and threonine levels (Figure 5-5A) is well correlated with the aforementioned 
behaviour. The other transporter of this system (Slc1a5) was also found to be upregulated, but 
not significantly. A previous study reported that it was down-regulated in response to high 
osmolarity (Shen et al. 2010), an observation that is opposite to the findings presented herein 
(as presented in Appendix VIII).  
The slc6a9 transporter from system Gly transports glycine bi-directionally. Chloride 
and sodium are used as co-solutes (Eulenburg et al. 2005). The accumulation of intracellular 
glycine intracellularly (Figure 5-5B) can be associated with the 7-fold increase of the 
transporter’s mRNA levels at stationary phase (Figure 5-5C), aiming to the efflux of this 
amino acid.  
 System N transporters function in the exchange mode. One neutral amino acid with 
the aid of a sodium ion is exchanged for a proton (Mackenzie and Erickson 2004a). The 5-
fold upregulation of slc38a5 transporter mRNA at stationary phase (Figure 5-5C) is well 
correlated with asparagine depletion, both intracellularly (Figure 5-5B) and extracellularly 
(Figure 5-5A). There is also a correlation with glutamine uptake and/or excretion. The levels 
of the latter amino acid were found to oscillate.    
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Figure 5-5: A possible mapping of amino acid transport for the highest producing cell 
line (GS46), assuming that the significantly regulated within culture transporters are 
the most important. 
A) The extra-cellular a.a. concentrations (mM) for the four days of culture where RNA 
analysis took place are presented (day 3, in white; day 4, in light grey; day 6, in dark 
grey and day 7 in the darkest grey). Cysteine (Cys) and cystine levels were not 
quantifiable by the employed a.a. analysis method (see section 4.10) and hence their 
levels are not presented. B) The intracellular a.a. concentrations in femtomol/cell/day 
are depicted. C) The mRNA levels scaled to the housekeeping gene actb for each time-
interval are depicted for the genes found to be regulated (statistically higher than two 
fold from the lowest sample) within cell culture. D) Sodium (mM), potassium (mM), 
osmolarity (mM) and pH levels for the relevant days, where RNA analysis took place, 
are presented. In all cases error bars represent one standard deviation of biological 
triplicate samples. The levels of some a.a. (e.g. serine and asparagine) are presented 
more than one times in the case they are carried by more than one system. Obtained 
from Kyriakopoulos et al. (2013) with licence. 
 
Acidic amino acids are carried by systems X-AG and x-C. Aspartate and glutamate are 
carried by the former. A proton and sodium are needed as co-solutes with an amino acid in 
exchange for a potassium ion (Kanai and Hediger 2004). Slc1a2 transporter of system X-AG 
was found to be upregulated on day 6 (Figure 5-5C). System x-c operates synergistically with 
system X-AG. The former exchanges glutamate, carried intracellularly by a transporter of the 
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X-AG system, with extracellular cystine (Verrey et al. 2004). The sole transporter slc7a11 
from system x-c, was found to be highly upregulated at stationary phase (more than 14-fold 
from exponential). The observed upregulation can be attributed to the requirement of cystine 
for glutathione synthesis, as discussed earlier (section 5.3).  
 Basic amino acids, i.e. arginine, lysine, and histidine, are carried by system y+ (Verrey 
et al. 2004). Transporter slc7a1 of this system is found to be higher than 2-fold elevated in 
stationary phase (p=0.053, Figure 5-5C). The trans-stimulation mechanism of the transporter 
may be the reason of the observed accumulation intracellularly (Figure 5-5B) of basic amino 
acids, while extracellularly (Figure 5-5A), their levels decrease. Trans-stimulation would 
mean that amino acids would be carried toward the side of the membrane, where the highest 
concentration occurs. 
Finally, system y+L exchanges basic amino acids against neutral (particularly 
branched chain) amino acids with sodium as a co-solute (Verrey et al. 2004). The levels of 
slc7a7 transporter appear to be highly upregulated at stationary phase (Figure 5-5C). This is 
correlated with the need to export intracellularly accumulating basic amino acids (Figure 
5-5B) in exchange for other substrates of the system (Figure 5-5A). 
 Most of the aforementioned differentially expressed transporters are reported to have 
high affinity for their substrates. A transporter having an affinity constant (Km) of less than 
100μM for its substrates, is considered as a high affinity transporter (Hediger et al. 2004). 
The latter transporters might be employed more often than the rest. This is because cells 
would be able to uptake or excrete substrates with the highest efficiency and selectivity. The 
differentially expressed transporters, discussed earlier, by the high producer cell line, namely 
slc1a4, slc6a9, slc1a2, slc7a11 and slc7a7; all are reported to have a high affinity for their 
respective substrates (Appendix II). On the other hand, two of the differentially expressed 
transporters, slc38a4 and slc7a1, are reported to show medium affinity for their substrates 
(i.e. Km values between 100-1000μM). The transporter slc38a5 from system N is reported to 
have a low affinity for its substrates (Km value greater than 1000μM).  
An extra level of information at the transcriptome and metabolome level has been 
presented in this part to compliment the recently published CHO genome as presented in Xu 
et al. (2011). A basis for comparing various CHO-derived hosts employed industrially with 
the aforementioned multi-omics approach has been set. Also important genes for further 
proteomic studies have been identified.  
In general, the findings presented herein highlight the complexity of amino acid 
transport in CHO cells. Several transporters have been identified as differentially expressed, 
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while some transporters were found to be expressed at very low levels (fractional copies per 
cell). Currently, it is unknown how the latter transporters can influence the studied system.  
The list of genes that are highly upregulated towards stationary phase, imply the 
“discomfort” of the cells under the conditions of batch culture due to nutrient limitations. 
These genes can be targeted to design more insightful feeding strategies. For example a 
feeding strategy can be designed based on the aforementioned differentially expressed 
transporters, where basic amino acids can be fed first and then branched chain amino acids. A 
staged feeding approach, however with different cooperating systems, has been also 
successfully followed for human cell lines in Nicklin et al. (2009), discussed in section 2.1.4. 
A better understanding of the system dynamics would be accomplished by a combination of 
dynamic feeding of individual amino acids, coupled with transcriptomic and proteomic 
analysis.   
 
5.6 Conclusions   
   
A combined transcriptomic and metabolomic study towards the understanding of the 
transmembrane transport of amino acids is presented in this chapter. Three CHO variants 
under batch conditions were analysed: a non-producer and two recombinant protein-
producers with different levels of productivity. Most amino acid transporters mRNA levels 
appear upregulated in response to decreasing extracellular concentrations. One-to-one 
relationships between transporter systems and individual amino acids are difficult to be 
established. This is because of the complexity of the transport regulation in mammalian cells, 
as well as the overlap of substrates for most a.a. transporters. Two genes, namely slc43a2 
(system L) and slc1a2 (system X-AG), were found to be constantly upregulated for rprotein 
producer cell lines and hence can be further explored as markers of productivity.  
Furthermore, a.a. transporters associated with the transport of a.a. related with the 
glutathione biosynthesis pathway (slc1a4, slc6a9, slc1a2, slc7a11), a well-known oxidative 
stress marker in mammalian cells, were significantly upregulated during culture for all the 
tested cell lines. Finally, extracellular analysis revealed comparable rates of amino acid 
uptake/secretion despite the observed differences in rprotein production levels. A finding that 
leads to the conclusion that transport of a.a. is not the limiting step for rprotein synthesis.  
A proteomic study in similar conditions will help establish a link between 
transcriptomic levels and actual transport capability. Such a study will aid in a better 
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understanding of the cellular response to starvation, as well as the regulation of homeostasis. 
This understanding could ultimately aid in the design of enhanced feeding strategies during 
bioprocesses. 
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Chapter 6                                                     
Design of fed-batch strategies 
  
As presented in part 2.2.3, the fed-batch strategy is the preferred mode of operation 
industrially for mammalian cells bioprocessing. The inefficiencies of cellular metabolism and 
the inherent biological variability, even between cell lines resulting from the same parent (Lu 
et al. 2013), both dictate the individual optimisation of media and feeds for each cell line. In 
this chapter several feeding strategies are designed and tested in an attempt to get a step 
closer to faster and more cell line-specific feeding strategies. Some of the designed feeding 
strategies also use the insight from the a.a. transport study in the previous chapter (Chapter 
5). All the aforementioned feeding strategies have been tested using the highest producing 
cell line GS46 (see also section 4.1).  
This chapter is divided in two parts. The first presents the rationale behind the design of 
the tested feeding strategies for the purposes of this thesis. In the second part the obtained 
results are discussed. 
 
6.1 Designed feeds 
 
This section will demonstrate the rationale of the design of all the feeds tested.  The 
final concentrations of nutrients in the feeds, as well as the way the feeds were prepared are 
presented in parts 4.2 and 4.3, respectively.  
  
6.1.1 Feed design based on nutrient consumption in batch (F_all) 
 
As presented in 2.2.2, a design of experiments (DOE) approach for twenty a.a. and 
glucose, at two levels only for each one of them (e.g. low and high), would result in more 
than two million experimental runs. In an attempt to design a fast and traceable way to 
calculate the amounts of the aforementioned components in the feeds and more importantly 
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in order to assess to what extent the consumption rates of nutrients in batch culture can be 
extrapolated based on integral viable cell concentration (IVCC), the method described in 4.2 
was followed. In brief, assuming that the consumption during fed-batch culture will remain 
the same as that in batch up until the point where the first measurable nutrient becomes 
limiting (Figure 6-1B), the observed consumption rates were scaled up in order to triple 
IVCC. The current poor understanding of the system does not allow for the accurate 
estimation of the IVCC target value and the days of culture at which this will occur (tharvest, 
see also Equation 8 and Equation 9 in 4.2). The reasons for this are discussed in 2.2.2 and 
mainly involve the inefficiencies of metabolism, which are difficult to quantify. These 
include the amount of glucose converted to lactate, that of glutamine broken down to 
ammonia, and the amount of TCA intermediates exported by the cells, which are all highly 
affected by the selected feeding strategy as well as the used medium.     
The target of tripling IVCC was chosen based on previous reports for fed-batch 
studies (Fan et al. 2009; Zhang et al. 2013), in-house knowledge for this cell line (personal 
communication, Colin Jaques, Lonza Biologics) and the reported duration of industrial fed-
batch cultures (De Jesus and Wurm 2011; Kelley 2009; Shaughnessy 2012). Furthermore, as 
the current approach attempts to answer whether consumption in batch culture can be scaled 
up based on IVCC projection, the selection of tripling the IVCC can also be seen as an 
optimisation target.  
 The average viable cell concentration observed in stationary phase of batch culture 
was used as an average Xv value up until the calculated IVCC was  tripled, as depicted in 
Figure 6-1A. It has been reported that feeding may increase maximum cell concentration 
significantly, as well as elongate stationary phase (Fan et al. 2009; Wlaschin and Hu 2006; 
Xie and Wang 1996). Hence, the approach presented herein presents an effort to couple both 
of these observed phenotypes, since it is very difficult to a priori predict how the feeding 
strategy will affect Xv. Based on the calculations presented herein the tripling of IVCC is 
predicted to occur on the eighteenth day of cell culture (Figure 6-1A). 
In stationary phase, the consumption rate of nutrients per cell is expected to be lower 
than those at the exponential phase used for this design (Carinhas et al. 2013; Martinez et al. 
2013). However, an increased IVCC will have to be maintained and hence this approach is 
justified. 
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Figure 6-1: Rationale behind the design of feeds based on linearly scaling up 
consumption rates observed in batch culture to achieve an increase in the integral viable 
concentration (IVCC). 
A) The left hand side graph presents the observed viable cell concentration (Xv) in batch 
culture (green colour) and the “predicted” (red colour) by the extrapolation of the 
stationary phase concentration in order to triple the IVCC obtained in batch. The 
tripling of IVCC is “predicted” to occur on the eighteenth day (marked with a vertical 
dashed black line) for the high producing cell line (GS46). This day is taken as harvest 
day (tharvest) for the calculation presented in part 4.2. B) The right hand side graph 
shows the concentration profile with time of all a.a. and glucose (pink line, much higher 
than the concentration of all other a.a.). On day five (marked with a vertical dashed 
black line), Asp (dark blue) and Glu (faint red) are depleted from the medium. The 
specific consumption rates until tlim (qS_tlim) have been selected as a representative 
average for subsequent fed-batch cultivation (see also text and part 4.2).   
 
In order to reduce the effects of essential components other than a.a. and glucose, the 
calculated amounts were diluted 1:1 in CD CHO medium (Invitrogen UK), which was used 
for their routine maintenance and as a medium for the fed-batch cultures. The final 
concentrations of a.a. and glucose in the F_all feed are presented in Table 4-1 in part 4.2. The 
feed was added in a 1:10 feed to culture volumetric ratio. The latter suggests that the addition 
of the commercial medium in the feed will have minimal effect as it is diluted to a final value 
of twenty times, when added to the culture.     
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6.1.2 Feed containing 40% more in all components than F_all (F_all_pl40) 
 
A straightforward strategy for determining whether there is a linear correlation 
between a.a. availability and IVCC is to further increase or decrease a.a. concentrations 
beyond those in the F_all feed. It was decided to increase the concentration of a.a. and to 
keep the previous ratios constant. This would maintain the principles of the proposed method 
of scaling up from batch and would also help assess whether these ratios would result in the 
same levels of by-product formation (ammonia and lactate) and rprotein yield. 40% more 
from all the nutrients discussed in the first fed-batch experiment in 6.1.1 was added in this 
feed, except for tyrosine. Tyrosine was already beyond the theoretical solubility limits in 
F_all (a clear solution was achieved with the method discussed in 4.3) and was decided not to 
further increase its concentration. The final composition of this F_all_pl40 feed is depicted in 
Table 4-1 in part 4.2 and was again prepared in a one to one ratio of water with the medium 
ordinarily used for these kinds of cell lines (CD CHO, Invitrogen, UK). 
 
6.1.3 Negative control feed (F_all_pl40_NO_CD_CHO) 
 
In order to assess the effect of components other than a.a. and glucose in the culture a 
feed was prepared based on F_all_pl40 that however was not one to one diluted in the 
commercial medium (CD CHO, Invitrogen, UK). This can be described as a negative control 
feed. 
 
6.1.4 Amino acid transport based feeds (F_M_TBC_1hr, F_BC_TM_1hr, 
F_M_TBC_pl40_12hr)  
 
As discussed in section 5.5, a feeding strategy based on the basic understanding of 
transport via the differentially expressed transporters for the high producing cell line could be 
devised. Given that the transporter y+L and several others carrying neutral amino acids were 
found to be upregulated, a very basic strategy was designed based on the one presented for 
human cell lines in 2.1.4 (Nicklin et al. 2009).  
Transporter y+L exchanges basic amino acids for branched chain a.a. (as presented in 
section 5.5 and Table II-9 in Appendix II). Transporters of the y+L system have similar 
substrate stereo-selectivity with system L (described in 2.1.4) and are also heteromeric with a 
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light chain encoded for by the slc3a2 gene. System L transporters were not found to be 
differentially expressed and hence the exact same strategy as in Nicklin et al. (2009) was not 
followed. Instead it was hypothesized that the differentially expressed transporters in batch 
would be more important for the system studied.  
Also, it is not possible to follow the exact same strategy as in the aforementioned 
study, where the extracellular environment was preloaded with glutamine, which, however, is 
not desirable in the GS system employed herein (as discussed in 2.1.3). In addition, in the 
aforementioned study, the experiment only took place for a few hours, whereas it is expected 
that cell culture will last for more than ten days in a bioprocessing context. For this reason, 
cells would require the majority of the amino acids and not only four of them.  
Given that branched chain amino acids are found to directly feed the TCA cycle with 
carbon in CHO cells (Carinhas et al. 2013; Selvarasu et al. 2012) and other mammalian cells 
(Nicklin et al. 2009), a staged feeding strategy targeting y+L transporter, was devised. 
Specifically, based either on F_all or F_all_pl40, branched chain amino acids (isoleucine, 
leucine, valine), followed at specified time intervals, the addition of the rest of the amino 
acids in culture (first most then branched chain feeds, F_M_TBC). The remaining amino 
acids include all the proteinogenic amino acids except Ala, Gln and Gly that were found to be 
accumulating, as described in 4.2. Also, the opposite was tested, which was not found to have 
beneficial effects in the study described in 2.1.4 (Nicklin et al. 2009), i.e. feeding first with 
branched chain and then with the rest of the amino acids (first most then branched chain 
feeds, F_BC_TM). The staged feeding took place at 1 hr and 12 hr intervals, as it is unknown 
when and if cells can be triggered by this way of transport. In Nicklin et al. (2009) a 1 hr 
interval was found to be enough, however, a different cell line and experimental system is 
employed herein.  
As it is: a) unknown which amino acids are exactly carried by system y+L, b) what are 
the exact operational characteristics (Km, vmax values, further discussed in 2.1.4) of this a.a. 
transport system for CHO cells and c) mainly that the majority of amino acids need to be fed 
as opposed to the staged feeding case described above in Nicklin et al. (2009); there are 
multiple of staged feeding strategies that can be devised. Consequently, a study supplying 
only the basic amino acids that are exchanged for branched chain by the transporter is beyond 
the purposes of the current thesis. However, even not with the optimal conditions, such an 
experiment can aid in identifying the robustness of the cells in multiple environments of 
amino acids. Ultimately, such a strategy could lead to conclusions regarding amino acid 
transport specificity in relation to growth and rprotein production in a bioprocessing context.  
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6.2 Results & discussion 
 
This part is further divided into four parts. The first part presents the performance of all 
tested feeds for the purposes of this thesis until day eighteen, i.e. the day when the tripling of 
the integral of viable cell concentration (IVCC) was initially predicted to occur. Secondly, the 
performance of all the feeds is compared and contrasted with respect to main cell culture 
indicators, IVCC, product yield and specific productivity, for results obtained on day ten, 
when the batch cell culture is no longer viable. Also, the same indicators are compared for 
day fourteen, when viability for all tested feeds falls below 80%. Thirdly, the results of the 
extracellular analysis of nutrients/ metabolites for the most successful feeds are presented. 
The final part discusses how the use of flux balance analysis can aid in the design of feeds. 
   
6.2.1 Growth characteristics of all tested feeds until day eighteen or until 
viability drops to zero 
 
Results for IVCC for the designed fed-batch cultures vs values for batch cultures (all 
in 50mL Erlenmeyer flasks) are presented in Figure 6-2. None of the designed feeding 
strategies manage to achieve the target value of IVCC. This has been set as a value close to 
three (3.06) times that of batch culture (Figure 6-2, red bar). The commercial feed, however, 
reaches the highest value, 2.8 times the IVCC of batch culture, closer to that intended for the 
designed feeds. This shows that the predicted IVCC target value is achievable. Furthermore, 
none of the designed feeding strategies are able to sustain viable cells until the eighteenth day 
of culture. Viability for all the feeds drops to zero on day seventeen (data not shown), apart 
from the feed that did not include CD-CHO, for which viability drops to zero on day twelve.  
There are several reasons for which the designed feeds are not sufficient to sustain a 
higher IVCC. The feed supplied induces the production of toxic by-products in culture, e.g. 
ammonia and/or lactate. Another reason could be that the calculated concentration of a.a. is 
not sufficient, or that other components such as lipids, vitamins, buffers, other carbon sources 
(e.g. pyruvate) vital for cellular growth should be supplied at higher concentrations than those 
in the designed feeds. The latter would involve for example preparing the feeds in the full 
amount of basal medium. However, analysis of these species did not take place in batch for 
the purposes of the current thesis, so conclusive results cannot be drawn.  
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Figure 6-2: Comparison of integral of viable cell concentration (IVCC) until day 
eighteen, or until viability drops to zero, for all the feeding strategies tested against 
batch culture performance for the high producing cell line GS46.  
From left to right the feeds tested and their coding is: “Batch_300mL”, batch with a 
starting volume of 300mL in CD CHO medium (Invitrogen, UK); “Batch_50mL”, batch 
with a starting volume of 50mL in CD CHO medium (Invitrogen, UK); “F_all”, fed-
batch culture with 50mL starting volume and feed prepared from scaling up the 
observed in “Batch_300mL” a.a. and Glc rates and diluting one to one in the medium 
(CD CHO, Invitrogen, UK); “F_M_TBC_1hr”, fed-batch culture with 50mL starting 
volume and feed prepared based on “F_all”, however now branched amino acids (BC) 
follow the addition of most amino acids (M) at 1hr intervals; “F_BC_TM_1hr”, reverse 
staged feeding strategy as the one for feed “F_M_TBC_1hr”; “F_all_pl40”, feed 
containing 40% more than the ingredients in “F_all”, also diluted one to one in CD 
CHO medium (Invitrogen, UK); “F_M_TBC_pl40_12hr”, feed similar with 
“F_M_TBC_1hr”, however, now staged feeding occurs at 12 hour intervals and the feed 
is prepared based on “F_all_pl40”; “F_all_pl40_NO_CD_CHO”, exact same feed as 
“F_all_pl40”, however, not diluted one to one in CD CHO (Invitrogen, UK); 
“F_C_Inv”, commercially available feed for GS-CHO cells lines (CD EfficientFeedTM C 
AGTTM, Invitrogen, UK) and “Predicted”, this does not correspond to a feeding 
experiment, but to the IVCC to be reached based on the design of feeds, i.e. about three 
times that of the batch. Error bars correspond to one standard deviation of biological 
triplicates. Statistical analysis on biological triplicates is depicted as: one star (*) 
represents 95% confidence (p<0.05) and two (**) 99% (p<0.01). 
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Another conclusion from Figure 6-2 is that the staged feeding experiments at one hour 
intervals depicted based on whether branched chain amino acids follow the addition or are 
followed by the addition of the other amino acids, in the yellow and orange colour, 
respectively, sustain a higher IVCC than both of the non-staged feeds prepared for the 
purposes of this thesis. This shows that staged feeding demonstrates desired characteristics in 
bioprocessing.    
The presented IVCC results aid in appreciating what is an achievable IVCC target 
during fed-batch cultures. A valid IVCC estimate can aid in the improved design of feeds, as 
well as an assessment of newly designed feeds. The latter would involve, for example, 
investigating what is the maximum IVCC fold change in a fed vs batch culture assuming that 
similar kind of basal media are used. The advantage of a batch culture using for example an 
industrial relevant medium is that experiments last for much shorter time than fed cultures. 
This is exactly what the approach presented herein attempts, i.e. establishing a technique that 
requires a much shorter time for developing a feed, based on a pre-existing medium. A better 
insight in current industrial practices could possibly provide a better answer to this question, 
since papers in the literature (as discussed in 2.2.3) rarely make such comparisons. Usually in 
literature studies the approach involves using a new medium during the feeding strategy or, in 
most cases, a comparison with the batch has not been included.     
 
6.2.2 Growth and productivity characteristics of all tested feeds until day ten and 
fourteen 
 
The performance of the tested feeds is evaluated on days ten and fourteen of cell 
culture in this part. Day ten has been selected in order to compare all feeds at the time when 
viability drops to zero in both batch experiments (day 10 for 50mL and day 9 for 300mL). 
Day fourteen has been selected as a more representative harvest day than day eighteen, since 
at this day viability drops just below 80%. Viability on day fourteen was between 76% and 
85% for all feeds (except the batch cultures and the feed not diluted one to one in the 
commercial medium), with no statistical difference (data not shown). Harvesting cells with 
low viability may significantly affect downstream separations (Hogwood et al. 2013; Tait et 
al. 2012) and for this reason comparison of feeds at a later stage when viability is even lower 
was not considered. Also, IVCC results are discussed for the aforementioned sampling days 
as it is important to perform the comparisons of the feeds for all bioprocess relevant 
performance indicators (IVCC and yield).   
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Day ten results 
Interestingly, the yield by all fed cultures on day ten is statistically higher than the 
batch cultures and the fed culture not diluted in the basal medium (Figure 6-3A). The 
commercial feed and the F_all_pl40 present statistically higher yield than all the other feeds. 
The commercial feed presents the highest fold change from the 300mL culture, i.e. about 3.4 
times higher, whereas the F_all_pl40 observed yield is 2.5 times that of the batch, statistically 
lower than the commercial feed at the 95% confidence interval. As can be seen in A, the 
commercial (pink) and the F_all (black) feeds, as well as the staged strategy feeds based on 
F_all (yellow and orange) present a slightly higher IVCC than the following feeds: batch 
culture in 300mL (bright green), the F_all_pl40 (grey) and the staged feed at 12 hours 
interval based on F_all_pl40 (light blue). None of the aforementioned feeds present statistical 
significant difference from the 50mL batch culture. 
The comparison of specific productivities achieved on day ten, reveals that the 
commercial feed along with the F_all_pl40 based feeds present statistically higher 
productivities than all the other feeds. The latter feeds include the F_M_TBC_pl40_12hr, i.e. 
the staged feed based on F_all_pl40, where branched chain amino acids follow the addition 
of most amino acids at twelve hours interval. There is also a statistical difference between the 
specific productivities of all the F_all based staged feeds (F_M_TBC_1hr and FBC_TM_1hr) 
from the feed based on F_all_pl40 but not diluted in the basal medium and the two different 
batch feeds (in 300mL and 50mL of culture volume).    
 
Day fourteen results 
In Figure 6-3B the same culture indicators are compared and contrasted for all tested 
feeds for day fourteen of cell culture. Regarding the IVCC, the commercial feed achieves a 
statistical significant higher IVCC than any other feed. While from the rest feeds it is 
interesting that the feed based on F_all_pl40, but not diluted one to one with the commercial 
medium, cannot sustain growth until day fourteen. This shows the importance of other 
nutrients in the feeds, as well as that optimization of certain components in feeds should take 
place in the complete feed, rather than in a feed where only a few groups of nutrients are 
present. The latter refers to the fact that the aforementioned feed only contains the main 
carbon source glucose and a.a., i.e. two only groups of nutrients. It does not, for example, 
contain nucleic acid derivatives or lipids, which are both essential for cellular growth.  
The presented underperformance of the feed not diluted with the basal medium 
(F_all_pl40_NO_CD_CHO) is mainly attributed to the fact that essential medium 
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components that are not present in the feed, such as vitamins, trace elements, etc., are 
exhausted from the basal medium as well as diluted to very low levels because of the feeds. 
This feed is therefore unable to sustain higher growth. In the other feeds, it appears that the 
supplementation of the medium components in a one to twenty ratio at feeding intervals is 
sufficient to ensure that other non-a.a. components are not overly diluted. 
Continuing the discussion of the IVCC observed results on day fourteen (Figure 
6-3B), it also appears that the staged feeding experiments based on F_all (F_M_TBC_1hr and 
FBC_TM_1hr) present a higher IVCC than the F_All_pl40 feed, but not from the F_all feed. 
In Figure 6-2, where the IVCC is compared based on day eighteen of cell culture for all 
feeds, the staged feeds present a statistically higher IVCC. This shows that the staged feeding 
strategy might be beneficial towards increasing IVCC during the decline phase of cell culture.  
Additionally, the presented results for IVCC on both Figure 6-2 and Figure 6-3 
demonstrate that there is no linear relationship with amino acids addition and IVCC. This is 
because the F_all_pl40 feed containing 40% more of all components than F_all does not 
sustain a higher IVCC. There might be plenty of reasons for this observation, e.g. increased 
toxic by-products that are further discussed in the next part (6.2.3), where extracellular 
analysis of nutrients is presented. 
The comparison of the yield achieved with the different feeds on day fourteen 
presents a clearer picture on the more successful feeds (Figure 6-3B). As it is evident, all 
staged feeding experiments perform poorly when compared with the rest of the feeds. The 
highest rprotein yield on day fourteen is achieved with the commercial feed (F_C_Inv, pink), 
at approximately 2.46±0.15 g/L (error represents one standard deviation of biological 
triplicates), 4.5 times higher than the batch culture yield (not shown but extracted from data 
in Figure 6-3). Interestingly, F_all_pl40 performs slightly better than the F_All feed, both of 
which present 3.5 (1.902±0.003 g/L) and 3.1 (1.70±0.05 g/L) times the yield observed in 
batch, respectively. 
As far as specific productivity is concerned a slightly different picture is presented. 
F_All_pl40 feed presents a statistically significant higher productivity than feed F_All 
(Figure 6-3B); however F_C_Inv does not present statistical difference between any of the 
aforementioned feeds. Interestingly, the staged feed based on F_All_pl40 at 12 hour intervals 
does not present statistical difference from F_All. 
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Figure 6-3: Integral of viable cell concentration (IVCC), yield and specific productivity 
(spec. productivity) comparisons for batch and fed-batch experiments for days ten (A, 
top) and fourteen (B, bottom). 
A) Comparison of IVCC, yield and specific productivity on day ten of cell culture, when 
the viability for batch cultures drops to zero. From left to right the feeds are as 
presented in the legend and are encoded as described in Figure 6-2. The viability for all 
the presented fed-batch experiments is more than 90% and there is no statistical 
significant difference between viability values (data not shown). All cell culture 
indicators presented are scaled based on the 300mL batch culture (bright green). 
B)  IVCC, yield and specific productivity on day fourteen of cell culture for all feeds 
tested. Batch experiments and the prepared feed not diluted one to one in CD CHO 
(Invitrogen, UK) are not viable by the presented day. Regarding the viability of the 
other feeding experiments, this is between 75% and 86% with no statistical significant 
differences between tested feeds (data not shown). The cell culture indicators presented 
have been scaled based on the lowest value for each one of the following feeds: F_all (set 
at one in yield and specific productivity) or F_all_pl40 (set at one in IVCC). 
 In all cases error bars represent one standard deviation of biological triplicate 
samples. One star (*) represents 95% (p<0.05) confidence.  
  
Overall discussion 
The results presented herein demonstrate how important cellular growth is during cell 
culture. The commercial feed (F_C_Inv) sustains higher growth and although productivity 
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remains close to the levels of the other tested feeds, it results in a much higher yield.      
Nevertheless, a higher than threefold increase in yield occurs for both of the designed feeds 
compared to batch. This suggests that the scale-up method described herein is partially 
successful. This is particularly true if one takes into account that a single batch experiment 
was enough to design a feed with 18 components that achieves comparable results to 
commercial solutions.  
Moreover, no further analytical methods were used, such as for example measurement 
of osmolarity or other nutrients (such as lipids, vitamins, etc.). The feeds only included amino 
acids (except Ala, Gln, and Gly), were diluted with the basal medium used for routine cell 
maintenance and the pH was adjusted to 7 with a 5N NaOH solution. The simplicity of the 
design arguably suggests that cells are robust in regulating nutrient consumption and also that 
a.a. metabolism is highly interconnected with other important nutrients.  
As far as the reasons why the feed with the 40% more amino acids (F_All_pl40) 
presents a higher productivity than F_All are concerned, they can be attributed to the higher 
osmolarity of the extracellular space. Although osmolarity has not been measured 
extracellularly, arguably the 40% more concentrated feed will present an increased 
extracellular space osmolarity than the original. It has been shown that increased osmolarity 
aids in increasing rprotein yield (Ho et al. 2012; Kim et al. 2002; Takagi et al. 2001).  
The underperformance of the staged feeding strategies can be attributed to the fact 
that in most cases all amino acids remain in the extracellular space. For example, the second 
day of cell culture when most amino acids are fed (in one of the F_M_TBC feeds tested, i.e. 
first most and then branched chain amino acids), branched chain amino acids have not been 
depleted. A better strategy would ensure that these amino acids would be at low levels in the 
extracellular environment, before their supplementation. 
Arguably, staged feeding would represent a more complicated strategy than those 
currently used in the industry. It would only be preferred if it could be proven that the 
resulting yield is significantly higher than the established approach. The experimental results 
show that these strategies are able in certain cases to maintain a higher IVCC, i.e. the feeding 
strategies at 1 hr intervals, showing that there might be a potential of further investigating this 
way of feeding. However, this increased IVCC comes with a sacrifice in specific productivity 
in this study.  
Further experiments could be designed to test whether the staged feeding strategy can 
be beneficial. A strategy that would involve supplying the required amount of only one type 
of amino acids, rather than several, followed by the branched chain ones would potentially be 
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more beneficial. Also, other types of amino acids can be tested, e.g. feeding only basic amino 
acids and then branched chain ones. Close to what was presented in Nicklin et al. (2009), 
another feeding strategy could involve supplying glutamate first and then a mix of the 
remaining a.a. In my view a comprehensive analysis of a.a. transporter protein levels in fed-
batch cultures should be devised prior to any other staged feeding. The results of such a 
proteomic study could provide a better insight in designing a more promising feeding 
strategy. 
 
6.2.3 Extracellular nutrients analysis 
 
Analysis of extracellular rates was also carried out for the three most successful feeds: 
F_all, F_all_pl40 and F_C_Inv. This analysis was performed in order to identify the reasons 
for the underperformance of the designed feeds.  
 
Figure 6-4: Growth characteristics of the tested feeds: F_all (black), F_all_pl40 (grey) 
and F_C_Inv (pink). 
All feeds are in further detail discussed in part 4.2. The top left graph presents the 
viable cells concentration (Xv, in cells/mL). The top right graph presents the integral of 
viable cells concentration (IVCC, in cells/mL*hr*10^6). The bottom left graph the non-
viable cells concentration (Xd, in cells/mL). The bottom right graph presents the 
viability (% of total cells).  
 
The growth characteristics for the three most successful feeds for fourteen days of 
culture are depicted in Figure 6-4. It appears that all feeds can sustain a similar growth 
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profile. The commercial feed achieves a higher maximum density, as well as a more 
elongated stationary phase at higher viable cells concentration (Xv) than any other of the 
designed feeds. F_all_pl40 (feed containing 40% of all nutrients except from tyrosine than 
F_all) presents a lower growth rate in exponential phase, but a very similar maximum cell 
density with the F_all feed. The commercial feed achieves a higher IVCC, also discussed in 
the previous part (6.2.1 and better depicted in Figure 6-3B). Non-viable cells’ concentration 
is similar for all feeds, as well as viability, both depicted in the bottom part of Figure 6-4.  
Achieved yield for the three feeds through the time-course of culture is presented in 
Figure 6-5 (right panel, second plot from top). Yield analysis for all three feeds is discussed 
in the previous part (6.2.2 and Figure 6-3B). The time-course concentration of rprotein shows 
that in the commercial feed saturation of antibody concentration occurs earlier (on day 
eleven) than any other of the two feeds. 
 
Depleted and accumulating amino acids  
Extracellular time-course concentration data for the amino acids found to be depleted 
in fed-batch culture is depicted in the bottom four graphs of Figure 6-5. The time-course 
concentrations of the remaining amino acids along with pyruvate are depicted in Figure XI-1 
and Figure XI-2 in Appendix XI. Depletion and accumulation are important process 
performance indicators and that is why they are analysed in this part. Depleting amino acids 
limit growth and rprotein yield, while accumulating amino acids may also act as inhibitors of 
growth (Curriden and Englesberg 1981). 
Extracellular a.a. concentration analysis revealed depletion of histidine (His) and 
tryptophan (Trp) along with a consumption of glutamine after day nine and partial depletion 
of asparagine (Asn) on day ten for F_all (Figure 6-5). Glutamine (Gln) is possibly consumed 
to compensate for histidine depletion (with no evidence based on published CHO 
biochemical networks, further discussed in the following part 6.2.4), which is also evident 
from the fact that rprotein concentration keeps increasing even after day 9 (Figure 6-5). The 
nature, however, of the His and Trp depletion, i.e. very sudden, when compared to the 
depletion of Asn, also suggests that another component such as a nucleic acid derivative (see 
also part 2.2.1) might be limiting, without also excluding a possible mis-derivatization during 
a.a. analysis (described in 4.10). This depletion may be the reason of the reduced viable cell 
concentration during stationary phase in comparison with the commercial feed.  
Interestingly, the depletion of histidine is also apparent in F_All_pl40 feed one day 
earlier than in F_All (Figure 6-5, bottom left plot), although the former contains 40% more of 
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this amino acid. Tryptophan (Figure 6-5, bottom right plot) is sustained in low levels during 
the F_all_pl40 culture, but does not appear to be depleted. Both of the aforementioned amino 
acids present the sudden depletion described earlier for F_all. Asparagine presents a 
minimum of 4.2±0.1 mM (error represents one standard deviation of biological duplicates). 
Glutamine accumulates at much higher levels than any of the other feeds, reaching a 
concentration of 5.31±0.05 mM. Glutamine also does not present the sudden consumption 
phenotype of F_all culture after day eight of culture. This can be attributed to the fact that Trp 
does not deplete as in the F_all culture. 
Histidine and tryptophan remain at much higher levels in the commercial feed 
(F_C_Inv, Figure 6-5, plots at the bottom). This also shows that the mis-derivatization 
discussed earlier for both of these a.a. in F_all is possibly not a likely explanation. 
Asparagine depletes much earlier than in any other feed, since it appears to be in a much 
lower concentration in this feed. Another notable difference with Feed C is that tyrosine 
appears to deplete on day ten (bottom left plot in Figure XI-2 in Appendix XI). This amino 
acid, however, is not depleted in the two prepared feeds. The low solubility of this amino acid 
(depicted in Table 4-1 in section 4.2) might be the reason for not including it in higher 
concentrations in the commercial feed.     
Higher asparagine consumption has been shown to increase alanine, glycine and 
ammonia concentrations in CHO cell culture (Hansen and Emborg 1994; Selvarasu et al. 
2012), which does not occur for the data presented herein for alanine and glycine. Higher 
asparagine consumption occurs in cultures with both of the prepared feeds, as also depicted 
with the PCA of the observed consumption rates of the nutrients presented later on (Figure 
6-6). The highest consumption rate of asparagine is observed in the feed where it is supplied 
with the highest concentration (F_all_pl40). This is evident from the sharp decline of the 
concentration of asparagine for the majority of the feeding intervals of F_all_pl40 in Figure 
6-5, as opposed to the other feeds.  
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Figure 6-5: Extracellular profiles of main metabolites and main and/or limiting amino 
acids for the three different feeds tested. 
From left to right and top to bottom the concentration of the following metabolites 
within culture of CHO cells for three different feeds in Erlenmeyer flasks is depicted: 
ammonia (Amm), glucose (Glc), lactate (Lac), recombinant protein (rprotein), 
asparagine (Asn), glutamine (Gln), histidine (His), tryptophan (Trp). The three 
different feeds are: F_all (contains glucose and a.a. and is diluted one to one with the 
commercial medium), F_all_pl40 (contains 40% more in all components than F_all, 
except tyrosine, see text for details) and a commercial feed: F_C_Inv (CD 
EfficientFeedTM C AGTTM, Invitrogen, UK). Error bars represent one standard 
deviation from biological duplicate samples.  
 
Interestingly, glycine accumulation is similar in all feeds (presented in Figure XI-1, 
right panel third plot from the top, in Appendix XI). Glycine levels reach a concentration of 
4.14±0.05 mM (error represents one standard deviation of biological duplicates) in F_all, 
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3.60±0.04 mM in F_all_pl40 and 3.35±0.03 mM in F_C_Inv. The fact that glycine levels 
reach a similar level (maximum difference is 20%, between F_all and F_C_Inv) demonstrates 
that the metabolic reactions related with the accumulation of glycine (further described in 
6.2.4) occur at comparable rates in all cultures.  
On the other hand, alanine presents greater differences between the three feeds (levels 
are depicted in the top right plot of Figure XI-1 in Appendix XI). F_all, as with glycine, 
presents the higher accumulation of alanine (16.4±0.2 mM, error represents one standard 
deviation of biological duplicates). The feed containing 40% more of all components than in 
F_all (F_all_pl40) presents an alanine accumulation in the culture up to 12.2±0.1 mM. The 
commercial feed (F_C_Inv) presents the lowest accumulation of alanine (8.1±0.1 mM). It 
appears that metabolic reactions associated with alanine accumulation occur with a much 
higher level than all the other feeds in culture treated with F_all (further discussed in 6.2.4). 
 
Ammonia, Lactate and Glucose 
In addition with the depletion of amino acids, the profile of the well-documented by-
products ammonia and lactate, along with that of the main carbon source, i.e. glucose, are 
analysed. This is in order to understand the observed performance of the tested feeding 
strategies.  
Ammonia accumulates at much higher levels in the designed feeds than in the 
commercial feed. Ammonia accumulation reaches a maximum of 13.4±0.4 mM (error 
represents one standard deviation of biological duplicates) on day fourteen for F_all 
(presented in Figure 6-4, top left graph). As far as F_all_pl40 is concerned, this results in 
60% higher levels of ammonia than F_all (21.6±0.1 mM). On the other hand the commercial 
feed presents a maximum value of 4.90±0.01 mM.  
Evidently, the toxic nature of ammonia can explain the observed differences in IVCC 
for the three feeds (discussed in 6.2.2 and visualized in Figure 6-5). A linear relationship is 
observed between ammonia accumulation and reduction of IVCC in the cultures fed with the 
three tested feeds. It appears that ammonia levels above 5 mM (the value of ammonia reached 
with the commercial feed) are toxic for cells, which is also reported in other studies (Hayter 
et al. 1991). However, it is also reported that levels between 2 and 5mM are also growth 
inhibiting (Altamirano et al. 2013). Interestingly, the high ammonia levels do not appear to 
affect specific productivity as F_all_pl40 culture displays the exact same specific 
productivity with the commercial feed, described in 6.2.2. This has not been previously 
reported in the literature. It is widely reported that ammonia inhibits growth and subsequently 
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the resulting yield in bioprocesses, as reviewed in Altamirano et al. (2013). Also, ammonia 
affects glycosylation of the rprotein, reviewed in Altamirano et al. (2013). The latter has not 
been evaluated for the purposes of this thesis.  
There is also a linear relationship between the amount of asparagine in the feed and 
ammonia accumulation. Clearly, the commercial feed contains the lowest level of asparagine. 
This interesting correlation will be discussed in more detail in part 6.2.4, where the 
biochemical network is also analysed. 
The other reported growth-limiting by-product, lactate, was found to accumulate until 
day six of culture for F_all (Figure 6-5, left panel, second from top plot) reaching a maximum 
concentration of 13.9±0.6 mM (error represents one standard deviation of biological 
duplicates). Following this, it accumulates again after day eleven to a concentration of 9±1 
mM on day fourteen. F_all_pl40 presents a similar lactate production phase reaching a 
maximum of 12.4±0.4 mM on day six, after which a net lactate consumption phase is 
observed until lactate is depleted. The commercial feed again peaks at the same day as the 
other feeds with a maximum of 14.25±0.7 mM. After this maximum the culture exhibits a net 
consumption rate, however, lactate levels appear to oscillate during culture.  
 Glucose does not deplete in any of the three tested feeds (Figure 6-5, top right plot). 
The observed consumption rates for the three different feeds are further analysed in the next 
section using PCA. 
 The fact that none of the metabolites or glucose is depleted until day six of culture 
demonstrates that net lactate consumption, which is observed for all three feeds, does not 
occur due to depletion of nutrients. This is discussed in a few manuscripts in the literature, 
where lactate consumption in batch cultures is attributed to glutamine (Zagari et al. 2013) or 
glucose (Martinez et al. 2013) depletion. As is evident from the results presented herein, 
lactate consumption probably occurs because of the high levels of lactate extracellularly, 
since all three feeds present a similar value of maximum lactate concentration. This is also 
discussed in Mulukutla et al. (2012), where metabolic flux and transcriptome analysis for a 
mouse myeloma cell line led the researchers to conclude that high extracellular lactate 
concentrations along with reduced glycolytic flux were the main reasons for the metabolic 
shift from net lactate production to net consumption.  
However, Le et al. (2012) discuss that lactate consumption is independent of glucose 
and lactate concentrations at the point of the shift. In that study, the researchers used 
multivariate methods to analyse 134 process parameters during production and inoculum 
train of 243 industrial bioreactor runs. It would be interesting to test whether the 
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experimentally observed phenotype for the feeds prepared for the purposes of this thesis 
occurs in a more industrially relevant culture environment, i.e. where pH would be controlled 
to constant neutral levels (Li et al. 2010).   
 The fact that all the designed feeds maintain this lactate phenotype is of particular 
importance, since this is a desirable phenotype during bioprocessing that generally enhances 
productivity (Luo et al. 2012; Zagari et al. 2013). However, Li et al. (2012) discuss that the 
complete depletion of lactate is not entirely favourable, since their observations suggest that 
under those conditions CO2 partial pressure and ammonia build-up were much higher than in 
cultures where lactate was not entirely depleted. The results presented herein largely support 
these findings. However, interestingly, the culture where lactate is depleted (F_all_pl40) 
presents a higher yield than F_all, despite the significant accumulation of ammonia.  
In general terms, however, the observed lactate phenotype for both of the designed 
feeds validates that the method presented herein demonstrates desirable characteristics in 
CHO cell culture. Consequently, such a method can be used for further optimisation of feeds, 
where other components have to be optimised as well.  
 
Formal comparison of specific production/consumption rates using PCA 
Principal component analysis (PCA) of the specific rates of all the analysed 
metabolites for the three feeds readily depicts the differences in specific rates between the 
commercial feed and the two prepared feeds. This, multivariate analysis of specific rates 
rather than concentrations, is a strategy also presented in Selvarasu et al. (2010b), however 
not for the comparison of different feeds. The aforementioned differences in the three feeds is 
evident in Figure 6-6, where the prepared feeds arrows fall much closer to each other than the 
commercial feed loading arrow. Interestingly, PCA also reveals a greater consumption of 
nutrients early in cell culture for the commercial feed. This is depicted by the fact that 
towards the loading arrow of the commercial feed specific rates of metabolites with a more 
yellow colour are depicted (Figure 6-6, left plot).   
Design of fed-batch strategies  115   
 
Figure 6-6: Principal component analysis of the specific rates for the three tested feeds 
and for the first two principal components. 
The scores represent the specific rates of all measured metabolites, along with the 
apparent growth and death rates, between the feeding intervals for the feeds: F_all 
(black), F_all_pl40 (grey) and a commercial feed F_C_Inv (pink), see part 4.2 for more 
details. The loadings represent the three feeds. Both plots present the exact same data, 
however the left is coloured based on the interval of cell culture. Specific rates start 
from yellow for the rates between days 2 to 4 (“days 2-4”) and gradually approach the 
red colour at the last interval (“days 12-14”). The right graph is coloured based on the 
different specific rates presented, 26 in total: glucose (qGlc), ammonia (qAmm), lactate 
(qLac), for 19 a.a. and apparent specific growth (muapp) and death (kdapp) rates. The 
blue rectangle reprents the zoomed area for the next plot presented in Figure 6-7.    
 
The same occurs for the consumption of the nutrients with the highest consumption 
rates, i.e. glucose and asparagine. Glucose is consumed with a higher rate until day eight by 
the cells treated with the commercial feed (glucose consumption between days two and four 
is not depicted as the value was higher and falls out of the bounds of the presented graph). 
After day eight the prepared feeds present higher consumption rates of glucose than the 
commercial feeds.  
Asparagine consumption is higher for the commercial feed until day four, when the 
consumption rates for the other two feeds start to increase much higher for the prepared 
feeds. This is depicted better in the right plot of Figure 6-6, where with a light green colour at 
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the top of the graph all the asparagine consumption rates are positioned, pointed by the 
arrows of the two designed feeds. 
Other nutrients that evidently present greater consumption rates early in the culture 
for the commercial feeds include serine, leucine and valine. The latter a.a. are all marked with 
yellow colour in the left plot of Figure 6-6 and are present at the bottom of the graph, close to 
the F_C_Inv loading arrow. Another notable difference regarding the consumption of amino 
acids is the increased consumption of aspartate in the commercial feed, as presented by the 
pink cloud of aspartate scores in the bottom right corner of the right plot of Figure 6-6. As 
also depicted in Figure XI-1 in Appendix XI, the concentration of aspartate in the commercial 
feeds is much higher than in the designed feeds. 
As far as non-amino acid components are concerned, ammonia production is higher 
for the most of the intervals for the prepared feeds. This is depicted by the green ammonia 
scores pointed by both prepared feeds arrows in the right plot of Figure 6-6, which also 
confirms what was mentioned previously about ammonia accumulation. Lactate, on the other 
hand seems to be produced with a higher rate between days four and six for the designed 
feeds, while it appears to be consumed with a higher rate between day six to eight and eight 
to ten for both the designed feeds than the commercial feed.    
Figure 6-7 presents the zoomed blue rectangle from Figure 6-6 in greater detail. There 
it is also evident that some more amino acids are consumed with a higher rate earlier in 
culture for the commercial feed. The amino acids depicted in the left plot of Figure 6-7, 
higher consumed from the cells treated with the commercial feed between days two and four 
(marked with yellow) are the following: lysine, isoleucine, proline, tyrosine and arginine. As 
it is also depicted glycine accumulates at a higher rate for the same time interval for the same 
feed.  
Another notable observation from Figure 6-7, better observed in the right plot this 
time is that serine (depicted with a violet colour) is consumed with the highest rate in the 
commercial feed between all feeding intervals except the day 12 to 14 one  (see also Figure 
XI-2 in Appendix XI, second from bottom plot in left panel). From the same graph a greater 
glutamate consumption is observed in the designed feeds (grey area close to the prepared 
feeds loading arrow. Also a higher glutamine (light violet colour) and lactate accumulation 
(light blue colour) for the designed feeds is also evident from the right plot of Figure 6-7.    
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Figure 6-7: Principal component analysis of the specific rates for the three tested feeds 
and for the first two principal components presented in the blue rectangle in Figure 6-6. 
The scores represent the specific rates of all measured metabolites, along with the 
apparent growth and death rates, between the feeding intervals for the feeds: F_all 
(black), F_all_pl40 (grey) and a commercial feed F_C_Inv (pink), see part 4.2 for more 
details. The loadings represent the three feeds. Both plots present the exact same data, 
however the left is coloured based on the interval of cell culture. Specific rates start 
from yellow for the rates between days 2 to 4 (days 2-4) and gradually approach the red 
colour at the last interval (“days 12-14”). The right graph is coloured based on the 
different specific rates presented, 26 in total: glucose (qGlc), ammonia (qAmm), lactate 
(qLac), for 19 a.a. and apparent specific growth (muapp) and death (kdapp) rates. The 
red rectangle reprents the zoomed area for the next plot presented in Figure 6-8.    
 
Figure 6-8 presents in more detail the red rectangle of Figure 6-7. In the former the 
greater rprotein production for the commercial feed is presented (right plot of Figure 6-8, 
rprotein scores with a pink colour), which appears to be greatest between days six and eight 
(since it is further away from the x=zero, y=zero point of the graph). Interestingly, the latter 
interval is also when the lactate shift occurs. However, the prepared feeds present a better 
production between days twelve and fourteen that backups the observed saturation of rprotein 
produced after day eleven for the commercial feed (discussed earlier). Other notable 
differences in this figure include the greater threonine, valine, isoleucine and leucine 
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consumption for the commercial feed throughout all the presented feeding intervals. While, 
the designed feeds appear to consume tryptophan with a higher rate. 
   
Figure 6-8: Principal component analysis of the specific rates for the three tested feeds 
presented in the red rectangle in Figure 6-7. 
The scores represent the specific rates of all measured metabolites, along with the 
apparent growth and death rates, between the feeding intervals for the feeds: F_all 
(black), F_all_pl40 (grey) and a commercial feed F_C_Inv (pink), see part 4.2 for more 
details. The loadings represent the three feeds. Both plots present the exact same data, 
however the left is coloured based on the interval of cell culture. Specific rates start 
from yellow for the rates between days 2 to 4 (days 2-4) and gradually approach the red 
colour at the last interval (“days 12-14”). The right graph is coloured based on the 
different specific rates presented, 26 in total: glucose (qGlc), ammonia (qAmm), lactate 
(qLac), for 19 a.a. and apparent specific growth (muapp) and death (kdapp) rates. The 
green rectangle includes all apparent death and growth rates that are all towards the 
commercial feed loading arrow.    
 
The green rectangle of Figure 6-8 includes only the specific apparent growth and 
death rates, so it is not further zoomed. All are closer to the commercial feed due to the 
higher presented growth and the higher achieved non-viable cell density. The latter is 
attributed to the higher achieved growth than the two designed feeds. 
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Overall, PCA depicts great differences between the designed feeds vs the commercial. 
The most notable difference is the higher consumption of most amino acids early in the 
culture for the commercial feed. This higher consumption may be attributed to the fact that 
the feed contains better buffering capacity than the designed feeds, as well as other ions (e.g. 
Na+, Ca2+) that act as co-substrates in some cases for some of the cell membrane nutrient 
transporters. The fact that a.a. are eventually metabolized in the designed feeds demonstrates, 
as also discussed earlier (section 6.2.2), the great robustness of the cells in rich nutrient 
conditions.    
Other differences include higher asparagine and glutamate consumption in the 
designed feeds, whereas serine appears to be with a higher rate consumed by cells treated 
with the commercial feed. The designed feeds present higher alanine, glutamine and 
ammonia accumulation. The reported correlation of asparagine consumption and ammonia 
accumulation is evident by the aforementioned. As well, as the glutamate and glutamine link 
due mainly to the fact that the cells used experimentally have the glutamine synthetase gene 
as selection marker (further analysed in section 2.1.3). All this correlations are in greater 
detail discussed in 6.2.4, where the relevant biochemical network for CHO cells is analysed.  
As far as lactate is concerned, this reaches a similar maximum concentration in all 
three tested feeds, when its concentration starts to reduce, i.e. net lactate consumption is 
observed. Interestingly enough this maximum occurs in similar time point during cell culture 
for all feeds. This finding leads to the conclusion that the high lactate concentration is 
possibly the reason for the observed metabolism shift: from net production to consumption. 
The designed feeding strategies helped to understand asparagine, ammonia and lactate 
metabolism in CHO cells. Moreover, an interesting relationship was revealed between 
histidine, tryptophan and glutamine that remains to be further investigated at the intracellular 
metabolism level. The latter will be further discussed in the following section 6.2.4. 
 
6.2.4 FBA and design of feeds 
 
The technique of flux balance analysis (FBA) can prove a useful tool for 
understanding cellular metabolism and designing feeding strategies. It is first essential to 
identify the most suitable metabolic network for the selected cell line. The network then 
needs to be evaluated in terms of being capable of reproducing experimental results. Both of 
the aforementioned are the purpose of the first part of this section. The first part also 
demonstrates how FBA can be used to further understand cellular metabolism, while some 
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disadvantages are also discussed. Then the evaluated network can be used to explain 
observed metabolic behaviour that can possibly guide improved feeding strategies. The latter 
is discussed in the second part of this section.  
 
Network evaluation & analysis of observed fluxes in batch culture 
In order to evaluate the intracellular network described in section 4.15, the 
experimentally observed fluxes between days zero (inoculation) and five of the batch cell 
culture of the high producing cell line (GS46, see section 4.1) were analysed. These are the 
rates until the first measurable component becomes limiting, which were used to design the 
feeds described in this chapter (see also part 6.1.1).  
The network for the FBA was based on a redefined version of the network in Carinhas 
et al. (2013). This was reformed in order to accommodate certain features, mainly in terms of 
biomass composition following the work of Selvarasu et al. (2012). The latter is the only 
study that has performed experiments for biomass content determination specifically in CHO 
cells, whereas other studies have taken biomass data mainly from hybridoma (i.e. mouse) 
cells (e.g. most of the literature presented in Table V-14 in Appendix V). The redefined 
network includes twenty more reactions (highlighted with green in Table X-20 in Appendix 
X) than the Carinhas et al. (2013). These reactions have been added firstly to include more 
biomass components as discussed earlier and secondly to also include glycosylation of the 
host proteins and not only of the product (see section 4.15 for more details). This is because 
only the latter glycosylation occurs in the initial network. Hence, the network presented 
herein, is the first based on constraint flux analysis that includes the glycosylation of proteins 
in the biomass expression.   
A visualization of the entire network used is presented in Figure 6-9. In the same figure 
the experimentally observed fluxes for the day zero to five interval discussed earlier have 
been used as an input to assess the steady state flux of all the reactions of the network. The 
thickness of the presented arrows is proportional to the calculated intracellular flux. The 
widely observed inefficient metabolism at the exponential phase of cultured mammalian cells 
is apparent in the same figure (also discussed in 2.1.3). This is depicted by the fact that most 
of the glycolytic flux (depicted as “glclss” in the figure) is converted to lactate and excreted 
to the extracellular environment. 
 As discussed in part 2.3.3, pseudo-steady state (PSS) has to occur in order to be able 
to apply FBA. This has been assumed, firstly, because no metabolite is depleted and hence it 
is assumed that cellular metabolism remains constant throughout the day zero to five period. 
Design of fed-batch strategies  121   
 
Secondly, the intracellular accumulation of amino acids at this interval is not at all 
comparable with the experimentally observed extracellular fluxes (Figure 6-10 B and C). 
Specifically, the highest observed intracellular flux of amino acids is 1.8% of the associated 
extracellular flux and this occurs for proline. Intracellular amino acid analysis has been 
performed for the specified interval as described in 4.9. PSS for the day zero to five interval 
is also assumed since cells present a net lactate producing phenotype, which is a metabolic 
phenotype commonly used to separate culture phases, i.e. lactate consuming vs lactate 
producing phases (described in part 2.1.3). In Chapter 5, this is depicted for the day zero to 
four interval (also depicted in Table 5-1) for the same cell line. The concentration of lactate 
presents a plateau between days four and five and hence the day zero to five interval can be 
safely used for the purposes of this part as well. 
  
Figure 6-9: Considered metabolic network for the purposes of the current thesis. 
The network has been mainly adopted from Carinhas et al. (2013), while it includes 
some parts of the network in Selvarasu et al. (2012). It includes glycolysis (glclss), 
tricarboxylic acid cycle (TCA), nucleotide and nucleotide sugar metabolism, excretion 
of TCA intermediates, lipids and a.a. metabolism. The observed day zero (inoculation) 
to five fluxes in batch culture of the high producing cell line (GS46) have been visualized 
in this graph. The inefficient metabolism at exponential phase is depicted, where most of 
the glucose flux (main carbon source, visualized in the centre of the current Figure) is 
diverted to lactate (visualized in the right hand side thick arrow close to the “Lactate” 
label).  
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The network is used as an FBA approach (rather than a MFA, see also part 2.3.3), 
since several extracellular species have not been measured experimentally and hence there 
are several degrees of freedom, as also in detail presented in part 4.15. The FBA approach 
solves the linear optimization problem of optimizing the biomass and rprotein flux (μ and 
specific productivity respectively). While, the linear optimisation problem has been 
constrained by the experimentally measured fluxes (within one standard deviation) of 
nineteen a.a., ammonia, glucose, lactate and pyruvate.    
In order to achieve better accuracy for the intracellular network, the fluxes of all the 
extracellularly occurring metabolites of the network have to be measured (twelve more in 
total than those measured for the purposes of this thesis, see also part 4.15). This will allow to 
truly identify whether the current network is valid for the selected cell line. Biologically, this 
confirmation would necessitate monitoring intracellular rates, as well ensuring that the 
enzymes catalysing the reactions of the network are expressed. The latter would be difficult 
to monitor, since the presented network is lumped, i.e. some of the presented reactions are 
catalysed by more than one enzyme. Nevertheless, by constraining the undetermined 
extracellular values with data from similar cell lines from Carinhas et al. (2013), as discussed 
in 4.15, valuable conclusions can be drawn.    
As depicted in Figure 6-10A experimentally observed amino acid extracellular rates 
(bright green) are in close proximity with the calculated by the FBA (blue). Cysteine is not 
considered in the network and hence the relevant FBA calculated flux does not appear in the 
graph. The experimental cysteine flux in the same graph represents the calculated cysteine 
flux based on biomass and rprotein demands calculated as described in 4.2, for the day zero 
to five interval. In close proximity are also ammonia, glucose and lactate experimental fluxes 
with the calculated from FBA (data not shown). This in principle demonstrates that the 
network can be used for similar cell lines. The greatest difference is depicted for proline, 
which however demonstrates the highest experimental error. The lysine standard deviation 
had to be adjusted 2% in order to be able to achieve the observed growth rate for the specified 
interval. This demonstrates the need to accurately quantify the biomass content for the 
specific cell line to be used, rather than extract this from literature values. 
A further analysis of the amino acid fluxes obtained by the FBA until limiting 
component in batch culture for the high producing cell line is depicted in Figure 6-10B and 
C, in an attempt to demonstrate the capabilities of the method. In Figure 6-10B, the total 
fluxes of amino acids for the several “functions” of cellular metabolism are depicted, e.g. 
amount to biomass, amount to rprotein, amount to other a.a., amount to nucleotides, amount 
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to nucleotide sugars, amount to glycolysis, etc. This has been calculated by assessing the 
calculated flux of every single reaction of the network.  
Figure 6-10: FBA of observed experimental amino acid fluxes in batch culture until 
limiting component. 
A) Experimental amino acid fluxes (bright green) vs fluxes (all fluxes in 
femtomol/cell/day) obtained from the flux balance analysis (blue colour). Error bars 
represent one standard deviation of biological duplicates and were used to constrain the 
FBA. A 2% increase in the standard deviation of lysine had to be employed in order to 
ensure that the observed growth would be satisfied. Cysteine (Cys) is not included in the 
FBA network and hence the FBA flux is set to not-applicable (“NA”). The experimental 
cysteine flux was also not directly determined, since the a.a. analysis method used 
herein does not quantify it. Cysteine fluxes satisfy the biomass and rprotein 
requirements for the specified interval (the calculation is further analysed in 4.2). 
B) Total flux of each amino acid (femtomol/cell/day). The different parts of the bars 
represent the following fluxes (from bottom to top in the legend presented at the right 
hand side): observed consumption (“IN”, blue colour), observed production (“OUT”, 
red colour), towards biomass (“BIOMASS”, green with a red border), towards rprotein 
(“cB72.3”, purple with a black border), towards glycolysis (“Glclss”, light blue), 
towards TCA cycle (orange), towards lipids (blue with a black border), towards 
simultaneously to nucleotides and TCA (“Ncltds & TCA”, light red), towards 
nucleotides (“Ncltds”, light green), towards nucleotide sugars (Ncltd Sug), towards 
essential biomass components (5-Methyltetrahydrofolate, MTHF and putrescine, 
PTRSC), from other a.a., to other a.a., to by-products, measured intracellular 
consumption and production (“INTRA Cons.” and “INTRA Prod.”, respectively).      
C) Fluxes presented in B) are presented as percentages of total flux. 
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As the results presented herein are not entirely conclusive, the analysis is mainly 
focussed on presenting the features of the network rather than the solution of the FBA 
problem. The amino acid that demonstrates the higher extracellular flux for the specified 
interval in batch culture is asparagine, demonstrated from the highest blue bar (labelled as 
“IN”) in Figure 6-10B. However, the a.a. with the highest total flux is glutamate, 
demonstrated with the highest stacked bar in Figure 6-10B. As depicted in Figure 6-10C, 
about 20% of glutamate total flux is diverted to other a.a. and specifically glutamine (i.e. the 
glutamine synthetase reaction, number #21 in Table X-20 in Appendix X). A large portion of 
the total glutamate flux (about 15%) fuels the TCA cycle demonstrating the importance of 
glutamate. While about 40% of total glutamate flux is from other a.a. 
Other notable amino acids can be readily depicted from Figure 6-10C and involve 
amino acids that have multiple stacked bars. This demonstrates that the particular a.a. is 
involved in multiple metabolic reactions. Such amino acids are arginine (essential to produce 
a biomass component, i.e. putrescine, PTRSC), aspartate (needed for nucleotide synthesis), 
glutamine (needed for both nucleotides and nucleotide sugars), glycine (essential for the 
biomass component 5-Methyltetrahydrofolate, MTHF) and serine (utilized for synthesis of 
lipids, it also fuels glycolysis and is required for nucleotide synthesis). 
A similar strategy as in Figure 6-10 has been performed for glucose and ammonia 
fluxes, presented in Figure 6-11A and B, respectively. The added amounts of sugars and 
nucleotide sugars in the biomass reactions were included to illustrate the glycosylation of 
host cell proteins as described in 4.15. It was found that these reactions do not affect the large 
glycolytic flux. This can be readily calculated by the difference of the labelled as “IN” bar of 
Figure 6-11A (i.e. experimentally observed consumption rate) vs the bar chart labelled as 
“From F6P split”, which is the point where the six carbon glycolysis flux splits into two 
three-carbon fluxes, resulting to a doubling of the flux (reaction number #3 in Table X-20 in 
Appendix X). The fluxes towards nucleotides and nucleotide sugars have also been included 
as bars in the same graph. Based on the structure of the presented network, the sugars and 
nucleotide sugars related fluxes have been deducted before the F6P split. This is not entirely 
valid based on the biochemical network as demonstrated in KEGG, however this 
simplification does not affect the assessment of the glucose flux intracellularly.  
 The other notable flux from Figure 6-11A is the one towards lactate. This is slightly 
larger than the observed consumption of glucose experimentally. The theoretical maximum of 
lactate production could be up to two times the flux of glucose, as lactate is a three carbon 
molecule, while glucose is a six carbon one. This large flux demonstrates the inefficiency of 
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metabolism during exponential phase, also described in 2.1.3, since a large portion of the 
glucose flux is diverted to lactate, rather than being more effectively used in the TCA cycle 
(also depicted in Figure 6-9). 
 
 Figure 6-11: Glucose and ammonia related fluxes from FBA, calculated from 
experimentally observed fluxes between days zero (inoculation) and day five for the 
high producing cell line (GS46). 
A) Glycolysis related fluxes are displayed. The dark grey bars represent fluxes that 
increase total glycolytic flux, whereas light grey fluxes that reduce glycolytic flux. From 
left to right the following fluxes are presented: experimentally observed consumption of 
glucose (“IN”), towards the production of nucleotides (“To Ncltds”), towards the 
production of lipids (“To Lipids”), to by-products associated with lipid metabolism (“To 
Lipid by-products”, e.g. glycerol), to glycogen (component of biomass), from the 
fructose-6-phosphate split (“From F6P split”, i.e. where the six carbons flux splits to 
two three carbons molecules), to lactate efflux, to TCA cycle, from some a.a. and flux 
towards other a.a. 
B) Ammonia (NH4+) related fluxes are depicted. Pie slices with grey colour demonstrate 
fluxes contributing to higher ammonia concentration, whereas fluxes with light grey are 
consuming ammonia. 
 
In Figure 6-11B the flux towards or from ammonia is analysed. The dark grey colour 
demonstrates flux increasing ammonia concentration intracellularly, while with light grey is 
the flux reducing it (e.g. efflux). Light grey (positive) and dark grey (negative) fluxes add up 
to zero, which is the main assumption in order to perform FBA, i.e. no accumulation of any 
of the species occurs. The same occurs for the glucose case in the previous paragraph. As it is 
evident, the greatest increase of ammonia concentration is due to asparagine metabolism, 
which was also discussed in section 6.2.3 of this chapter. The importance of ammonia is 
demonstrated as a large part is used to create glutamine, as well as for nucleotide synthesis. 
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Other a.a. sources of ammonia are serine, glutamate, threonine and glycine. The relevant 
reactions are depicted in Table X-20 in Appendix X. 
  
Limitations of FBA 
The previous paragraphs of this part demonstrate the applicability of FBA in studying 
cellular metabolism, by only extracellular measurements. Some disadvantages are discussed 
in the following few paragraphs.  
The main disadvantage of FBA is that is only applicable for intervals where steady 
state occurs. The latter cannot be objectively defined (as also described in 2.3.3). For example 
here it has been shown that a.a. do not accumulate intracellularly for the time interval that 
FBA is applied, however other metabolites have not been measured intracellularly. 
Another disadvantage is that it is largely dependent on the associated network, as also 
discussed in section 2.3.3. A representative example is the asparagine synthetase gene, with 
enzyme commission (E.C.) number 6.3.5.4 that encodes for an enzyme catalysing the 
reversible reaction of aspartate and glutamine to asparagine and glutamate. The FBA network 
in Selvarasu et al. (2012), for example, includes this enzyme, which is also depicted in the 
recently added CHO (Cricetulus griseus) metabolic network in KEGG. However, 
experimental results, in Quek et al. (2010) suggest that asparagine synthetase possibly has the 
functionality of asparaginase (E.C. 3.5.1.1) in CHO cell culture. Asparaginase catalyses the 
reaction of asparagine to aspartate and ammonia, i.e. the reaction number #41 in Table X-20 
in Appendix X and interestingly is not reported to occur in mammalian cells. These 
researchers were not able to simulate observed ammonia accumulation without including this 
reaction. This reaction is also used in Carinhas et al. (2013) and so also in the work presented 
herein. Results presented herein also demonstrate that observed specific rates for ammonia 
and asparagine would have not been reproduced if the “correct” mammalian function of 
asparagine synthetase had been included in the network. It has also been reported that 
asparagine is spontaneously degraded to ammonia and aspartate (Kurano et al. 1990), 
however, recent degradation studies in the literature did not show this to occur (Murphy and 
Young 2013).   
With regard to the network structure disadvantages, Selvarasu et al. (2012) report 
amino acid derivatives as by-products in CHO cell culture that are, however, not included in 
the presented network herein. Such derivatives include six species, namely 5-L-glutamyl-L-
alanine, dimethyl-L-arginine, N-acetyl-L-leucine, N-acetyl-L-phenylalanine, N-
acetylmethionine, and N-formyl-L-methionine. Hence, advanced analytical techniques (or a 
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combination of the existing) are needed to further evaluate all the possible by-products in 
mammalian cell culture and help identify the underlying biochemical networks. Also, the 
network for specific cell lines has to be enhanced with proteomic analyses, in order to 
identify present metabolic enzymes. 
Another disadvantage of FBA is that its results are dependent on the biomass 
composition, since all metabolic fluxes largely ensure that the biomass content will be met. 
This holds for the exponential growth phase, where cells actively grow as opposed to the 
stationary phase. As can be seen in Figure 6-10C a large part of most a.a. fluxes is towards 
biomass. This has also been discussed for lysine earlier, since the observed lysine flux 
between days zero and five was not enough to sustain the lysine content in the experimentally 
observed biomass growth.  
The main problem with biomass is that the content in Selvarasu et al. (2012) is 
reported in mmol per dry cell weight. However, experiments for the determination of dry cell 
weight for the purposes of this thesis (described in 4.4) demonstrate that dry cell weight 
changes within culture. Specifically, the dry cell weight at the exponential phase of the high 
producer cell line (GS46, see part 4.1) in batch culture was found to be 219±24 
picograms/cell (error represents one standard deviation of biological duplicate experiments). 
During stationary phase of batch culture this was found to be 174±2 picograms/cell, i.e. 
reduced. However, fed-batch culture of the same cell line with F_All_pl40 (as discussed in 
4.2) resulted in a dry cell weight of 311±3 picograms/cell at stationary phase. This increase of 
dry cell weight in fed batch conditions is also reported in Carinhas et al. (2013). What the 
latter do not discuss is that change in weight is probably also associated with changing 
biomass content qualitatively during culture, e.g. less amount of a specific amino acid, or 
more amount of some nucleotides may be present in the biomass. This would mean that 
different biomass coefficients should be used, e.g. ratios between the components of the 
biomass and not the same as for example is done in Carinhas et al. (2013). The latter 
researchers rescale components based on the resulting dry cell weight, which is also 
commonly used in the literature (Table V-14 in Appendix V).  
Finally, another disadvantage of FBA is that linear relationships are depicted between 
consumption of nutrients and biomass growth or rprotein production. For example, the higher 
the rate of consumption for all nutrients introduced as inputs for the model, the more biomass 
or IgG will be calculated. However, as the results in this chapter demonstrate biomass will 
not grow indefinitely since it will be inhibited by, for example, high ammonia concentrations.  
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Design of feeding strategies & potential genetic engineering targets 
After the network has been evaluated, it can be used with data from bioprocessing 
relevant culture conditions to analyse fluxes where PSS occurs. In relation with feeding 
strategies, if the FBA had been carried out at the time of the design, one would have been 
able to identify the large flux of asparagine to ammonia and while scaling up the feeds would 
have added less asparagine in the feed. The latter is the strategy of choice for the 
commercially available feed evaluated in this study (CD EfficientFeedTM C AGTTM, 
Invitrogen, UK) as presented in 6.2.3. A further investigation of the actual function of the 
enzyme catalysing the reaction of asparagine to aspartate could also possibly lead to a 
promising genetic engineering target. If this enzyme was deleted, then less ammonia would 
be generated even if asparagine was supplied in high concentrations.   
The evaluated network could be also used to explain observations in cell culture. For 
example, the histidine and tryptophan depletion discussed in 6.2.3, with the concomitant 
glutamine consumption could be explained. However, the network used herein, mainly 
adopted from Carinhas et al. (2013), does not depict such a relationship of either of these two 
amino acids with glutamine. The same occurs in the network presented in Selvarasu et al. 
(2012). Histidine, as depicted in reaction #44 in Table X-20 in Appendix X, is irreversibly 
converted to glutamate and ammonia. Tryptophan, as depicted in reaction #28 in Table X-20 
in Appendix X irreversibly produces lactate as well as fuels the TCA cycle.   
Another notable amino acid from the discussion in 6.2.3 was glycine, which was found 
to be accumulating to similar levels for all tested feeds. The reactions leading to the 
accumulation of glycine are reactions #22 and #23 in Table X-20 in Appendix X. The first 
reaction involves the conversion of threonine to glycine and the second the conversion of 
serine to glycine. The conversion of threonine is associated with the fuelling of the TCA 
cycle. The conversion of serine is associated with the production of nucleotides. Neither can 
explain the experimentally observed results discussed in 6.2.3. Based on the latter, it appears 
that all the feeds present similar glycine levels; however, it appears that the commercial feed 
presents higher serine and threonine consumption between all feeding intervals. Possibly, 
some more reactions not depicted in the presented network are responsible for the observed 
experimental results, e.g. some other non-measured metabolites may result in serine and 
threonine intracellularly, which cannot be accounted for by the FBA, since only net 
extracellular rates are used as inputs. 
Finally, the accumulation of alanine is also discussed in 6.2.3. Reactions #16 and #28 in 
Table X-20 in Appendix X are associated with alanine production. They involve the 
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conversion of glutamate and tryptophan to alanine, respectively. Both are with higher rate 
consumed in the two designed feeds for the purposes of this thesis, as discussed in 6.2.3. 
Hence, explain the increased alanine accumulation in the aforementioned feeds as opposed to 
the commercial feed.      
 
6.3 Conclusions 
 
A simple way to calculate the amount of 17 amino acids and glucose in feeds from 
monitoring their levels in batch experiments is presented herein, which increases productivity 
threefold from batch culture. This is accomplished in cultures where the same medium is 
used in both batch and fed-batch mode, and for which the final feed is prepared in one to one 
medium to nutrient mix (dissolved in water) ratio. Adding 40% more of nutrients, except for 
the least soluble amino acid (tyrosine), to the same feed further increases yield to 3.5 times 
than that in batch. Expanding this approach to more nutrients that have not been 
experimentally measured for the purposes of this thesis could potentially achieve even higher 
yields. Results are compared and contrasted with a commercial feed able to increase 
productivity up to 4.5 times of that in batch. Staged feeding experiments, resulting from a 
basic understanding of a.a. transport, have also been tested for the first time in a 
bioprocessing context. The results show that, although staged feeding is potentially beneficial 
for increasing IVCC (more experiments are needed to conclude this), this approach fails to 
achieve increase in recombinant protein yield. 
The results further demonstrate that there is no linear correlation of amino acid 
addition and IVCC. The initially developed feed presents a higher IVCC than the feed that 
contains 40% higher concentrations of all the nutrients. The reduction of IVCC, in the latter 
culture, is attributed to the high levels of ammonia achieved. However, the results for the first 
time demonstrate that high ammonia concentration does not affect specific productivity. In 
fact, the feed containing 40% more of all components presents both higher ammonia 
accumulation and higher specific productivity than the feed containing less concentration of 
nutrients. Also, the fact that the commercial feed maintains ammonia levels close to 5mM 
(much lower than the two designed feeds) shows that this is a representative threshold toxic 
ammonia concentration value, correlating well with literature data. The latter occurs because 
the commercial feed presents the highest IVCC from all the tested feeds. 
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The higher rate of ammonia accumulation can be attributed to the increased 
asparagine consumption. This has also been confirmed with the use of flux balance analysis. 
An investigation of the enzyme involved in this reaction could result in a strategy similar to 
the glutamine synthetase, where reduced ammonia concentrations have been achieved by not 
introducing glutamine in the feed. A possible deletion of the enzyme that appears to convert 
asparagine to ammonia and aspartate may lead to reduced ammonia concentrations in the 
medium (except if this reaction occurs spontaneously). Also, a reduced asparagine to 
aspartate ratio can also be beneficial in media and feeds, which is a strategy adopted in the 
commercial feed. 
The highest performance feed presents the maximum lactate concentration in culture. 
This correlates well with literature data on the importance of lactate in mammalian cell 
culture. Also, all three tested feeds present the lactate production/consumption phenotype, 
regularly observed in mammalian cell culture. The fact that this occurs on the same day for 
all feeds, demonstrates that the method described herein does not significantly alter the 
aforementioned phenotype. Also, results demonstrate that high lactate concentration is the 
cause of the lactate shift towards consumption of lactate and not the depletion of glucose or 
low glycolytic flux. This is because all the feeds reach a close maximum lactate concentration 
value (between 12.35 and 14.25 mM). 
 Regarding the use of FBA for the design of feeds, this has to be extensively evaluated 
in order to aid in the design of feeding strategies. In order to ensure this, a wide-range of 
experiments has to take place. The experiments would involve the accurate qualitative and 
quantitative analysis of biomass composition, the accurate extracellular analysis of well-
known by-products, including TCA cycle intermediates and a.a. derivatives. Finally, 
proteomic analysis of the cell line in question would aid in a better understanding of the 
intracellular metabolic network. 
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Chapter 7                                                              
A methodology for analysing cell 
culture data 
 
This chapter is focussing on the code created for the purposes of analysing the data 
generated in this thesis initially presented in 4.14. The code is designed to calculate all 
possible fluxes for the different time intervals within both batch and fed-batch cultures. The 
following subparagraphs will compare the computed rates with other methods; demonstrate 
the functionality and some of the potential uses of the created code. 
 
7.1 Calculated data sets and comparison with other methods  
 
The code reads extracellular time-course concentration data of nutrients and cells 
directly from “.csv” files and calculates all specific rates between the different time points. 
The code has been written as a function in R software (R Development Core Team 2010). 
The user has to fill in the file presented in 4.14 (Figure 4-2) and then the developed function 
automatically at the current stage: 
a) calculates all possible specific apparent growth, death, nutrient consumption/ 
production  rates for the different combinations of experimental time points and for all 
user-defined nutrients (e.g. for 14 days of culture it calculates 105 sets of rates). The 
data are supplied in a “.csv” file in a new folder, named “Results” in the working 
directory. 
b)  ranks the highest apparent growth, death and specific productivity time intervals and 
provides figures of the results in three separate “.pdf” files along with the calculated 
rates (in “.csv” files) for all the nutrients at the highest ranked intervals.  
As demonstrated in 2.3.4 the existing methods in the literature use either logistic 
equations (Goudar 2012; Goudar et al. 2005), or linear correlations (Murphy and Young 
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2013) to calculate specific rates. The method presented herein directly calculates the rates 
based on component material balances.  
In Figure 7-1A a comparison is presented of the specific glucose consumption rates 
for the industrial feed (presented in 4.2) calculated with (A) the mass balances approach 
presented herein, (B) the regression analysis method presented in Murphy and Young (2013) 
and (C) a graphic method based on plotting the integral viable cell concentration (IVCC) vs 
the cumulative concentration. The latter is another convenient technique that has been used in 
the past (Altamirano et al. 2006; Chen et al. 2012a; Li et al. 2010; Martinez et al. 2013; 
Ozturk and Palsson 1991; Tsao et al. 2005). The rates have been calculated between all 
feeding intervals. The reader is reminded here that feeding occurs every two days, starting on 
day 2 of culture.  The rates calculated between consecutive feeding times are comparable for 
all methods and in no case different when the 95% confidence intervals are taken into 
account (presented in the error bars in Figure 34A). 
Figure 7-1: Comparison of specific glucose consumption (negative) rates calculated with 
three different methods: (a) The developed method using material balances (“q Glc 
MB”, green), (b) a Matlab toolbox (“q Glc ETA”, red) presented in Murphy and Young 
(2013) and (c) by plotting the IVCC vs the cumulative concentration (“q Glc IVCC vs 
Cum cons”, orange).  
A) The calculated glucose consumption rates between all feeding intervals (e.g. “0 to 2” 
refers to the interval between days zero and two) are presented as calculated with each 
of the aforementioned methods. Error bars represent the 95% confidence interval for 3 
biological replicates for the industrial feed (discussed in 4.2) using a t-distribution.  
B) The reason why differences occur between methods A and C is presented in the plot. 
Method A, represented with the green line, only calculates the rate between the 
different points after feeding and before the next feeding takes place, whereas method C 
takes into consideration the different time point in the middle as well. 
C) The different way of calculating apparent specific growth rates in methods A and B 
is presented (μMB in green box and μETA in red box, respectively). The calculation of μ 
affects the specific consumption rates of all nutrients.   
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The main reason for the rates not being identical for methods A and B relates to the 
way of approximating the apparent specific growth rate (μapp). The approximation of the 
specific growth rate largely affects the subsequent calculation of specific nutrient 
consumption/production rates. The different methods are presented in Figure 7-1C.  
While A and C present a similar way to approximate specific rates the differences 
relate to the use of the linear approximation in B. As presented in Figure 7-1B, method A 
calculates the rates between the two distinct points (after feeding on the left with a lower 
IVCC value and just before the next feeding point on the far right of the plot, approximated 
with the green line), whereas method C also takes into consideration the middle point, i.e. the 
experimental point between the feeding days. The slight difference in the slope is the reason 
for the observed difference in rate calculation.  
Another reason that the specific rates are different is that the method presented herein 
includes the volume of the culture at the two different time points between which the rate is 
calculated. For example, for the data presented in Figure 7-1A, the culture volume directly 
after the addition of the feed is 50mL, whereas just before the addition of the feed it is 46mL, 
due to the two sampling points in-between. Even if slight, this volume change affects 
calculated rates. This calculation of the volume, however, has to be included in order to 
obtain a more representative rate. 
There are several advantages of the developed method compared with methods in the 
literature. There is no need for parameter estimation as in the logistic equation way (Goudar 
2012; Goudar et al. 2005). Parameter estimation techniques are computationally expensive 
and also require appropriate initial estimates, making the whole procedure even more time 
consuming. Also, the calculation of the rates includes a mechanistic understanding in the 
presented method, as opposed to the logistic equations way. Moreover, the presented method 
does not involve the use of slope calculation (as both methods B and C do), which includes 
additional complicated calculations. 
Another advantage of the method is that it is able to calculate rates both in fed-batch 
and batch culture mode. Data are not shown for the latter, but by setting the feeding interval 
to zero no feeding takes place. Contrary to this method, both methods B and C presented 
earlier require the concentration of a component after a feeding event to be provided, 
therefore not accommodating batch operation. Another notable attribute of the presented 
method, related with the aforementioned, is that the feeding interval can be set to a user-
defined value. This can be very useful in devising entire feeding strategies, e.g. including 
timing of addition, as well as the concentrations of the nutrients in the feed.   
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The presented method also has the advantage of automatically calculating all possible 
rates between the different experimental time points, as opposed to the manual effort required 
in Murphy and Young (2013). In the latter, all the different rates for each of the data points 
and nutrients have to be manually selected by the user, introducing a time consuming step. In 
Goudar (2012) only the instantaneous rates are calculated, i.e. not allowing for the calculation 
of rates in larger intervals. 
Another advantageous feature is that the code is written in freely available software. 
Other methods in the literature (Goudar 2012; Murphy and Young 2013) require commercial 
software available at a fee. 
 On the other hand, some weaknesses of the presented code are the following. The 
code is valid at the current stage only for bolus addition of feeds, where feeding takes place 
much faster than the entire process. Hence, in the current format the code cannot be used for 
continuous feeding. Another disadvantage at the current stage is that constant sampling and 
feeding intervals and volumes are only taken into consideration. This means that feeding 
occurring for example every 8 hours at a certain part of the process and every 12 hours at 
another cannot be accommodated with the current state of the code. The same occurs if 
different amount of volume is added. However, additional event vectors can be introduced for 
such feeding strategies. Another disadvantage is that does not allow for rapid statistical 
analysis as in Murphy and Young (2013), however can be easily coupled to calculate user-
defined confidence intervals, e.g. 95% confidence. Finally, the fact that discrete integration is 
being used as opposed with using functions introduces higher error in the calculated specific 
rates, which is also discussed in Goudar (2012). 
 
7.2 Intracellular dynamics at maximum specific rprotein production rate 
 
A potential use of the presented code is to investigate the metabolism at intervals 
where maximum growth or productivity rates occur. This part demonstrates how the code can 
be used to investigate the dynamics at maximum specific rprotein productivity. Templeton et 
al. (2013) demonstrate using a combined flux balance and experimental analysis that 
maximum antibody productivity occurs at the lactate shift, where cells demonstrate a shift 
from net lactate production to net lactate consumption. At this point also cells exhibit a high 
rate of oxidative metabolism, demonstrated by reduced glycolysis rates and increased TCA 
ones. In order to investigate this further, the rprotein specific rates for each of the different 
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feeds tested were ranked by descending order based on the calculated average minus one 
standard deviation (presented in 4.2). Interestingly, the maximum antibody productivity 
occurs close to the lactate shift for all the feeds (results depicted in Figure 7-2 for F_all_pl40, 
also in Figure XII-3 for F_all and Figure XII-4 for F_C_Inv, both the latter in Appendix XII), 
however this cannot be concluded with 95% confidence due to the associated experimental 
error and the small number of biological replicates. 
Figure 7-2: Analysis of maximum antibody productivity intervals (middle) for feed 
F_all_pl40 (see part 4.2 for reference) in relation with growth (top) and lactate 
phenotypes (bottom). 
The specific productivities (qmAb in pg/cell/day) are ranked based on the average 
minus one standard deviation. In the bar chart presented in the middle panel on the left, 
the first fifteen ranked production rates for the different time intervals are presented, 
these are with descending productivity: from day 12 to day 13 (“12 to 13”), “10 to 11”, 
“9 to 11”, “6 to 7”, “9 to 10”, “8 to 11”, “9 to 13”, “8 to 13”, “10 to 13”, “9 to 12”, “8 to 
10”, “5 to 7”, “6 to 11”, “8 to 12” and “5 to 11”. Specific growth rates (in 1/day) at the 
exact same ranked intervals are presented in the top left graph, while specific lactate 
rates (in femtomol/cell/day)  are presented in the bottom left graph. The graphs in the 
right panel represent from top to bottom: the cells concentration (Xv_exp, in cells/mL) 
for the experimental time course (t_exp in days), the rprotein concentration (mAb_exp, 
in g/L) and the lactate profile (Lac_exp, in mM). The dilution due to feeding has not 
been included in the latter graphs at the feeding intervals. Error bars represent the 
95% confidence interval using a t-distribution and assuming triplicate samples for the 
calculation of specific rates (left panel). One standard deviation of biological triplicate 
samples for Xv and duplicate samples for lactate and rprotein are depicted in the right 
panel.    
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As for example presented in Figure 7-2 (left panel, middle) for the feed encoded as 
F_all_pl40 the fifteen highest ranked specific productivities of all intervals include the lactate 
shift point between days 6 and 7 (Figure 7-2, right panel, bottom). This interval is ranked as 
the fourth highest in specific productivity. The highest productivity occurs between days 12 
and 13, where lactate appears to entirely deplete (Figure 7-2, right panel, bottom). 
 
Figure 7-3: FBA at the maximum observed rprotein specific productivity interval for 
F_all_pl40 (see part 4.2 for reference). 
A) The entire metabolic network structure along with the relative rate levels calculated 
by the FBA (further analysed in part 4.15) is presented, where increased oxidative 
metabolism is observed. The latter is represented by thick arrows in the TCA cycle, 
when compared to the glycolysis (glclss) rates. White circles represent metabolites, 
whereas diamonds indicate reactions (red colour is used for irreversible, whereas green 
for reversible reactions).   
B) A reduced version of the map in A is presented that includes the metabolites 
presenting the highest metabolic rates. These are: glucose (Glc, consumed), lactate (Lac, 
consumed), alanine (Ala, produced), leucine (Leu, consumed), valine (Val, consumed), 
lysine (Lys, consumed), glutamate (Glu, consumed), glutamine (Gln, produced), 
ammonia (NH4+, produced), asparagine (Asn, consumed), aspartate (Asp, produced 
from Asn), acetate (produced) and glycerol (produced).   
 
The calculated rates can then be used to perform FBA as for example displayed in 
Figure 7-3. The rates of all metabolites for the interval where the third highest observed 
rprotein production occurs, where lactate is also consumed, i.e. between days 9 and 11, in the 
particular set of fed-batch experiments, have been used as inputs of the model described in 
4.15. Hence, metabolism can be analysed at this stage. Pseudo-steady state (PSS), as 
discussed in 4.15, is not considered at this point as this is only a case study. As can be seen in 
Figure 7-3A, an increased rate of oxidative metabolism is observed. This is demonstrated by 
A methodology for analysing cell culture data  137   
 
thicker reaction arrows in the TCA cycle and less so in glycolytic reactions, along with the 
fact that lactate is consumed. In Figure 7-3B, the flux distribution of the amino acids largely 
consumed at that point, namely Leu, Val, Lys, Glu and Asn, are presented. These amino acids 
can be characterised as the main providers of energy when close to maximum rprotein 
productivity occurs. A potential optimal addition of these a.a. could possibly maintain this 
observed phenotype for longer. Again, the fact that several metabolites of the network have 
not been quantified (as discussed in 6.2.4) does not allow concluding this with confidence; 
however, this case study effectively demonstrates the use of the presented code.  
 
7.3 Calculation of time course concentration data from calculated 
specific rates 
 
In addition to the features presented in 7.1, the code has been evaluated in terms of its 
usefulness for back-calculating time profiles of concentrations from the observed specific 
rates; however at the current stage this is not included in the presented code. This is a feature 
that has not been included in Murphy and Young (2013), while in Goudar (2012) the 
concentration of metabolites can be readily calculated. However, in the latter, rates can be 
calculated only for product and cells in fed-batch culture, i.e. not for metabolites.    
Figure 7-4 (top left) presents the viable cell concentration (Xv) back-calculation using 
the obtained specific growth rates between sampling intervals. The reader is reminded here 
that sampling occurs every day. Hence, the calculated specific growth rates at all fourteen 
time intervals have been used to back calculate the concentration of cells by using the same 
initial concentration (inoculum size and density). The green line in the top left graph 
represents the exact back-calculation of the cell concentration. This line underestimates the 
experimentally observed growth, which is represented with the black dots in the same figure.  
The fact that the specific growth rate has been approximated with discrete time points is 
largely the reason for this underestimation.  
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Figure 7-4: Calculation of time course concentrations from experimentally observed apparent 
growth and consumption/production rates. 
Top left: The green (labelled as “Back-calc.”) dashed line represents the back-calculated viable 
cell concentration (Xv, in cells/mL) using the specific growth rates calculated between all 
sampling points (i.e. every day of the culture, presented with the black dots). The red line 
(“Back-calc._not_dil”) presents the cell concentration results by not including the volume 
dilutions due to feeding. The blue line (“Back-calc._Ave”) represents the average of the both.  
Top right: The back-calculation of glucose concentration profile with the three aforementioned 
approaches: “Experimental” (black dots), exact back-calculated (“Back-calc.”, green line), 
back-calculated without including the dilution due to feeding (“Back-cal_not_dil”, red line), 
average of the latter two (“Back-calc._Ave”, blue line).  
Bottom left: A case study is presented where the average of the two ways for back-calculating 
cell concentration is used (blue line, “Back-calc._Ave”). The light brown line (“Back-
calc._Ave_Diff_Feed_Interval”) represents the calculated diluted cell concentration if feeding 
took place once every day using the same amount of volume. As with the above plot, the black 
dots represent the actual experimental data points. 
Bottom right: A case study is presented, where the observed consumption rates of glucose 
between the different sampling intervals have been used to simulate a different starting and feed 
concentration of glucose from the experimental concentrations. Initial concentration for the 
blue line (“Back-calc._Ave_Diff_Cinit&CIN”) is 21mM instead of 38 mM (in the experimental), 
whereas the concentration of the feed is set to 180mM instead of 202mM. The light brown line 
(“Back-calc._Ave_Diff_Feed_Interval”) that is associated with the light brown Xv presented in 
the bottom left graph represents another case study where glucose is fed every single day with 
the same feeding volume as the experimental. The concentration of glucose in the feed is 90mM, 
whereas the starting concentration in the medium is 21mM.  
The error bars represent one standard deviation of duplicate samples for glucose, while 
triplicates are used for concentration of cells. 
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Interestingly, however, when volume dilutions due to feeding are not included, the 
growth rate is overestimated. The latter calculation is represented with the red line in Figure 
7-4 top left. This behaviour (data not shown) has been seen for all the results of the feeds 
tested for the purposes of this thesis, discussed in 4.2, and although there is no rational reason 
for this, it aids in back-calculating the correct Xv profile. This can be accomplished by taking 
the average of the of the back-calculations of including the volume dilutions and the back-
calculations of not including them (presented by the blue line in Figure 7-4 top left). The fact 
that this occurs for all feeds reinforces that this approximation can be used. However, this has 
to be done with caution, especially when batch data are simulated where the dilution due to 
sampling is negligible. The error bars represent one standard deviation. As is evident, the 
back-calculated error is very large, reaching a maximum of approximately 57% towards the 
last point (day fourteen). This is associated with the compounded error of all the specific 
growth rates used for this calculation, i.e. fourteen in total. 
The fact that the approximated growth is underestimated by no means implies that an 
invalid specific rate estimate has been calculated. The reader is reminded here that an 
apparent rate is calculated, which is valid only between the two points where the calculation 
took place. A way to approximate Xv in a more accurate way would involve ranking all 
calculated specific rates based on the associated error. This has not been attempted yet, but 
might involve using the same apparent rate for wider time intervals rather than only between 
the sampling points. Another way would involve more frequent sampling (computational or 
experimental) in order to better discretize the time space.    
At its present form, the code can successfully simulate time course metabolite 
concentrations as can be seen in Figure 7-4 (right panel, top), as long as the Xv has been 
estimated successfully. The figure represents the time-course concentration of glucose 
(dashed lines) that corresponds to the estimates of Xv as explained earlier. This occurs by 
assuming same consumption/production rates between the different sampling points, exactly 
as with the back-calculation of Xv. The linear relationship between concentrations and IVCC 
(directly calculated from Xv) ensures a more accurate approximation of concentrations than 
the one achieved for Xv.   
Figure 7-4 (right panel, bottom) presents case studies relevant to the design of media 
and feeding strategies. The dashed blue line (“Back-calc._Ave_Diff_Cinit&CIN”) presents a 
case study where the back-calculated concentration of cells (represented with the blue line, 
“Back-calc._Ave”, in the left panel of Figure 7-4, bottom graph) is subject to a changed 
initial concentration of glucose (21mM instead of 38mM) than that used experimentally 
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(represented with the black dots), as well as a different concentration of glucose in the feed 
(180mM instead of 202mM). The consumption rates of glucose between sampling intervals 
have been set to those experimentally observed.  
The brown line of the same plot (Figure 7-4, right panel, bottom) represents a feeding 
strategy in which the same feed volume as that added experimentally was introduced; 
however, the feeding interval occurs every single day of the culture this time. The initial 
glucose concentration is 21mM, whereas the concentration of glucose of the feed is this time 
90mM. The brown line in Figure 7-4 (left panel, bottom, “Back-calc._Ave_Feed_Interval”) 
represents the diluted back-calculated cells presenting the same growth rate with the blue 
line, “Back-calc._Ave”, in the same graph, however their concentration is diluted due to the 
changing volume. The same occurs with the concentration of glucose at the different feeding 
intervals, since it is significantly diluted due to the increasing volume of the culture from the 
daily feed additions.  
Both the aforementioned case studies demonstrate the features of the developed code. 
This involves the ability to simulate any medium or feeding strategy involving bolus feed 
addition. Just by setting the feeding interval to the desired value, any type of feeding can be 
accommodated. Medium changes can be simulated simply by changing the starting 
concentration of the nutrients. Such kind of a feature, to the best of my knowledge, has not 
been presented in the past. The automated way presented herein is a consequence of the novel 
way that the constructed vectors of sampling and feeding have been introduced, described in 
more detail in section 4.14. Such kind of a method can potentially be used for informing 
kinetic models, by including the presented vectors of sampling and feeding as continuous 
functions.     
The case studies also show a potential use of the developed code as a means to 
develop media and feeds. At the current stage, for example, a feeding strategy can be 
designed where all the nutrients are supplied in such a way that their concentration in the feed 
is minimized and simultaneously ensure no depletion of any of the nutrients. For such type of 
calculation the growth rate, as well as, nutrient consumption rates between the sampling 
points would have to be kept constant. It has to be clearly stated at this point that all the 
calculations that occur for glucose (Figure 7-4, right panel, bottom) are readily also applied to 
the other user-defined nutrients. Also, the simulations demonstrate the impact that the 
dilutions have. As can be seen in Figure 7-4 (right panel, bottom), the increase of the 
concentration of glucose before and after the feeding interval reduces as the culture 
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progresses, due to the increased volume of the culture, as the feeding volume remains the 
same.    
 
Figure 7-5: The main challenge in current bioprocesses: prediction of consumption 
rates for a given set of extracellular concentrations. 
The prediction of consumption/production rates (μ, kd, q) from a given set of 
extracellular concentrations (C) will remain a great challenge in bioprocessing. Such a 
prediction would facilitate the a priori design of optimal media and feeding strategy. 
The accumulation of several metabolites, some of which may be untraceable, as well as 
the unknown intracellular network that regulates nutrient consumption and by-product 
formation in connection with the complicated nature of cellular metabolism (involving a 
vast array of enzymes) are some of the main reasons that such kind of prediction is 
extremely challenging. 
 
Arguably, the cases presented in Figure 7-4 (bottom panel) represent very simple 
studies. As the results in Chapter 6 have shown, the consumption rates of nutrients for 
different feeds would definitely involve altered growth rates, resulting in different 
consumption/production rates of metabolites. Ideally, a way to calculate consumption rates 
from observed concentrations during a bioprocess run would have solved all the problems of 
bioprocessing. It would be difficult to develop such a method given the current level of 
understanding of the system. This is due to unknown by-products and the uncertainty of 
intracellular reaction network that regulates nutrient consumption (see also Figure 7-5). The 
current code can be set as a basis for analysing observed consumption rates under various 
conditions. Such a method would involve exactly what is presented in Figure 7-5, i.e. to 
connect observed concentrations with observed rates in multiple bioprocess runs, involving 
an array of conditions. The developed code could be beneficial in that it presents a platform 
to accommodate data analysis of both observed concentration and consumption rates, further 
facilitating the creation of libraries.    
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7.4 Other uses and further development of the developed code 
 
Some potential uses and further development of the presented code are summarised in 
this part. The automated nature of the calculation of the rates can be used for universal 
comparison of observed rates in industry. For example, it can be used to analyse and compare 
rates for different feeding strategies or cell lines. This would increase the understanding of 
current bioprocesses, as well as facilitate the creation of data libraries as described in 7.3. 
Another use of the code can be for parameter estimates in Monod models. The consumption 
rates for the studied interval (e.g. between inoculation and the day of harvest) may be used as 
initial guesses for parameter estimation campaigns. 
Future development would involve transforming the simple code to a bioprocessing-
relevant software platform. This can be readily done from the current structure by using the 
user-supplied data from bioprocesses to provide user-defined graphs helping to visualise and 
understand the observed data. Ultimately, the code could also aid in calculating amounts of 
nutrients in feeds, including, for example, the linear scale-up of consumption rates until the 
limiting component to an IVCC estimate approximation, presented in Chapter 6.  
The code can be further developed to be directly coupled with FBA. The calculated 
intervals can be set as inputs to a user-defined FBA network and have the associated fluxes 
through the reactions of the network calculated. The code can also be coupled with 
multivariate analysis that can provide some greater insights, when comparing different 
bioprocessing conditions, as in the study presented in Le et al. (2012), but also the PCA in 
part 6.2.3 of this thesis. 
 
7.5 Conclusions  
 
The code presented herein is capable of calculating all possible growth and nutrient 
specific rates observed in batch and fed-batch cultures and ranking the different intervals 
based on maximum observed growth, death and production rates. The code uses a novel 
discrete way to include feeding, sampling and any other user-defined volume-altering 
additions or removals during a bioprocess run, in the calculations of the specific rates. The 
latter gives a great advantage in automating the calculations of the rates under multiple bolus-
feeding conditions, a strategy that can potentially be used in continuous models as well. The 
calculated rates can be used for further FBA analysis, comparison between different feeding 
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strategies and rates observed between different cell lines. Ultimately the code can be 
developed to a bioprocessing-relevant software platform allowing for visualization of 
bioprocessing related data, calculating concentrations of nutrients in medium and feeds and 
as a library where observed concentrations would be correlated with observed consumption 
rates.     
   144 
Chapter 8                                            
Conclusions & future work  
  
This chapter presents a summary of the results and discusses the conclusions that can 
be drawn before suggesting relevant future work. 
 
8.1 Summary of results and conclusions 
 
In this thesis, the development of feeds with optimal amounts of amino acids (a.a.) 
was attempted based on understanding of a.a. transport and metabolism. In Chapter 1 the 
main motivation for this research was outlined, followed by the presentation of the aims of 
this thesis. In Chapter 2 the important literature/ theoretical background was summarised. In 
Chapter 3 the research objectives were presented and discussed. In Chapter 4 the materials 
and methods used for this thesis were presented.   
The results of the a.a. transport study were presented in Chapter 5. There, mRNA 
levels of the majority of a.a. transporters were quantified in different phases of batch cell 
culture for three CHO variants, a null GS-CHO and two antibody-producing GS-CHO cell 
lines with different levels of productivity. Intra- and extra-cellular a.a. analysis 
complemented the transcriptomic study. The majority of the transporters were found to be 
elevated for the rprotein producer cell lines, however very few genes were identified to be 
differentially expressed for the rprotein producers vs the null cell line (slc43a2 and slc1a2). 
Only one gene (slc6a6), not involved in the transport of proteinogenic a.a., was found to be 
differentially expressed between low and high producer cell lines. The majority of the 
transporters were found to be elevated at stationary phase of batch cell culture in response to 
reduced concentrations of nutrients in the extracellular environment for all cell lines. Further 
analysis demonstrated that, from the aforementioned, four transporters (slc1a4, slc6a9, 
slc1a2, slc7a11) involved in glutathione biosynthesis were significantly upregulated for all 
three tested cell lines at stationary phase. The latter demonstrates the importance of this 
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pathway in CHO cells, which has also been shown in relevant studies in the literature; 
however this is the first time that a.a. transporters are linked to the pathway. Analysis of 
extracellular nutrient production/consumption rates demonstrated that differences between 
cell lines do not follow a specific pattern. Hence, it is concluded that a.a. transport is not the 
limiting step in rprotein synthesis, since also not many genes were found to be differentially 
expressed for the high producer cell line vs the low. A possible map of a.a. transport for the 
high producing cell line was also constructed, by coupling differentially expressed 
transporters within culture with intra- and extra-cellular a.a. concentrations. This map was 
used as a guide for the a.a. transport based feeding strategies designed and tested in Chapter 
6.    
In the following section (Chapter 6) the results of six devised feeding strategies were 
presented. The feeds were designed by linearly scaling up observed consumption rates in 
batch (until the first limiting measurable component) and extrapolating to an integral of 
viable cell concentration (IVCC) estimate (three times that of batch). Three of the 
aforementioned feeds were prepared in order to test whether the basic a.a. transport 
understanding, achieved in the previous section (Chapter 5), would be beneficial. The latter 
involved staged feeding strategies, where branched chain a.a. followed the addition of the rest 
amino acids (apart from those found to be accumulating in batch, e.g. alanine, glutamine and 
glycine). Also, the reverse strategy was tested, i.e. branched chain amino acids being fed first 
and then the rest amino acids. All feeds were prepared by adding the calculated amount of 
nutrients in one to one water to medium, routinely used for the cultivation of this kind of 
cells, ratio. Hence, a pre-existing medium is necessary in order for the feeds to be designed 
with the presented method. One feed was not diluted with the medium and hence was used as 
a negative control. Furthermore, one of the feeds was designed in order to assess whether 
linear correlation can be achieved between IVCC and increased concentration of nutrients in 
the feed. This feed contained 40% more of all nutrients (except from the least soluble a.a., 
tyrosine) than the initially prepared feed that resulted from the extrapolation of consumption 
rates in batch to an IVCC estimate. The performance of all designed feeds was compared and 
contrasted against that of a commercially available feed. 
All feeds designed based on the transport study were found to underperform when 
compared to the feeds where all amino acids were added to the culture simultaneously. There 
is, however, a possibility of increasing IVCC with the aforementioned feeds, although more 
experiments are needed to improve their formulation and the timing of addition.  
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The highest IVCC and growth was achieved for the commercial feed that achieved 4.5 
times the yield in batch. The directly scaled up feed from consumption rates in batch and the 
IVCC estimate, managed to achieve a yield close to 3.1 times of that in the batch culture, 
while the feed containing 40% more of all components than the aforementioned feed 
achieved 3.5 times more of the yield in batch. Interestingly the feed that was not prepared in 
one to one water to medium ratio presented poor growth and rprotein yield. This was 
attributed to the fact that other essential components of the medium (e.g. nucleic acid 
derivatives) were overly diluted due to the feeding events, occurring every other day of cell 
culture. As it appears nutrients in the initial medium even when diluted in one to twenty, as 
occurs for the rest feeds, demonstrate beneficial effects in cell culture.  
The results in Chapter 6 showed that there was not a linear relationship between 
IVCC and a.a. availability. As the feed that contained 40% more of all the nutrients than the 
initial feed, achieved lower IVCC, however the former demonstrated the highest specific 
productivity. In fact, the latter specific productivity was identical with that in the commercial 
feed. Overall, the fact that the cells are able to grow in an environment where mainly a.a. and 
glucose are supplied from the total of 50-100 components that media and feeds may contain, 
also shows that cells are very robust in regulating the metabolism of nutrients in their 
extracellular environment. This is also backed-up by the fact that the cultures, where the 
designed feeds were used, reached much higher ammonia levels than the reported toxic levels 
for CHO cells. Nevertheless, the tested feeds achieved comparable results with the 
commercial feed in terms of yield.  
The other reported toxic by-product, lactate, was found in Chapter 6 to accumulate to 
a similar concentration value for all tested feeds, where amino acids were fed all together, 
when cells started to consume it. This phenotype is typically observed in continuous cultured 
mammalian cell lines and the fact that similar lactate concentrations were attained for all 
feeds demonstrates that the lactate metabolic shift occurs possibly because of the high lactate 
concentration and not due to the depletion of any of the nutrients. This is contrary to other 
studies in the literature, which have hypothesised that the depletion of nutrients is the cause 
of lactate consumption in batch cultures.   
In the same Chapter, flux balance analysis (FBA) was used to analyse observed 
nutrients consumption rates in batch culture. An enhanced metabolic network that can 
effectively describe observed phenotype was devised by combining two networks from 
different studies in the literature. An analysis of a.a., glucose and ammonia fluxes was 
presented in more detail in an attempt to demonstrate how FBA can aid in the understanding 
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of cellular metabolism and subsequently the design of feeding strategies. Some limitations of 
FBA were also presented. The FBA analysis confirmed that lowering asparagine in the feeds 
can result in reduced ammonia concentration in the extracellular environment, a strategy that 
as it appears is also used by the commercial feed manufacturers.   
In Chapter 7, a code developed in R software was presented. The code is able to 
calculate all (between all possible combinations of sampling points) growth and nutrient 
specific rates in batch and fed-batch cultures. The obtained results from the calculation of 
specific rates were compared against other similar approaches in the literature. The code was 
also used to calculate the interval where the maximum rprotein production rate occurs. This 
was performed in an attempt to correlate this with lactate levels and cell growth, as reports in 
the literature demonstrate that maximum rprotein productivity occurs at the point, where 
cellular metabolism shifts from net lactate production to consumption. Interestingly, this 
point is within the 5 top ranked rprotein rates (from the total of 105) for all tested feeds (those 
that a.a. were supplied in one dose). The latter was used as a demonstration of the potential 
for the developed code to be used as a framework to analyse typical bioprocessing data, i.e. 
time course concentrations of nutrients and cells. Furthermore, the developed code was 
evaluated in back-calculating concentration data from observed specific rates. The results 
were not very promising for the latter, as the actual calculation underestimates the 
experimentally observed concentration. A way was found to accurately estimate viable cells 
concentration, which involves taking the average between the back-calculation of 
concentration of the growth specific rate, where the volume dilutions are included and where 
the volume dilutions are not included. Some more simulations with different starting 
concentrations of glucose, as well as, different concentrations of glucose in the feeds were 
presented. Another simulation also tested glucose supplementation at 24 hr intervals, rather 
than 48 hr, as in the tested feeds in Chapter 6, in order to demonstrate the enhanced feature of 
the developed code, which is that feeding intervals are user-defined.    
 
8.2 Main Conclusions 
 
The overall thesis conclusions are presented in this part. The following conclusions 
demonstrate the main contributions of the work accomplished herein, as well as some general 
conclusions regarding CHO cells bioprocessing resulting from the presented literature.  
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First, the recent publication of the CHO genome and the fact that the knowledge of 
the intracellular regulatory network in cultured CHO cells is currently insufficient 
necessitates the thorough exploration of the functionality of the genome in bioprocess 
relevant conditions. In addition, the associated experimental error, inherent in biological 
systems, along with the aforementioned limited understanding of the system studied, cannot 
yet enable the development of accurate and predictive mathematical models. For this to 
happen, more experiments have to be undertaken to ultimately test the functionality of the 
published genome. Further experimentation should involve conditions that perturb the 
cellular state in bioprocess relevant conditions. 
Herein, the first study of amino acid transport in bioprocess relevant CHO cell lines 
was presented. The transport study concluded that a.a. transport was not limiting rprotein 
formation. Several promising genetic engineering targets were identified that remain to be 
tested experimentally. The targets involved genes mainly associated with the glutathione 
biosynthesis pathway. Glutathione is an antioxidant in mammalian cell culture, high levels of 
which have been linked with high producing cell lines.  
This was also the first study to report a traceable method to calculate the necessary 
amount of a.a. in feeds. A simple method was followed, which was shown to increase 
rprotein yield in fed-batch cultures up to 3.5-fold from batch. The method involved the linear 
projection of a.a. consumption rates in batch until the first measurable component becomes 
limiting to an IVCC estimate (three times that of batch). The disadvantage of the method, 
however, was that a pre-existing medium has to be used. Another disadvantage is that, in 
most cases, more than one experimental run has to be conducted in order to optimize the 
concentration of a.a. in feeds. Expanding this approach for more nutrients than only a.a. and 
glucose, as well as increasing the aspartate over asparagine ratio may result in higher yield 
than the aforementioned.  
Simultaneously, this was the first study that a staged feeding strategy was tested in a 
bioprocessing context. Results are not very promising; however, a better insight for the 
regulated transporters in proteomic level (and not transcriptomic, as presented in this thesis) 
may indicate an improved feeding strategy. 
An enhanced FBA network for CHO cells was presented by combining two pre-
existing in the literature. The network can ultimately aid in designing media and feeds with 
23 nutrients (19 a.a., glucose, folate, spermine, choline). The network also incorporated for 
the first time glycans of the host proteins in the biomass equation. 
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A code to calculate all possible fluxes within cell culture was created that a) can 
facilitate objective comparison between different bioprocesses or for different cell lines, b) 
can provide kinetic estimates for Monod based models, c) can provide input specific rates for 
FBA, d) can aid in designing feeds by assuming constant consumption at certain parts of cell 
culture, e) can be set as a basis to calculate all important bioprocessing indicators (e.g. IVCC, 
integral of moles of all the species) in one place and also facilitate the creation of libraries of 
consumption rates vs observed concentrations of nutrients. The latter can aid in a better 
understanding, as well as in predicting subsequent consumption/ production rates of nutrients/ 
metabolites from online monitoring of bioprocesses. Also, the method of creating the 
artificial/ constructed vectors of feeding and sampling events can be proven useful for kinetic 
models of cell culture in order to continuously integrate the resulting ODEs. Currently, the 
solution process involves the re-initialisation of the set of ODEs in order to incorporate the 
feeding concentrations at feeding intervals. 
Overall, this thesis contributed both experimentally and computationally to the 
mammalian cells bioprocessing field. A large amount of experiments were conducted that 
allow for a better understanding of current bioprocesses. From the computational side, the 
basis for a useful bioprocessing software platform was established.    
 
8.3 Future work 
 
The following few paragraphs will present some suggested future work for every 
distinct part of this thesis that can be used to continue the work presented herein. The distinct 
parts include the a.a. transporters work, the design of feeding strategies, the FBA and the 
developed code in R. 
 
8.3.1 Amino acid transport 
 
As it is extensively discussed in Chapter 5, proteomics analysis has to complement the 
transcriptomic work on a.a. transporters presented. This would allow establishing a more 
accurate understanding of the system with more confidence, as the actual a.a. transporter 
proteins are those that facilitate the uptake of a.a. A similar study would be very beneficial to 
occur during fed-batch culture, which is more representative in a bioprocessing context. A 
study under fed-batch conditions would allow truly identifying which transporters are 
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responsive to starvation. Furthermore, such a study would provide a better insight on 
regulated transporters and possibly could lead to the design of improved feeding strategies. 
Regarding the several genes that were found to be significantly regulated within 
culture of all cell lines, an over-expression of some of these genes could lead to cell lines 
with enhanced phenotypes. For example, one such target could be gene slc7a11 that was 
found to be more than 14-fold upregulated in stationary phase of the high producer cell line 
vs the exponential. This gene is associated with the glutathione biosynthesis pathway, in 
terms that it carries cystine intracellularly, which is an important substrate for the production 
of glutathione. The latter is an important antioxidant in CHO cell culture, high levels of 
which have been associated with high productivity. Here, however the complicated biology 
underlying the transport mechanisms in mammalian cells has to be taken under consideration. 
For example the transporter is reported to exchange glutamate for one cystine molecule. 
Glutamate is a very important amino acid, especially for the glutamine synthetase cell lines. 
Hence, a possible overexpression of the aforementioned transporter might lead to the 
exhaustion of glutamate intracellularly, given that cystine is in the extracellular environment. 
Moreover, the aforementioned transporter is a heteromeric transporter coupled with a protein 
encoded by the slc3a2 gene, hence a possible overexpression of slc7a11 gene, might also 
require the overexpression of the slc3a2 gene.     
 
8.3.2 Feeding strategies 
 
Future work based on the analysis in Chapter 6 would involve testing a feeding 
strategy with a reduced asparagine to aspartate ratio. This ratio could be reduced in such a 
way that ensures that depletion of asparagine would not occur. Since cells appear to 
preferentially consume asparagine at a higher rate than any other a.a., a strategy could be to 
feed more frequently than the two-day interval that was used in this work. 
Another future experiment would involve testing the quality of the resulting product 
(mAb) from the designed feeds vs that from the culture treated with the commercial feed, 
particularly with respect to protein glycosylation. In the case that the glycan distribution is 
not within the acceptable range then the feeds would have to be enhanced with other 
frequently used media components (e.g. nucleotide precursors, metals, etc.). 
In order to test whether the presented strategy can be beneficial in a more bioprocess-
relevant context, experiments have also to take place in pH controlled bioreactors. The 
performance of feeds could also be evaluated using biphasic cell cultures, i.e. starting at 
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physiological temperature and switching to mild hypothermia at the end of the exponential 
growth phase. 
Furthermore, an alteration of the ratios of the a.a. resulting from the method presented 
in Chapter 6 using DOE could give a more accurate picture of whether the technique 
presented herein is anywhere close to optimal. What would be tested with such experiments 
is whether the availability of each a.a. itself is enough for the cells to produce certain amounts 
of rprotein, or if the ratio of a.a. significantly affects process performance. 
Other interesting options to be investigated include: 
a) How the addition of alanine and glycine might affect feeding strategies. These amino 
acids were found to accumulate during cell culture and so it would be interesting to 
test how their addition affects the process.  
b) How the timing of addition of the feeds affects the process. This would, for example, 
involve feeding less frequently. A more complicated feeding scheme could even be 
tested, where feeds would be provided without using a constant feeding interval. The 
timing of addition may have a significant impact in cellular performance during a 
bioprocess run. 
 
After most of the above have been considered then the resulting feeds can be tested 
for other cell lines as well. This would ensure that a valid tailored strategy has been 
developed. Moreover, cells grown on several different basal media have to be tested, in order 
to ensure that different media do not affect the presented method. This is because a pre-
existing medium is required for the method described in Chapter 6.  
 
8.3.3 Flux balance analysis  
 
The immediate future work resulting from the discussion on FBA in Chapter 6 would 
involve a further investigation of the asparagine synthetase gene. A transcriptomic and 
proteomic study can provide some insight on the regulation of this enzyme, as well as its 
function. In the case that this gene has the role of asparaginase, i.e. converting asparagine to 
aspartate and ammonia then a possible silencing of this gene could be beneficial. The latter 
would result in reduced amount of ammonia in cell culture and hence improved cell growth. 
  Another future objective arising from the FBA presented herein is the accurate 
biomass composition during a bioprocess run. This would allow identifying whether and to 
what extent biomass composition changes throughout a process. Such an analysis would 
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facilitate more accurate FBA results leading to a better understanding of the underlying 
system. Towards that also a large scale proteomic analysis along the course of the culture 
would be beneficial. This would lead to conclusions on active or not metabolic enzymes that 
would aid in a further enhancement of the FBA network.  
 
8.3.4 Methodology for analysing cell culture data 
 
The algorithm presented in Chapter 7 can be developed to a bioprocessing software 
platform. The latter would be able to facilitate comparison of cell cultures treated with 
different conditions or comparison between different cell lines. Plots of cell culture data can 
be also included, as well as multivariate analysis (PCA, PLS). Another application may 
involve direct coupling of the calculated rates with a user-defined FBA network. Generally 
the envisaged idea is for the code to be used as a library correlating observed concentrations 
with subsequent production/consumption specific rates. Such a library will facilitate the 
prediction of the aforementioned rates from data generated from online monitoring of 
bioprocesses, resulting to a more controllable process in terms of feed addition rates.   
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Appendix I The twenty proteinogenic amino acids 
Table I-1: The twenty proteinogenic amino acids classified based on chemistry of side 
chain. Modified from: Papadoyannis and Theodoridis (2009) and Alberts et al. (2002).  
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Table I-1 (continued): The twenty proteinogenic amino acids classified based on 
chemistry of side chain. Modified from: Papadoyannis and Theodoridis (2009) and 
Alberts et al. (2002).  
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Appendix II Selectivity and operational characteristics of amino acid 
transporters  
 
Amino acid transporter systems and their genes are presented in the following tables, 
along with their substrates and their mechanisms of transport, as reported for mainly human 
cell lines. In all cases substrates correspond to L- amino acids unless otherwise specified. 
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Table II-2: Amino acid transporters of system A.  
Sym= symport; medium affinity corresponds to a Km value between 100μM to 1mM; MeAIB= 2-methylaminoisobutyric acid (Broer 
2008; Guidotti and Gazzola 1992; Hediger et al. 2004; Kilberg et al. 1993; Mann et al. 2003; McGivan and Pastor-Anglada 1994; 
Shotwell et al. 1983). 
System 
Isoforms 
(gene/ 
protein) 
Selectivity Operation 
Cell types Additional references- Comments 
Predo-
minant 
Substrates 
Side Chains Analogs 
α amino group 
alkyl 
substituted 
substrates   
Affinity Mecha-
nism 
Ion 
Depen-
dency 
A 
(T.C.: 
2.A.18)  
SLC38A1/ 
SNAT1, 
SAT1, 
ATA1 
Gln, Ala, 
Asn, Cys, 
His, Ser 
short, 
unbranched, 
aliphatic 
MeAIB Accepted 
medium Sym Na+ 
brain (glutamatergic and 
GABAergic neurons, 
ependyma), retina, heart, 
placenta, adrenal gland 
Schioth et al. (2013), Tsitsiou 
et al. (2009), Grillo et al. 
(2008), Melone et al. (2004), 
Mackenzie and Erickson 
(2004b)  
SLC38A2/ 
SNAT2, 
SAT2, 
ATA2 
Ala, Asn, 
Cys, Gln, 
Gly, His, 
Met, Pro, 
Ser 
medium Sym Na+ 
brain, spinal cord 
(neurons), placenta, 
ovary, adrenal glands, 
testis, thymus, muscle, 
liver, intestine, kidney, 
lung, adipose tissue, 
spleen, skin 
Schioth et al. (2013), 
Drummond et al. (2010), 
Tsitsiou et al. (2009), Grillo et 
al. (2008), Mackenzie and 
Erickson (2004b), Lopez-
Fontanals et al. (2003) 
SLC38A4/ 
SNAT4, 
ATA3 
Ala, Asn, 
Cys, Gly, 
Ser, Thr 
medium 
(Desforges 
vs 
Hatanaka)* 
Sym 
Na+, in 
some 
cases- 
placenta: 
none 
liver, skeletal muscle, 
kidney, pancreas, 
placenta 
*Hatanaka reports higher 
affinity for cationic a.a. than 
other two isoforms whereas 
Desforges the opposite; 
Schioth et al. (2013), 
Desforges et al. (2009), Grillo 
et al. (2008), Melone et al. 
(2004), Mackenzie and 
Erickson (2004b), Hatanaka et 
al. (2001), Sugawara et al. 
(2000)  
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Table II-3: Amino acid transporters of systems ASC, asc and B0.  
An= antiport; Sym= symport, low affinity: Km>1mM, high: Km<100μM. Question mark “?” is used where data do not exist. BCH= 2- 
aminobicyclo(2,2,1)heptanes-2-carboxylic acid (Broer 2008; Guidotti and Gazzola 1992; Hediger et al. 2004; Kilberg et al. 1993; Mann 
et al. 2003; McGivan and Pastor-Anglada 1994; Shotwell et al. 1983). 
System 
Isoforms 
(gene/ 
protein) 
Selectivity Operation 
Cell types References- Comments Predominant 
Substrates Side Chains Analogs 
α amino 
group alkyl 
substituted 
substrates   
Affinity Mecha-
nism 
Ion 
Depen-
dency 
ASC 
(T.C.: 
2.A.23) 
SLC1A4/ 
ASCT1, 
SATT 
Ala, Ser, Cys 
unbranched, 
short, polar 
Cysteic 
Acid 
rejected 
high An Na+ widespread 
Kanai et al. (2013) ,Gesemann et al. 
(2010), Kanai and Hediger (2004), Marin 
et al. (2003) 
SLC1A5/ 
ASCT2, 
AAAT 
Ala, Ser, 
Thr, Cys, 
Gln 
- high An Na+ 
lung, skeletal 
muscle, large 
intestine, kidney, 
testis, adipose tissue, 
epithelial cells 
Kanai et al. (2013) ,Gesemann et al. 
(2010), Kanai and Hediger (2004), Marin 
et al. (2003) 
asc 
SLC3A2, 
SLC7A10
/ 4F2 hc, 
asc1 
[hetero-
meric] 
Ala, Cys, 
Gly, Ser, 
Thr, AIB 
small, 
neutral D-Ser ? 
high An none 
(human) brain, 
heart, placenta, 
skeletal muscle and 
kidney 
Fotiadis et al. (2013), Palacin and Kanai 
(2004), Verrey et al. (2004) 
?, 
SLC7A12
/ ?, asc2 
[hetero-
meric] 
Ala, Cys, 
Gly, Ser, 
Thr, AIB 
? An none 
epithelial, mouse 
kidney, oocytes, not 
in humans 
Fotiadis et al. (2013), Pelland et al. 
(2009), Closs et al. (2006), Palacin and 
Kanai (2004), Chairoungdua et al. (2001) 
B0 
SLC6A19
/ B0AT1 neutral  neutral BCH ? low Sym Na
+
 
intestine and renal 
proximal tubule 
(apical) 
Pramod et al. (2013), Nickel et al. (2010), 
Verrey et al. (2004), Chen et al. (2004) 
SLC6A15
/ B0AT2 
Pro, Leu, 
Val, Ile, Met large, neutral BCH ? high Sym Na
+
 
brain (amygdala, 
putamen, corpus 
callosum) 
Pramod et al. (2013), Nickel et al. (2010), 
Verrey et al. (2004), Chen et al. (2004) 
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Table II-4: Amino acid transporters of systems B0,+, b0,+, β and Gly.  
An= antiport; Sym= symport, high affinity: Km<100μM; question mark “?” is used where data do not exist; BCH= 2- 
aminobicyclo(2,2,1)heptanes-2-carboxylic acid (Broer 2008; Guidotti and Gazzola 1992; Hediger et al. 2004; Kilberg et al. 1993; Mann 
et al. 2003; McGivan and Pastor-Anglada 1994; Shotwell et al. 1983). 
System 
Isoforms 
(gene/ 
protein) 
Selectivity Operation 
Cell types References- Comments Predo-
minant 
Substrates 
Side 
Chains Analogs 
α amino group 
alkyl substituted 
substrates   
Affinity Mecha-
nism 
Ion 
Depen-
dency 
B0,+ SLC6A14/ ATB0,+ 
cationic, 
neutral, 
beta- 
alanine 
cationic, 
neutral BCH ? high Sym Na
+
, Cl- 
lung, trachea, 
salivary gland, 
mammary gland, 
stomach, intestine, 
pituitary, cancer cells 
Pramod et al. (2013), Karunakaran et 
al. (2008), Chen et al. (2004)  
b0,+ 
SLC3A1, 
SLC7A9/ 
rBAT, b0,+AT 
[hetero-meric] 
L-Arg, L-
Lys, 
ornithine, 
Cystine 
cationic, 
large 
neutral  
- ? high An None 
small intestine, 
kidney, lung, 
placenta, brain, liver 
/ apical in epithelial 
cells 
Fotiadis et al. (2013), Palacin and 
Kanai (2004), Verrey et al. (2004) 
β (T.C.: 
2.A.22, 
23) 
SLC6A6/ TauT 
taurine, 
beta-
alanine 
- - ? high Sym Na+, Cl- 
brain, retina, liver, 
kidney, heart, spleen, 
pancreas, ovary 
Pramod et al. (2013), Tabuchi et al. 
(2010), Chen et al. (2004) 
Gly 
(T.C.: 
2.A.22, 
23) 
SLC6A18/ 
XT2 Gly 
only 
glycine 
- ? ? ? Na+, Cl- kidney and small intestine (apical) 
Singer et al suggest to rename it as 
B0AT3 and add it to B0 group; 
Pramod et al. (2013), Singer et al. 
(2009) 
SLC6A9/ 
Glyt1 Gly - ? high Sym Na
+
, Cl- 
GLYT1a: brain, 
pancreas, uterus, 
stomach, spleen, 
liver, lung 
GLYT1b,c: neurons 
Pramod et al. (2013), Howard and 
Hirst (2011), Eulenburg and Gomeza 
(2010), Chen et al. (2004) 
 SLC6A5/ 
Glyt2 Gly - ? high Sym Na
+
, Cl- spinal cord, brain (glycinergic neurons) 
Pramod et al. (2013), Howard and 
Hirst (2011), Eulenburg and Gomeza 
(2010), Chen et al. (2004) 
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Table II-5: Amino acid transporters of systems IMINO and L.  
An= antiport; Sym= symport; Un= uniport; high affinity: Km<100μM; medium: Km between 100μM and 1mM; low: Km>1mM. 
Question mark “?” is used where data do not exist. BCH= 2- aminobicyclo(2,2,1)heptanes-2-carboxylic acid; MeAIB= 2-
methylaminoisobutyric acid (Broer 2008; Guidotti and Gazzola 1992; Hediger et al. 2004; Kilberg et al. 1993; Mann et al. 2003; 
McGivan and Pastor-Anglada 1994; Shotwell et al. 1983). 
 
System 
Isoforms 
(gene/ 
protein) 
Selectivity Operation 
Cell types References Predo-
minant 
Substrates 
Side Chains Analogs 
α amino 
group 
alkyl 
substituted 
substrates   
Affinity Mecha-
nism 
Ion 
Depen-
dency 
IMINO 
(T.C.: 
2.A.22, 
23) 
SLC6A20/ 
IMINO, 
SIT1 
proline, 
hydroxy-
proline 
imino acids MeAIB ? medium Sym Na
+
, 
Cl- 
intestine, kidney proximal 
tubule, choroid plexus, 
microglia, meninges of the 
brain, ovary 
Pramod et al. (2013), Nickel et al. 
(2010), Verrey et al. (2004), Chen et 
al. (2004) 
L  
(T.C.: 
2.A.3; 
T.C.: 
8.A.9; 
T.C.: 
2.A.1) 
SLC3A2, 
SLC7A5/ 
4F2 hc, 
LAT1 
[hetero-
meric] 
Cys, Leu, 
Phe, Trp, 
Val, Tyr, 
Ile, His, 
Met 
large, 
branched, 
heterocyclic 
BCH 
accepted 
high  An none 
brain, ovary, testis, 
placenta, blood-brain 
barrier, fetal liver, 
activated lymphocytes, 
tumor cells 
Fotiadis et al. (2013), Oda et al. 
(2010), Tsitsiou et al. (2009), Verrey 
et al. (2004), Palacin and Kanai 
(2004) 
SLC3A2, 
SLC7A8/ 
4F2 hc, 
LAT2 
[hetero-
meric] 
neutral 
except 
proline 
BCH medium An none 
small intestine, kidney, 
brain, placenta, ovary, 
testis, skeletal muscle / 
basolateral in epithelial 
cells 
Fotiadis et al. (2013), Oda et al. 
(2010), Tsitsiou et al. (2009), Verrey 
et al. (2004), Palacin and Kanai 
(2004) 
SLC43A1/ 
LAT3 
Leu, Ile, 
Met, Phe BCH Low Un none 
pancreas, liver, skeletal 
muscle, kidney (podocyte) Bodoy et al. (2013), He et al. (2009) 
SLC43A2/ 
LAT4 
Leu, Ile, 
Met, Phe BCH Low Un none placenta, kidney, intestine Bodoy et al. (2013), He et al. (2009) 
SLC43A3/ 
EEG1 ? ? ? ? ? ? 
fetal liver, lung, placenta, 
kidney, thyroid Bodoy et al. (2013), He et al. (2009) 
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Table II-6: Amino acid transporters of systems N and PAT. 
Sym= symport; Un= uniport; high affinity: Km<100μM; medium: Km between 100μM and 1mM; low: Km>1mM; question mark “?” is used where 
data do not exist. MeAIB= 2-methylaminoisobutyric acid (Broer 2008; Guidotti and Gazzola 1992; Hediger et al. 2004; Kilberg et al. 1993; Mann et 
al. 2003; McGivan and Pastor-Anglada 1994; Shotwell et al. 1983). 
System 
Isoforms 
(gene/ 
protein) 
Selectivity Operation 
Cell types References Predominant 
Substrates Side Chains Analogs 
α amino 
group alkyl 
substituted 
substrates   
Affinity Mecha-
nism 
Ion 
Depen-
dency 
N 
(T.C.2.A.1
8) 
SLC38A3/ 
SNAT3 
Gln, His, 
Ala, Asn 
neutral 
- 
rejected 
Low Sym 
2Na+ 
(Sym), 
1H+(An) 
astrocytes in brain and 
retina; liver, kidney, 
adipose tissue 
Schioth et al. (2013), 
Yoshioka et al. 
(2009), Mackenzie 
and Erickson 
(2004b)  
SLC38A5/ 
SNAT5 
Gln, Asn, 
His, Ser - Low Sym 
Na+ 
(Sym), 
H+(An) 
stomach, brain, liver, 
lung, small intestine, 
spleen, colon, kidney 
Schioth et al. (2013), 
Mackenzie and 
Erickson (2004b) 
PAT (T.C.: 
2.A.18) 
SLC36A1/ 
PAT1 
Gly, Ala, D- 
and L- Pro, 
GABA, D-
Ala, β- Ala, 
taurine 
imino acids, 
small, neutral 
MeAIB ? Low Sym H+ (Sym) 
brain (neurons), intestine, 
colon, kidney, lung, liver, 
spleen / lysosomes 
(neurons), apical 
membrane (Caco-2 cells) 
Schioth et al. (2013), 
Heublein et al. 
(2010)  
SLC36A2/ 
PAT2 
Gly, Ala, 
Pro MeAIB ? Medium Sym H
+
 (Sym) 
lung, heart, kidney, 
muscle, testis, spleen, 
adrenal gland, thymus, 
sciatic nerve (Schwann 
cells) 
Schioth et al. (2013), 
Heublein et al. 
(2010) 
SLC36A3/ 
PAT3 ? ? ? ? ? ? testis 
Schioth et al. (2013), 
Heublein et al. 
(2010) 
SLC36A4/ 
PAT4 Ala, Pro, Trp 
imino, small & 
heterocyclic - ? High Un none Xenopus laevis oocytes 
Schioth et al. (2013), 
Heublein et al. 
(2010) 
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Table II-7: Amino acid transporters of systems T and X-AG.  
Sym= symport; ; Un= uniport; high affinity: Km<100μM; low: Km>1mM; question mark “?” is used where data do not exist (Broer 
2008; Guidotti and Gazzola 1992; Hediger et al. 2004; Kilberg et al. 1993; Mann et al. 2003; McGivan and Pastor-Anglada 1994; 
Shotwell et al. 1983). 
System 
Isoforms 
(gene/ 
protein) 
Selectivity Operation 
Cell types References Predominant 
Substrates Side Chains Analogs 
α amino 
group alkyl 
substituted 
substrates   
Affinity Mecha-
nism 
Ion 
Depen-
dency 
T (T.C.: 
2.A.1) 
SLC16A10/ 
TAT1 Phe, Tyr, Trp 
aromatic, 
heterocyclic - ? low Un none 
Kidney 
(basolateral), 
intestine, muscle, 
placenta, heart 
Halestrap (2013) 
X-AG 
(T.C.: 
2.A.23) 
SLC1A1/ 
EAAT3 
L-Glu, D / L-
Asp 
linear, anionic D- Asp rejected 
high Sym 
Na+, H+ 
(Sym) and 
K+ (An) 
neurons, epithelial 
cells, intestine, 
kidney, liver, heart 
cotransports 3 Na+ and one H+ 
with each glutamate molecule, 
while return of the carrier 
facilitated by K+ binding; Kanai 
et al. (2013) ,Gesemann et al. 
(2010), Kanai and Hediger 
(2004)  
SLC1A2/ 
EAAT2 
L-Glu, D / L-
Asp high Sym 
Na+, H+ 
(Sym) and 
K+ (An) 
brain, liver, glia 
cells, epithelial 
Kanai et al. (2013) ,Gesemann 
et al. (2010), Kanai and 
Hediger (2004) 
SLC1A3/ 
EAAT1, 
GLAST 
L-Glu, D / L-
Asp ? Sym 
Na+, H+ 
(Sym) and 
K+ (An) 
astrocytes, heart, 
skeletal muscle, 
placenta, glia cells 
Kanai et al. (2013) ,Gesemann 
et al. (2010), Kanai and 
Hediger (2004) 
SLC1A6/ 
EAAT4 
L-Glu, D / L-
Asp ? Sym 
Na+, H+ 
(Sym) and 
K+ (An) 
cerebellum 
Kanai et al. (2013) ,Gesemann 
et al. (2010), Kanai and 
Hediger (2004) 
SLC1A7/ 
EAAT5 
L-Glu, D / L-
Asp ? Sym 
Na+, H+ 
(Sym) and 
K+ (An) 
retina 
Kanai et al. (2013) ,Gesemann 
et al. (2010), Kanai and 
Hediger (2004) 
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Table II-8: Amino acid transporters of systems x-c and y+.  
An= antiport; Un= uniport; high affinity: Km<100μM; medium: Km between 100μM and 1mM; question mark “?” is used where data 
do not exist (Broer 2008; Guidotti and Gazzola 1992; Hediger et al. 2004; Kilberg et al. 1993; Mann et al. 2003; McGivan and Pastor-
Anglada 1994; Shotwell et al. 1983).  
System 
Isoforms 
(gene/ 
protein) 
Selectivity Operation 
Cell types References Predo-
minant 
Substrates 
Side 
Chains Analogs 
α amino 
group alkyl 
substituted 
substrates   
Affinity Mecha-
nism 
Ion 
Depen-
dency 
x
-
c 
(T.C.: 
2.A.3; 
T.C.: 
8.A.9) 
SLC3A2, 
SLC7A11/ 
4F2 hc, 
xCT 
[hetero-
meric] 
Glu, 
Cystine 
linear, 
long, 
anionic 
- ? high An None 
macrophages, brain, 
retinal pigment cells, 
liver, kidney / 
basolateral in 
epithelial cells, 
human corneal 
epithelium 
Fotiadis et al. (2013), 
Langford et al. (2010),  
Verrey et al. (2004) 
y+ 
(T.C.: 
2.A.3) 
SLC7A1/ 
CAT-1 
Arg, Lys, 
His, 
Ornithine 
long, 
cationic - Rejected 
medium Un None 
ubiquitous except for 
liver, basolateral and 
intracellular 
membranes in 
epithelial cells 
Fotiadis et al. (2013), 
Rotoli et al. (2009), 
Closs et al. (2006), 
Verrey et al. (2004)  
SLC7A2A/ 
CAT-2A 
Arg, Lys, 
His ? Un None 
liver, skeletal 
muscle, pancreas 
Fotiadis et al. (2013), 
Closs et al. (2006), 
Verrey et al. (2004) 
SLC7A2B/ 
CAT-2B 
Arg, Lys, 
His ? Un None 
inducible in many 
cell types 
Fotiadis et al. (2013), 
Closs et al. (2006), 
Verrey et al. (2004) 
SLC7A3/ 
CAT-3 
Arg, Lys, 
His ? Un None 
thymus, ovary, testis, 
brain (neurons) 
Fotiadis et al. (2013), 
Closs et al. (2006), 
Verrey et al. (2004) 
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Table II-9: Amino acid transporters of systems y+L and a system carrying histidine & small peptides.  
An= antiport; Sym= symport; high affinity: Km<100μM; question mark “?” is used where data do not exist (Broer 2008; Guidotti and 
Gazzola 1992; Hediger et al. 2004; Kilberg et al. 1993; Mann et al. 2003; McGivan and Pastor-Anglada 1994; Shotwell et al. 1983). 
System 
Isoforms 
(gene/ 
protein) 
Selectivity Operation 
Cell types References- Comments Predo-
minant 
Substrates 
Side 
Chains Analogs 
α amino 
group alkyl 
substituted 
substrates   
Affinity Mecha-
nism 
Ion 
Depen-
dency 
y+L 
(T.C.: 
2.A.3; 
T.C.: 
8.A.9) 
SLC3A2, 
SLC7A7/ 
4F2 hc, 
y+LAT1 
[hetero-
meric] 
Lys, Arg, 
Gln, His, 
Leu, Met, 
Val, Ile Na
+
 
indep.: 
cationic, 
Na+ 
depen.: 
large 
neutral 
- 
? high An Na
+
 or 
none 
small intestine, 
kidney, leucocytes, 
placenta, lung / 
basolateral in 
epithelial cells 
Fotiadis et al. (2013), 
Tsitsiou et al. (2009), 
Verrey et al. (2004), 
Palacin and Kanai (2004) 
SLC3A2, 
SLC7A6/ 
4F2 hc, 
y+LAT2 
[hetero-
meric] 
Lys, Arg, 
Gln, His, 
Leu, Met, 
Ala, Cys, 
Val, Ile 
? high An Na
+
 or 
none 
red blood cells, brain, 
small intestine, testis, 
parotis, heart, kidney, 
lung, thymus/ 
basolateral in 
epithelial cells 
Fotiadis et al. (2013), 
Tsitsiou et al. (2009), 
Verrey et al. (2004), 
Palacin and Kanai (2004) 
histidine 
& small 
pep-tides 
(not in a 
system- 
TC: 
2.A.17) 
SLC15A3/ 
PHT2 His small 
peptides 
& 
histidine 
- ? ? Sym H
+
 
(Sym) 
lung, spleen, thymus 
(faintly in brain, 
liver, adrenal gland, 
heart), thyroid 
affinity mainly reported 
for peptides; Smith et al. 
(2013), Romano et al. 
(2010) 
SLC15A4/ 
PHT1 His - ? ? Sym 
H+ 
(Sym) 
brain, retina, 
placenta, thyroid 
affinity mainly reported 
for peptides; Smith et al. 
(2013), Romano et al. 
(2010) 
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Table II-10: Vesicular amino acid transporters.  
Modified from: Hediger et al. (2004); Sym= symport; An= antiport; medium affinity: Km between 100μM and 1mM; low: Km>1mM; 
question mark “?” is used where data do not exist. 
System 
Isoforms 
(gene/ 
protein) 
Selectivity Operation 
Cell types References- Comments 
Predo-
minant 
Substrates 
Side 
Chains Analogs 
α amino 
group alkyl 
substituted 
substrates   
Affinity Mecha-
nism 
Ion 
Depen-
dency 
Vesi-
cular 
(TC: 
2.A.1; 
2.A.18) 
SLC17A5/ 
VEAT 
Asp, Glu, 
Sialic acid Anionic   ? low Sym 
H+, 
Sialic 
acid 
ubiquitous 
Reimer (2013), 
Sreedharan et al. 
(2010), Miyaji et al. 
(2008) 
SLC17A6/ 
VGLUT2 Glu 
Glu 
- ? low An H+  brain (neurons 
only), endocrine 
Reimer (2013), 
Sreedharan et al. 
(2010)  
SLC17A7/ 
VGLUT1 Glu - ? low An H
+
  
brain (neurons 
only), endocrine 
Reimer (2013), 
Sreedharan et al. 
(2010) 
SLC17A8/ 
VGLUT3 Glu - ? ? An H
+
  
brain (neurons and 
glia), 
liver, kidney 
Reimer (2013), 
Sreedharan et al. 
(2010) 
SLC32A1/ 
VIAAT 
Gly, 
GABA 
Small, 
neutral - ? medium Sym Cl
-
 
CNS (GABAergic 
and glycinergic 
neurons), pituitary 
(GH and POMC 
cells), pineal, 
pancreas, testis; 
synaptic vesicles, 
secretory granules 
Schioth et al. (2013) 
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Table II-11: Mitochondrial amino acid transporters.  
Modified from: Hediger et al. (2004); Sym= symport; An= antiport; medium affinity: Km between 100μM and 1mM; low: Km>1mM; 
question mark “?” is used where data do not exist. 
System 
Isoforms 
(gene/ 
protein) 
Selectivity Operation 
Cell types References- Comments 
Predo-
minant 
Substrates 
Side 
Chains Analogs 
α amino 
group alkyl 
substituted 
substrates   
Affinity Mecha-
nism 
Ion 
Depen-
dency 
mito-
chondrial 
(T.C: 
2.A.29) 
SLC25A2/ 
ORC2 
ornithine, 
citrulline, 
Lys, Arg, 
His 
basic, 
acidic 
- ? varies for 
substrates 
An: ornithine / 
citrulline + H+; 
ornithine / H+ 
liver, testis, spleen, lung, 
pancreas, small intestine, brain, 
kidney / inner mitochondrial 
membrane 
Palmieri (2013), 
Palmieri and 
Pierri (2010) 
SLC25A12/ 
AGC1 Asp, Glu - ? medium 
An: aspartate / 
glutamate + H+ 
brain, heart, skeletal muscle, lung, 
pancreas, kidney, but not in liver / 
inner mitochondrial membrane 
Palmieri (2013), 
Palmieri and 
Pierri (2010) 
SLC25A13/ 
AGC2 Asp, Glu - ? medium 
An: aspartate / 
glutamate + H+ 
liver, kidney, pancreas, heart, 
skeletal muscle, brain / inner 
mitochondrial membrane 
Palmieri (2013), 
Palmieri and 
Pierri (2010) 
SLC25A15/ 
ORC1 
ornithine, 
citrulline, 
Lys, Arg 
- ? varies for 
substrates 
An: ornithine / 
citrulline + H+; 
ornithine / H+ 
liver, pancreas, lung, testis, small 
intestine, spleen, kidney, brain, 
heart / inner mitochondrial 
membrane 
Palmieri (2013), 
Palmieri and 
Pierri (2010) 
SLC25A18/ 
GC2 Glu - ? medium 
Sym: glutamate + 
H+; A: glutamate / 
OH- 
brain, testis, heart, pancreas, 
kidney, lung / inner mitochondrial 
membrane 
Palmieri (2013), 
Palmieri and 
Pierri (2010) 
SLC25A22/ 
GC1 Glu - ? low 
Sym: glutamate + 
H+; A: glutamate / 
OH- 
pancreas, brain, liver, testis, 
spleen, kidney, heart, lung, small 
intestine, pancreatic β cells / inner 
mitochondrial membrane 
Palmieri (2013), 
Palmieri and 
Pierri (2010) 
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Appendix III CHO literature on a.a. cell membrane transporters at 
transcriptomic and proteomic levels 
Table III-12: Amino acid transporters systems, genes, substrates, mechanisms of action 
and CHO literature on transcriptomic and protein levels. 
 
SYSTEM GENE SUBSTRATES MECHANISM (coupling ions) 
Literature 
on CHO 
(mRNA) 
Literature 
on CHO 
(protein) 
A 
slc38a1 Gln, Ala, Asn, Cys, His, Ser 
Symport (Na+) 
- - 
slc38a2 
Ala, Asn, Cys, Gln, 
Gly, His, Met, Pro, 
Ser 
Becker et al. 
(2011); 
Birzele et al. 
(2010); Shen 
et al. (2010); 
Lopez-
Fontanals et 
al. (2003) 
Baycin-
Hizal et al. 
(2012)  
slc38a4 Ala, Asn, Cys, Gly, Ser, Thr 
Birzele et al. 
(2010); - 
ASC 
slc1a4 Ala, Ser, Cys 
Antiport (Na++ aa 
in exchange to an 
aa) 
Birzele et al. 
(2010); 
Doolan et al. 
(2010); Marin 
et al. (2003) 
Baycin-
Hizal et al. 
(2012)  
slc1a5 Ala, Ser, Cys, Thr, Gly, Gln 
Shen et al. 
(2010); 
Birzele et al. 
(2010) 
Baycin-
Hizal et al. 
(2012)  
Asc slc7a10/ 
slc3a2 
small neutral aa, 
e.g.: Ala, Cys, Gly, 
Ser, Thr 
Antiport - - 
B0 
slc6a19 
neutral a.a., e.g.: 
Ile, Leu, Met, Trp, 
Asn, Gln, Tyr Symport (Na+) 
- - 
slc6a15 
neutral a.a., e.g.: 
Ile, Leu, Met, Trp, 
Asn, Gln, Tyr 
Becker et al. 
(2011)  - 
B0,+ slc6a14 
neutral a.a. & 
cationic, e.g.: Ile, 
Leu, Met, Trp, 
Asn, Gln, Tyr, Arg, 
Lys, His 
Symport (Na+, Cl-) - - 
b0,+ slc7a9/ 
slc3a1 
large neutral & 
cationic, e.g.: Ile, 
Leu, Met, Trp, 
Asn, Gln, Tyr, Arg, 
Lys, His 
Antiport 
(preferentially 
extracellular 
cationic in 
exchange with 
intracellular 
neutral) 
- - 
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Table III-12 (continued): Amino acid transporters systems, genes, substrates, 
mechanisms of action and CHO literature on transcriptomic and protein levels. 
 
SYSTEM GENE SUBSTRATES MECHANISM (coupling ions) 
Literature on 
CHO (mRNA) 
Literature 
on CHO 
(protein) 
Β slc6a6 Tau, β-Ala Symport (Na+, Cl-) Birzele et al. (2010)  
Baycin-Hizal 
et al. (2012)  
Gly 
slc6a9 Gly 
Symport (Na+,Cl-) 
Birzele et al. 
(2010)  - 
slc6a5 Gly - - 
slc6a18 Gly - - 
IMINO slc6a20 Pro Symport (Na+) - - 
L 
slc7a5/ 
slc3a2 
Ile, Leu, Phe, Trp, 
Val, Tyr, His, Met Antiport (aa in for aa 
out) 
- 
Baycin-Hizal 
et al. (2012)  
slc7a8/ 
slc3a2 
Ile, Leu, Phe, Trp, 
Val, Tyr, His, Met 
Birzele et al. 
(2010)  - 
slc43a1 Leu, Ile, Met, Phe, Trp Uniport - - 
slc43a2 Leu, Ile, Met, Phe, Trp Uniport 
Birzele et al. 
(2010)  - 
slc43a3 putative, Leu, Ile, Met, Phe, Trp putative uniport - - 
N 
slc38a3 Gln, His, Ala, Asn Antiport (Na
++ aa in 
exchange to an aa + 
H+) 
Birzele et al. 
(2010)  - 
slc38a5 Gln, Asn, His, Ser Birzele et al. (2010)  - 
PAT 
slc36a1 Gly, Ala, Pro, Tau Symport (H+) 
Birzele et al. 
(2010)  - 
slc36a2 Gly, Ala, Pro - - 
slc36a3 putative Putative - - 
slc36a4 Ala, Pro, Trp Uniport 
Becker et al. 
(2011); Birzele 
et al. (2010) 
- 
T slc16a10 Phe, Tyr, Trp Uniport - - 
X-AG 
slc1a1 Asp, Glu 
Antiport (Na++ H++ 
aa in exchange to K+ 
or aa) 
Birzele et al. 
(2010)  - 
slc1a2 Asp, Glu Birzele et al. (2010)  - 
slc1a3 Asp, Glu 
Birzele et al. 
(2010); Ji et al. 
(2007) 
Baycin-Hizal 
et al. (2012)  
slc1a6 Asp, Glu - - 
slc1a7 Asp, Glu - Baycin-Hizal 
et al. (2012)  
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Table III-12 (continued): Amino acid transporters systems, genes, substrates, 
mechanisms of action and CHO literature on transcriptomic and protein levels. 
SYSTEM GENE SUBSTRATES MECHANISM (coupling ions) 
Literature on 
CHO (mRNA) 
Literature 
on CHO 
(protein) 
x-c 
slc7a11/ 
slc3a2 Glu, Cystine 
Antiport (preferentially 
extracellular Cystine 
for intracellular 
Glutamate) 
Becker et al. 
(2011); Birzele et 
al. (2010) 
- 
y+ 
slc7a1 Arg, Lys, His 
Uniport 
Becker et al. 
(2011); Birzele et 
al. (2010); Wang et 
al. (1996) 
Baycin-Hizal 
et al. (2012)  
slc7a2 Arg, Lys, His - - 
slc7a3 Arg, Lys, His Birzele et al. (2010)  - 
y+L 
slc7a7/ 
slc3a2 
Ile, Leu, Phe, Trp, 
Val, Tyr, Met, 
Arg, Lys, His 
Antiport (preferentially 
extracellular neutral aa 
+ Na+ in exchange of 
intracellular basic aa) 
Birzele et al. 
(2010)  - 
slc7a6/ 
slc3a2 
Ile, Leu, Phe, Trp, 
Val, Tyr, Met, 
Arg, Lys, His 
Becker et al. 
(2011); Birzele et 
al. (2010) 
- 
His & small 
peptides 
slc15a3 His 
Symport (H+) 
Birzele et al. 
(2010)  - 
slc15a4 His Birzele et al. (2010)  - 
Heavy 
subunits of 
heteromeric 
slc3a1 Heavy subunit of slc7a9 (system b0,+) Birzele et al. (2010)  - 
slc3a2 
Heavy subunit of slc7a10 (system asc), 
slc7a5 & slc7a8 (system L), slc7a11 (system 
x
-
c), slc7a6 & slc7a7 (system y+L) 
Becker et al. 
(2011); Birzele et 
al. (2010); Fenczik 
et al. (1997) 
- 
Not in a 
system 
slc6a7 Pro Symport (Na+, Cl-) not in CHO genome database - 
slc6a17 Neutral Symport (Na+) - - 
slc7a13 Asp, Glu Antiport not in CHO genome database - 
slc12a8 polyamines, amino 
acids Symport - - 
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Appendix IV Constituents of a basal medium for mammalian cells 
Table IV-13: Basal medium for a wide range of mammalian cells.  
From: Wolfe et al. (1993). 
COMPONENT Concentration (mM) COMPONENT 
Concentration 
(mM) 
Carbohydrates and Derivatives Amino Acid Derivatives 
D-Glucose 20 Glutathione 0.001 
Na Pyruvate 1 Putrescine 2HCl 0.0003 
Bulk Ions & Trace Elements Water Soluble Vitamins and Co-enzyme 
CaCl2.2H2O 1 Biotin 0.00003 
CuSO4.5H2O 0.000003 D-Ca pantothenate 0.02 
FeSO4.7H2O 0.01 Folic acid 0.006 
Fe(NO3)3.9H2O 0.0002 Folinic acid (Ca)5H2O 0.001 
KCl 4 Niacinamide (Nicotinamide) 0.03 
MgSO4.7H2O 0.8 p-Aminobenzoic acid 0.003 
NaCl 105 Pyridoxal HCl 0.01 
Na2HPO4.7H2O 0.3 Pyridoxine HCl 0.0003 
NaH2PO4.2H2O 0.6 Vitamin B12 0.0003 
Na2SeO3.5H2O 0.00003 Nucleic Acid Derivatives 
Na2SiO3.9H2O 0.01 Adenine 0.001 
(NH4)6Mo7O24.4H2O 0.000003 Hypoxathine (Na) 0.007 
NH4VO3 0.0000005 Thymidine HCl 0.01 
NiSO4.6H2O 0.0000003 Lipids and Derivatives  
ZnSO4.7H2O 0.0008 Choline chloride 0.1 
Amino acids Ethanolamine HCl 0.02 
L-Arg 0.8 i-Inositol 0.1 
L-Cys HCl.H2O 0.3 Linoleic acid 0.0001 
L-Gln 5 Lipoic acid 0.0002 
L-His HCl.H2O 0.2 Buffers 
L- Hydroxy-Pro 0.1 Zwitterionic Buffer (selected from: HEPS, 
MOPSO, BES, TAPSO or combination)* 25 L-Ile 0.6 L-Leu 0.6 
L-Lys HCl 0.08 NaOH 12.3 
L-Met 1 NaHCO3 3 
L-Phe 0.3 
* average value, it is dependent upon particular buffer used L-Thr 0.6 
L-Trp 0.06 
L-Tyr (diNa+)2H2O 0.3 
L-Val 0.6 
L-Ala 0.02 
L-Asn.H2O 0.3 
L-Asp 0.02 
L-Glu 0.02 
Gly 0.05 
L-Pro 0.2 
L-Ser 0.3 
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Appendix V Constraint network modelling literature on CHO cells 
Table V-14: Most notable constraint network modelling approaches for CHO cells post 
2010 listed from oldest to more recent. 
Purpose Key findings/ limitations Cell line/ Process mode 
Type of 
model 
# of rxns/ 
# of 
mtblts 
Reference 
Transfer a pre-
existing model 
from mouse 
hybridoma to 
CHO cells 
Hybridoma model was 
successfully applied for 
CHO cells by altering a 
certain set of reactions. The 
authors highlight the 
importance of getting precise 
measurements from the 
analytical techniques used. 
No special analysis for CHO 
cells. 
Super-CHO cell 
line expressing 
transferrin and 
insulin-like-
growth-factor-1/ 
Batch mode 
MFA 272/ 228 Quek et al. (2010) 
Validation of a 
simplified 
intracellular 
network to be 
used for further 
bioprocess 
optimization 
studies using 
isotopomer 
analysis 
The initial model was well 
validated and intracellular 
investigation revealed 
among others for the last 3 
days of culture: Glc uptake 
was 5 times more than Gln, 
41% of Glc was channelled 
through pentose- phosphate 
pathway, flux of pyruvate 
towards TCA was equal to 
flux towards lactate.    
Suspension CHO 
cells/ Perfussion 
mode 
MFA & 
mixture 
of 1-13C 
and U-13C 
labelled 
glucose 
87/62 Goudar et 
al. (2010) 
Present a kinetic 
model of CHO 
cell metabolism, 
by introducing 
kinetic equations 
for a subset of 
intracellular 
reactions, 
indirectly 
dependent by 
extracellular 
concentrations 
Model accurately predicts 
substrate concentrations 
while varying several 
process variables, including: 
temperature shift, seeding 
density, specific productivity 
and initial concentration of 
basic components in the 
medium. Novel redox and 
temperature dependent 
variables./ Omits important 
metabolites (e.g. several 
amino acids); biomass 
equation very simplistic, 
over parameterized.  
High and low 
CHO-K1 lines/ 
Fed-batch 
culture (Feeding 
daily after day 3) 
DMFA 34/ 24 Nolan and Lee (2011) 
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Table V-14 (continued): Most notable constraint network modelling approaches for 
CHO cells post 2010 listed from oldest to more recent. 
Purpose Key findings/ limitations 
Cell line/ Process 
mode 
Type of 
model 
# of 
rxns/ # 
of 
mtblts 
Reference 
Investigate CHO 
metabolism during 
late non-growth 
phase and also the 
impact of: 
medium strength, 
dissolved carbon 
dioxide and 
combined 
temperature and 
dissolved oxygen 
at this stage of 
culture   
Most of consumed 
glucose is diverted to 
pentose-phosphate 
pathway possibly to 
generate NADPH in 
response to increased 
oxidative metabolism. 
All pyruvate flux enters 
TCA cycle with very 
little loss to lactate. All 
different conditions 
tested have significant 
impact on the process. 
Lonza 
GS-CHO SF18 
cell line/ Fed-
batch culture 
MFA & 
mixture 
of 1-13C 
and U-
13C 
labelled 
glucose 
58/ 43 Sengupta et al. (2011) 
Investigate 
metabolism in 
exponential and 
early stationary 
phase 
Distinct differences of 
metabolism between 
exponential and entering 
in non-growth phase (for 
the latter: reduced 
glycolytic flux, lactate 
uptake, less anaplerosis 
from TCA cycle to 
glycolysis, increased rate 
through pentose-
phosphate pathway)/ 
Adherent cell line, not 
relevant industrially. 
Adherent CHO-
K1, not 
expressing 
recombinant 
protein/ Fed-batch 
(only Glucose 
every 2 days) 
MFA & 
[1,2-
13C] 
glucose 
73/ 77 
Ahn and 
Antoniewicz 
(2011) 
Optimizing amino 
acid composition 
based on data 
obtained from two 
steady states 
Met, Trp, Asn, Ser 
limiting, whereas Ala, 
Arg, Gln, Gly in excess; 
new feed increased max 
Xv 55% and titer 27%/ 
No quantitative analysis 
Proprietary CHO 
cell line 
expressing an 
antibody fusion 
protein/ 
Continuous 
culture 
MFA 23/ 32 Xing et al. (2011) 
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Table V-14 (continued): Most notable constraint network modelling approaches for 
CHO cells post 2010 listed from oldest to more recent. 
Purpose Key findings/ limitations Cell line/ Process mode 
Type 
of 
model 
# of rxns/ 
# of 
mtblts 
Reference 
Understanding 
of CHO 
metabolism 
during fed-
batch culture 
First study to report biomass 
content for CHO cells. First CHO-
microarray and metabolite analysis 
enriched FBA model. Highlights the 
importance of having accurate 
biomass data. Reduced metabolic 
activity associated with poor lipids’ 
metabolism at late exponential 
phase. Observed glycolysis rate at 
stationary phase can be associated 
with heat shock or signal 
transduction cellular functions, but 
more work is needed to validate 
this. Reduced fluxes of nucleotides 
and lipids during stationary phase. 
Secretion of amino acids derivatives 
observed experimentally 
successfully reproduced in silico./ 
Model includes many irrelevant 
reaction for CHO cells 
bioprocessing (e.g. unused carbon 
sources), also many dead end 
metabolites that further complicate 
the solution process.     
CHO mAb 
M250-9 for 
FBA (250 nM 
MTX 
amplification), 
for biomass 
content also: 
CHO mAb 
M500-7, 
CHO-K1, 
CHO DG44, 
CHO DXB11/ 
Fed-batch (Gln 
automatically 
controlled at 
0.6 mM)   
FBA 1540/ 1302 
Selvarasu et al. 
(2012) 
Investigate 
metabolism 
before and 
after the 
Lactate 
metabolism 
shift 
Novel approach (for mammalian 
cells) to optimise based on 
minimization- maximization of 
ATP yield. Fluxes through the 
lower part of the TCA similar for 
both phases. During lac consuming 
phase energy efficiency is 6 times 
greater than during the lac 
producing one/ Authors attributed 
lac consumption to glc 
consumption. Two distinct models 
for the two phases. 
CHO-XL99 
(CHO-K1)/ 
Batch 
FBA 
Lac 
production 
phase: 
270/ 321; 
Lac 
consumpti
on: 336/ 
381 
Martinez et al. 
(2013) 
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Table V-14 (continued): Most notable constraint network modelling approaches for 
CHO cells post 2010 listed from oldest to more recent. 
Purpose Key findings/ limitations 
Cell line/ Process 
mode 
Type of 
model 
# of 
rxns/ 
# of 
mtblts 
Reference 
Develop dynamic 
metabolic models 
from large MFA 
networks based on an 
improved approach of 
the  “elementary flux 
modes” technique. 
The latter involves a 
systemic way to 
identify feasible 
routes 
(thermodynamically 
and 
stoichiometrically) to 
convert substrates to 
products during cell 
culture.  
Initial model was 
successfully cut 
down to 18 reactions/ 
Batch culture has to 
be divided into 3 
distinct phases: 
exponential, 
transition and death.  
CHO-320/ Batch DMFA 100/ 72 
Zamorano et al. 
(2013) 
Transfer a pre-
existing plant model 
to characterize CHO 
cell culture 
Model able to 
successfully simulate 
behaviour during 
batch and sodium 
butyrate treated CHO 
cell cultures. Novel 
kinetic equations 
describing all 
included variables./ 
Product formation is 
not included. 
Biomass equation is 
over-simplified.   
Recombinant t-PA 
producing CHO 
cell line/ Batch and 
fed-batch with 
sodium butyrate 
DMFA 30/ 36 Ghorbaniaghdam 
et al. (2013) 
Investigate 
metabolism at four 
distinct phases during 
fed-batch culture  
Maximum antibody 
production rate is 
associated with a 
lactate metabolism 
shift (i.e. from Lac 
production to 
consumption) 
DHFR CHO cell 
line expressing a 
mAb/ Fed- batch 
(feeding interval 
every 3 days) 
MFA & 
Cocktail 
of 13C 
glc 
tracers 
and [U-
15N2, 
U-13C5] 
gln 
71/ 25 Templeton et al. (2013) 
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Table V-14 (continued): Most notable constraint network modelling approaches for 
CHO cells post 2010 listed from oldest to more recent. 
Purpose Key findings/ limitations 
Cell line/ 
Process 
mode 
Type 
of 
model 
# of rxns/ # 
of mtblts Reference 
Characterize 
different CHO 
producers 
during batch 
(control) and 
sodium 
butyrate 
treated 
cultures  
Identified several metabolic by-products 
(several TCA cycle intermediates, 
Glycerol, several a.a. metabolism 
associated byproducts) suggesting 
several metabolic inefficiencies. Early 
sodium butyrate treatment associated 
with high nutrient consumption rates. 
First study to include glycosylation of 
product into MFA. Asparagine is 
consumed with the highest rate and is 
used as main nitrogen source. Serine is 
another highly consumed a.a. leading to 
glycine and formate accumulation.   
GS-CHO 
cells 
producing 
IgG4 mAb 
(CHO K1 
SV, Lonza)/ 
Batch & 
Fed-batch 
with 
sodium 
butyrate  
MFA 117/ 83 Carinhas et 
al. (2013) 
Model the 
coupling of 
intracellular 
and 
extracellular 
environments 
towards 
understanding 
cell death 
Novel approach to model the interaction 
of metabolites with proteins regulating 
cell death, coupled by the different 
populations of cells and ammonia 
production. Validation with medium 
replacement experiments and with 
media including different Gln & serum 
concentrations, also with different 
seeding densities./ Initial network is 
reduced to a very simplified network. 
Model is over-parameterized. Medium 
used is not defined, i.e. contains serum. 
CHO 
producing 
IgG1/ 
Batch 
DMFA 8/9 Meshram et 
al. (2013) 
Systematic 
reduction of 
complicated 
metabolic 
networks 
Managed to cut down initial network to 
only 9 reactions. Identified that 
respiratory quotient should be close to 
one (CO2 production over O2 
consumption) during culture. Metabolic 
bottlenecks such as pyruvate & NADH 
into mitochondria, Glu dehydrogenation 
into TCA./ Only central carbon 
metabolism (glycolysis, TCA and 
glutaminolysis) are considered and 
hence only three amino acids are 
included in the final macroscopic model. 
Network is oversimplified. 
GS-CHO 
(CHO-K1 
SV) 
producing 
IgG1/ Fed-
batch 
MFA 
& 
DMFA 
35/37 Niu et al. (2013) 
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Appendix VI Primer sequences of tested a.a. transporter genes 
Table VI-15: Primers used for each amino acid transporter gene and product size. 
SYSTEM GENE NCBI access Forward Primer (5'-3') Reverse Primer (5'-3') Prod. Size 
A 
slc38a1 EGV95191 CATCTCTGACCGTGAAAGCA TCATCACATTTCCTTTTCTCCA 66 
slc38a2 EGV95189 AGACTGCCAATGAAGGAGGA GCATTGTAATCGATCCAGAGG 99 
slc38a4 EGV95185 CCTGAGGTCCTTCCCATCTAC CCTGTGATGGAAATGTTGGA 83 
ASC slc1a4 EGW01240 GAGACGGCGGCTAGGAAAT CCATACCAGCGCCCACTAT 100 
slc1a5 EGW03558 TGTTCATCAGACTGGGCAAG CGGGGGAAGAGGAAGTAGAT 97 
Asc slc7a10/ 
slc3a2 EGW06008 GCACTCATCATTGGTGTTGG TCCAGAATGTGAAGGCATTG 85 
B0 
slc6a19 EGW07533 TCATCGCCTTTTGTGAGATG AGAAAATGTTGGGCTTGTGG 102 
slc6a15 EGW08102 CAACCTCTTCCTTGGGATCA CAATGCCTCCCTGTACCAGT 114 
B0,+ slc6a14 XM_003510187.1 NOT TESTED 
b0,+ slc7a9/ 
slc3a1 EGW06771 CATGCTCAAAGTGCTCTCGT TGATGTCACCAGGGATGATG 107 
Β slc6a6 EGV97716 GCCTGGGCCACATACTACCT AGGGTGTCCTCCATGCAAT 101 
Gly 
slc6a9 EGW08106 GTTTCCACCGCCTCTCTTCT TGTAGGTGATTGGCCGGTAT 107 
slc6a5 EGV98884 CATGGAACACACCAGAATGC ATAGGCGGTCATGCAGAAAG 113 
slc6a18 EGW07534 GGTCCTGTGGTTCTTCCTCA ACTCCTGCACAAAGCCTGTT 92 
IMINO slc6a20 EGW08363 AAGGAGGCCATTTCAGGTCT CCAGTAGTTCCCAGCTTCCA 81 
L 
slc7a5/ 
slc3a2 EGV94093 CTCTGCTACGCCGAGTTAGG GCCGTATACCTCCAGCATGT 75 
slc7a8/ 
slc3a2 EGV98719 GACAGATAGTCCTTCGCTGGAA AGCAGGAAGGCCCAGAAC 100 
slc43a1 EGW09624 AGCAGGACGAGATGCTCAAC TGTGGTAGCACTCAGCAGGA 62 
slc43a2 EGW15295 CACAAGATCACAGGGAAGCA ACAGCTTGTGGCCCTCCT 121 
slc43a3 EGW09626 ACTACTGTGGCCCGCCTTAT GCAGAGGTGAAGGCAATGAT 71 
N slc38a3 XM_003500406.1 NOT TESTED 
slc38a5 EGW10125 TTTATTGGGTCCACCTCAGC CAAGGGTTCCACCTCAGAAG 90 
PAT 
slc36a1 EGW08831 CCAGCATCACACTCAACCTG TGTGAAGAAGATGCCTATGGAG 80 
slc36a2 EGW08830 TTGCCCAGTACATCATCCAG GGCTGTTCCAAAGAAGAGAGG 92 
slc36a3 EGW08829 GCACAGCCATCTTCACCTTT GATACAGCACGGCAGGAAAT 93 
slc36a4 EGV99604 GATGAAATCAAGGGCAGCAT CACGAAAATGCCAAAGGAAT 93 
T slc16a10 EGW10125 GTCCTCCAGTTGCAGGGTTA TAAAGGGAGGGATTCCAGCA 81 
X-AG 
slc1a1 EGW07658 TTTGCCTTGTCTTCGGACTT CAATGCGTTGAAGAAATCCA 77 
slc1a2 EGV94211 GGCATCTTTCTCCCCTTGAT ACAGGCAAAGTTCCAGCAC 125 
slc1a3 EGV97558 TCCTCCCCCTTATCATCTCC TGGTCATGTAATAGACCACAGC 102 
slc1a6 EGV95471 GGTCTTCTCTGTGGCCTTTG GTCGAAGAAGTCCCTCAGGA 76 
slc1a7 EGV91747 CTCCCTGGATGCCAAGAC ATGATGATGCCCACAATGAC 96 
x-c 
slc7a11/ 
slc3a2 EGW07000 GTGTTCGCTGTCTCCAGGTT CAGAGGAGTGTGCTTGTGGA 96 
y+ 
slc7a1 EGV93355 CGGTTGGAACCTGATTCTCT GGTTTGCCTATCAGCTCGTC 90 
slc7a2 EGV99926 GCCCAAGAATCTTTCTTCCAT CGCATCTCATGGGGAGTAAT 83 
slc7a3 EGV95053 ACCGGCTGGAATCTTATCCT AGGTTGTCAAAAGCAGAACTCC 80 
y+L 
slc7a7/ 
slc3a2 EGV98702 GGCTGCTTCCAGGCTTCTAT TGAACCGCTCAACATGAATC 83 
slc7a6/ 
slc3a2 EGW10095 CTTCCCCACTTGTGATCCTC TGTACTCGTGTGCCCCACT 111 
His & 
small 
peptides 
slc15a3 EGW06744 GACCCTTGTGCCTTACTGGA GAAGATGTTGGGGATTTGGA 88 
slc15a4 EGW11273 CAGGTGGCAGCTATTGATGTT GTGGGCTCAGGACTGTTAGC 93 
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Table VI-15 (continued): Primers used for each amino acid transporter gene and 
product size. 
SYSTEM GENE NCBI access Forward Primer (5'-3') Reverse Primer (5'-3') Prod. Size 
Heavy 
subunits of 
heteromeric 
slc3a1 EGW03199 GCAGGTCCCATGTACCAGAT GAGGCGATGTAGTCCAGCTT 104 
slc3a2 EGW04475 GACGTCAATGGAACCGACTT GGGAGTGAGGTCCAAAATGA 120 
Not in a 
system 
slc6a7 NOT IN CHO GENOME DATABASE 
slc6a17 
EGW13942; 
EGW10894; 
EGW03996 
NOT TESTED 
slc7a13 NOT IN CHO GENOME DATABASE 
slc12a8 EGV96400 NOT TESTED 
Housekeeping 
actb EGV95774 GTCCCTGTATGCCTCTGGTC GGAGAGCGTAGCCCTCATAG 95 
b2m EGV97187 CTTTTGGCTCACACGGAGTT ACCTTGGGCTCCTTCAGAGT 86 
eif3i EGW00112 CTGATGTTCAAGACTCGTGGAG CGGCAGATCAATGACATCC 105 
hirip3 EGW09873 TGCAGTGACCCAGAGAGAAA TGAGCAGTCTGGACTGGATG 81 
pabpn1 EGV98723 CAAAACGAGGTAGAGAAGCAGA CGTAGATAGAACGGGCATCA 109 
vezt EGW08392 GATGTCAACACAGCGTGGTC GGGATTGAAAGCTTCAGAGG 75 
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Appendix VII Efficiency of a.a. transporter genes tested primers 
Table VII-16: Calculated efficiency of primer pairs used and associated data. 
SYSTEM GENE Amplification Efficiency CV dilution points intron- exxon 
region 
A 
slc38a1 98% 2.46% 6 NO (=exxon 
only) 
slc38a2 92% 0.84% 5 YES 
slc38a4 96% 1.28% 6 YES 
ASC slc1a4 110% 0.92% 5 NO 
slc1a5 98% 1.12% 5 NO 
Asc slc7a10/ slc3a2 87% - 4 YES 
B0 slc6a19 97% - 5 YES 
slc6a15 91% 0.03% 5 YES 
B0,+ slc6a14 NOT TESTED 
b0,+ slc7a9/ slc3a1 82% - 6 YES 
Β slc6a6 97% 1.49% 6 NO 
Gly 
slc6a9 86% 0.21% 5 YES 
slc6a5 90% - 4 YES 
slc6a18 No product YES 
IMINO slc6a20 98% 1.69% 4 YES 
L 
slc7a5/ slc3a2 93% 0.86% 6 NO 
slc7a8/ slc3a2 109% 1.28% 4 YES 
slc43a1 101% 1.64% 5 NO 
slc43a2 90% 0.05% 4 NO 
slc43a3 90% 1.63% 4 YES 
N slc38a3 NOT TESTED 
slc38a5 88% 0.44% 4 YES 
PAT 
slc36a1 92% 2.64% 6 YES 
slc36a2 97% - 5 YES 
slc36a3 89% - 5 YES 
slc36a4 90% 1.34% 6 YES 
T slc16a10 85% - 5 YES 
X-AG 
slc1a1 95% 1.99% 6 NO 
slc1a2 83% 1.80% 5 YES 
slc1a3 89% 0.02% 6 YES 
slc1a6 85% 2.25% 4 NO 
slc1a7 94% 2.82% 4 NO 
x-c slc7a11/ slc3a2 91% 0.26% 5 YES 
y+ 
slc7a1 91% 0.98% 5 YES 
slc7a2 91% 3.07% 5 NO 
slc7a3 90% 1.26% 4 YES 
y+L 
slc7a7/ slc3a2 86% 2.02% 6 YES 
slc7a6/ slc3a2 89% 0.28% 6 YES 
His & small 
peptides 
slc15a3 85% 1.53% 6 YES 
slc15a4 85% 1.76% 5 YES 
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Table VII-16 (continued): Calculated efficiency of primer pairs used and associated 
data. 
SYSTEM GENE Amplification Efficiency CV 
dilution 
points 
intron- exxon 
region 
Heavy subunits 
of heteromeric 
slc3a1 88% - 4 YES 
slc3a2 88% 0.52% 6 YES 
Not in a system 
slc6a7 NOT IN CHO GENOME DATABASE 
slc6a17 NOT TESTED 
slc7a13 NOT IN CHO GENOME DATABASE 
slc12a8 NOT TESTED 
Housekeeping 
Actb 96% 0.10% 6 NO 
B2m 85% 0.58% 4 NO 
Eif3i 87% 1.21% 4 YES 
Hirip3 82% 2.93% 4 YES 
Pabpn1 82% 0.13% 4 YES 
Vezt 89% 0.91% 5 YES 
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Appendix VIII  Complete dataset from mRNA analysis 
Table VIII-17: Average (n=3) copies/cell (assuming 3000 actb copies per cell). 
SYSTEM GENE 
GSn8 GS35 GS46 
day4 day6 day7 day9 day3 day4 day6 day7 day3 day4 day6 day7 
A 
slc38a2 48 154 132 132 172 171 199 174 204 244 307 193 
slc38a4 3 9 6 3 1 2 6 3 1 2 7 3 
ASC 
slc1a4 6 20 28 17 9 12 29 28 11 10 39 21 
slc1a5 9 29 42 49 7 7 14 13 6 5 14 9 
B0 slc6a15 31 77 73 87 51 47 52 48 51 79 50 38 
Β slc6a6 40 20 23 21 33 30 14 14 79 119 41 24 
Gly slc6a9 33 156 181 187 22 38 182 149 20 23 236 149 
L 
slc7a5/ 
slc3a2 
60 164 158 71 142 137 180 180 131 115 209 123 
slc43a2 6 7 7 5 58 57 34 30 71 72 48 36 
slc43a3 4 6 6 2 8 10 12 9 5 6 8 6 
N slc38a5 0.20 0.4 1 3 0.5 0.5 3 3 0.4 0.3 2 2 
PAT 
slc36a1 14 17 21 34 24 26 33 37 19 21 25 23 
slc36a4 36 81 70 88 54 60 61 69 61 64 57 55 
X-AG 
slc1a2 1.1 5 1 3 6 9 12 15 5 7 11 8 
slc1a3 46 104 79 102 111 117 117 100 102 111 125 57 
x-c 
slc7a11/ 
slc3a2 
24 319 325 70 31 24 318 288 30 19 306 265 
y+ slc7a1 32 94 93 83 68 88 175 167 84 83 210 144 
y+L 
slc7a7/ 
slc3a2 
43 89 87 95 16 21 49 41 10 12 52 32 
slc7a6/ 
slc3a2 
45 47 49 39 71 65 42 40 71 69 44 29 
His & small 
peptides 
slc15a3 24 38 29 17 55 59 43 35 59 57 76 39 
slc15a4 36 50 54 107 33 33 26 35 32 32 20 17 
Heavy 
subunits of 
heteromeric 
slc3a2 399 1808 1909 3327 374 373 1019 955 311 348 1122 744 
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Table VIII-18: Standard deviation (copies/ cell) of the levels reported in previous table. 
SYSTEM GENE 
GSn8 GS35 GS46 
day4 day6 day7 day9 day3 day4 day6 day7 day3 day4 day6 day7 
A 
slc38a2 4 78 44 18 30 26 14 12 39 40 17 16 
slc38a4 1 4 1 1 0.1 0.1 0.2 0.3 0.3 1 1 0.2 
ASC 
slc1a4 0.4 2 4 2 0.4 1 3 2 1 2 4 4 
slc1a5 1 5 7 5 1 1 1 1 0.4 0.3 2 1 
B0 slc6a15 1 25 19 14 2 4 6 3 9 20 6 4 
Β slc6a6 8 0.2 2 4 2 2 1 1 3 18 6 1 
Gly slc6a9 5 34 6 7 2 3 11 10 0.4 2 10 19 
L 
slc7a5/ 
slc3a2 
3 33 13 3 9 7 36 7 8 18 15 12 
slc43a2 1 1 0.3 2 8 14 6 2 4 10 2 4 
slc43a3 1 1 1 0.4 0.2 1 0.4 0.4 1 1 0.3 0.1 
N slc38a5 0.03 0.1 0.2 2 0.2 0.1 0.2 0.1 0.04 0.05 0.2 0.1 
PAT 
slc36a1 3 4 1 2 2 2 1 1 1 1 2 2 
slc36a4 3 15 14 6 2 4 3 4 21 11 10 11 
X-AG 
slc1a2 0.4 1 1 1 1 2 0.3 3 1 3 1 2 
slc1a3 4 30 12 7 9 6 4 9 19 26 12 8 
x-c 
slc7a11/ 
slc3a2 
2 79 28 5 3 2 14 12 7 4 37 46 
y+ slc7a1 6 16 14 11 4 5 3 7 23 21 35 20 
y+L 
slc7a7/ 
slc3a2 
7 13 15 19 1 2 1 1 1 2 7 3 
slc7a6/ 
slc3a2 
4 4 5 2 7 6 0.3 5 7 14 5 1 
His & small 
peptides 
slc15a3 2 5 7 0.3 2 2 2 1 15 10 24 10 
slc15a4 2 7 11 8 2 2 2 1 2 5 2 1 
Heavy 
subunits of 
heteromeric 
slc3a2 57 159 175 86 30 19 52 67 11 62 78 74 
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Appendix IX Glutathione associated metabolic reactions 
 
Table IX-19: Reactions associated with glutathione metabolism and the enzymes (or cell 
membrane transport proteins) catalysing them.  
Taken from the supplementary material in Selvarasu et al. (2012). ALA= alanine, 
GLU= glutamate, GLY= glycine, CYS= cysteine, CYS-GLY= cysteine-glycine dipeptide, 
ALA-GLY= alanine-glycine dipeptide, GSH= reduced glutathione, R-S-ALA=R-S-
alanine (where S is sulphur), R= free alkyl group, R-S-GT=R-S-glutathione (where S is 
sulphur), GSSG=oxidized glutathione. 
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Appendix X Flux balance analysis network used for this thesis 
Table X-20: Metabolic network used for FBA.  
Adopted mainly from Carinhas et al. (2013), whereas some reactions were added 
(highlighted with green) based on Selvarasu et al. (2012) network. Abbreviations: [c]= 
cytosol, [e]= extracellular space. 
# Reaction name Stoichiometric equations of the reactions in the model 
1 Glclss1 [c] : Glc + ATP --> G6P + ADP 
2 Glclss2 [c] : G6P <==> F6P 
3 Glclss3 [c] : F6P + ATP --> DHAP + GAP + ADP 
4 Glclss4 [c] : DHAP <==> GAP 
5 Glclss5 [c] : GAP + NAD + ADP <==> 3PG + NADH + ATP 
6 Glclss6 [c] : 3PG + ADP --> Pyr + ATP 
7 TCA1 [c] : Pyr + NAD + CoASH --> AcCoA + CO2 + NADH 
8 TCA2 [c] : AcCoA + Oxal --> Cit + CoASH 
9 TCA3 [c] : Cit + NADP --> αKG + CO2 + NADPH 
10 TCA4 [c] : αKG + CoASH + NAD --> SucCoA + CO2 + NADH 
11 TCA5 [c] : SucCoA + GDP <==> Succ + GTP + CoASH 
12 TCA6 [c] : Succ + FAD <==>  Fum + FADH2 
13 TCA7 [c] : Fum <==>  Mal 
14 TCA8 [c] : Mal + NAD <==>  Oxal + NADH 
15 Prvtfts1 [c] : Pyr + NADH <==>  Lac + NAD 
16 Prvtfts2 [c] : Pyr + Glu <==>  Ala + αKG 
17 PPP [c] : (3) G6P + (6) NADP --> (3) CO2 + (3) R5P + (6) NADPH 
18 Anplrss [c] : Mal + NADP <==>  Pyr + HCO3 + NADPH 
19 aamtblsm1 [c] : Glu + NADP <==>  αKG + NH4 + NADPH 
20 aamtblsm2 [c] : Oxal + Glu <==>  Asp + αKG 
21 aamtblsm3 [c] : Gln + ADP <==>  Glu + ATP + NH4 
22 aamtblsm4 [c] : Thr + NAD + CoASH --> Gly + NADH + AcCoA 
23 aamtblsm5 [c] : Ser + THF + NADP <==>  Gly + NADPH + N10FTHF 
24 aamtblsm6 [c] : N10FTHF + ADP <==>  ATP + Formate + THF 
25 aamtblsm7 [c] : Ser --> Pyr + NH4 
26 aamtblsm8 [c] : Thr -->  αKb + NH4 
27 aamtblsm9 [c] : αKb + CoASH + NAD + HCO3 + ATP --> SucCoA + ADP + NADH + CO2 
28 aamtblsm10 [c] : Trp --> Ala + (2) CO2 + αKa 
29 aamtblsm11 [c] : Lys + (2) αKG + (3) NADP + FAD --> αKa + (2) Glu + (3) NADPH + FADH2 
30 aamtblsm12 [c] : αKa + (2) CoASH + (2) NAD --> (2) AcCoA + (2) NADH + (2) CO2 
31 aamtblsm13 [c] : Val + αKG + CoASH + NAD --> IsobutCoA + Glu + CO2 + NADH 
32 aamtblsm14 [c] : IsobutCoA + FAD + (2) NAD + HCO3 + ATP --> SucCoA + ADP + FADH2 + (2) NADH 
+ CO2 
33 aamtblsm15 [c] : IsobutCoA --> Isobut 
34 aamtblsm16 [c] : Ile + αKG + (2) CoASH + (2) NAD + FAD + HCO3 + ATP --> AcCoA + SucCoA + ADP 
+ Glu + CO2 + (2) NADH + FADH2 
35 aamtblsm17 [c] : Leu + αKG + CoASH + NAD --> IsovalCoA + Glu + CO2 + NADH 
36 aamtblsm18 [c] : IsovalCoA + FAD + ATP + CO2 + SucCoA + CoASH --> (3) AcCoA + Succ + FADH2 + ADP 
37 aamtblsm19 [c] : IsovalCoA --> Isoval 
38 aamtblsm20 [c] : Phe + NADH --> Tyr + NAD 
39 aamtblsm21 [c] : Tyr + αKG + SucCoA + CoASH --> Fum + (2) AcCoA + Succ + Glu + CO2 
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Table X-20: Metabolic network used for FBA.  
Adopted mainly from Carinhas et al. (2013), whereas some reactions were added 
(highlighted with green) based on Selvarasu et al. (2012) network. Abbreviations: [c]= 
cytosol, [e]= extracellular space. 
# Reaction 
name 
Stoichiometric equations of the reactions in the model 
40 aamtblsm22 [c] : Met + Ser + ATP --> αKb + NH4 + AMP 
41 aamtblsm23 [c] : Asn <==>  Asp + NH4 
42 aamtblsm24 [c] : Pro + NADP <==>  Glu + NADPH 
43 aamtblsm25 [c] : Arg + αKG + NADP --> (2) Glu + NADPH + Urea 
44 aamtblsm26 [c] : His --> Glu + NH4 
45 aamtblsm27 [c] : Arg -->  Orn +  Urea 
46 aamtblsm28 [c] : Orn -->  PTRSC +  CO2 
47 aamtblsm29 [c] : Met +  ATP -->  SAM 
48 aamtblsm30 [c] : SAM -->  DSAM +  CO2 
49 aamtblsm31 [c] : DSAM +  PTRSC -->  5MTA +  SPRMD 
50 aamtblsm32 [c] : 5MTA + SPRM --> DSAM + SPRMD 
51 glcgnsnthss1 [c] : G6P --> G1P 
52 glcgnsnthss2 [c] : G1P + UMPRN + (2) ATP --> UDPG + (2) ADP 
53 glcgnsnthss3 [c] : UDPG --> Glycogen + UDP 
54 ncltdsnthss1 [c] : R5P + ATP --> PRPP + AMP 
55 ncltdsnthss2 [c] : PRPP + (2) Gln + Gly + Asp + (5) ATP + CO2 + (2) N10FTHF --> IMP + (2) Glu + Fum + (5) ADP + (2) THF 
56 ncltdsnthss3 [c] : IMP + Asp + GTP --> AMPRN + Fum + GDP 
57 ncltdsnthss4 [c] : IMP + Gln + ATP + NAD --> GMPRN + Glu + AMP + NADH 
58 ncltdsnthss5 [c] : HCO3 + NH4 + Asp + (2) ATP + NAD --> Orotate + (2) ADP + NADH 
59 ncltdsnthss6 [c] : Orotate + PRPP --> UMPRN + CO2 
60 ncltdsnthss7 [c] : UMPRN + Gln + ATP --> CMPRN + Glu + ADP 
61 ncltdsnthss8 [c] : AMPRN --> dAMP 
62 ncltdsnthss9 [c] : GMPRN --> dGMP 
63 ncltdsnthss10 [c] : CMPRN --> dCMP 
64 ncltdsnthss11 [c] : UMPRN --> dTMP 
65 lpdsnthss1 [c] : Choline + ATP --> Pcholine + ADP 
66 lpdsnthss2 [c] : Pcholine + (18) AcCoA + Glyc3P + (22) ATP + (33) NADH --> PC + (16) ADP + (6) AMP + (33) NAD + (18) CoASH 
67 lpdsnthss3 [c] : PC + Ser <==>  PS + Choline 
68 lpdsnthss4 [c] : PS --> PE + CO2 
69 lpdsnthss5 [c] : Choline + Glyc3P <==>  Glyc3PC 
70 lpdsnthss6 [c] : G6P --> Inositol 
71 lpdsnthss7 [c] : Inositol + (18) AcCoA + Glyc3P + (22) ATP + (33) NADH --> PI + (16) ADP + (6) AMP + (33) NAD + (18) CoASH 
72 lpdsnthss8 [c] : (18) AcCoA + (2) Glyc3P + (22) ATP + (33) NADH --> PG + (16) ADP + (6) AMP + (33) NAD 
+ (18) CoASH 
73 lpdsnthss9 [c] : (2) PG --> DPG + Glyc 
74 lpdsnthss10 [c] : (16) AcCoA + Ser + Choline + (16) ATP + (29) NADPH --> SM + (2) CO2 + (14) ADP + (2) AMP + (29) NADP + (16) CoASH 
75 lpdsnthss11 [c] : (18) AcCoA + (18) ATP + (14) NADPH --> Cholesterol + (9) CO2 + (18) ADP + (14) NADP + (18) CoASH 
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Table X-20: Metabolic network used for FBA.  
Adopted mainly from Carinhas et al. (2013), whereas some reactions were added 
(highlighted with green) based on Selvarasu et al. (2012) network. Abbreviations: [c]= 
cytosol, [e]= extracellular space. Biomass coefficients are in femtomol/cell (with a 
219pg/cell biomass dry weight), whereas for the rprotein (IgG) in femtomol/ngIgG.  
# Reaction 
name 
Stoichiometric equations of the reactions in the model 
76 Biomass 
[c] : (88.038) Ala + (54.1149) Arg + (54.6624) Asn + (101.835) Asp + (60.4002) Gln + (143.2041) 
Glu + (90.2061) Gly + (15.1986) His + (44.8731) Ile + (91.3887) Leu + (103.7403) Lys + (23.0388) 
Met + (41.61) Phe + (51.8592) Pro + (66.6198) Ser + (54.6843) Thr + (7.01895) Trp + (22.8855) Tyr + 
(65.3934) Val + (9450.507) ATP + (11.043513) AMPRN + (3.055269) Cholesterol + (8.038614) 
CMPRN + (3.721686) dAMP + (2.665668) dCMP + (2.79444) dGMP + (0.5913) DPG + (3.696063) 
dTMP + (94.6299) Glycogen  + (7.437459) GMPRN + (11.622111) PC + (4.407156) PE + (0.22119) 
PG + (1.59651) PI + (0.438) PS + (1.382985) SM + (11.006064) UMPRN + (0.47085) NAD + 
(0.02847) NADP + (0.00219) FAD + (0.01095) NADH + (0.0876) NADPH + (0.001314) SucCoA + 
(0.01095) AcCoA + (0.012264) CoASH + (10.95) MTHF + (7.665) PTRSC + (1.533) SPRMD + 
(1.8615) Neu5Ac + (15.6110876633767) GlcNAc + (4.43910147525) GalNAc + (22.2914663844697) 
Mann + (11.1737454501697) Gal + (1.90541988436811) Fuc + (0.101196069636236) Neu5Gc --> (1) 
Biomass + (9450.507) ADP 
77 bprdct1 [c] : AcCoA + AMP <==>  Acetate + CoASH + ATP 
78 bprdct2 [c] : DHAP + NADH <==>  Glyc3P + NAD 
79 bprdct3 [c] : Glyc3P <==>  Glyc 
80 glcsltn1 [c] : UDPG <==>  UDPGal 
81 glcsltn2 [c] : Glc + ATP + GTP --> GDPMann + ADP 
82 glcsltn3 [c] : F6P + Gln + AcCoA + UTP --> UDPNAG + Glu + CoASH 
83 glcsltn4 [c] : UDPNAG + ATP + 3PG + CTP --> CMPNeu5Ac + UDP + ADP 
84 glcsltn5 [c] : GDPMann + NADPH --> GDPFuc + NADP 
85 glcsltn6 [c] : UDPNAG <==>  UDP +  GlcNAc 
86 glcsltn7 [c] : UDPNAG <==>  UDPGalNAc 
87 glcsltn8 [c] : UDPGalNAc <==> GalNAc + UDP 
88 glcsltn9 [c] : GDPMann <==>  Mann + GDP 
89 glcsltn10 [c] : UDPGal <==> Gal + UDP 
90 glcsltn11 [c] : CMPNeu5Ac <==>  CMP +  Neu5Ac 
91 glcsltn12 [c] : GDPFuc <==>  GDP +  Fuc 
92 glcsltn13 [c] : CMPNeu5Ac <==>  CMPNeu5Gc 
93 glcsltn14 [c] : CMPNeu5Gc <==> CMP + Neu5Gc 
94 vtmnmtblsm1 [c] : Fol +  NADH -->  THF +  NAD 
95 vtmnmtblsm2 [c] : Gly +  THF +  NAD <==>  METTHF +  NH4 +  CO2 +  NADH 
96 vtmnmtblsm3 [c] : MTHF +  NADP <==>  METTHF +  NADPH 
97 IgG 
[c] : (445.108324965733) Ala + (209.462741160345) Arg + (340.376954385561) Asn + 
(353.468375708082) Asp + (471.291167610776) Gln + (484.382588933298) Glu + 
(576.022538190949) Gly + (183.279898515302) His + (196.371319837824) Ile + 
(733.119594061208) Leu + (615.296802158514) Lys + (91.639949257651) Met + 
(340.376954385561) Phe + (549.839695545906) Pro + (1191.31934034946) Ser + 
(720.028172738686) Thr + (183.279898515302) Trp + (392.742639675647) Tyr + 
(785.485279351294) Val + (10.992)  GDPFuc + (54.962) UDPNAG + (32.977) GDPMann + (21.985) 
UDPGal + (21.985) CMPNeu5Ac --> (32.977) GDP + (21.985) UDP + (21.985) CMP + (1) IgG 
98 trnsprt1 Acetate[e] <==> Acetate[c] 
99 trnsprt2 ADP[e] <==> ADP[c] 
100 trnsprt3 Ala[e] <==> Ala[c] 
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Table X-20: Metabolic network used for FBA.  
Adopted mainly from Carinhas et al. (2013), whereas some reactions were added 
(highlighted with green) based on Selvarasu et al. (2012) network. Abbreviations: [c]= 
cytosol, [e]= extracellular space. 
# Reaction 
name 
Stoichiometric equations of the reactions in the model 
101 trnsprt4 AMP[e] <==> AMP[c] 
102 trnsprt5 Arg[e] <==> Arg[c] 
103 trnsprt6 Asn[e] <==> Asn[c] 
104 trnsprt7 Asp[e] <==> Asp[c] 
105 trnsprt8 ATP[e] <==> ATP[c] 
106 trnsprt10 Choline[e] <==> Choline[c] 
107 trnsprt11 Cit[e] <==> Cit[c] 
108 trnsprt12 CMP[e] <==> CMP[c] 
109 trnsprt13 CO2[e] <==> CO2[c] 
110 trnsprt14 CoASH[e] <==> CoASH[c] 
111 trnsprt15 CTP[e] <==> CTP[c] 
112 trnsprt16 FAD[e] <==> FAD[c] 
113 trnsprt17 FADH2[e] <==> FADH2[c] 
114 trnsprt18 Fol[e] <==> Fol[c] 
115 trnsprt19 Formate[e] <==> Formate[c] 
116 trnsprt20 Fum[e] <==> Fum[c] 
117 trnsprt21 GDP[e] <==> GDP[c] 
118 trnsprt22 Glc[e] <==> Glc[c] 
119 trnsprt23 Gln[e] <==> Gln[c] 
120 trnsprt24 Glu[e] <==> Glu[c] 
121 trnsprt25 Gly[e] <==> Gly[c] 
122 trnsprt26 Glyc[e] <==> Glyc[c] 
123 trnsprt27 Glyc3PC[e] <==> Glyc3PC[c] 
124 trnsprt28 GTP[e] <==> GTP[c] 
125 trnsprt29 His[e] <==> His[c] 
126 trnsprt31 Ile[e] <==> Ile[c] 
127 trnsprt32 Isobut[e] <==> Isobut[c] 
128 trnsprt33 Isoval[e] <==> Isoval[c] 
129 trnsprt34 Lac[e] <==> Lac[c] 
130 trnsprt35 Leu[e] <==> Leu[c] 
131 trnsprt36 Lys[e] <==> Lys[c] 
132 trnsprt37 Mal[e] <==> Mal[c] 
133 trnsprt38 Met[e] <==> Met[c] 
134 trnsprt39 NAD[e] <==> NAD[c] 
135 trnsprt40 NADH[e] <==> NADH[c] 
136 trnsprt41 NADP[e] <==> NADP[c] 
137 trnsprt42 NADPH[e] <==> NADPH[c] 
138 trnsprt43 NH4[e] <==> NH4[c] 
139 trnsprt44 Pcholine[e] <==> Pcholine[c] 
140 trnsprt45 Phe[e] <==> Phe[c] 
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Table X-20: Metabolic network used for FBA.  
Adopted mainly from Carinhas et al. (2013), whereas some reactions were added 
(highlighted with green) based on Selvarasu et al. (2012) network. Abbreviations: [c]= 
cytosol, [e]= extracellular space. 
# Reaction 
name 
Stoichiometric equations of the reactions in the model 
141 trnsprt46 Pro[e] <==> Pro[c] 
142 trnsprt47 Pyr[e] <==> Pyr[c] 
143 trnsprt48 Ser[e] <==> Ser[c] 
144 trnsprt49 SPRM[e] <==> SPRM[c] 
145 trnsprt50 Succ[e] <==>  Succ[c] 
146 trnsprt51 Thr[e] <==> Thr[c] 
147 trnsprt52 Trp[e] <==> Trp[c] 
148 trnsprt53 Tyr[e] <==> Tyr[c] 
149 trnsprt54 UDP[e] <==> UDP[c] 
150 trnsprt55 UTP[e] <==> UTP[c] 
151 trnsprt56 Val[e] <==> Val[c] 
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Appendix XI Extracellular metabolite concentrations of basic feeding 
experiments 
Figure XI-1: Extracellular profiles of pyruvate and amino acids for the three different 
feeds tested. 
From left to right and top to bottom the concentration of the following metabolites 
within culture of CHO cells for three different feeds in Erlenmeyer flasks is depicted: 
pyruvate (Pyr), alanine (Ala), arginine (Arg), aspartate (Asp), glutamate (Glu), glycine 
(Gly), isoleucine (Ile) and leucine (Leu). The three different feeds are: F_all (contains 
glucose and a.a. and is diluted one to one with the commercial medium), F_all_pl40 
(contains 40% more in all components than F_all, except tyrosine, see text for details) 
and an industrial feed: F_C_Inv (CD EfficientFeedTM C AGTTM, Invitrogen, UK). Error 
bars represent one standard deviation from biological duplicate samples. 
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Figure XI-2: Extracellular profiles of amino acids for the three different feeds tested. 
From left to right and top to bottom the concentration of the following metabolites 
within culture of CHO cells for three different feeds in Erlenmeyer flasks is depicted: 
lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), 
threonine (Thr), tyrosine (Tyr) and valine (Val). The three different feeds are: F_all 
(contains glucose and a.a. and is diluted one to one with the commercial medium), 
F_all_pl40 (contains 40% more in all components than F_all, except tyrosine, see text 
for details) and an industrial feed: F_C_Inv (CD EfficientFeedTM C AGTTM, Invitrogen, 
UK). Error bars represent one standard deviation from biological duplicate samples. 
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Appendix XII Maximum rprotein productivity case study for the tested 
feeds 
Figure XII-3: Analysis of maximum antibody productivity intervals (middle) for feed 
F_all (see part 4.2 for reference) in relation with growth (top) and lactate phenotypes 
(bottom). 
The specific productivities (qmAb in pg/cell/day) are ranked based on the average 
minus one standard deviation. In the barchart presented in the middle panel on the left, 
the first fifteen ranked production rates for the different time intervals are presented, 
these are with descending productivity: from day 12 to day 13 (“12 to 13”), 11 to 13, 6 to 
7, 8 to 9, 5 to 7, 11 to 12, 5 to 6, 4 to 7, 3 to 7, 2 to 7, 1 to 7, 0 to 7, 5 to 9, 8 to 13, 11 to 14. 
Specific growth rates (1/day) at the exact same ranked intervals are presented in the top 
left graph, while specific lactate rates (femtomol/cell/day) are presented in the bottom 
left graph. The graphs in the right panel represent from top to bottom: the cells 
concentration (Xv_exp, in cells/mL) for the experimental time course (t_exp in days), 
the rprotein concentration (mAb_exp, in g/L) and the lactate profile (Lac_exp, in mM). 
The dilution due to feeding has not been included in the latter graphs at the feeding 
intervals. Error bars represent the 95% confidence interval using a t-distribution and 
assuming triplicate samples for the calculation of specific rates (left panel). One 
standard deviation of biological triplicate samples for Xv and duplicate samples for 
lactate and rprotein are depicted in the right panel. 
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Figure XII-4: Analysis of maximum antibody productivity intervals (middle) for feed 
F_C_Inv (see part 4.2 for reference) in relation with growth (top) and lactate 
phenotypes (bottom). 
The specific productivities (qmAb in pg/cell/day) are ranked based on the average 
minus one standard deviation. In the barchart presented in the middle panel on the left, 
the first fifteen ranked production rates for the different time intervals are presented, 
these are with descending productivity: from day 6 to day 7 (“6 to 7”), 6 to 8, 7 to 8, 5 to 
8, 4 to 8, 5 to 7, 3 to 8, 2 to 8, 1 to 8, 0 to 8, 9 to 12, 4 to 7, 6 to 12, 6 to 9, 5 to 12. Specific 
growth rates (1/day) at the exact same ranked intervals are presented in the top left 
graph, while specific lactate rates (femtomol/cell/day) are presented in the bottom left 
graph. The graphs in the right panel represent from top to bottom: the cells 
concentration (Xv_exp, in cells/mL) for the experimental time course (t_exp in days), 
the rprotein concentration (mAb_exp, in g/L) and the lactate profile (Lac_exp, in mM). 
The dilution due to feeding has not been included in the latter graphs at the feeding 
intervals. Error bars represent the 95% confidence interval using a t-distribution and 
assuming triplicate samples for the calculation of specific rates (left panel). One 
standard deviation of biological triplicate samples for Xv and duplicate samples for 
lactate and rprotein are depicted in the right panel. 
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Appendix XIII  Code in R to calculate specific rates in cell culture 
 
The function in R workspace (R Development Core Team 2010) that performs the 
calculations of specific rates for given experimental data points is presented below. The data 
(encoded as exdata in the code presented later on) are read from “.csv” file, exactly as the one 
presented in Figure 4-2 in 4.14. The “#” sign denotes a comment. 
 
fromtomusqs_v1<-function(exdata){ 
 
# Read main data: 
 
signdig<-exdata[1,2] 
 
Vinitial<- signif(exdata[2,2],digits=signdig) 
sd.Vinitial<-signif(exdata[3,2],digits=signdig) 
 
tharvest<-signif(exdata[4,2],digits=signdig) 
sd.time<-signif(exdata[5,2],digits=signdig) 
 
exp.reps<-signif(exdata[6,2],digits=signdig) 
 
conf<-signif(exdata[7,2],digits=signdig) 
r.conf<-signif(conf/100,digits=signdig) 
t.value<-signif(qt(1-(1-r.conf)/2, exp.reps-1),digits=signdig) 
sdmultconf<-t.value/sqrt(exp.reps) 
if(is.nan(sdmultconf)){ 
sdmultconf<-0 
}else{ 
sdmultconf<-t.value/sqrt(exp.reps) 
} 
 
##FEEDING DETAILS (a) 
fint<-signif(exdata[8,2],digits=signdig) 
 
 
sd.fint<-signif(exdata[9,2],digits=signdig) 
Vf<-signif(exdata[10,2],digits=signdig) 
sd.Vf<-signif(exdata[11,2],digits=signdig) 
tF<-signif(exdata[12,2],digits=signdig) 
sd.tF<-signif(exdata[13,2],digits=signdig) 
FIN<-signif(Vf/tF,digits=signdig) 
FIN[is.nan(FIN)]<-0 
sd.FIN<-signif(FIN*sqrt((sd.Vf/Vf)^2+(sd.tF/tF)^2),digits=signdig) 
sd.FIN[is.nan(sd.FIN)]<-0 
 
##SAMPLING DETAILS (b) 
sint<-signif(exdata[14,2],digits=signdig) 
sd.sint<-signif(exdata[15,2],digits=signdig) 
sVout<-signif(exdata[16,2],digits=signdig) 
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sd.sVout<-signif(exdata[17,2],digits=signdig) 
tS<-signif(exdata[18,2],digits=signdig) 
sd.tS<-signif(exdata[19,2],digits=signdig) 
sFOUT<-signif(sVout/tS,digits=signdig) 
sFOUT[is.nan(sFOUT)]<-0 
sd.sFOUT<-signif(sFOUT*sqrt((sd.sVout/sVout)^2+(sd.tS/tS)^2),digits=signdig) 
sd.sFOUT[is.nan(sd.sFOUT)]<-0 
 
##after feeding SAMPLING DETAILS (c) 
safFVout<-signif(exdata[20,2],digits=signdig) 
sd.safFVout<-signif(exdata[21,2],digits=signdig) 
tSafF<-signif(exdata[22,2],digits=signdig) 
sd.tSafF<-signif(exdata[23,2],digits=signdig) 
safFFOUT<-signif(safFVout/tSafF,digits=signdig) 
safFFOUT[is.nan(safFFOUT)]<-0 
sd.safFFOUT<-
signif(safFFOUT*sqrt((sd.safFVout/safFVout)^2+(sd.tSafF/tSafF)^2),digits=signdig) 
sd.safFFOUT[is.nan(sd.safFFOUT)]<-0 
 
## t, a, b, c vectors: 
 
texp<-seq(0,tharvest,sint) 
sd.texp<-rep(sd.time,tharvest+1) 
if (fint==0){ 
nf<-0 
}else{ 
nf<-seq(1,(tharvest-1)/fint,1)} 
ns<-seq(1,(tharvest-1)/sint,1) 
 
tcomp<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
sd.tcomp<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
 
at<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
bt<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
ct<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
 
nf1<-1 
ic<-2 
 
for (i in (2:length(texp))){ 
 
tcomp[ic]<-signif(texp[i],digits=signdig) 
sd.tcomp[ic]<-signif(sd.texp[i],digits=signdig) 
at[ic]<-0 
bt[ic]<-0 
ct[ic]<-0 
 
if(i!=length(texp)) { 
 if(i!=(nf1*fint)+1){ 
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  tcomp[ic+1]<-signif(texp[i],digits=signdig)+signif(tS/2,digits=signdig) 
 
  sd.tcomp[ic+1]<-
sqrt(signif(sd.texp[i],digits=signdig)^2+signif(sd.tS/2,digits=signdig)^2) 
  at[ic+1]<-0  
  bt[ic+1]<-2 
  ct[ic+1]<-0  
  tcomp[ic+2]<-signif(texp[i],digits=signdig)+signif(tS,digits=signdig) 
  sd.tcomp[ic+2]<-
sqrt(signif(sd.texp[i],digits=signdig)^2+signif(sd.tS,digits=signdig)^2) 
  at[ic+2]<-0  
  bt[ic+2]<-0 
  ct[ic+2]<-0  
  
  ic<-ic+3 
 
 }else { 
  tcomp[ic+1]<-signif(tcomp[ic],digits=signdig)+signif(tS/2,digits=signdig) 
  sd.tcomp[ic+1]<-
sqrt(signif(sd.tcomp[ic],digits=signdig)^2+signif(sd.tS/2,digits=signdig)^2) 
  at[ic+1]<-0  
  bt[ic+1]<-2 
  ct[ic+1]<-0   
 
  tcomp[ic+2]<-signif(tcomp[ic],digits=signdig)+signif(tS,digits=signdig) 
  sd.tcomp[ic+2]<-
sqrt(signif(sd.tcomp[ic],digits=signdig)^2+signif(sd.tS,digits=signdig)^2) 
  at[ic+2]<-0  
  bt[ic+2]<-0 
  ct[ic+2]<-0  
   
  tcomp[ic+3]<-signif(tcomp[ic+2],digits=signdig)+signif(tF/2,digits=signdig) 
  sd.tcomp[ic+3]<-
sqrt(signif(sd.tcomp[ic+2],digits=signdig)^2+signif(sd.tF/2,digits=signdig)^2) 
  at[ic+3]<-2  
  bt[ic+3]<-0 
  ct[ic+3]<-0    
   
  tcomp[ic+4]<-signif(tcomp[ic+2],digits=signdig)+signif(tF,digits=signdig) 
  sd.tcomp[ic+4]<-
sqrt(signif(sd.tcomp[ic+2],digits=signdig)^2+signif(sd.tF,digits=signdig)^2) 
  at[ic+4]<-0  
  bt[ic+4]<-0 
  ct[ic+4]<-0    
 
  tcomp[ic+5]<-
signif(tcomp[ic+4],digits=signdig)+signif(tSafF/2,digits=signdig) 
  sd.tcomp[ic+5]<-
sqrt(signif(sd.tcomp[ic+4],digits=signdig)^2+signif(sd.tSafF/2,digits=signdig)^2) 
  at[ic+5]<-0  
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  bt[ic+5]<-0 
  ct[ic+5]<-2  
 
  tcomp[ic+6]<-signif(tcomp[ic+4],digits=signdig)+signif(tSafF,digits=signdig) 
  sd.tcomp[ic+6]<-
sqrt(signif(sd.tcomp[ic+4],digits=signdig)^2+signif(sd.tSafF,digits=signdig)^2) 
  at[ic+6]<-0  
  bt[ic+6]<-0 
  ct[ic+6]<-0   
   
  nf1<-nf1+1 
  ic<-ic+7 
  } 
 } 
} 
 
##Volume: 
 
delta<-function(var1){ 
var<-rep(0,length(tcomp)) 
for(i in 2:length(tcomp)){ 
var[i]<-var1[i]-var1[i-1] 
} 
return(var) 
} 
 
dt<-delta(signif(tcomp,digits=signdig)) 
 
stdevsumcol<-function(var2){ 
var<-rep(0,length(tcomp)) 
for(i in 2:length(tcomp)){ 
var[i]<-sqrt(var2[i]^2+var2[i-1]^2) 
} 
return(var) 
} 
 
sd.dt<-stdevsumcol(signif(sd.tcomp,digits=signdig)) 
 
atFIN<-at*signif(FIN,digits=signdig) 
 
sd.atFIN<-at*signif(sd.FIN,digits=signdig) 
 
 
btsFOUT<-bt*signif(sFOUT,digits=signdig) 
sd.btsFOUT<-bt*signif(sd.sFOUT,digits=signdig) 
 
ctsafFFOUT<-ct*signif(safFFOUT,digits=signdig) 
sd.ctsafFFOUT<-ct*signif(sd.safFFOUT,digits=signdig) 
 
sumcolover2<-function(var3){ 
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var<-rep(0,length(tcomp)) 
for(i in 2:length(tcomp)) 
var[i]<-(var3[i]+var3[i-1])/2 
return(var) 
} 
 
SatFINover2<-sumcolover2(signif(atFIN,digits=signdig)) 
sd.SatFINover2<-stdevsumcol(signif(sd.atFIN,digits=signdig))/2 
 
SbtsFOUTover2<-sumcolover2(signif(btsFOUT,digits=signdig)) 
sd.SbtsFOUTover2<-stdevsumcol(signif(sd.btsFOUT,digits=signdig))/2 
 
SctsafFFOUTover2<-sumcolover2(signif(ctsafFFOUT,digits=signdig)) 
sd.SctsafFFOUTover2<-stdevsumcol(signif(sd.ctsafFFOUT,digits=signdig))/2 
 
stdevmult<-function(var4,sd.var4,var5,sd.var5){ 
var45<-rep(0,length(tcomp)) 
for(i in 1:length(tcomp)){ 
var45[i]<-abs(var4[i]*var5[i])*sqrt((sd.var4[i]/var4[i])^2+(sd.var5[i]/var5[i])^2) 
if(is.nan(var45[i])) 
{ 
var45[i]<-0 
}else{ 
var45[i] 
} 
} 
return(var45) 
} 
 
stdevmultsingle<-function(var4,sd.var4,var5,sd.var5){ 
var45<-abs(var4*var5)*sqrt((sd.var4/var4)^2+(sd.var5/var5)^2) 
if(is.nan(var45)) 
{ 
var45<-0 
}else{ 
var45 
} 
return(var45) 
} 
 
 
SatFINover2dt<-signif(SatFINover2,digits=signdig)*signif(dt,digits=signdig) 
sd.SatFINover2dt<-
stdevmult(signif(SatFINover2,digits=signdig),signif(sd.SatFINover2,digits=signdig),signif(dt
,digits=signdig),signif(sd.dt,digits=signdig)) 
 
SbtsFOUTover2dt<-signif(SbtsFOUTover2,digits=signdig)*signif(dt,digits=signdig) 
sd.SbtsFOUTover2dt<-
stdevmult(signif(SbtsFOUTover2,digits=signdig),signif(sd.SbtsFOUTover2,digits=signdig),s
ignif(dt,digits=signdig),signif(sd.dt,digits=signdig)) 
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SctsafFFOUTover2dt<-signif(SctsafFFOUTover2,digits=signdig)*signif(dt,digits=signdig) 
sd.SctsafFFOUTover2dt<-
stdevmult(signif(SctsafFFOUTover2,digits=signdig),signif(sd.SctsafFFOUTover2,digits=sig
ndig),signif(dt,digits=signdig),signif(sd.dt,digits=signdig)) 
 
trapintegmul2<-function(var6){ 
var<-rep(0,length(tcomp)) 
for(i in 2:length(tcomp)){ 
var[i]<-var6[i]+var[i-1] 
} 
return(var) 
} 
 
SatFINdt<-trapintegmul2(signif(SatFINover2dt,digits=signdig)) 
SbtsFOUTdt<-trapintegmul2(signif(SbtsFOUTover2dt,digits=signdig)) 
SctsafFFOUTdt<-trapintegmul2(signif(SctsafFFOUTover2dt,digits=signdig)) 
 
sd.trapintegmul2<-function(var7){ 
var<-rep(0,length(tcomp)) 
for(i in 2:length(tcomp)){ 
var[i]<-sqrt(var7[i]^2+var[i-1]^2) 
} 
return(var) 
} 
 
sd.SatFINdt<-sd.trapintegmul2(signif(sd.SatFINover2dt,digits=signdig)) 
sd.SbtsFOUTdt<-sd.trapintegmul2(signif(sd.SbtsFOUTover2dt,digits=signdig)) 
sd.SctsafFFOUTdt<-sd.trapintegmul2(signif(sd.SctsafFFOUTover2dt,digits=signdig)) 
 
Vt<-c(signif(Vinitial,digits=signdig),rep(0,length(tcomp)-1)) 
sd.Vt<-c(signif(sd.Vinitial,digits=signdig),rep(0,length(tcomp)-1)) 
 
for(i in 2:length(tcomp)){ 
Vt[i]<-SatFINdt[i]-SatFINdt[i-1]-SbtsFOUTdt[i]+SbtsFOUTdt[i-1]-
SctsafFFOUTdt[i]+SctsafFFOUTdt[i-1]+Vt[i-1] 
sd.Vt[i]<-sqrt(sd.SatFINdt[i]^2+sd.SatFINdt[i-1]^2+sd.SbtsFOUTdt[i]^2+sd.SbtsFOUTdt[i-
1]^2+sd.SctsafFFOUTdt[i]^2+sd.SctsafFFOUTdt[i-1]^2+sd.Vt[i-1]^2) 
} 
 
dV<-delta(signif(Vt,digits=signdig)) 
sd.dV<-stdevsumcol(signif(sd.Vt,digits=signdig)) 
 
## Viable and dead Cells: 
 
Xvcomp<-c(signif(exdata$Xv[1],digits=signdig),rep(0,tharvest+1+2* 
ns[length(ns)]+4*nf[length(nf)]-1)) 
sd.Xvcomp<-c(signif(exdata$sd.Xv[1],digits=signdig),rep(0,tharvest+1+2* 
ns[length(ns)]+4*nf[length(nf)]-1)) 
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Xdcomp<-c(signif(exdata$Xd[1],digits=signdig),rep(0,tharvest+1+2* 
ns[length(ns)]+4*nf[length(nf)]-1)) 
sd.Xdcomp<-c(signif(exdata$sd.Xd[1],digits=signdig),rep(0,tharvest+1+2* 
ns[length(ns)]+4*nf[length(nf)]-1)) 
 
A<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
B<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
C<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
D<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
 
AXd<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
BXd<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
CXd<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
DXd<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
 
 
nf1<-1 
ic<-2 
 
for (i in (2:length(texp))){ 
Xvcomp[ic]<-signif(exdata$Xv[i],digits=signdig) 
sd.Xvcomp[ic]<-signif(exdata$sd.Xv[i],digits=signdig) 
 
Xdcomp[ic]<-signif(exdata$Xd[i],digits=signdig) 
sd.Xdcomp[ic]<-signif(exdata$sd.Xd[i],digits=signdig) 
 
if(i!=length(texp)) { 
 if(i!=(nf1*fint)+1){ 
 
Xvcomp[ic+1]<-
(signif(exdata$Xv[i],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[i
c],digits=signdig)*signif(exdata$Xv[i],digits=signdig))/signif(Vt[ic+1],digits=signdig) 
A[ic+1]<-
stdevmultsingle(signif(exdata$Xv[i],digits=signdig),signif(exdata$sd.Xv[i],digits=signdig),si
gnif(Vt[ic],digits=signdig),signif(sd.Vt[ic],digits=signdig)) 
B[ic+1]<-
(bt[ic]+ct[ic])*stdevmultsingle(signif(dV[ic],digits=signdig),signif(sd.dV[ic],digits=signdig),
signif(exdata$Xv[i],digits=signdig),signif(exdata$sd.Xv[i],digits=signdig)) 
C[ic+1]<-sqrt(A[ic+1]^2+B[ic+1]^2) 
D[ic+1]<-
(signif(exdata$Xv[i],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[i
c],digits=signdig)*signif(exdata$Xv[i],digits=signdig)) 
sd.Xvcomp[ic+1]<-
Xvcomp[ic+1]*sqrt((C[ic+1]/D[ic+1])^2+(signif(sd.Vt[ic+1],digits=signdig)/signif(Vt[ic+1],
digits=signdig))^2) 
 
Xvcomp[ic+2]<-
(signif(Xvcomp[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*si
gnif(dV[ic+1],digits=signdig)*signif(Xvcomp[ic+1],digits=signdig))/signif(Vt[ic+2],digits=s
igndig) 
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A[ic+2]<-
stdevmultsingle(signif(Xvcomp[ic+1],digits=signdig),signif(sd.Xvcomp[ic+1],digits=signdig
),signif(Vt[ic+1],digits=signdig),signif(sd.Vt[ic+1],digits=signdig)) 
B[ic+2]<-
(bt[ic+1]+ct[ic+1])*stdevmultsingle(signif(dV[ic+1],digits=signdig),signif(sd.dV[ic+1],digits
=signdig),signif(Xvcomp[ic+1],digits=signdig),signif(sd.Xvcomp[ic+1],digits=signdig)) 
C[ic+2]<-sqrt(A[ic+2]^2+B[ic+2]^2) 
D[ic+2]<-
(signif(Xvcomp[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*si
gnif(dV[ic+1],digits=signdig)*signif(Xvcomp[ic+1],digits=signdig)) 
sd.Xvcomp[ic+2]<-
Xvcomp[ic+2]*sqrt((C[ic+2]/D[ic+2])^2+(signif(sd.Vt[ic+2],digits=signdig)/signif(Vt[ic+2],
digits=signdig))^2) 
 
Xdcomp[ic+1]<-
(signif(exdata$Xd[i],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[i
c],digits=signdig)*signif(exdata$Xd[i],digits=signdig))/signif(Vt[ic+1],digits=signdig) 
AXd[ic+1]<-
stdevmultsingle(signif(exdata$Xd[i],digits=signdig),signif(exdata$sd.Xd[i],digits=signdig),si
gnif(Vt[ic],digits=signdig),signif(sd.Vt[ic],digits=signdig)) 
BXd[ic+1]<-
(bt[ic]+ct[ic])*stdevmultsingle(signif(dV[ic],digits=signdig),signif(sd.dV[ic],digits=signdig),
signif(exdata$Xd[i],digits=signdig),signif(exdata$sd.Xd[i],digits=signdig)) 
CXd[ic+1]<-sqrt(AXd[ic+1]^2+BXd[ic+1]^2) 
DXd[ic+1]<-
(signif(exdata$Xd[i],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[i
c],digits=signdig)*signif(exdata$Xd[i],digits=signdig)) 
sd.Xdcomp[ic+1]<-
Xdcomp[ic+1]*sqrt((CXd[ic+1]/DXd[ic+1])^2+(signif(sd.Vt[ic+1],digits=signdig)/signif(Vt[
ic+1],digits=signdig))^2) 
 
Xdcomp[ic+2]<-
(signif(Xdcomp[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*si
gnif(dV[ic+1],digits=signdig)*signif(Xdcomp[ic+1],digits=signdig))/signif(Vt[ic+2],digits=s
igndig) 
AXd[ic+2]<-
stdevmultsingle(signif(Xdcomp[ic+1],digits=signdig),signif(sd.Xdcomp[ic+1],digits=signdig
),signif(Vt[ic+1],digits=signdig),signif(sd.Vt[ic+1],digits=signdig)) 
BXd[ic+2]<-
(bt[ic+1]+ct[ic+1])*stdevmultsingle(signif(dV[ic+1],digits=signdig),signif(sd.dV[ic+1],digits
=signdig),signif(Xdcomp[ic+1],digits=signdig),signif(sd.Xdcomp[ic+1],digits=signdig)) 
CXd[ic+2]<-sqrt(AXd[ic+2]^2+BXd[ic+2]^2) 
DXd[ic+2]<-
(signif(Xdcomp[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*si
gnif(dV[ic+1],digits=signdig)*signif(Xdcomp[ic+1],digits=signdig)) 
sd.Xdcomp[ic+2]<-
Xdcomp[ic+2]*sqrt((CXd[ic+2]/DXd[ic+2])^2+(signif(sd.Vt[ic+2],digits=signdig)/signif(Vt[
ic+2],digits=signdig))^2) 
 
ic<-ic+3 
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 }else { 
Xvcomp[ic+1]<-
(signif(exdata$Xv[i],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[i
c],digits=signdig)*signif(exdata$Xv[i],digits=signdig))/signif(Vt[ic+1],digits=signdig) 
A[ic+1]<-
stdevmultsingle(signif(exdata$Xv[i],digits=signdig),signif(exdata$sd.Xv[i],digits=signdig),si
gnif(Vt[ic],digits=signdig),signif(sd.Vt[ic],digits=signdig)) 
B[ic+1]<-
(bt[ic]+ct[ic])*stdevmultsingle(signif(dV[ic],digits=signdig),signif(sd.dV[ic],digits=signdig),
signif(exdata$Xv[i],digits=signdig),signif(exdata$sd.Xv[i],digits=signdig)) 
C[ic+1]<-sqrt(A[ic+1]^2+B[ic+1]^2) 
D[ic+1]<-
(signif(exdata$Xv[i],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[i
c],digits=signdig)*signif(exdata$Xv[i],digits=signdig)) 
sd.Xvcomp[ic+1]<-
Xvcomp[ic+1]*sqrt((C[ic+1]/D[ic+1])^2+(signif(sd.Vt[ic+1],digits=signdig)/signif(Vt[ic+1],
digits=signdig))^2) 
 
 
Xvcomp[ic+2]<-
(signif(Xvcomp[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*si
gnif(dV[ic+1],digits=signdig)*signif(Xvcomp[ic+1],digits=signdig))/signif(Vt[ic+2],digits=s
igndig) 
A[ic+2]<-
stdevmultsingle(signif(Xvcomp[ic+1],digits=signdig),signif(sd.Xvcomp[ic+1],digits=signdig
),signif(Vt[ic+1],digits=signdig),signif(sd.Vt[ic+1],digits=signdig)) 
B[ic+2]<-
(bt[ic+1]+ct[ic+1])*stdevmultsingle(signif(dV[ic+1],digits=signdig),signif(sd.dV[ic+1],digits
=signdig),signif(Xvcomp[ic+1],digits=signdig),signif(sd.Xvcomp[ic+1],digits=signdig)) 
C[ic+2]<-sqrt(A[ic+2]^2+B[ic+2]^2) 
D[ic+2]<-
(signif(Xvcomp[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*si
gnif(dV[ic+1],digits=signdig)*signif(Xvcomp[ic+1],digits=signdig)) 
sd.Xvcomp[ic+2]<-
Xvcomp[ic+2]*sqrt((C[ic+2]/D[ic+2])^2+(signif(sd.Vt[ic+2],digits=signdig)/signif(Vt[ic+2],
digits=signdig))^2) 
 
 
Xvcomp[ic+3]<-
(signif(Xvcomp[ic+2],digits=signdig)*signif(Vt[ic+2],digits=signdig)+(bt[ic+2]+ct[ic+2])*si
gnif(dV[ic+2],digits=signdig)*signif(Xvcomp[ic+2],digits=signdig))/signif(Vt[ic+3],digits=s
igndig) 
A[ic+3]<-
stdevmultsingle(signif(Xvcomp[ic+2],digits=signdig),signif(sd.Xvcomp[ic+2],digits=signdig
),signif(Vt[ic+2],digits=signdig),signif(sd.Vt[ic+2],digits=signdig)) 
B[ic+3]<-
(bt[ic+2]+ct[ic+2])*stdevmultsingle(signif(dV[ic+2],digits=signdig),signif(sd.dV[ic+2],digits
=signdig),signif(Xvcomp[ic+2],digits=signdig),signif(sd.Xvcomp[ic+2],digits=signdig)) 
C[ic+3]<-sqrt(A[ic+3]^2+B[ic+3]^2) 
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D[ic+3]<-
(signif(Xvcomp[ic+2],digits=signdig)*signif(Vt[ic+2],digits=signdig)+(bt[ic+2]+ct[ic+2])*si
gnif(dV[ic+2],digits=signdig)*signif(Xvcomp[ic+2],digits=signdig)) 
sd.Xvcomp[ic+3]<-
Xvcomp[ic+3]*sqrt((C[ic+3]/D[ic+3])^2+(signif(sd.Vt[ic+3],digits=signdig)/signif(Vt[ic+3],
digits=signdig))^2) 
 
Xvcomp[ic+4]<-
(signif(Xvcomp[ic+3],digits=signdig)*signif(Vt[ic+3],digits=signdig)+(bt[ic+3]+ct[ic+3])*si
gnif(dV[ic+3],digits=signdig)*signif(Xvcomp[ic+3],digits=signdig))/signif(Vt[ic+4],digits=s
igndig) 
A[ic+4]<-
stdevmultsingle(signif(Xvcomp[ic+3],digits=signdig),signif(sd.Xvcomp[ic+3],digits=signdig
),signif(Vt[ic+3],digits=signdig),signif(sd.Vt[ic+3],digits=signdig)) 
B[ic+4]<-
(bt[ic+3]+ct[ic+3])*stdevmultsingle(signif(dV[ic+3],digits=signdig),signif(sd.dV[ic+3],digits
=signdig),signif(Xvcomp[ic+3],digits=signdig),signif(sd.Xvcomp[ic+3],digits=signdig)) 
C[ic+4]<-sqrt(A[ic+4]^2+B[ic+4]^2) 
D[ic+4]<-
(signif(Xvcomp[ic+3],digits=signdig)*signif(Vt[ic+3],digits=signdig)+(bt[ic+3]+ct[ic+3])*si
gnif(dV[ic+3],digits=signdig)*signif(Xvcomp[ic+3],digits=signdig)) 
sd.Xvcomp[ic+4]<-
Xvcomp[ic+4]*sqrt((C[ic+4]/D[ic+4])^2+(signif(sd.Vt[ic+4],digits=signdig)/signif(Vt[ic+4],
digits=signdig))^2) 
 
Xvcomp[ic+5]<-
(signif(Xvcomp[ic+4],digits=signdig)*signif(Vt[ic+4],digits=signdig)+(bt[ic+4]+ct[ic+4])*si
gnif(dV[ic+4],digits=signdig)*signif(Xvcomp[ic+4],digits=signdig))/signif(Vt[ic+5],digits=s
igndig) 
A[ic+5]<-
stdevmultsingle(signif(Xvcomp[ic+4],digits=signdig),signif(sd.Xvcomp[ic+4],digits=signdig
),signif(Vt[ic+4],digits=signdig),signif(sd.Vt[ic+4],digits=signdig)) 
B[ic+5]<-
(bt[ic+4]+ct[ic+4])*stdevmultsingle(signif(dV[ic+4],digits=signdig),signif(sd.dV[ic+4],digits
=signdig),signif(Xvcomp[ic+4],digits=signdig),signif(sd.Xvcomp[ic+4],digits=signdig)) 
C[ic+5]<-sqrt(A[ic+5]^2+B[ic+5]^2) 
D[ic+5]<-
(signif(Xvcomp[ic+4],digits=signdig)*signif(Vt[ic+4],digits=signdig)+(bt[ic+4]+ct[ic+4])*si
gnif(dV[ic+4],digits=signdig)*signif(Xvcomp[ic+4],digits=signdig)) 
sd.Xvcomp[ic+5]<-
Xvcomp[ic+5]*sqrt((C[ic+5]/D[ic+5])^2+(signif(sd.Vt[ic+5],digits=signdig)/signif(Vt[ic+5],
digits=signdig))^2) 
 
Xvcomp[ic+6]<-
(signif(Xvcomp[ic+5],digits=signdig)*signif(Vt[ic+5],digits=signdig)+(bt[ic+5]+ct[ic+5])*si
gnif(dV[ic+5],digits=signdig)*signif(Xvcomp[ic+5],digits=signdig))/signif(Vt[ic+6],digits=s
igndig) 
A[ic+6]<-
stdevmultsingle(signif(Xvcomp[ic+5],digits=signdig),signif(sd.Xvcomp[ic+5],digits=signdig
),signif(Vt[ic+5],digits=signdig),signif(sd.Vt[ic+5],digits=signdig)) 
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B[ic+6]<-
(bt[ic+5]+ct[ic+5])*stdevmultsingle(signif(dV[ic+5],digits=signdig),signif(sd.dV[ic+5],digits
=signdig),signif(Xvcomp[ic+5],digits=signdig),signif(sd.Xvcomp[ic+5],digits=signdig)) 
C[ic+6]<-sqrt(A[ic+6]^2+B[ic+6]^2) 
D[ic+6]<-
(signif(Xvcomp[ic+5],digits=signdig)*signif(Vt[ic+5],digits=signdig)+(bt[ic+5]+ct[ic+5])*si
gnif(dV[ic+5],digits=signdig)*signif(Xvcomp[ic+5],digits=signdig)) 
sd.Xvcomp[ic+6]<-
Xvcomp[ic+6]*sqrt((C[ic+6]/D[ic+6])^2+(signif(sd.Vt[ic+6],digits=signdig)/signif(Vt[ic+6],
digits=signdig))^2) 
 
Xdcomp[ic+1]<-
(signif(exdata$Xd[i],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[i
c],digits=signdig)*signif(exdata$Xd[i],digits=signdig))/signif(Vt[ic+1],digits=signdig) 
AXd[ic+1]<-
stdevmultsingle(signif(exdata$Xd[i],digits=signdig),signif(exdata$sd.Xd[i],digits=signdig),si
gnif(Vt[ic],digits=signdig),signif(sd.Vt[ic],digits=signdig)) 
BXd[ic+1]<-
(bt[ic]+ct[ic])*stdevmultsingle(signif(dV[ic],digits=signdig),signif(sd.dV[ic],digits=signdig),
signif(exdata$Xd[i],digits=signdig),signif(exdata$sd.Xd[i],digits=signdig)) 
CXd[ic+1]<-sqrt(AXd[ic+1]^2+BXd[ic+1]^2) 
DXd[ic+1]<-
(signif(exdata$Xd[i],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[i
c],digits=signdig)*signif(exdata$Xd[i],digits=signdig)) 
sd.Xdcomp[ic+1]<-
Xdcomp[ic+1]*sqrt((CXd[ic+1]/DXd[ic+1])^2+(signif(sd.Vt[ic+1],digits=signdig)/signif(Vt[
ic+1],digits=signdig))^2) 
 
Xdcomp[ic+2]<-
(signif(Xdcomp[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*si
gnif(dV[ic+1],digits=signdig)*signif(Xdcomp[ic+1],digits=signdig))/signif(Vt[ic+2],digits=s
igndig) 
AXd[ic+2]<-
stdevmultsingle(signif(Xdcomp[ic+1],digits=signdig),signif(sd.Xdcomp[ic+1],digits=signdig
),signif(Vt[ic+1],digits=signdig),signif(sd.Vt[ic+1],digits=signdig)) 
BXd[ic+2]<-
(bt[ic+1]+ct[ic+1])*stdevmultsingle(signif(dV[ic+1],digits=signdig),signif(sd.dV[ic+1],digits
=signdig),signif(Xdcomp[ic+1],digits=signdig),signif(sd.Xdcomp[ic+1],digits=signdig)) 
CXd[ic+2]<-sqrt(AXd[ic+2]^2+BXd[ic+2]^2) 
DXd[ic+2]<-
(signif(Xdcomp[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*si
gnif(dV[ic+1],digits=signdig)*signif(Xdcomp[ic+1],digits=signdig)) 
sd.Xdcomp[ic+2]<-
Xdcomp[ic+2]*sqrt((CXd[ic+2]/DXd[ic+2])^2+(signif(sd.Vt[ic+2],digits=signdig)/signif(Vt[
ic+2],digits=signdig))^2) 
 
 
Xdcomp[ic+3]<-
(signif(Xdcomp[ic+2],digits=signdig)*signif(Vt[ic+2],digits=signdig)+(bt[ic+2]+ct[ic+2])*si
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gnif(dV[ic+2],digits=signdig)*signif(Xdcomp[ic+2],digits=signdig))/signif(Vt[ic+3],digits=s
igndig) 
AXd[ic+3]<-
stdevmultsingle(signif(Xdcomp[ic+2],digits=signdig),signif(sd.Xdcomp[ic+2],digits=signdig
),signif(Vt[ic+2],digits=signdig),signif(sd.Vt[ic+2],digits=signdig)) 
BXd[ic+3]<-
(bt[ic+2]+ct[ic+2])*stdevmultsingle(signif(dV[ic+2],digits=signdig),signif(sd.dV[ic+2],digits
=signdig),signif(Xdcomp[ic+2],digits=signdig),signif(sd.Xdcomp[ic+2],digits=signdig)) 
CXd[ic+3]<-sqrt(AXd[ic+3]^2+BXd[ic+3]^2) 
DXd[ic+3]<-
(signif(Xdcomp[ic+2],digits=signdig)*signif(Vt[ic+2],digits=signdig)+(bt[ic+2]+ct[ic+2])*si
gnif(dV[ic+2],digits=signdig)*signif(Xdcomp[ic+2],digits=signdig)) 
sd.Xdcomp[ic+3]<-
Xdcomp[ic+3]*sqrt((CXd[ic+3]/DXd[ic+3])^2+(signif(sd.Vt[ic+3],digits=signdig)/signif(Vt[
ic+3],digits=signdig))^2) 
 
Xdcomp[ic+4]<-
(signif(Xdcomp[ic+3],digits=signdig)*signif(Vt[ic+3],digits=signdig)+(bt[ic+3]+ct[ic+3])*si
gnif(dV[ic+3],digits=signdig)*signif(Xdcomp[ic+3],digits=signdig))/signif(Vt[ic+4],digits=s
igndig) 
AXd[ic+4]<-
stdevmultsingle(signif(Xdcomp[ic+3],digits=signdig),signif(sd.Xdcomp[ic+3],digits=signdig
),signif(Vt[ic+3],digits=signdig),signif(sd.Vt[ic+3],digits=signdig)) 
BXd[ic+4]<-
(bt[ic+3]+ct[ic+3])*stdevmultsingle(signif(dV[ic+3],digits=signdig),signif(sd.dV[ic+3],digits
=signdig),signif(Xdcomp[ic+3],digits=signdig),signif(sd.Xdcomp[ic+3],digits=signdig)) 
CXd[ic+4]<-sqrt(AXd[ic+4]^2+BXd[ic+4]^2) 
DXd[ic+4]<-
(signif(Xdcomp[ic+3],digits=signdig)*signif(Vt[ic+3],digits=signdig)+(bt[ic+3]+ct[ic+3])*si
gnif(dV[ic+3],digits=signdig)*signif(Xdcomp[ic+3],digits=signdig)) 
sd.Xdcomp[ic+4]<-
Xdcomp[ic+4]*sqrt((CXd[ic+4]/DXd[ic+4])^2+(signif(sd.Vt[ic+4],digits=signdig)/signif(Vt[
ic+4],digits=signdig))^2)  
 
Xdcomp[ic+5]<-
(signif(Xdcomp[ic+4],digits=signdig)*signif(Vt[ic+4],digits=signdig)+(bt[ic+4]+ct[ic+4])*si
gnif(dV[ic+4],digits=signdig)*signif(Xdcomp[ic+4],digits=signdig))/signif(Vt[ic+5],digits=s
igndig) 
AXd[ic+5]<-
stdevmultsingle(signif(Xdcomp[ic+4],digits=signdig),signif(sd.Xdcomp[ic+4],digits=signdig
),signif(Vt[ic+4],digits=signdig),signif(sd.Vt[ic+4],digits=signdig)) 
BXd[ic+5]<-
(bt[ic+4]+ct[ic+4])*stdevmultsingle(signif(dV[ic+4],digits=signdig),signif(sd.dV[ic+4],digits
=signdig),signif(Xdcomp[ic+4],digits=signdig),signif(sd.Xdcomp[ic+4],digits=signdig)) 
CXd[ic+5]<-sqrt(AXd[ic+5]^2+BXd[ic+5]^2) 
DXd[ic+5]<-
(signif(Xdcomp[ic+4],digits=signdig)*signif(Vt[ic+4],digits=signdig)+(bt[ic+4]+ct[ic+4])*si
gnif(dV[ic+4],digits=signdig)*signif(Xdcomp[ic+4],digits=signdig)) 
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sd.Xdcomp[ic+5]<-
Xdcomp[ic+5]*sqrt((CXd[ic+5]/DXd[ic+5])^2+(signif(sd.Vt[ic+5],digits=signdig)/signif(Vt[
ic+5],digits=signdig))^2) 
 
Xdcomp[ic+6]<-
(signif(Xdcomp[ic+5],digits=signdig)*signif(Vt[ic+5],digits=signdig)+(bt[ic+5]+ct[ic+5])*si
gnif(dV[ic+5],digits=signdig)*signif(Xdcomp[ic+5],digits=signdig))/signif(Vt[ic+6],digits=s
igndig) 
AXd[ic+6]<-
stdevmultsingle(signif(Xdcomp[ic+5],digits=signdig),signif(sd.Xdcomp[ic+5],digits=signdig
),signif(Vt[ic+5],digits=signdig),signif(sd.Vt[ic+5],digits=signdig)) 
BXd[ic+6]<-
(bt[ic+5]+ct[ic+5])*stdevmultsingle(signif(dV[ic+5],digits=signdig),signif(sd.dV[ic+5],digits
=signdig),signif(Xdcomp[ic+5],digits=signdig),signif(sd.Xdcomp[ic+5],digits=signdig)) 
CXd[ic+6]<-sqrt(AXd[ic+6]^2+BXd[ic+6]^2) 
DXd[ic+6]<-
(signif(Xdcomp[ic+5],digits=signdig)*signif(Vt[ic+5],digits=signdig)+(bt[ic+5]+ct[ic+5])*si
gnif(dV[ic+5],digits=signdig)*signif(Xdcomp[ic+5],digits=signdig)) 
sd.Xdcomp[ic+6]<-
Xdcomp[ic+6]*sqrt((CXd[ic+6]/DXd[ic+6])^2+(signif(sd.Vt[ic+6],digits=signdig)/signif(Vt[
ic+6],digits=signdig))^2) 
 
  nf1<-nf1+1 
  ic<-ic+7 
  } 
 } 
} 
 
 
XvV<-rep(0,length(tcomp)) 
sd.XvV<-rep(0,length(tcomp)) 
for(i in 1:length(tcomp)){ 
XvV[i]<-Xvcomp[i]*Vt[i] 
sd.XvV[i]<-XvV[i]*sqrt((sd.Xvcomp[i]/Xvcomp[i])^2+(sd.Vt[i]/Vt[i])^2) 
if(is.nan(sd.XvV[i])){ 
sd.XvV[i]<-0 
}else{ 
sd.XvV[i]<-XvV[i]*sqrt((sd.Xvcomp[i]/Xvcomp[i])^2+(sd.Vt[i]/Vt[i])^2)} 
} 
 
 
dXvV<-c(XvV[1],rep(0,length(tcomp)-1)) 
sd.dXvV<-c(sd.XvV[1],rep(0,length(tcomp)-1)) 
for(i in 2:length(tcomp)){ 
dXvV[i]<-XvV[i]-XvV[i-1]+dXvV[i-1] 
sd.dXvV[i]<-sqrt(sd.XvV[i]^2+sd.XvV[i-1]^2+sd.dXvV[i-1]^2) 
} 
 
XvVover2<-sumcolover2(XvV) 
sd.XvVover2<-stdevsumcol(sd.XvV)/2 
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XvVover2dt<-XvVover2*dt 
sd.XvVover2dt<-stdevmult(XvVover2,sd.XvVover2,dt,sd.dt) 
 
IVC<-trapintegmul2(XvVover2dt) 
sd.IVC<-sd.trapintegmul2(sd.XvVover2dt) 
 
IVCexp<-c(IVC[1],rep(0,length(texp)-1)) 
sd.IVCexp<-c(IVC[1],rep(0,length(texp)-1)) 
 
nf1<-1 
ic<-2 
for (i in (2:length(texp))){ 
IVCexp[i]<-IVC[ic] 
sd.IVCexp[i]<-sd.IVC[ic] 
 if(i!=length(texp)) { 
  if(i!=(nf1*fint)+1){ 
  IVCexp[i]<-IVC[ic] 
  sd.IVCexp[i]<-sd.IVC[ic] 
  ic<-ic+3 
   }else{nf1<-nf1+1 
    IVCexp[i]<-IVC[ic] 
    sd.IVCexp[i]<-sd.IVC[ic] 
    ic<-ic+7 
    } 
    } 
} 
 
 
bFoutXv<-bt*Xvcomp*sFOUT 
sd.bFoutXv<-Xvcomp*sFOUT*bt*sqrt((sd.Xvcomp/Xvcomp)^2+(sd.sFOUT/sFOUT)^2) 
 
bFoutXvover2<-sumcolover2(bFoutXv) 
sd.bFoutXvover2<-stdevsumcol(sd.bFoutXv)/2 
 
bFoutXvover2dt<-bFoutXvover2*dt 
sd.bFoutXvover2dt<-stdevmult(bFoutXvover2,sd.bFoutXvover2,dt,sd.dt) 
 
SbFoutXvdt<-trapintegmul2(bFoutXvover2dt) 
 
sd.SbFoutXvdt<-sd.trapintegmul2(sd.bFoutXvover2dt) 
 
cFoutafFXv<-ct*Xvcomp*safFFOUT 
sd.cFoutafFXv<-
Xvcomp*safFFOUT*ct*sqrt((sd.Xvcomp/Xvcomp)^2+(sd.safFFOUT/safFFOUT)^2) 
 
cFoutafFXvover2<-sumcolover2(cFoutafFXv) 
sd.cFoutafFXvover2<-stdevsumcol(sd.cFoutafFXv)/2 
 
cFoutafFXvover2dt<-cFoutafFXvover2*dt 
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sd.cFoutafFXvover2dt<-stdevmult(cFoutafFXvover2,sd.cFoutafFXvover2,dt,sd.dt) 
 
ScFoutafFXvdt<-trapintegmul2(cFoutafFXvover2dt) 
sd.ScFoutafFXvdt<-sd.trapintegmul2(sd.cFoutafFXvover2dt) 
 
deltavcells<-rep(0,length(tcomp)) 
sd.deltavcells<-rep(0,length(tcomp)) 
sd.deltavcells2<-rep(0,length(tcomp)) 
for(i in 2:length(tcomp)){ 
deltavcells[i]<-XvV[i]-XvV[i-1]+SbFoutXvdt[i]-SbFoutXvdt[i-1]+ScFoutafFXvdt[i]-
ScFoutafFXvdt[i-1] 
sd.deltavcells[i]<-sqrt(sd.XvV[i]^2+sd.XvV[i-1]^2+sd.SbFoutXvdt[i]^2+sd.SbFoutXvdt[i-
1]^2+sd.ScFoutafFXvdt[i]^2+sd.ScFoutafFXvdt[i-1]^2) 
sd.deltavcells2[i]<-sqrt(sd.dXvV[i]^2+sd.dXvV[i-
1]^2+sd.SbFoutXvdt[i]^2+sd.SbFoutXvdt[i-
1]^2+sd.ScFoutafFXvdt[i]^2+sd.ScFoutafFXvdt[i-1]^2) 
} 
 
currentvcells<-rep(0,length(tcomp)) 
sd.currentvcells<-rep(0,length(tcomp)) 
sd.currentvcells2<-rep(0,length(tcomp)) 
for(i in 1:length(tcomp)){ 
currentvcells[i]<-XvV[i]+SbFoutXvdt[i]+ScFoutafFXvdt[i] 
sd.currentvcells[i]<-sqrt(sd.XvV[i]^2+sd.SbFoutXvdt[i]^2+sd.ScFoutafFXvdt[i]^2) 
sd.currentvcells2[i]<-sqrt(sd.dXvV[i]^2+sd.SbFoutXvdt[i]^2+sd.ScFoutafFXvdt[i]^2) 
} 
 
# coerce back to the experimental data points for the cells 
currentvcellsexp<-c(currentvcells[1],rep(0,length(texp)-1)) 
sd.currentvcellsexp<-c(sd.currentvcells[1],rep(0,length(texp)-1)) 
sd.currentvcellsexp2<-c(sd.currentvcells2[1],rep(0,length(texp)-1)) 
 
nf1<-1 
ic<-2 
for (i in (2:length(texp))){ 
currentvcellsexp[i]<-currentvcells[ic] 
sd.currentvcellsexp[i]<-sd.currentvcells[ic] 
sd.currentvcellsexp2[i]<-sd.currentvcells2[ic] 
 
 if(i!=length(texp)) { 
  if(i!=(nf1*fint)+1){ 
  currentvcellsexp[i]<-currentvcells[ic] 
  sd.currentvcellsexp[i]<-sd.currentvcells[ic] 
  sd.currentvcellsexp2[i]<-sd.currentvcells2[ic] 
   ic<-ic+3 
   }else{nf1<-nf1+1 
    currentvcellsexp[i]<-currentvcells[ic] 
    sd.currentvcellsexp[i]<-sd.currentvcells[ic] 
    sd.currentvcellsexp2[i]<-sd.currentvcells2[ic] 
    ic<-ic+7 
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    } 
    } 
} 
 
 
stdevdivsingle<-function(var4,sd.var4,var5,sd.var5){ 
var45<-abs(var4/var5)*sqrt((sd.var4/var4)^2+(sd.var5/var5^2)) 
if(is.nan(var45)){ 
var45<-0} 
else{var45}  
return(var45) 
} 
 
ic<-1 
from<-NULL 
to<-NULL 
muapp<-NULL 
Amuapp<-NULL 
Bmuapp<-NULL 
sd.Amuapp<-NULL 
sd.Amuapp2<-NULL 
sd.Bmuapp<-NULL 
sd.muapp<-NULL 
sd.muapp2<-NULL 
for (n in (2:length(texp))){ 
for (m in (1:n)){ 
muapp[ic]<-(currentvcellsexp[n]-currentvcellsexp[m])/(IVCexp[n]-IVCexp[m]) 
Amuapp[ic]<-(currentvcellsexp[n]-currentvcellsexp[m]) 
sd.Amuapp[ic]<-sqrt(sd.currentvcellsexp[n]^2+sd.currentvcellsexp[m]^2) 
sd.Amuapp2[ic]<-sqrt(sd.currentvcellsexp2[n]^2+sd.currentvcellsexp2[m]^2) 
Bmuapp[ic]<-(IVCexp[n]-IVCexp[m]) 
sd.Bmuapp[ic]<-sqrt(sd.IVCexp[n]^2+sd.IVCexp[m]^2) 
sd.muapp[ic]<-stdevdivsingle(Amuapp[ic],sd.Amuapp[ic],Bmuapp[ic],sd.Bmuapp[ic]) 
sd.muapp2[ic]<-stdevdivsingle(Amuapp[ic],sd.Amuapp2[ic],Bmuapp[ic],sd.Bmuapp[ic]) 
from[ic]<-m-1 
to[ic]<-n-1 
ic<-ic+1 
} 
} 
 
 
deltaIVC<-delta(IVC) 
sd.deltaIVC<-stdevsumcol(sd.IVC) 
 
stdevdiv<-function(var4,sd.var4,var5,sd.var5){ 
var45<-rep(0,length(tcomp)) 
for(i in 1:length(tcomp)){ 
var45[i]<-abs(var4[i]/var5[i])*sqrt((sd.var4[i]/var4[i])^2+(sd.var5[i]/var5[i])^2) 
if(is.nan(var45[i])) 
{ 
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var45[i]<-0 
}else{ 
var45[i] 
}  
} 
return(var45) 
} 
 
muappinst<-deltavcells/deltaIVC 
sd.muappinst<-stdevdiv(deltavcells,sd.deltavcells,deltaIVC,sd.deltaIVC) 
sd.muappinst2<-stdevdiv(deltavcells,sd.deltavcells2,deltaIVC,sd.deltaIVC) 
 
muappinstexp<-c(muappinst[1],rep(0,length(texp)-1)) 
sd.muappinstexp<-c(sd.muappinst[1],rep(0,length(texp)-1)) 
sd.muappinstexp2<-c(sd.muappinst2[1],rep(0,length(texp)-1)) 
 
nf1<-1 
ic<-2 
for (i in (2:length(texp))){ 
muappinstexp[i]<-muappinst[ic] 
sd.muappinstexp[i]<-sd.muappinst[ic] 
sd.muappinstexp2[i]<-sd.muappinst2[ic] 
 
 if(i!=length(texp)) { 
  if(i!=(nf1*fint)+1){ 
  muappinstexp[i]<-muappinst[ic] 
  sd.muappinstexp[i]<-sd.muappinst[ic] 
  sd.muappinstexp2[i]<-sd.muappinst2[ic] 
  ic<-ic+3 
   }else{nf1<-nf1+1 
    muappinstexp[i]<-muappinst[ic] 
    sd.muappinstexp[i]<-sd.muappinst[ic] 
    sd.muappinstexp2[i]<-sd.muappinst2[ic] 
    ic<-ic+7 
    } 
    } 
} 
 
XdV<-rep(0,length(tcomp)) 
sd.XdV<-rep(0,length(tcomp)) 
for(i in 1:length(tcomp)){ 
XdV[i]<-Xdcomp[i]*Vt[i] 
sd.XdV[i]<-XdV[i]*sqrt((sd.Xdcomp[i]/Xdcomp[i])^2+(sd.Vt[i]/Vt[i])^2) 
if(is.nan(sd.XdV[i])){ 
sd.XdV[i]<-0 
}else{ 
sd.XdV[i]<-XdV[i]*sqrt((sd.Xdcomp[i]/Xdcomp[i])^2+(sd.Vt[i]/Vt[i])^2)} 
} 
 
dXdV<-c(XdV[1],rep(0,length(tcomp)-1)) 
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sd.dXdV<-c(sd.XdV[1],rep(0,length(tcomp)-1)) 
for(i in 2:length(tcomp)){ 
dXdV[i]<-XdV[i]-XdV[i-1]+dXdV[i-1] 
sd.dXdV[i]<-sqrt(sd.XdV[i]^2+sd.XdV[i-1]^2+sd.dXdV[i-1]^2) 
} 
 
XdVover2<-sumcolover2(XdV) 
sd.XdVover2<-stdevsumcol(sd.XdV)/2 
 
XdVover2dt<-XdVover2*dt 
sd.XdVover2dt<-stdevmult(XdVover2,sd.XdVover2,dt,sd.dt) 
 
IDC<-trapintegmul2(XdVover2dt) 
sd.IDC<-sd.trapintegmul2(sd.XdVover2dt) 
 
IDCexp<-c(IDC[1],rep(0,length(texp)-1)) 
sd.IDCexp<-c(IDC[1],rep(0,length(texp)-1)) 
nf1<-1 
ic<-2 
for (i in (2:length(texp))){ 
IDCexp[i]<-IDC[ic] 
sd.IDCexp[i]<-sd.IDC[ic] 
 if(i!=length(texp)) { 
  if(i!=(nf1*fint)+1){ 
  IDCexp[i]<-IDC[ic] 
  sd.IDCexp[i]<-sd.IDC[ic] 
  ic<-ic+3 
   }else{nf1<-nf1+1 
    IDCexp[i]<-IDC[ic] 
    sd.IDCexp[i]<-sd.IDC[ic]      
    ic<-ic+7 
    } 
    } 
} 
 
bFoutXd<-bt*Xdcomp*sFOUT 
sd.bFoutXd<-Xdcomp*sFOUT*bt*sqrt((sd.Xdcomp/Xdcomp)^2+(sd.sFOUT/sFOUT)^2) 
 
bFoutXdover2<-sumcolover2(bFoutXd) 
sd.bFoutXdover2<-stdevsumcol(sd.bFoutXd)/2 
 
bFoutXdover2dt<-bFoutXdover2*dt 
sd.bFoutXdover2dt<-stdevmult(bFoutXdover2,sd.bFoutXdover2,dt,sd.dt) 
 
SbFoutXddt<-trapintegmul2(bFoutXdover2dt) 
 
sd.SbFoutXddt<-sd.trapintegmul2(sd.bFoutXdover2dt) 
 
cFoutafFXd<-ct*Xdcomp*safFFOUT 
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sd.cFoutafFXd<-
Xdcomp*safFFOUT*ct*sqrt((sd.Xdcomp/Xdcomp)^2+(sd.safFFOUT/safFFOUT)^2) 
 
cFoutafFXdover2<-sumcolover2(cFoutafFXd) 
sd.cFoutafFXdover2<-stdevsumcol(sd.cFoutafFXd)/2 
 
cFoutafFXdover2dt<-cFoutafFXdover2*dt 
sd.cFoutafFXdover2dt<-stdevmult(cFoutafFXdover2,sd.cFoutafFXdover2,dt,sd.dt) 
 
ScFoutafFXddt<-trapintegmul2(cFoutafFXdover2dt) 
sd.ScFoutafFXddt<-sd.trapintegmul2(sd.cFoutafFXdover2dt) 
 
deltadcells<-rep(0,length(tcomp)) 
sd.deltadcells<-rep(0,length(tcomp)) 
sd.deltadcells2<-rep(0,length(tcomp)) 
for(i in 2:length(tcomp)){ 
deltadcells[i]<-XdV[i]-XdV[i-1]+SbFoutXddt[i]-SbFoutXddt[i-1]+ScFoutafFXddt[i]-
ScFoutafFXddt[i-1] 
sd.deltadcells[i]<-sqrt(sd.XdV[i]^2+sd.XdV[i-1]^2+sd.SbFoutXddt[i]^2+sd.SbFoutXddt[i-
1]^2+sd.ScFoutafFXddt[i]^2+sd.ScFoutafFXddt[i-1]^2) 
sd.deltadcells2[i]<-sqrt(sd.dXdV[i]^2+sd.dXdV[i-
1]^2+sd.SbFoutXddt[i]^2+sd.SbFoutXddt[i-
1]^2+sd.ScFoutafFXddt[i]^2+sd.ScFoutafFXddt[i-1]^2) 
} 
 
currentdcells<-rep(0,length(tcomp)) 
sd.currentdcells<-rep(0,length(tcomp)) 
sd.currentdcells2<-rep(0,length(tcomp)) 
for(i in 1:length(tcomp)){ 
currentdcells[i]<-XdV[i]+SbFoutXddt[i]+ScFoutafFXddt[i] 
sd.currentdcells[i]<-sqrt(sd.XdV[i]^2+sd.SbFoutXddt[i]^2+sd.ScFoutafFXddt[i]^2) 
sd.currentdcells2[i]<-sqrt(sd.dXdV[i]^2+sd.SbFoutXddt[i]^2+sd.ScFoutafFXddt[i]^2) 
} 
 
currentdcellsexp<-c(currentdcells[1],rep(0,length(texp)-1)) 
nf1<-1 
ic<-2 
for (i in (2:length(texp))){ 
currentdcellsexp[i]<-currentdcells[ic] 
 if(i!=length(texp)) { 
  if(i!=(nf1*fint)+1){ 
  currentdcellsexp[i]<-currentdcells[ic] 
  ic<-ic+3 
   }else{nf1<-nf1+1 
    currentdcellsexp[i]<-currentdcells[ic]   
   
    ic<-ic+7 
    } 
    } 
} 
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sd.currentdcellsexp<-c(sd.currentdcells[1],rep(0,length(texp)-1)) 
nf1<-1 
ic<-2 
 
for (i in (2:length(texp))){ 
sd.currentdcellsexp[i]<-sd.currentdcells[ic] 
 if(i!=length(texp)) { 
  if(i!=(nf1*fint)+1){ 
  sd.currentdcellsexp[i]<-sd.currentdcells[ic] 
  ic<-ic+3 
   }else{nf1<-nf1+1 
    sd.currentdcellsexp[i]<-sd.currentdcells[ic]   
   
    ic<-ic+7 
    } 
    } 
} 
 
sd.currentdcellsexp2<-c(sd.currentdcells2[1],rep(0,length(texp)-1)) 
nf1<-1 
ic<-2 
 
for (i in (2:length(texp))){ 
sd.currentdcellsexp2[i]<-sd.currentdcells2[ic] 
 if(i!=length(texp)) { 
  if(i!=(nf1*fint)+1){ 
  sd.currentdcellsexp2[i]<-sd.currentdcells2[ic] 
  ic<-ic+3 
   }else{nf1<-nf1+1 
    sd.currentdcellsexp2[i]<-sd.currentdcells2[ic]  
    
    ic<-ic+7 
    } 
    } 
} 
 
ic<-1 
from<-NULL 
to<-NULL 
kdapp<-NULL 
Akdapp<-NULL 
Bkdapp<-NULL 
sd.Akdapp<-NULL 
sd.Akdapp2<-NULL 
sd.Bkdapp<-NULL 
sd.kdapp<-NULL 
sd.kdapp2<-NULL 
for (n in (2:length(texp))){ 
for (m in (1:n)){ 
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kdapp[ic]<-(currentdcellsexp[n]-currentdcellsexp[m])/(IDCexp[n]-IDCexp[m]) 
Akdapp[ic]<-(currentdcellsexp[n]-currentdcellsexp[m]) 
sd.Akdapp[ic]<-sqrt(sd.currentdcellsexp[n]^2+sd.currentdcellsexp[m]^2) 
sd.Akdapp2[ic]<-sqrt(sd.currentdcellsexp2[n]^2+sd.currentdcellsexp2[m]^2) 
Bkdapp[ic]<-(IDCexp[n]-IDCexp[m]) 
sd.Bkdapp[ic]<-sqrt(sd.IDCexp[n]^2+sd.IDCexp[m]^2) 
sd.kdapp[ic]<-stdevdivsingle(Akdapp[ic],sd.Akdapp[ic],Bkdapp[ic],sd.Bkdapp[ic]) 
sd.kdapp2[ic]<-stdevdivsingle(Akdapp[ic],sd.Akdapp2[ic],Bkdapp[ic],sd.Bkdapp[ic]) 
from[ic]<-m-1 
to[ic]<-n-1 
ic<-ic+1 
} 
} 
 
deltaIDC<-delta(IDC) 
sd.deltaIDC<-stdevsumcol(sd.IDC) 
 
kdappinst<-deltadcells/deltaIDC 
sd.kdappinst<-stdevdiv(deltadcells,sd.deltadcells,deltaIDC,sd.deltaIDC) 
sd.kdappinst2<-stdevdiv(deltadcells,sd.deltadcells2,deltaIDC,sd.deltaIDC) 
 
kdappinstexp<-c(kdappinst[1],rep(0,length(texp)-1)) 
sd.kdappinstexp<-c(sd.kdappinst[1],rep(0,length(texp)-1)) 
sd.kdappinstexp2<-c(sd.kdappinst2[1],rep(0,length(texp)-1)) 
nf1<-1 
ic<-2 
for (i in (2:length(texp))){ 
kdappinstexp[i]<-kdappinst[ic] 
sd.kdappinstexp[i]<-sd.kdappinst[ic] 
sd.kdappinstexp2[i]<-sd.kdappinst2[ic] 
 
 
 if(i!=length(texp)) { 
  if(i!=(nf1*fint)+1){ 
  kdappinstexp[i]<-kdappinst[ic] 
  sd.kdappinstexp[i]<-sd.kdappinst[ic] 
  sd.kdappinstexp2[i]<-sd.kdappinst2[ic] 
 
  ic<-ic+3 
   }else{nf1<-nf1+1 
    kdappinstexp[i]<-kdappinst[ic] 
    sd.kdappinstexp[i]<-sd.kdappinst[ic] 
    sd.kdappinstexp2[i]<-sd.kdappinst2[ic] 
      
    ic<-ic+7 
    } 
    } 
} 
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## METABOLITES 
 
cscomp<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.cscomp<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
namecscomp<-NULL 
namesd.cscomp<-NULL 
k<-1 
for (l in seq(8,ncol(exdata),by=2)){ 
cscomp[,k]<-c(signif(exdata[1,l],digits=signdig),rep(0,tharvest+1+2* 
ns[length(ns)]+4*nf[length(nf)]-1)) 
sd.cscomp[,k]<-c(signif(exdata [1,l+1],digits=signdig),rep(0,tharvest+1+2* 
ns[length(ns)]+4*nf[length(nf)]-1)) 
namecscomp[k]<-colnames(exdata)[l] 
namesd.cscomp[k]<-colnames(exdata)[l+1] 
k<-k+1 
} 
colnames(cscomp)<-namecscomp 
colnames(sd.cscomp)<-namesd.cscomp 
 
 
k<-1 
for (l in seq(8,ncol(exdata),by=2)){ 
 
 
if(signif(exdata[length(texp)+3,l] ,digits=signdig)<=0){ 
 
A<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
A1<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
B<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
B1<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
B2<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
B21<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
B3<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
C<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
D<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
 
nf1<-1 
ic<-2 
for (i in (2:length(texp))){ 
cscomp[ic,k]<-signif(exdata [i,l],digits=signdig) 
sd.cscomp[ic,k]<-signif(exdata [i,l+1],digits=signdig) 
 
if(i!=length(texp)) { 
 if(i!=(nf1*fint)+1){ 
 
cscomp[ic+1,k]<-
(signif(exdata[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[ic],
digits=signdig)*signif(exdata[i,l],digits=signdig)+at[ic]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic],digits=signdig)+ 
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signif(exdata[length(texp)+3,l] ,digits=signdig)* signif(exdata 
[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)*dt[ic])/signif(Vt[ic+1],digits=signdig) 
A[ic+1]<-
stdevmultsingle(signif(exdata[i,l],digits=signdig),signif(exdata[i,l+1],digits=signdig),signif(V
t[ic],digits=signdig),signif(sd.Vt[ic],digits=signdig)) 
A1[ic+1]<- signif(exdata[i,l],digits=signdig)*signif(Vt[ic],digits=signdig) 
B[ic+1]<-
(bt[ic]+ct[ic])*stdevmultsingle(signif(dV[ic],digits=signdig),signif(sd.dV[ic],digits=signdig),
signif(exdata[i,l],digits=signdig),signif(exdata [i,l+1],digits=signdig)) 
B1[ic+1]<-at[ic]*stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic],digits=signdig),signif(sd.dV[ic],digits=signdig)) 
B2[ic+1]<- stdevmultsingle(A1[ic+1], 
A[ic+1],signif(dt[ic],digits=signdig),signif(sd.dt[ic],digits=signdig)) 
B21[ic+1]<- signif(exdata 
[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)*signif(dt[ic],digits=signdig) 
B3[ic+1]<- stdevmultsingle(B21[ic+1], B2[ic+1], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+1]<-sqrt(A[ic+1]^2+B[ic+1]^2+B1[ic+1]^2+ B3[ic+1]^2) 
D[ic+1]<- 
(signif(exdata[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[ic],
digits=signdig)*signif(exdata[i,l],digits=signdig)+at[ic]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(exdata[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)*dt[ic]) 
sd.cscomp[ic+1,k]<- 
cscomp[ic+1,k]*sqrt((C[ic+1]/D[ic+1])^2+(signif(sd.Vt[ic+1],digits=signdig)/signif(Vt[ic+1]
,digits=signdig))^2) 
 
cscomp[ic+2,k]<-
(signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*s
ignif(dV[ic+1],digits=signdig)*signif(cscomp[ic+1,k],digits=signdig)+at[ic+1]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+1],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)*dt[ic+1])/signif(Vt[ic
+2],digits=signdig) 
A[ic+2]<-
stdevmultsingle(signif(cscomp[ic+1,k],digits=signdig),signif(sd.cscomp[ic+1,k],digits=signdi
g),signif(Vt[ic+1],digits=signdig),signif(sd.Vt[ic+1],digits=signdig)) 
A1[ic+2]<- signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig) 
B[ic+2]<-
(bt[ic+1]+ct[ic+1])*stdevmultsingle(signif(dV[ic+1],digits=signdig),signif(sd.dV[ic+1],digits
=signdig), signif(cscomp[ic+1,k],digits=signdig),signif(sd.cscomp[ic+1,k],digits=signdig)) 
B1[ic+2]<-at[ic+1]* stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic+1],digits=signdig),signif(sd.dV[ic+1],digits=signdig)) 
B2[ic+2]<- stdevmultsingle(A1[ic+2], A[ic+2], 
signif(dt[ic+1],digits=signdig),signif(sd.dt[ic+1],digits=signdig)) 
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B21[ic+2]<- 
signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)*signif(dt[ic+1],digits=
signdig) 
B3[ic+2]<- stdevmultsingle(B21[ic+2], B2[ic+2], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+2]<-sqrt(A[ic+2]^2+B[ic+2]^2+B1[ic+2]^2+ B3[ic+2]^2) 
D[ic+2]<- 
(signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*s
ignif(dV[ic+1],digits=signdig)*signif(cscomp[ic+1,k],digits=signdig)+at[ic+1]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+1],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)*dt[ic+1]) 
sd.cscomp[ic+2,k]<- 
cscomp[ic+2,k]*sqrt((C[ic+2]/D[ic+2])^2+(signif(sd.Vt[ic+2],digits=signdig)/signif(Vt[ic+2]
,digits=signdig))^2) 
 
 
ic<-ic+3 
 
 }else { 
   
cscomp[ic+1,k]<-(signif(exdata 
[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[ic],digits=signdig
)*signif(exdata [i,l],digits=signdig)+at[ic]* signif(exdata[length(texp)+1,l],digits=signdig)* 
signif(dV[ic],digits=signdig)+ signif(exdata[length(texp)+3,l] ,digits=signdig)* signif(exdata 
[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)*dt[ic])/signif(Vt[ic+1],digits=signdig) 
A[ic+1]<-stdevmultsingle(signif(exdata [i,l],digits=signdig),signif(exdata 
[i,l+1],digits=signdig),signif(Vt[ic],digits=signdig),signif(sd.Vt[ic],digits=signdig)) 
A1[ic+1]<- signif(exdata[i,l],digits=signdig)*signif(Vt[ic],digits=signdig) 
B[ic+1]<-
(bt[ic]+ct[ic])*stdevmultsingle(signif(dV[ic],digits=signdig),signif(sd.dV[ic],digits=signdig),
signif(exdata[i,l],digits=signdig),signif(exdata [i,l+1],digits=signdig)) 
B1[ic+1]<-at[ic]*stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic],digits=signdig),signif(sd.dV[ic],digits=signdig)) 
B2[ic+1]<- stdevmultsingle(A1[ic+1], 
A[ic+1],signif(dt[ic],digits=signdig),signif(sd.dt[ic],digits=signdig)) 
B21[ic+1]<- signif(exdata 
[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)*signif(dt[ic],digits=signdig) 
B3[ic+1]<- stdevmultsingle(B21[ic+1], B2[ic+1], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+1]<-sqrt(A[ic+1]^2+B[ic+1]^2+B1[ic+1]^2+ B3[ic+1]^2) 
D[ic+1]<- 
(signif(exdata[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[ic],
digits=signdig)*signif(exdata[i,l],digits=signdig)+at[ic]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(exdata[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)*dt[ic]) 
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sd.cscomp[ic+1,k]<- 
cscomp[ic+1,k]*sqrt((C[ic+1]/D[ic+1])^2+(signif(sd.Vt[ic+1],digits=signdig)/signif(Vt[ic+1]
,digits=signdig))^2) 
 
cscomp[ic+2,k]<-
(signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*s
ignif(dV[ic+1],digits=signdig)*signif(cscomp[ic+1,k],digits=signdig)+at[ic+1]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+1],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)*dt[ic+1])/signif(Vt[ic
+2],digits=signdig) 
A[ic+2]<-
stdevmultsingle(signif(cscomp[ic+1,k],digits=signdig),signif(sd.cscomp[ic+1,k],digits=signdi
g),signif(Vt[ic+1],digits=signdig),signif(sd.Vt[ic+1],digits=signdig)) 
A1[ic+2]<- signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig) 
B[ic+2]<-
(bt[ic+1]+ct[ic+1])*stdevmultsingle(signif(dV[ic+1],digits=signdig),signif(sd.dV[ic+1],digits
=signdig), signif(cscomp[ic+1,k],digits=signdig),signif(sd.cscomp[ic+1,k],digits=signdig)) 
B1[ic+2]<-at[ic+1]* stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic+1],digits=signdig),signif(sd.dV[ic+1],digits=signdig)) 
B2[ic+2]<- stdevmultsingle(A1[ic+2], A[ic+2], 
signif(dt[ic+1],digits=signdig),signif(sd.dt[ic+1],digits=signdig)) 
B21[ic+2]<- 
signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)*signif(dt[ic+1],digits=
signdig) 
B3[ic+2]<- stdevmultsingle(B21[ic+2], B2[ic+2], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+2]<-sqrt(A[ic+2]^2+B[ic+2]^2+B1[ic+2]^2+ B3[ic+2]^2) 
D[ic+2]<- 
(signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*s
ignif(dV[ic+1],digits=signdig)*signif(cscomp[ic+1,k],digits=signdig)+at[ic+1]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+1],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)*dt[ic+1]) 
sd.cscomp[ic+2,k]<- 
cscomp[ic+2,k]*sqrt((C[ic+2]/D[ic+2])^2+(signif(sd.Vt[ic+2],digits=signdig)/signif(Vt[ic+2]
,digits=signdig))^2) 
 
cscomp[ic+3,k]<-
(signif(cscomp[ic+2,k],digits=signdig)*signif(Vt[ic+2],digits=signdig)+(bt[ic+2]+ct[ic+2])*s
ignif(dV[ic+2],digits=signdig)*signif(cscomp[ic+2,k],digits=signdig)+at[ic+2]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+2],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp[ic+2,k],digits=signdig)*signif(Vt[ic+2],digits=signdig)*dt[ic+2])/signif(Vt[ic
+3],digits=signdig) 
A[ic+3]<-
stdevmultsingle(signif(cscomp[ic+2,k],digits=signdig),signif(sd.cscomp[ic+2,k],digits=signdi
g),signif(Vt[ic+2],digits=signdig),signif(sd.Vt[ic+2],digits=signdig)) 
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A1[ic+3]<- signif(cscomp[ic+2,k],digits=signdig)*signif(Vt[ic+2],digits=signdig) 
B[ic+3]<-
(bt[ic+2]+ct[ic+2])*stdevmultsingle(signif(dV[ic+2],digits=signdig),signif(sd.dV[ic+2],digits
=signdig), signif(cscomp[ic+2,k],digits=signdig),signif(sd.cscomp[ic+2,k],digits=signdig)) 
B1[ic+3]<-at[ic+2]* stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic+2],digits=signdig),signif(sd.dV[ic+2],digits=signdig)) 
B2[ic+3]<- stdevmultsingle(A1[ic+3], A[ic+3], 
signif(dt[ic+2],digits=signdig),signif(sd.dt[ic+2],digits=signdig)) 
B21[ic+3]<- 
signif(cscomp[ic+2,k],digits=signdig)*signif(Vt[ic+2],digits=signdig)*signif(dt[ic+2],digits=
signdig) 
B3[ic+3]<- stdevmultsingle(B21[ic+3], B2[ic+3], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+3]<-sqrt(A[ic+3]^2+B[ic+3]^2+B1[ic+3]^2+ B3[ic+3]^2) 
D[ic+3]<- 
(signif(cscomp[ic+2,k],digits=signdig)*signif(Vt[ic+2],digits=signdig)+(bt[ic+2]+ct[ic+2])*s
ignif(dV[ic+2],digits=signdig)*signif(cscomp[ic+2,k],digits=signdig)+at[ic+2]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+2],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp[ic+2,k],digits=signdig)*signif(Vt[ic+2],digits=signdig)*dt[ic+2]) 
sd.cscomp[ic+3,k]<- 
cscomp[ic+3,k]*sqrt((C[ic+3]/D[ic+3])^2+(signif(sd.Vt[ic+3],digits=signdig)/signif(Vt[ic+3]
,digits=signdig))^2) 
 
cscomp[ic+4,k]<-
(signif(cscomp[ic+3,k],digits=signdig)*signif(Vt[ic+3],digits=signdig)+(bt[ic+3]+ct[ic+3])*s
ignif(dV[ic+3],digits=signdig)*signif(cscomp[ic+3,k],digits=signdig)+at[ic+3]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+3],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp[ic+3,k],digits=signdig)*signif(Vt[ic+3],digits=signdig)*dt[ic+3])/signif(Vt[ic
+4],digits=signdig) 
A[ic+4]<-
stdevmultsingle(signif(cscomp[ic+3,k],digits=signdig),signif(sd.cscomp[ic+3,k],digits=signdi
g),signif(Vt[ic+3],digits=signdig),signif(sd.Vt[ic+3],digits=signdig)) 
A1[ic+4]<- signif(cscomp[ic+3,k],digits=signdig)*signif(Vt[ic+3],digits=signdig) 
B[ic+4]<-
(bt[ic+3]+ct[ic+3])*stdevmultsingle(signif(dV[ic+3],digits=signdig),signif(sd.dV[ic+3],digits
=signdig), signif(cscomp[ic+3,k],digits=signdig),signif(sd.cscomp[ic+3,k],digits=signdig)) 
B1[ic+4]<-at[ic+3]* stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic+3],digits=signdig),signif(sd.dV[ic+3],digits=signdig)) 
B2[ic+4]<- stdevmultsingle(A1[ic+4], A[ic+4], 
signif(dt[ic+3],digits=signdig),signif(sd.dt[ic+3],digits=signdig)) 
B21[ic+4]<- 
signif(cscomp[ic+3,k],digits=signdig)*signif(Vt[ic+3],digits=signdig)*signif(dt[ic+3],digits=
signdig) 
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B3[ic+4]<- stdevmultsingle(B21[ic+4], B2[ic+4], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+4]<-sqrt(A[ic+4]^2+B[ic+4]^2+B1[ic+4]^2+ B3[ic+4]^2) 
D[ic+4]<- 
(signif(cscomp[ic+3,k],digits=signdig)*signif(Vt[ic+3],digits=signdig)+(bt[ic+3]+ct[ic+3])*s
ignif(dV[ic+3],digits=signdig)*signif(cscomp[ic+3,k],digits=signdig)+at[ic+3]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+3],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp[ic+3,k],digits=signdig)*signif(Vt[ic+3],digits=signdig)*dt[ic+3]) 
sd.cscomp[ic+4,k]<- 
cscomp[ic+4,k]*sqrt((C[ic+4]/D[ic+4])^2+(signif(sd.Vt[ic+4],digits=signdig)/signif(Vt[ic+4]
,digits=signdig))^2) 
 
cscomp[ic+5,k]<-
(signif(cscomp[ic+4,k],digits=signdig)*signif(Vt[ic+4],digits=signdig)+(bt[ic+4]+ct[ic+4])*s
ignif(dV[ic+4],digits=signdig)*signif(cscomp[ic+4,k],digits=signdig)+at[ic+4]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+4],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp[ic+4,k],digits=signdig)*signif(Vt[ic+4],digits=signdig)*dt[ic+4])/signif(Vt[ic
+5],digits=signdig) 
A[ic+5]<-
stdevmultsingle(signif(cscomp[ic+4,k],digits=signdig),signif(sd.cscomp[ic+4,k],digits=signdi
g),signif(Vt[ic+4],digits=signdig),signif(sd.Vt[ic+4],digits=signdig)) 
A1[ic+5]<- signif(cscomp[ic+4,k],digits=signdig)*signif(Vt[ic+4],digits=signdig) 
B[ic+5]<-
(bt[ic+4]+ct[ic+4])*stdevmultsingle(signif(dV[ic+4],digits=signdig),signif(sd.dV[ic+4],digits
=signdig), signif(cscomp[ic+4,k],digits=signdig),signif(sd.cscomp[ic+4,k],digits=signdig)) 
B1[ic+5]<-at[ic+4]* stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic+4],digits=signdig),signif(sd.dV[ic+4],digits=signdig)) 
B2[ic+5]<- stdevmultsingle(A1[ic+5], A[ic+5], 
signif(dt[ic+4],digits=signdig),signif(sd.dt[ic+4],digits=signdig)) 
B21[ic+5]<- 
signif(cscomp[ic+4,k],digits=signdig)*signif(Vt[ic+4],digits=signdig)*signif(dt[ic+4],digits=
signdig) 
B3[ic+5]<- stdevmultsingle(B21[ic+5], B2[ic+5], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+5]<-sqrt(A[ic+5]^2+B[ic+5]^2+B1[ic+5]^2+ B3[ic+5]^2) 
D[ic+5]<- 
(signif(cscomp[ic+4,k],digits=signdig)*signif(Vt[ic+4],digits=signdig)+(bt[ic+4]+ct[ic+4])*s
ignif(dV[ic+4],digits=signdig)*signif(cscomp[ic+4,k],digits=signdig)+at[ic+4]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+4],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp[ic+4,k],digits=signdig)*signif(Vt[ic+4],digits=signdig)*dt[ic+4]) 
sd.cscomp[ic+5,k]<- 
cscomp[ic+5,k]*sqrt((C[ic+5]/D[ic+5])^2+(signif(sd.Vt[ic+5],digits=signdig)/signif(Vt[ic+5]
,digits=signdig))^2) 
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cscomp[ic+6,k]<-
(signif(cscomp[ic+5,k],digits=signdig)*signif(Vt[ic+5],digits=signdig)+(bt[ic+5]+ct[ic+5])*s
ignif(dV[ic+5],digits=signdig)*signif(cscomp[ic+5,k],digits=signdig)+at[ic+5]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+5],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp[ic+5,k],digits=signdig)*signif(Vt[ic+5],digits=signdig)*dt[ic+5])/signif(Vt[ic
+6],digits=signdig) 
A[ic+6]<-
stdevmultsingle(signif(cscomp[ic+5,k],digits=signdig),signif(sd.cscomp[ic+5,k],digits=signdi
g),signif(Vt[ic+5],digits=signdig),signif(sd.Vt[ic+5],digits=signdig)) 
A1[ic+6]<- signif(cscomp[ic+5,k],digits=signdig)*signif(Vt[ic+5],digits=signdig) 
B[ic+6]<-
(bt[ic+5]+ct[ic+5])*stdevmultsingle(signif(dV[ic+5],digits=signdig),signif(sd.dV[ic+5],digits
=signdig), signif(cscomp[ic+5,k],digits=signdig),signif(sd.cscomp[ic+5,k],digits=signdig)) 
B1[ic+6]<-at[ic+5]* stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic+5],digits=signdig),signif(sd.dV[ic+5],digits=signdig)) 
B2[ic+6]<- stdevmultsingle(A1[ic+6], A[ic+6], 
signif(dt[ic+5],digits=signdig),signif(sd.dt[ic+5],digits=signdig)) 
B21[ic+6]<- 
signif(cscomp[ic+5,k],digits=signdig)*signif(Vt[ic+5],digits=signdig)*signif(dt[ic+5],digits=
signdig) 
B3[ic+6]<- stdevmultsingle(B21[ic+6], B2[ic+6], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+6]<-sqrt(A[ic+6]^2+B[ic+6]^2+B1[ic+6]^2+ B3[ic+6]^2) 
D[ic+6]<- 
(signif(cscomp[ic+5,k],digits=signdig)*signif(Vt[ic+5],digits=signdig)+(bt[ic+5]+ct[ic+5])*s
ignif(dV[ic+5],digits=signdig)*signif(cscomp[ic+5,k],digits=signdig)+at[ic+5]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+5],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp[ic+5,k],digits=signdig)*signif(Vt[ic+5],digits=signdig)*dt[ic+5]) 
sd.cscomp[ic+6,k]<- 
cscomp[ic+6,k]*sqrt((C[ic+6]/D[ic+6])^2+(signif(sd.Vt[ic+6],digits=signdig)/signif(Vt[ic+6]
,digits=signdig))^2) 
 
 
 
  nf1<-nf1+1 
  ic<-ic+7 
  } 
 } 
} 
 
}else{ 
 
A<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
A1<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
A2<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
B<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
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B1<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
B2<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
B21<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
B3<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
C<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
D<-rep(0,tharvest+1+2* ns[length(ns)]+4*nf[length(nf)]) 
 
nf1<-1 
ic<-2 
for (i in (2:length(texp))){ 
cscomp[ic,k]<-signif(exdata [i,l],digits=signdig) 
sd.cscomp[ic,k]<-signif(exdata [i,l+1],digits=signdig) 
 
if(i!=length(texp)) { 
 if(i!=(nf1*fint)+1){ 
 
cscomp[ic+1,k]<-
(signif(exdata[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[ic],
digits=signdig)*signif(exdata[i,l],digits=signdig)+at[ic]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(exdata$Gln[i],digits=signdig)*signif(Vt[ic],digits=signdig)*dt[ic])/signif(Vt[ic+1],digi
ts=signdig) 
A[ic+1]<-
stdevmultsingle(signif(exdata[i,l],digits=signdig),signif(exdata[i,l+1],digits=signdig),signif(V
t[ic],digits=signdig),signif(sd.Vt[ic],digits=signdig)) 
A1[ic+1]<- signif(exdata$Gln[i],digits=signdig)*signif(Vt[ic],digits=signdig) 
A2[ic+1]<- 
stdevmultsingle(signif(exdata$Gln[i],digits=signdig),signif(exdata$sd.Gln[i],digits=signdig),
signif(Vt[ic],digits=signdig),signif(sd.Vt[ic],digits=signdig)) 
B[ic+1]<-
(bt[ic]+ct[ic])*stdevmultsingle(signif(dV[ic],digits=signdig),signif(sd.dV[ic],digits=signdig),
signif(exdata[i,l],digits=signdig),signif(exdata [i,l+1],digits=signdig)) 
B1[ic+1]<-at[ic]*stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic],digits=signdig),signif(sd.dV[ic],digits=signdig)) 
B2[ic+1]<- stdevmultsingle(A1[ic+1], 
A2[ic+1],signif(dt[ic],digits=signdig),signif(sd.dt[ic],digits=signdig)) 
B21[ic+1]<- A1[ic+1]*signif(dt[ic],digits=signdig) 
B3[ic+1]<- stdevmultsingle(B21[ic+1], B2[ic+1], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+1]<-sqrt(A[ic+1]^2+B[ic+1]^2+B1[ic+1]^2+ B3[ic+1]^2) 
D[ic+1]<- 
(signif(exdata[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[ic],
digits=signdig)*signif(exdata[i,l],digits=signdig)+at[ic]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(exdata$Gln[i],digits=signdig)*signif(Vt[ic],digits=signdig)*dt[ic]) 
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sd.cscomp[ic+1,k]<- 
cscomp[ic+1,k]*sqrt((C[ic+1]/D[ic+1])^2+(signif(sd.Vt[ic+1],digits=signdig)/signif(Vt[ic+1]
,digits=signdig))^2) 
 
cscomp[ic+2,k]<-
(signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*s
ignif(dV[ic+1],digits=signdig)*signif(cscomp[ic+1,k],digits=signdig)+at[ic+1]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+1],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp$Gln[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig)*dt[ic+1])/signif(Vt[
ic+2],digits=signdig) 
A[ic+2]<-
stdevmultsingle(signif(cscomp[ic+1,k],digits=signdig),signif(sd.cscomp[ic+1,k],digits=signdi
g),signif(Vt[ic+1],digits=signdig),signif(sd.Vt[ic+1],digits=signdig)) 
A1[ic+2]<- signif(cscomp$Gln[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig) 
A2[ic+2]<- 
stdevmultsingle(signif(cscomp$Gln[ic+1],digits=signdig),sd.cscomp$sd.Gln[ic+1],signif(Vt[i
c+1],digits=signdig),signif(sd.Vt[ic+1],digits=signdig)) 
B[ic+2]<-
(bt[ic+1]+ct[ic+1])*stdevmultsingle(signif(dV[ic+1],digits=signdig),signif(sd.dV[ic+1],digits
=signdig), signif(cscomp[ic+1,k],digits=signdig),signif(sd.cscomp[ic+1,k],digits=signdig)) 
B1[ic+2]<-at[ic+1]* stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic+1],digits=signdig),signif(sd.dV[ic+1],digits=signdig)) 
B2[ic+2]<- stdevmultsingle(A1[ic+2], A2[ic+2], 
signif(dt[ic+1],digits=signdig),signif(sd.dt[ic+1],digits=signdig)) 
B21[ic+2]<- A1[ic+2]*signif(dt[ic+1],digits=signdig) 
B3[ic+2]<- stdevmultsingle(B21[ic+2], B2[ic+2], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+2]<-sqrt(A[ic+2]^2+B[ic+2]^2+B1[ic+2]^2+ B3[ic+2]^2) 
D[ic+2]<- 
(signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*s
ignif(dV[ic+1],digits=signdig)*signif(cscomp[ic+1,k],digits=signdig)+at[ic+1]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+1],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp$Gln[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig)*dt[ic+1]) 
sd.cscomp[ic+2,k]<- 
cscomp[ic+2,k]*sqrt((C[ic+2]/D[ic+2])^2+(signif(sd.Vt[ic+2],digits=signdig)/signif(Vt[ic+2]
,digits=signdig))^2) 
 
 
  ic<-ic+3 
 
 }else { 
   
cscomp[ic+1,k]<-(signif(exdata 
[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[ic],digits=signdig
)*signif(exdata [i,l],digits=signdig)+at[ic]* signif(exdata[length(texp)+1,l],digits=signdig)* 
signif(dV[ic],digits=signdig)+ signif(exdata[length(texp)+3,l] ,digits=signdig)* 
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signif(exdata$Gln[i],digits=signdig)*signif(Vt[ic],digits=signdig)*dt[ic])/signif(Vt[ic+1],digi
ts=signdig) 
A[ic+1]<-stdevmultsingle(signif(exdata [i,l],digits=signdig),signif(exdata 
[i,l+1],digits=signdig),signif(Vt[ic],digits=signdig),signif(sd.Vt[ic],digits=signdig)) 
A1[ic+1]<- signif(exdata$Gln[i],digits=signdig)*signif(Vt[ic],digits=signdig) 
A2[ic+1]<- 
stdevmultsingle(signif(exdata$Gln[i],digits=signdig),signif(exdata$sd.Gln[i],digits=signdig),
signif(Vt[ic],digits=signdig),signif(sd.Vt[ic],digits=signdig)) 
B[ic+1]<-
(bt[ic]+ct[ic])*stdevmultsingle(signif(dV[ic],digits=signdig),signif(sd.dV[ic],digits=signdig),
signif(exdata[i,l],digits=signdig),signif(exdata [i,l+1],digits=signdig)) 
B1[ic+1]<-at[ic]*stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic],digits=signdig),signif(sd.dV[ic],digits=signdig)) 
B2[ic+1]<- stdevmultsingle(A1[ic+1], 
A2[ic+1],signif(dt[ic],digits=signdig),signif(sd.dt[ic],digits=signdig)) 
B21[ic+1]<- A1[ic+1]*signif(dt[ic],digits=signdig) 
B3[ic+1]<- stdevmultsingle(B21[ic+1], B2[ic+1], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+1]<-sqrt(A[ic+1]^2+B[ic+1]^2+B1[ic+1]^2+ B3[ic+1]^2) 
D[ic+1]<- 
(signif(exdata[i,l],digits=signdig)*signif(Vt[ic],digits=signdig)+(bt[ic]+ct[ic])*signif(dV[ic],
digits=signdig)*signif(exdata[i,l],digits=signdig)+at[ic]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(exdata$Gln[i],digits=signdig)*signif(Vt[ic],digits=signdig)*dt[ic]) 
sd.cscomp[ic+1,k]<- 
cscomp[ic+1,k]*sqrt((C[ic+1]/D[ic+1])^2+(signif(sd.Vt[ic+1],digits=signdig)/signif(Vt[ic+1]
,digits=signdig))^2) 
 
cscomp[ic+2,k]<-
(signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*s
ignif(dV[ic+1],digits=signdig)*signif(cscomp[ic+1,k],digits=signdig)+at[ic+1]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+1],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp$Gln[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig)*dt[ic+1])/signif(Vt[
ic+2],digits=signdig) 
A[ic+2]<-
stdevmultsingle(signif(cscomp[ic+1,k],digits=signdig),signif(sd.cscomp[ic+1,k],digits=signdi
g),signif(Vt[ic+1],digits=signdig),signif(sd.Vt[ic+1],digits=signdig)) 
A1[ic+2]<- signif(cscomp$Gln[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig) 
A2[ic+2]<- 
stdevmultsingle(signif(cscomp$Gln[ic+1],digits=signdig),sd.cscomp$sd.Gln[ic+1],signif(Vt[i
c+1],digits=signdig),signif(sd.Vt[ic+1],digits=signdig)) 
B[ic+2]<-
(bt[ic+1]+ct[ic+1])*stdevmultsingle(signif(dV[ic+1],digits=signdig),signif(sd.dV[ic+1],digits
=signdig), signif(cscomp[ic+1,k],digits=signdig),signif(sd.cscomp[ic+1,k],digits=signdig)) 
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B1[ic+2]<-at[ic+1]* stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic+1],digits=signdig),signif(sd.dV[ic+1],digits=signdig)) 
B2[ic+2]<- stdevmultsingle(A1[ic+2], A2[ic+2], 
signif(dt[ic+1],digits=signdig),signif(sd.dt[ic+1],digits=signdig)) 
B21[ic+2]<- A1[ic+2]*signif(dt[ic+1],digits=signdig) 
B3[ic+2]<- stdevmultsingle(B21[ic+2], B2[ic+2], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+2]<-sqrt(A[ic+2]^2+B[ic+2]^2+B1[ic+2]^2+ B3[ic+2]^2) 
D[ic+2]<- 
(signif(cscomp[ic+1,k],digits=signdig)*signif(Vt[ic+1],digits=signdig)+(bt[ic+1]+ct[ic+1])*s
ignif(dV[ic+1],digits=signdig)*signif(cscomp[ic+1,k],digits=signdig)+at[ic+1]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+1],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp$Gln[ic+1],digits=signdig)*signif(Vt[ic+1],digits=signdig)*dt[ic+1]) 
sd.cscomp[ic+2,k]<- 
cscomp[ic+2,k]*sqrt((C[ic+2]/D[ic+2])^2+(signif(sd.Vt[ic+2],digits=signdig)/signif(Vt[ic+2]
,digits=signdig))^2) 
 
cscomp[ic+3,k]<-
(signif(cscomp[ic+2,k],digits=signdig)*signif(Vt[ic+2],digits=signdig)+(bt[ic+2]+ct[ic+2])*s
ignif(dV[ic+2],digits=signdig)*signif(cscomp[ic+2,k],digits=signdig)+at[ic+2]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+2],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp$Gln[ic+2],digits=signdig)*signif(Vt[ic+2],digits=signdig)*dt[ic+2])/signif(Vt[
ic+3],digits=signdig) 
A[ic+3]<-
stdevmultsingle(signif(cscomp[ic+2,k],digits=signdig),signif(sd.cscomp[ic+2,k],digits=signdi
g),signif(Vt[ic+2],digits=signdig),signif(sd.Vt[ic+2],digits=signdig)) 
A1[ic+3]<- signif(cscomp$Gln[ic+2],digits=signdig)*signif(Vt[ic+2],digits=signdig) 
A2[ic+3]<- 
stdevmultsingle(signif(cscomp$Gln[ic+2],digits=signdig),sd.cscomp$sd.Gln[ic+2],signif(Vt[i
c+2],digits=signdig),signif(sd.Vt[ic+2],digits=signdig)) 
B[ic+3]<-
(bt[ic+2]+ct[ic+2])*stdevmultsingle(signif(dV[ic+2],digits=signdig),signif(sd.dV[ic+2],digits
=signdig), signif(cscomp[ic+2,k],digits=signdig),signif(sd.cscomp[ic+2,k],digits=signdig)) 
B1[ic+3]<-at[ic+2]* stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic+2],digits=signdig),signif(sd.dV[ic+2],digits=signdig)) 
B2[ic+3]<- stdevmultsingle(A1[ic+3], A2[ic+3], 
signif(dt[ic+2],digits=signdig),signif(sd.dt[ic+2],digits=signdig)) 
B21[ic+3]<- A1[ic+3]*signif(dt[ic+2],digits=signdig) 
B3[ic+3]<- stdevmultsingle(B21[ic+3], B2[ic+3], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+3]<-sqrt(A[ic+3]^2+B[ic+3]^2+B1[ic+3]^2+ B3[ic+3]^2) 
D[ic+3]<- 
(signif(cscomp[ic+2,k],digits=signdig)*signif(Vt[ic+2],digits=signdig)+(bt[ic+2]+ct[ic+2])*s
ignif(dV[ic+2],digits=signdig)*signif(cscomp[ic+2,k],digits=signdig)+at[ic+2]* 
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signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+2],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp$Gln[ic+2],digits=signdig)*signif(Vt[ic+2],digits=signdig)*dt[ic+2]) 
sd.cscomp[ic+3,k]<- 
cscomp[ic+3,k]*sqrt((C[ic+3]/D[ic+3])^2+(signif(sd.Vt[ic+3],digits=signdig)/signif(Vt[ic+3]
,digits=signdig))^2) 
 
cscomp[ic+4,k]<-
(signif(cscomp[ic+3,k],digits=signdig)*signif(Vt[ic+3],digits=signdig)+(bt[ic+3]+ct[ic+3])*s
ignif(dV[ic+3],digits=signdig)*signif(cscomp[ic+3,k],digits=signdig)+at[ic+3]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+3],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp$Gln[ic+3],digits=signdig)*signif(Vt[ic+3],digits=signdig)*dt[ic+3])/signif(Vt[
ic+4],digits=signdig) 
A[ic+4]<-
stdevmultsingle(signif(cscomp[ic+3,k],digits=signdig),signif(sd.cscomp[ic+3,k],digits=signdi
g),signif(Vt[ic+3],digits=signdig),signif(sd.Vt[ic+3],digits=signdig)) 
A1[ic+4]<- signif(cscomp$Gln[ic+3],digits=signdig)*signif(Vt[ic+3],digits=signdig) 
A2[ic+4]<- 
stdevmultsingle(signif(cscomp$Gln[ic+3],digits=signdig),sd.cscomp$sd.Gln[ic+3],signif(Vt[i
c+3],digits=signdig),signif(sd.Vt[ic+3],digits=signdig)) 
B[ic+4]<-
(bt[ic+3]+ct[ic+3])*stdevmultsingle(signif(dV[ic+3],digits=signdig),signif(sd.dV[ic+3],digits
=signdig), signif(cscomp[ic+3,k],digits=signdig),signif(sd.cscomp[ic+3,k],digits=signdig)) 
B1[ic+4]<-at[ic+3]* stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic+3],digits=signdig),signif(sd.dV[ic+3],digits=signdig)) 
B2[ic+4]<- stdevmultsingle(A1[ic+4], A2[ic+4], 
signif(dt[ic+3],digits=signdig),signif(sd.dt[ic+3],digits=signdig)) 
B21[ic+4]<- A1[ic+4]*signif(dt[ic+3],digits=signdig) 
B3[ic+4]<- stdevmultsingle(B21[ic+4], B2[ic+4], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+4]<-sqrt(A[ic+4]^2+B[ic+4]^2+B1[ic+4]^2+ B3[ic+4]^2) 
D[ic+4]<- 
(signif(cscomp[ic+3,k],digits=signdig)*signif(Vt[ic+3],digits=signdig)+(bt[ic+3]+ct[ic+3])*s
ignif(dV[ic+3],digits=signdig)*signif(cscomp[ic+3,k],digits=signdig)+at[ic+3]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+3],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp$Gln[ic+3],digits=signdig)*signif(Vt[ic+3],digits=signdig)*dt[ic+3]) 
sd.cscomp[ic+4,k]<- 
cscomp[ic+4,k]*sqrt((C[ic+4]/D[ic+4])^2+(signif(sd.Vt[ic+4],digits=signdig)/signif(Vt[ic+4]
,digits=signdig))^2) 
 
cscomp[ic+5,k]<-
(signif(cscomp[ic+4,k],digits=signdig)*signif(Vt[ic+4],digits=signdig)+(bt[ic+4]+ct[ic+4])*s
ignif(dV[ic+4],digits=signdig)*signif(cscomp[ic+4,k],digits=signdig)+at[ic+4]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+4],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
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signif(cscomp$Gln[ic+4],digits=signdig)*signif(Vt[ic+4],digits=signdig)*dt[ic+4])/signif(Vt[
ic+5],digits=signdig) 
A[ic+5]<-
stdevmultsingle(signif(cscomp[ic+4,k],digits=signdig),signif(sd.cscomp[ic+4,k],digits=signdi
g),signif(Vt[ic+4],digits=signdig),signif(sd.Vt[ic+4],digits=signdig)) 
A1[ic+5]<- signif(cscomp$Gln[ic+2],digits=signdig)*signif(Vt[ic+4],digits=signdig) 
A2[ic+5]<- 
stdevmultsingle(signif(cscomp$Gln[ic+4],digits=signdig),sd.cscomp$sd.Gln[ic+4],signif(Vt[i
c+4],digits=signdig),signif(sd.Vt[ic+4],digits=signdig)) 
B[ic+5]<-
(bt[ic+4]+ct[ic+4])*stdevmultsingle(signif(dV[ic+4],digits=signdig),signif(sd.dV[ic+4],digits
=signdig), signif(cscomp[ic+4,k],digits=signdig),signif(sd.cscomp[ic+4,k],digits=signdig)) 
B1[ic+5]<-at[ic+4]* stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic+4],digits=signdig),signif(sd.dV[ic+4],digits=signdig)) 
B2[ic+5]<- stdevmultsingle(A1[ic+5], A[ic+5], 
signif(dt[ic+4],digits=signdig),signif(sd.dt[ic+4],digits=signdig)) 
B21[ic+5]<- A1[ic+5]*signif(dt[ic+4],digits=signdig) 
B3[ic+5]<- stdevmultsingle(B21[ic+5], B2[ic+5], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+5]<-sqrt(A[ic+5]^2+B[ic+5]^2+B1[ic+5]^2+ B3[ic+5]^2) 
D[ic+5]<- 
(signif(cscomp[ic+4,k],digits=signdig)*signif(Vt[ic+4],digits=signdig)+(bt[ic+4]+ct[ic+4])*s
ignif(dV[ic+4],digits=signdig)*signif(cscomp[ic+4,k],digits=signdig)+at[ic+4]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+4],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp$Gln[ic+4],digits=signdig)*signif(Vt[ic+4],digits=signdig)*dt[ic+4]) 
sd.cscomp[ic+5,k]<- 
cscomp[ic+5,k]*sqrt((C[ic+5]/D[ic+5])^2+(signif(sd.Vt[ic+5],digits=signdig)/signif(Vt[ic+5]
,digits=signdig))^2) 
 
cscomp[ic+6,k]<-
(signif(cscomp[ic+5,k],digits=signdig)*signif(Vt[ic+5],digits=signdig)+(bt[ic+5]+ct[ic+5])*s
ignif(dV[ic+5],digits=signdig)*signif(cscomp[ic+5,k],digits=signdig)+at[ic+5]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+5],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp$Gln[ic+5],digits=signdig)*signif(Vt[ic+5],digits=signdig)*dt[ic+5])/signif(Vt[
ic+6],digits=signdig) 
A[ic+6]<-
stdevmultsingle(signif(cscomp[ic+5,k],digits=signdig),signif(sd.cscomp[ic+5,k],digits=signdi
g),signif(Vt[ic+5],digits=signdig),signif(sd.Vt[ic+5],digits=signdig)) 
A1[ic+6]<- signif(cscomp$Gln[ic+5],digits=signdig)*signif(Vt[ic+5],digits=signdig) 
A2[ic+6]<- 
stdevmultsingle(signif(cscomp$Gln[ic+5],digits=signdig),sd.cscomp$sd.Gln[ic+5],signif(Vt[i
c+5],digits=signdig),signif(sd.Vt[ic+5],digits=signdig)) 
B[ic+6]<-
(bt[ic+5]+ct[ic+5])*stdevmultsingle(signif(dV[ic+5],digits=signdig),signif(sd.dV[ic+5],digits
=signdig), signif(cscomp[ic+5,k],digits=signdig),signif(sd.cscomp[ic+5,k],digits=signdig)) 
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B1[ic+6]<-at[ic+5]* stdevmultsingle(signif(exdata[length(texp)+1,l],digits=signdig), 
signif(exdata[length(texp)+2,l],digits=signdig), 
signif(dV[ic+5],digits=signdig),signif(sd.dV[ic+5],digits=signdig)) 
B2[ic+6]<- stdevmultsingle(A1[ic+6], A[ic+6], 
signif(dt[ic+5],digits=signdig),signif(sd.dt[ic+5],digits=signdig)) 
B21[ic+6]<- A1[ic+6]*signif(dt[ic+5],digits=signdig) 
B3[ic+6]<- stdevmultsingle(B21[ic+6], B2[ic+6], 
signif(exdata[length(texp)+3,l],digits=signdig), 
signif(exdata[length(texp)+4,l],digits=signdig))   
C[ic+6]<-sqrt(A[ic+6]^2+B[ic+6]^2+B1[ic+6]^2+ B3[ic+6]^2) 
D[ic+6]<- 
(signif(cscomp[ic+5,k],digits=signdig)*signif(Vt[ic+5],digits=signdig)+(bt[ic+5]+ct[ic+5])*s
ignif(dV[ic+5],digits=signdig)*signif(cscomp[ic+5,k],digits=signdig)+at[ic+5]* 
signif(exdata[length(texp)+1,l],digits=signdig)* signif(dV[ic+5],digits=signdig)+ 
signif(exdata[length(texp)+3,l] ,digits=signdig)* 
signif(cscomp$Gln[ic+5],digits=signdig)*signif(Vt[ic+5],digits=signdig)*dt[ic+5]) 
sd.cscomp[ic+6,k]<- 
cscomp[ic+6,k]*sqrt((C[ic+6]/D[ic+6])^2+(signif(sd.Vt[ic+6],digits=signdig)/signif(Vt[ic+6]
,digits=signdig))^2) 
 
  nf1<-nf1+1 
  ic<-ic+7 
  } 
 } 
} 
} 
k<-k+1 
} 
 
CV<-cscomp*Vt 
for (l in (1:ncol(cscomp))){ 
for(i in 1:length(tcomp)){ 
if(is.nan(CV[i,l])) 
{ 
CV[i,l]<-0 
}else{ 
CV[i,l]} 
}} 
 
sd.CV<-cscomp*Vt*sqrt((sd.cscomp/cscomp)^2+(sd.Vt/Vt)^2) 
 
for (l in (1:ncol(cscomp))){ 
for(i in 1:length(tcomp)){ 
if(is.nan(sd.CV[i,l])) 
{ 
sd.CV[i,l]<-0 
}else{ 
sd.CV[i,l]} 
}} 
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dCV<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.dCV<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
CVover2<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.CVover2<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
 
for (l in (1:ncol(cscomp))){ 
dCV[,l]<-c(CV[1,l],rep(0,length(tcomp)-1)) 
sd.dCV[,l]<-c(sd.CV[1,l],rep(0,length(tcomp)-1)) 
 
for(i in 2:length(tcomp)){ 
dCV[i,l]<-CV[i,l]-CV[i-1,l]+dCV[i-1,l] 
sd.dCV[i,l]<-sqrt(sd.CV[i,l]^2+sd.CV[i-1,l]^2+sd.dCV[i-1,l]^2) 
if(is.nan(sd.dCV[i,l])) 
{ 
sd.dCV[i,l]<-0 
}else{ 
sd.dCV[i,l] 
} 
} 
 
CVover2[,l]<-sumcolover2(CV[,l]) 
sd.CVover2[,l]<-stdevsumcol(sd.CV[,l])/2 
 
} 
 
colnames(dCV)<-namecscomp 
colnames(sd.dCV)<-namesd.cscomp 
 
CVover2dt<-CVover2*dt 
 
sd.CVover2dt<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
for (l in (1:ncol(cscomp))){ 
sd.CVover2dt[,l]<-stdevmult(CVover2[,l],sd.CVover2[,l],dt,sd.dt) 
} 
 
colnames(CVover2dt)<-namecscomp 
colnames(sd.CVover2dt)<-namesd.cscomp 
 
## for Gln ONLY 
IM<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.IM<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
 
for (l in (1:ncol(cscomp))){ 
IM[,l]<-trapintegmul2(CVover2dt$Gln) 
sd.IM[,l]<-sd.trapintegmul2(sd.CVover2dt$sd.Gln) 
} 
colnames(IM)<-namecscomp 
colnames(sd.IM)<-namesd.cscomp 
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kIM<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.kIM<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
kdegrad<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.kdegrad<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
 
l<-1 
for (k in seq(8,ncol(exdata),by=2)){ 
kIM[,l]<-IM[,l]*signif(exdata[length(texp)+3,k],digits=signdig) 
kdegrad[,l]<-signif(exdata[length(texp)+3,k] ,digits=signdig) 
sd.kdegrad[,l]<-signif(exdata[length(texp)+4,k] ,digits=signdig) 
sd.kIM[,l]<-stdevmult(IM[,l],sd.IM[,l],kdegrad[,l],sd.kdegrad[,l]) 
l<-l+1 
} 
 
colnames(kIM)<-namecscomp 
colnames(sd.kIM)<-namesd.cscomp 
colnames(kdegrad)<-namecscomp 
colnames(sd.kdegrad)<-namesd.cscomp 
 
kIMexp<-data.frame(matrix(0,nrow=length(texp),ncol=(ncol(exdata)-7)/2)) 
sd.kIMexp<-data.frame(matrix(0,nrow=length(texp),ncol=(ncol(exdata)-7)/2)) 
 
for (l in (1:ncol(cscomp))){ 
kIMexp[,l]<-c(kIM[1,l],rep(0,length(texp)-1)) 
sd.kIMexp[,l]<-c(sd.kIM[1,l],rep(0,length(texp)-1)) 
nf1<-1 
ic<-2 
for (i in (2:length(texp))){ 
kIMexp[i,l]<-kIM[ic,l] 
sd.kIMexp[i,l]<-sd.kIM[ic,l] 
 if(i!=length(texp)) { 
  if(i!=(nf1*fint)+1){ 
  kIMexp[i,l]<-kIM[ic,l] 
  sd.kIMexp[i,l]<-sd.kIM[ic,l] 
  ic<-ic+3 
   }else{nf1<-nf1+1 
    kIMexp[i,l]<-kIM[ic,l] 
    sd.kIMexp[i,l]<-sd.kIM[ic,l] 
    ic<-ic+7 
    } 
    } 
} 
} 
 
colnames(kIMexp)<-namecscomp 
colnames(sd.kIMexp)<-namesd.cscomp 
 
 
aFinCin<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
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sd.aFinCin<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
FINs<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.FINs<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
CINs<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.CINs<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
 
l<-1 
for (k in seq(8,ncol(exdata),by=2)){ 
aFinCin[,l]<-at*FIN*signif(exdata[length(texp)+1,k],digits=signdig) 
FINs[,l]<-FIN 
sd.FINs[,l]<-sd.FIN 
CINs[,l]<-signif(exdata[length(texp)+1,k] ,digits=signdig) 
sd.CINs[,l]<-signif(exdata[length(texp)+2,k] ,digits=signdig) 
sd.aFinCin[,l]<-at*stdevmult(FINs[,l],sd.FINs[,l],CINs[,l],sd.CINs[,l]) 
l<-l+1 
} 
 
colnames(aFinCin)<-namecscomp 
colnames(sd.aFinCin)<-namesd.cscomp 
colnames(CINs)<-namecscomp 
colnames(sd.CINs)<-namesd.cscomp 
 
bFoutC<-bt*cscomp*sFOUT 
sd.bFoutC<-bFoutC*sqrt((sd.cscomp/cscomp)^2+(sd.sFOUT/sFOUT)^2) 
cFoutafFC<-ct*cscomp*safFFOUT 
sd.cFoutafFC<-
cscomp*safFFOUT*ct*sqrt((sd.cscomp/cscomp)^2+(sd.safFFOUT/safFFOUT)^2) 
 
aFinCinover2<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.aFinCinover2<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
bFoutCover2<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.bFoutCover2<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
cFoutafFCover2<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.cFoutafFCover2<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
 
for (l in (1:ncol(cscomp))){ 
 
aFinCinover2[,l]<-sumcolover2(aFinCin[,l]) 
sd.aFinCinover2[,l]<-stdevsumcol(sd.aFinCin[,l])/2 
 
bFoutCover2[,l]<-sumcolover2(bFoutC[,l]) 
sd.bFoutCover2[,l]<-stdevsumcol(sd.bFoutC[,l])/2 
 
cFoutafFCover2[,l]<-sumcolover2(cFoutafFC[,l]) 
sd.cFoutafFCover2[,l]<-stdevsumcol(sd.cFoutafFC[,l])/2 
 
} 
 
aFinCinover2dt<-aFinCinover2*dt 
bFoutCover2dt<-bFoutCover2*dt 
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cFoutafFCover2dt<-cFoutafFCover2*dt 
 
sd.aFinCinover2dt<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.bFoutCover2dt<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.cFoutafFCover2dt<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
 
 
for (l in (1:ncol(cscomp))){ 
sd.aFinCinover2dt[,l]<-stdevmult(aFinCinover2[,l],sd.aFinCinover2[,l],dt,sd.dt) 
sd.bFoutCover2dt[,l]<-stdevmult(bFoutCover2[,l],sd.bFoutCover2[,l],dt,sd.dt) 
sd.cFoutafFCover2dt[,l]<-stdevmult(cFoutafFCover2[,l],sd.cFoutafFCover2[,l],dt,sd.dt) 
} 
 
SaFinCin<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.SaFinCin<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
SbFoutCdt<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.SbFoutCdt<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
ScFoutafFCdt<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.ScFoutafFCdt<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
 
for (l in (1:ncol(cscomp))){ 
SaFinCin[,l]<-trapintegmul2(aFinCinover2dt[,l]) 
sd.SaFinCin[,l]<-sd.trapintegmul2(sd.aFinCinover2dt[,l]) 
SbFoutCdt[,l]<-trapintegmul2(bFoutCover2dt[,l]) 
sd.SbFoutCdt[,l]<-sd.trapintegmul2(sd.bFoutCover2dt[,l]) 
ScFoutafFCdt[,l]<-trapintegmul2(cFoutafFCover2dt[,l]) 
sd.ScFoutafFCdt[,l]<-sd.trapintegmul2(sd.cFoutafFCover2dt[,l]) 
} 
 
 
deltacs<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.deltacs<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.deltacs2<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
currentcs<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.currentcs<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
sd.currentcs2<-data.frame(matrix(0,nrow=length(tcomp),ncol=(ncol(exdata)-7)/2)) 
 
 
for (l in (1:ncol(cscomp))){ 
currentcs[1,l]<-CV[1,l] 
sd.currentcs[1,l]<-sd.CV[1,l] 
sd.currentcs2[1,l]<-sd.dCV[1,l] 
for(i in 2:length(tcomp)){ 
 
deltacs[i,l]<-CV[i,l]-CV[i-1,l]+SaFinCin[i-1,l]-SaFinCin[i,l]+SbFoutCdt[i,l]-SbFoutCdt[i-
1,l]+ScFoutafFCdt[i,l]-ScFoutafFCdt[i-1,l]+kIM[i-1,l]-kIM[i,l] 
sd.deltacs[i,l]<-sqrt(sd.CV[i,l]^2+sd.CV[i-1,l]^2+sd.SaFinCin[i-
1,l]^2+sd.SaFinCin[i,l]^2+sd.SbFoutCdt[i,l]^2+sd.SbFoutCdt[i-
1,l]^2+sd.ScFoutafFCdt[i,l]^2+sd.ScFoutafFCdt[i-1,l]^2+sd.kIM[i-1,l]^2+sd.kIM[i,l]^2) 
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sd.deltacs2[i,l]<-sqrt(sd.dCV[i,l]^2+sd.dCV[i-1,l]^2+sd.SaFinCin[i-
1,l]^2+sd.SaFinCin[i,l]^2+sd.SbFoutCdt[i,l]^2+sd.SbFoutCdt[i-
1,l]^2+sd.ScFoutafFCdt[i,l]^2+sd.ScFoutafFCdt[i-1,l]^2) 
 
currentcs[i,l]<-CV[i,l]-SaFinCin[i,l]+SbFoutCdt[i,l]+ScFoutafFCdt[i,l]-kIM[i,l] 
sd.currentcs[i,l]<-
sqrt(sd.CV[i,l]^2+sd.SaFinCin[i,l]^2+sd.SbFoutCdt[i,l]^2+sd.ScFoutafFCdt[i,l]^2+sd.kIM[i,l
]^2) 
sd.currentcs2[i,l]<-
sqrt(sd.dCV[i,l]^2+sd.SaFinCin[i,l]^2+sd.SbFoutCdt[i,l]^2+sd.ScFoutafFCdt[i,l]^2+sd.kIM[i
,l]^2) 
} 
} 
 
colnames(deltacs)<-namecscomp 
colnames(sd.deltacs)<-namesd.cscomp 
colnames(sd.deltacs2)<-namesd.cscomp 
colnames(currentcs)<-namecscomp 
colnames(sd.currentcs)<-namesd.cscomp 
colnames(sd.currentcs2)<-namesd.cscomp 
 
#write.csv(data.frame(currentcs,sd.currentcs),"currentcs.csv") 
 
currentcsexp<-data.frame(matrix(0,nrow=length(texp),ncol=(ncol(exdata)-7)/2)) 
sd.currentcsexp<-data.frame(matrix(0,nrow=length(texp),ncol=(ncol(exdata)-7)/2)) 
sd.currentcs2exp<-data.frame(matrix(0,nrow=length(texp),ncol=(ncol(exdata)-7)/2)) 
 
 
for (l in (1:ncol(cscomp))){ 
currentcsexp[1,l]<-CV[1,l] 
sd.currentcsexp[1,l]<-sd.currentcs[1,l] 
sd.currentcs2exp[1,l]<-sd.currentcs2[1,l] 
 
nf1<-1 
ic<-2 
for (i in (2:length(texp))){ 
currentcsexp[i,l]<-currentcs[ic,l] 
sd.currentcsexp[i,l]<-sd.currentcs[ic,l] 
sd.currentcs2exp[i,l]<-sd.currentcs2[ic,l] 
 
if(i!=length(texp)) { 
  if(i!=(nf1*fint)+1){ 
  currentcsexp[i,l]<-currentcs[ic,l] 
  sd.currentcsexp[i,l]<-sd.currentcs[ic,l] 
  sd.currentcs2exp[i,l]<-sd.currentcs2[ic,l]   
  ic<-ic+3 
   }else{nf1<-nf1+1 
    currentcsexp[i,l]<-currentcs[ic,l] 
    sd.currentcsexp[i,l]<-sd.currentcs[ic,l] 
    sd.currentcs2exp[i,l]<-sd.currentcs2[ic,l] 
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    ic<-ic+7 
    } 
    } 
} 
} 
 
colnames(currentcsexp)<-namecscomp 
colnames(sd.currentcsexp)<-namesd.cscomp 
colnames(sd.currentcs2exp)<-namesd.cscomp 
 
 
stdevdivsingle<-function(var4,sd.var4,var5,sd.var5){ 
var45<-abs(var4/var5)*sqrt((sd.var4/var4)^2+(sd.var5/var5^2)) 
if(is.nan(var45)){ 
var45<-0} 
else{var45}  
return(var45) 
} 
 
from<-data.frame(matrix(0,nrow=0,ncol=0)) 
 
to<-data.frame(matrix(0,nrow=0,ncol=0)) 
 
qapp<-data.frame(matrix(0,nrow=0,ncol=0)) 
 
Aqapp<-data.frame(matrix(0,nrow=0,ncol=0)) 
 
Bqapp<-data.frame(matrix(0,nrow=0,ncol=0)) 
 
sd.Aqapp<-data.frame(matrix(0,nrow=0,ncol=0)) 
 
sd.Aqapp2<-data.frame(matrix(0,nrow=0,ncol=0)) 
 
sd.Bqapp<-data.frame(matrix(0,nrow=0,ncol=0)) 
 
sd.qapp<-data.frame(matrix(0,nrow=0,ncol=0)) 
 
sd.qapp2<-data.frame(matrix(0,nrow=0,ncol=0)) 
 
IVCs<-data.frame(matrix(0,nrow=length(texp),ncol=(ncol(exdata)-7)/2)) 
sd.IVCs<-data.frame(matrix(0,nrow=length(texp),ncol=(ncol(exdata)-7)/2)) 
 
for (l in (1:ncol(cscomp))){ 
IVCs[,l]<-IVCexp 
sd.IVCs[,l]<-sd.IVCexp 
} 
 
 
for (l in (1:ncol(cscomp))){ 
ic<-1 
APPENDIX  247   
 
for (n in (2:length(texp))){ 
 
for (m in (1:n)){ 
 
qapp[ic,l]<-(currentcsexp[n,l]-currentcsexp[m,l])/(IVCs[n,l]-IVCs[m,l]) 
Aqapp[ic,l]<-(currentcsexp[n,l]-currentcsexp[m,l]) 
sd.Aqapp[ic,l]<-sqrt(sd.currentcsexp[n,l]^2+sd.currentcsexp[m,l]^2) 
sd.Aqapp2[ic,l]<-sqrt(sd.currentcs2exp[n,l]^2+sd.currentcs2exp[m,l]^2) 
Bqapp[ic,l]<-(IVCs[n,l]-IVCs[m,l]) 
sd.Bqapp[ic,l]<-sqrt(sd.IVCs[n,l]^2+sd.IVCs[m,l]^2) 
sd.qapp[ic,l]<-stdevdivsingle(Aqapp[ic,l],sd.Aqapp[ic,l],Bqapp[ic,l],sd.Bqapp[ic,l]) 
sd.qapp2[ic,l]<-stdevdivsingle(Aqapp[ic,l],sd.Aqapp2[ic,l],Bqapp[ic,l],sd.Bqapp[ic,l]) 
from[ic,l]<-m-1 
to[ic,l]<-n-1 
ic<-ic+1 
} 
} 
} 
 
colnames(qapp)<-namecscomp 
colnames(sd.qapp)<-namesd.cscomp 
colnames(sd.qapp2)<-paste(namesd.cscomp,2,sep="") 
 
 
fromto<-na.omit(data.frame(paste(from[,1],to[,1],sep=" to "))) 
colnames(fromto)<-"t.interval" 
 
qs<-data.frame(matrix(0,nrow=nrow(qapp),ncol=3*ncol(cscomp))) 
 
ic<-1 
for (i in (1:ncol(cscomp))){ 
qs[,ic]<-qapp[,i] 
colnames(qs)[ic]<-namecscomp[i] 
qs[,ic+1]<-sd.qapp[,i] 
colnames(qs)[ic+1]<-namesd.cscomp[i] 
ic<-ic+3 
} 
 
#return a table with all rates: 
musqsfromto<-na.omit(data.frame(fromto,muapp,sd.muapp,qs,kdapp,sd.kdapp)) 
return(musqsfromto) 
 
} 
 
 
 
 
